"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2022/120412 A1,157-734-222-130-625,2022-06-16,2022,AU 2021/051451 W,2021-12-06,AU 2020/904627 A;;AU 2021/903707 A,2020-12-11,COUPLING ASSEMBLY,A coupling assembly for releasably attaching a ground engaging tool to earth moving equipment comprises a boss arrangement mounted onto a lip of an excavation implement ofthe equipment relative to an edge of the lip. The coupling assembly also comprises a boltcomprising a threaded portion and a flange. The threaded portion is received by a threaded aperture in the boss arrangement such that relative rotation between the bolt and boss arrangement causes rearward movement of the bolt and flange away from the edge. Aretainer is removably insertable between the flange and a bearing surface of the toolreadward the flange. The rearward movement causes the flange to engage the retainer andthe retainer to engage the bearing surface such that the bolt goes into compression andurges the tool toward the edge.,AVTRU PTY LTD;;PEXAN PTY LTD,VAUGHAN ALLEN,,https://lens.org/157-734-222-130-625,Patent Application,yes,5,0,4,4,0,E02F9/2833;;F16B39/28;;F16B21/09;;F16B23/0038;;F16B35/048;;F16B37/0807;;F16B37/14;;E02F9/2825;;E02F9/2858;;E02F9/2833;;E02F9/2825;;E02F9/2833;;F16B23/0038;;F16B37/0807;;F16B37/14;;F16B39/28,E02F9/28,,0,0,,,,PENDING
2,US,A1,US 2024/0018753 A1,040-983-367-403-588,2024-01-18,2024,US 202118036216 A,2021-12-06,AU 2020/904627 A;;AU 2021/903707 A;;AU 2021/051451 W,2020-12-11,COUPLING ASSEMBLY,A coupling assembly for releasably attaching a ground engaging tool to earth moving equipment comprises a boss arrangement mounted onto a lip of an excavation implement of the equipment relative to an edge of the lip. The coupling assembly also comprises a bolt comprising a threaded portion and a flange. The threaded portion is received by a threaded aperture in the boss arrangement such that relative rotation between the bolt and boss arrangement causes rearward movement of the bolt and flange away from the edge. A retainer is removably insertable between the flange and a bearing surface of the tool readward the flange. The rearward movement causes the flange to engage the retainer and the retainer to engage the bearing surface such that the bolt goes into compression and urges the tool toward the edge.,AVTRU PTY LTD;;PEXAN PTY LTD,VAUGHAN ALLEN,AVTRU PTY LTD (2023-05-11);;PEXAN PTY LTD (2023-05-11),https://lens.org/040-983-367-403-588,Patent Application,yes,0,0,4,4,0,E02F9/2833;;F16B39/28;;F16B21/09;;F16B23/0038;;F16B35/048;;F16B37/0807;;F16B37/14;;E02F9/2825;;E02F9/2858;;E02F9/2833;;E02F9/2825;;E02F9/2833;;F16B23/0038;;F16B37/0807;;F16B37/14;;F16B39/28,E02F9/28;;F16B37/08;;F16B39/28,,0,0,,,,PENDING
3,AU,A1,AU 2021/394455 A1,018-592-612-835-128,2023-06-15,2023,AU 2021/394455 A,2021-12-06,AU 2020/904627 A;;AU 2021/903707 A;;AU 2021/051451 W,2020-12-11,COUPLING ASSEMBLY,A coupling assembly for releasably attaching a ground engaging tool to earth moving equipment comprises a boss arrangement mounted onto a lip of an excavation implement ofthe equipment relative to an edge of the lip. The coupling assembly also comprises a boltcomprising a threaded portion and a flange. The threaded portion is received by a threaded aperture in the boss arrangement such that relative rotation between the bolt and boss arrangement causes rearward movement of the bolt and flange away from the edge. Aretainer is removably insertable between the flange and a bearing surface of the toolreadward the flange. The rearward movement causes the flange to engage the retainer andthe retainer to engage the bearing surface such that the bolt goes into compression andurges the tool toward the edge.,AVTRU PTY LTD;;PEXAN PTY LTD,VAUGHAN ALLEN,,https://lens.org/018-592-612-835-128,Patent Application,no,0,0,4,4,0,E02F9/2833;;F16B39/28;;F16B21/09;;F16B23/0038;;F16B35/048;;F16B37/0807;;F16B37/14;;E02F9/2825;;E02F9/2858;;E02F9/2833;;E02F9/2825;;E02F9/2833;;F16B23/0038;;F16B37/0807;;F16B37/14;;F16B39/28,E02F9/28,,0,0,,,,PENDING
4,US,B2,US 8776408 B2,195-745-459-098-530,2014-07-15,2014,US 19748908 A,2008-08-25,AU 2007/904570 A,2007-08-23,Shroud assembly,The present invention provides a protective shroud assembly for use on a wear edge of earthmoving machinery. The shroud assembly comprises a shroud adapted to be received with respect to the wear edge. The shroud has a wear region at a second end thereof which is adapted to engage the earth as the wear edge moves therethrough. The shroud assembly also comprises a locking means having a portion which is rotatably received in the shroud such that the shroud is releasably secured with respect to the wear edge when the locking means is in a locked position.,CHAPMAN AMY FRANCIS;;WEARFORCE PTY LTD;;CASTECH SOLUTIONS PTY LTD;;DAXIT PTY LTD,VAUGHAN ALLEN,DAXIT PTY LTD (2009-02-06);;CASTECH SOLUTIONS PTY LTD (2009-02-06);;WEARFORCE PTY LTD (2014-06-19),https://lens.org/195-745-459-098-530,Granted Patent,yes,29,10,7,7,0,F16B21/02;;F16B35/005;;F16B2/14;;E02F9/2883;;E02F9/2816;;E02F3/36;;E21C35/18;;E02F3/40;;F16B17/00;;E02F9/28;;E02F3/815,E02F9/28,37/455;;37/457;;37/903;;172/772,0,0,,,,ACTIVE
5,US,E,US RE047477 E,178-431-324-225-223,2019-07-02,2019,US 201615211775 A,2016-07-15,US 201615211775 A;;US 19748908 A;;AU 2007/904570 A,2007-08-23,Shroud assembly,The present invention provides a protective shroud assembly for use on a wear edge of earthmoving machinery. The shroud assembly comprises a shroud adapted to be received with respect to the wear edge. The shroud has a wear region at a second end thereof which is adapted to engage the earth as the wear edge moves therethrough. The shroud assembly also comprises a locking means having a portion which is rotatably received in the shroud such that the shroud is releasably secured with respect to the wear edge when the locking means is in a locked position.,WEARFORCE PTY LTD;;CASTECH SOLUTIONS PTY LTD;;DAXIT PTY LTD,VAUGHAN ALLEN,,https://lens.org/178-431-324-225-223,Amended Patent,yes,35,2,7,7,0,F16B21/02;;F16B35/005;;F16B2/14;;E02F9/2883;;E02F9/2816;;E02F3/36;;E21C35/18;;E02F3/40;;F16B17/00;;E02F9/28;;E02F3/815,E02F9/28,,0,0,,,,PENDING
6,CA,A1,CA 3198518 A1,115-284-295-130-715,2022-06-16,2022,CA 3198518 A,2021-12-06,AU 2020/904627 A;;AU 2021/903707 A;;AU 2021/051451 W,2020-12-11,COUPLING ASSEMBLY,A coupling assembly for releasably attaching a ground engaging tool to earth moving equipment comprises a boss arrangement mounted onto a lip of an excavation implement ofthe equipment relative to an edge of the lip. The coupling assembly also comprises a boltcomprising a threaded portion and a flange. The threaded portion is received by a threaded aperture in the boss arrangement such that relative rotation between the bolt and boss arrangement causes rearward movement of the bolt and flange away from the edge. Aretainer is removably insertable between the flange and a bearing surface of the toolreadward the flange. The rearward movement causes the flange to engage the retainer andthe retainer to engage the bearing surface such that the bolt goes into compression andurges the tool toward the edge.,AVTRU PTY LTD;;PEXAN PTY LTD,VAUGHAN ALLEN,,https://lens.org/115-284-295-130-715,Patent Application,no,0,0,4,4,0,E02F9/2833;;F16B39/28;;F16B21/09;;F16B23/0038;;F16B35/048;;F16B37/0807;;F16B37/14;;E02F9/2825;;E02F9/2858;;E02F9/2833;;E02F9/2825;;E02F9/2833;;F16B23/0038;;F16B37/0807;;F16B37/14;;F16B39/28,E02F9/28,,0,0,,,,PENDING
7,GB,B,GB 2598239 B,056-252-742-101-605,2023-10-25,2023,GB 202116426 A,2020-12-22,GB 202116426 A;;GB 202020376 A,2020-12-22,Pressure sensor testing,,HYCONTROL LTD,NIGEL VAUGHAN ALLEN,,https://lens.org/056-252-742-101-605,Granted Patent,no,1,0,3,9,0,G01L27/007;;G01L27/007;;F16K37/0075,G01L27/00;;F16K37/00,,0,0,,,,ACTIVE
8,GB,A,GB 2598239 A,087-785-334-095-513,2022-02-23,2022,GB 202116426 A,2020-12-22,GB 202116426 A;;GB 202020376 A,2020-12-22,Pressure sensor testing,A pressure sensor assembly 11 for remote testing of a pressure 15 adapted to monitor the air pressure developed in an interior 21 of a container (1 in figure 1) such as a silo holding particulate material. An enclosed chamber 25 has a first opening 31 arranged to communicate with the interior of the container/silo and a second opening 33 arranged to communicate with the pressure sensor 15 for monitoring air pressure developed in the interior of the container/silo. The chamber 25 defines a channel for transmission of pressure between the first opening and the second opening and contains a constriction 55. An air injection system 45 is adapted to inject a test pulse of air 47 into the enclosed chamber between the constriction and the second opening (leading to the sensor) so that it creates a back pressure. The functional operability of the pressure sensor is verified based on the pressure measured in response to the test pulse of air. Also claimed is a method of remote testing and a silo arranged with the pressure sensing assembly.,HYCONTROL LTD,NIGEL VAUGHAN ALLEN,,https://lens.org/087-785-334-095-513,Patent Application,no,1,0,3,9,0,G01L27/007;;G01L27/007;;F16K37/0075,G01L27/00;;F16K37/00,,0,0,,,,ACTIVE
9,GB,A,GB 957447 A,186-586-532-911-283,1964-05-06,1964,GB 2551761 A,1961-07-14,GB 2551761 A,1961-07-14,Improvements in and relating to structural elements having a facing of ceramic tiles,"A composition for affixing ceramic tiles to a backing comprises portland cement (25%), ground scrap rubber crumb (25%), and a small proportion of methyl cellulose (0.6%) mixed with a suitably stabilized mixture of rubber latex (14%) and reclaimed rubber (14%), water being added to 100%.ALSO:A composition for affixing ceramic tiles to a backing comprises ground scrap rubber crumb (25%), portland cement (25%), and a small proportion of methyl cellulose (0.6%), mixed with a suitably stabilised mixture of rubber latex (14%) and reclaimed rubber (14%), water being added to 100%.",BRITISH CERAMIC RES ASS,DINSDALE ALLEN;;VAUGHAN FRANK,,https://lens.org/186-586-532-911-283,Granted Patent,no,0,0,1,1,0,E04F13/0862,E04F13/08,C1H HCC           HCC;;C1H H120          HCC;;C1H H620          HCC;;C1H H783          HCC;;C1H H786          HCC;;C1H H787          HCC;;C3V VAH           VAH;;C3V VAL           VAL,0,0,,,,EXPIRED
10,CA,A,CA 252655 A,051-298-255-338-412,1925-08-11,1925,CA 252655D A,,CA 252655T A,,SAFETY RAZOR BLADE SHARPENER,,NOR ALLEN;;VAUGHAN JOHN,NOR ALLEN;;VAUGHAN JOHN,,https://lens.org/051-298-255-338-412,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
11,DE,A1,DE 3912897 A1,028-169-965-672-875,1989-11-02,1989,DE 3912897 A,1989-04-19,US 18316488 A,1988-04-19,Corner unit for a window-pane guiding channel,"A description is given of an insert for the attachment to one another, at a corner, of two strips of a guiding channel for the window pane of a motor vehicle, which channel has a reinforcing element. The insert has an elongate frame element. A tab protrudes from the frame element. The tab is assigned to the reinforcing elements of the window-pane guiding-channel strips in order to attach the two strips to one another at the corner.",STANDARD PRODUCTS CO,NAPLES DALE ALLEN;;VAUGHAN ROBERT ALLEN,,https://lens.org/028-169-965-672-875,Patent Application,no,0,12,1,1,0,B60J10/233;;B60J10/2335,B60J10/00,,0,0,,,,DISCONTINUED
12,GB,A,GB 2217761 A,041-348-902-155-39X,1989-11-01,1989,GB 8908487 A,1989-04-14,US 18361488 A,1988-04-19,CORNER STRUCTURE FOR GLASS RUN CHANNEL,,STANDARD PRODUCTS CO,NAPLES DALE ALLEN;;VAUGHAN ROBERT ALBERT,,https://lens.org/041-348-902-155-39X,Patent Application,no,6,4,9,9,0,B60J10/21;;B60J10/21,B60J10/04;;B60J10/00,E1J JED           JED;;U1S S1820,0,0,,,,EXPIRED
13,AU,A,AU 1989/032521 A,047-491-938-176-379,1989-10-26,1989,AU 1989/032521 A,1989-04-06,US 18361488 A,1988-04-19,CORNER STRUCTURE FOR A GLASS RUN CHANNEL,,STANDARD PRODUCTS CO,NAPLES DALE ALLEN;;VAUGHAN ROBERT ALBERT,,https://lens.org/047-491-938-176-379,Patent Application,no,0,0,9,9,0,B60J10/21;;B60J10/21,B60J10/04;;B60J10/00,,0,0,,,,PENDING
14,US,A,US 3152300 A,122-394-018-387-556,1964-10-06,1964,US 63841357 A,1957-02-05,US 63841357 A,1957-02-05,"Sensing circuit having a unidirectional, reversible polarity output signal",,SUPERIOR ELECTRIC CO,PERRINS ALLEN R;;VAUGHAN ERIC W,,https://lens.org/122-394-018-387-556,Granted Patent,no,6,0,1,1,0,G05F1/32;;G05F1/32,G05F1/32,,0,0,,,,EXPIRED
15,GB,B,GB 2425599 B,097-306-678-162-080,2009-11-04,2009,GB 0508394 A,2005-04-26,GB 0508394 A,2005-04-26,Apparatus and method for testing of a pressure sensor,,HYCONTROL LTD,ALLEN NIGEL VAUGHAN;;HICKS ROGER JOHN,,https://lens.org/097-306-678-162-080,Granted Patent,no,2,0,3,3,0,G01L19/06;;G01L19/08;;G01L19/083;;G01L19/086;;G01L27/00;;G01L27/007,G01L27/00;;G01L19/06;;G01L19/08,,0,0,,,,ACTIVE
16,AU,A,AU 1992/017011 A,140-203-973-524-967,1992-07-16,1992,AU 1992/017011 A,1992-05-20,US 18361488 A,1988-04-19,CORNER STRUCTURE FOR A GLASS RUN CHANNEL,,STANDARD PRODUCTS CO,NAPLES DALE ALLEN;;VAUGHAN ROBERT ALBERT,,https://lens.org/140-203-973-524-967,Patent Application,no,0,0,9,9,0,B60J10/21;;B60J10/21,B60J10/04;;B60J10/00,,0,0,,,,PENDING
17,GB,B,GB 2217761 B,196-538-489-359-046,1992-09-02,1992,GB 8908487 A,1989-04-14,US 18361488 A,1988-04-19,CORNER STRUCTURE FOR GLASS RUN CHANNEL,,STANDARD PRODUCTS CO,NAPLES DALE ALLEN;;VAUGHAN ROBERT ALBERT,,https://lens.org/196-538-489-359-046,Granted Patent,no,6,0,9,9,0,B60J10/21;;B60J10/21,B60J10/04;;B60J10/00,E1J JED           JED;;U1S S1820,0,0,,,,EXPIRED
18,CA,A,CA 751042 A,185-285-005-001-856,1967-01-17,1967,CA 751042D A,,CA 751042T A,,"SENSING CIRCUIT HAVING A UNIDIRECTIONAL, REVERSIBLE POLARITY OUTPUT SIGNAL",,SUPERIOR ELECTRIC CO,VAUGHAN ERIC W;;PERRINS ALLEN R,,https://lens.org/185-285-005-001-856,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
19,WO,A1,WO 2019/043527 A1,173-468-516-911-444,2019-03-07,2019,IB 2018056383 W,2018-08-23,ZA 201705858 A,2017-08-29,SPEARS FOR SPEARING FISH,"A spear 10 for spearing fish comprises a spear shaft 12 and a toggle 14. The spear shaft defines a sharpened spear tip 18 and has a locating pin 22 spaced from the tip at an upper side of the spear shaft, which is received in a locating slot 40 defined in the toggle for locating the toggle on the spear shaft. The toggle comprises a thin-walled toggle body 34 which is shaped to conform to the profile of the spear shaft. A leading end of the toggle abuts a pair of stop pins 28 which extend radially outwardly from opposite sides of the spear shaft when the toggle is seated on the spear shaft. The spear includes an attachment cord 26 attaching the toggle to the spear shaft. After the spear penetrates a fish, the toggle decouples from the spear shaft preventing separation of the fish from the spear.",ALLEN ROBIN VAUGHAN;;WILLIAMS JEREMY ROY,ALLEN ROBIN VAUGHAN;;WILLIAMS JEREMY ROY,,https://lens.org/173-468-516-911-444,Patent Application,yes,5,1,2,2,0,A01K81/04;;F42B6/08;;F41B13/10;;F42B6/02,A01K81/04;;F42B6/02,,0,0,,,,PENDING
20,FR,B1,FR 2630051 B1,001-412-640-515-676,1994-12-09,1994,FR 8905196 A,1989-04-19,US 18361488 A,1988-04-19,FR 2630051 B1,,STANDARD PRODUCTS CO,ALLEN NAPLES DALE;;ALBERT VAUGHAN ROBERT,,https://lens.org/001-412-640-515-676,Granted Patent,no,0,0,9,9,0,B60J10/21;;B60J10/21,B60J10/04;;B60J10/00,,0,0,,,,EXPIRED
21,ZA,B,ZA 201908406 B,166-083-720-183-674,2021-01-27,2021,ZA 201908406 A,2019-12-17,ZA 201705858 A;;IB 2018056383 W,2017-08-29,SPEARS FOR SPEARING FISH,,ALLEN ROBIN VAUGHAN;;WILLIAMS JEREMY ROY,ALLEN ROBIN VAUGHAN;;WILLIAMS JEREMY ROY,,https://lens.org/166-083-720-183-674,Granted Patent,no,0,0,2,2,0,A01K81/04;;F42B6/08;;F41B13/10;;F42B6/02,,,0,0,,,,ACTIVE
22,FR,A1,FR 2630051 A1,081-310-497-760-357,1989-10-20,1989,FR 8905196 A,1989-04-19,US 18361488 A,1988-04-19,STRUCTURE D'ANGLE POUR CANAL DE PASSAGE D'UNE VITRE DE VEHICULE,"<P>On décrit un élément rapporté pour la fixation de deux bandes 22, 24 d'un canal 20 pour le passage de la vitre d'un véhicule automobile comportant un élément de renforcement 32 d'angle. Cet élément comprend un élément allongé de cadre. Un mécanisme à pattes 34 est en saillie sur l'élément de cadre et est associé à l'élément de renforcement pour fixer ensemble les deux bandes.</P>",STANDARD PRODUCTS CO,NAPLES DALE ALLEN;;VAUGHAN ROBERT ALBERT,,https://lens.org/081-310-497-760-357,Patent Application,no,5,0,9,9,0,B60J10/21;;B60J10/21,B60J10/04;;B60J10/00,,0,0,,,,EXPIRED
23,GB,A,GB 2425599 A,163-718-380-705-356,2006-11-01,2006,GB 0508394 A,2005-04-26,GB 0508394 A,2005-04-26,Apparatus and method for testing a pressure sensor,"A pressure sensor adapted to monitor, and provide a signal output as a function of, air pressure developed in an interior of a container during charging of the container with air-fluidised particulate material is tested remotely by providing an enclosed chamber (16) communicating with the pressure sensor (18) and adapted to communicate with an upper region of the interior of the container (2) by means of a porous element (22). The porous element is adapted to permit two-way pressurised air flow thereacross between the interior of the container and the enclosed chamber at a predetermined restricted flow rate while substantially preventing transfer of the particulate material thereacross. A test pulse of air is injected at a predetermined pressure into the enclosed chamber (16) for sensing by the pressure sensor (18). Functional operability of the pressure sensor is verified if the resultant signal output therefrom is representative of a pressure higher than atmospheric pressure and less than the predetermined pressure.",HYCONTROL LTD,ALLEN NIGEL VAUGHAN;;HICKS ROGER JOHN,,https://lens.org/163-718-380-705-356,Patent Application,no,2,5,3,3,0,G01L19/06;;G01L19/08;;G01L19/083;;G01L19/086;;G01L27/00;;G01L27/007,G01L27/00;;G01L19/06;;G01L19/08,G1L L3M           L3M,0,0,,,,ACTIVE
24,FR,A,FR 732736 A,055-231-501-108-073,1932-09-24,1932,FR 732736D A,1932-03-05,FR 732736T A,1932-03-05,Dispositif pour maintenir les plis de vêtements,,,ALLEN LLEWELLYN AUSTIN VAUGHAN;;JIRAN JOSEPH WILLIAM,,https://lens.org/055-231-501-108-073,Granted Patent,no,0,0,1,1,0,A47G25/66,A47G25/66,,0,0,,,,EXPIRED
25,DE,T2,DE 69607356 T2,046-942-929-990-962,2000-12-07,2000,DE 69607356 T,1996-08-02,GB 9515988 A;;GB 9606816 A;;GB 9601858 W,1995-08-04,FELDELEKTRONENEMITTERENDE MATERIALEN UND VORRICHTUNGEN,,PRINTABLE FIELD EMITTERS LTD,TUCK RICHARD ALLEN;;LATHAM RODNEY VAUGHAN;;TAYLOR WILLIAM,,https://lens.org/046-942-929-990-962,Granted Patent,no,0,0,17,23,0,H01J1/304;;H01J1/3042;;H01J2201/319;;H01J1/30;;H01J1/304;;H01J1/3042;;H01J2201/319,H01J9/02;;H01J1/304;;H01J7/18;;H01J29/87;;H01J29/94;;H01J31/12,,0,0,,,,EXPIRED
26,US,B2,US 7809954 B2,128-173-930-759-708,2010-10-05,2010,US 54609005 A,2005-03-31,US 2005/0010612 W,2005-03-31,Biometric control of equipment,"An apparatus for allowing operation of equipment by an authorized operator comprises a biometric scanner 20 receiving a biometric input from an authorized operator, and transmitting an authorization signal as long as the biometric input is received from the authorized operator. The apparatus further includes an equipment control system 18 that allows the equipment to operate substantially only while the equipment control system receives the authorization signal from the biometric scanner 20 , and that prevents the equipment from operating shortly after the authorization signal is no longer received from the biometric scanner.",MILLER BRIAN SCOTT;;VAUGHAN JACK;;LADRIERE OSCAR ALLEN,MILLER BRIAN SCOTT;;VAUGHAN JACK;;LADRIERE OSCAR ALLEN,DEADMAN TECHNOLOGIES LLC (2011-03-14),https://lens.org/128-173-930-759-708,Granted Patent,yes,35,33,5,5,0,G06F21/32;;G06F21/83;;Y10T137/7759;;Y10T137/263;;Y10T137/0357;;Y10T137/2632;;Y10T137/2642;;G07C9/26;;G07C9/257;;Y10T137/7759;;Y10T137/263;;Y10T137/0357;;Y10T137/2632;;Y10T137/2642;;G06F21/83;;G06F21/32;;G07C9/257;;G07C9/26,G06F21/00;;G06F21/02;;G06F21/06,713/186;;713/182;;713/168;;726/16;;726/19;;726/21;;137/8;;137/115.21;;137/115.22;;137/115.26;;137/486,0,0,,,,INACTIVE
27,CA,C,CA 2603077 C,086-865-341-699-220,2015-03-24,2015,CA 2603077 A,2005-03-31,US 2005/0010612 W,2005-03-31,BIOMETRIC CONTROL OF EQUIPMENT,"An apparatus for allowing operation of equipment by an authorized operator comprises a biometric scanner (20) receiving a biometric input from an authorized operator, and transmitting an authorization signal as long as the biometric input is received from the authorized operator. The apparatus further includes an equipment control system (18) that allows the equipment to operate substantially only while the equipment control system receives the authorization signal from the biometric scanner (20), and that prevents the equipment from operating shortly after the authorization signal is no longer received from the biometric scanner.",MILLER BRIAN SCOTT;;VAUGHAN JACK;;LEDRIERE OSCAR ALLEN,MILLER BRIAN SCOTT;;VAUGHAN JACK;;LEDRIERE OSCAR ALLEN,,https://lens.org/086-865-341-699-220,Granted Patent,no,0,0,5,5,0,G06F21/32;;G06F21/83;;Y10T137/7759;;Y10T137/263;;Y10T137/0357;;Y10T137/2632;;Y10T137/2642;;G07C9/26;;G07C9/257;;Y10T137/7759;;Y10T137/263;;Y10T137/0357;;Y10T137/2632;;Y10T137/2642;;G06F21/83;;G06F21/32;;G07C9/257;;G07C9/26,G07C11/00;;B64F1/28,,0,0,,,,INACTIVE
28,ES,T3,ES 2146890 T3,113-752-285-304-015,2000-08-16,2000,ES 96925901 T,1996-08-02,GB 9515988 A;;GB 9606816 A,1995-08-04,"MATERIALES DE EMISION DE ELECTRONES DE CAMPO, Y DISPOSITIVOS QUE USAN TALES MATERIALES.","UN MATERIAL DE EMISION DE ELECTRONES POR CAMPO COMPRENDE UN SUSTRATO ELECTRICAMENTE CONDUCTOR (13, 14) Y, COLOCADAS SOBRE EL MISMO, PARTICULAS ELECTRICAMENTE CONDUCTORAS (11) FORMADAS EN UNA CAPA DE MATERIAL INORGANICO ELECTRICAMENTE AISLANTE (12) O RECUBIERTAS CON DICHO MATERIAL (POR EJEMPLO, CRISTAL). SE DEFINE UN PRIMER ESPESOR DE MATERIAL AISLANTE (15 ) ENTRE CADA PARTICULA (11) Y EL SUSTRATO (13,14) Y UN SEGUNDO ESPESOR (15) DE MATERIAL AISLANTE ENTRE LA PARTICULA (11) Y EL ENTORNO EN EL CUAL ESTA DISPUESTO EL MATERIAL. LAS DIMENSIONES DE CADA PARTICULA (11) ENTRE LOS ESPESORES PRIMERO Y SEGUNDO (15) ES SIGNIFICATIVAMENTE MAYOR QUE CADA UNO DE LOS ESPESORES (15). AL APLICAR UN CAMPO ELECTRICO SUFICIENTE, CADA ESPESOR (15) PROPORCIONA UN CANAL CONDUCTOR PARA HACER QUE LAS PARTICULAS EMITAN ELECTRONES. MEDIANTE EL USO DE UN MATERIAL AISLANTE INORGANICO (12) SE HAN OBTENIDO CONDICIONES DE ESTABILIDAD Y RENDIMIENTO SORPRENDENTEMENTE BUENAS. LAS PARTICULAS (11) PUEDEN SER RELATIVAMENTE PEQUEÑAS, POR LO QUE EL MATERIAL EMISOR DE ELECTRONES (11, 12) SE PUEDE APLICAR AL SUSTRATO (13, 14) MEDIANTE VARIOS METODOS ECONOMICOS, INCLUIDA LA IMPRESION. EL MATERIAL SE PUEDE UTILIZAR EN DIVERSOS DISPOSITIVOS, INCLUIDOS LOS DE ILUMINACION Y VISUALIZACION.",PRINTABLE FIELD EMITTERS LIMIT,TUCK RICHARD ALLEN;;LATHAM RODNEY VAUGHAN;;TAYLOR WILLIAM,,https://lens.org/113-752-285-304-015,Granted Patent,no,0,0,17,23,0,H01J1/304;;H01J1/3042;;H01J2201/319;;H01J1/30;;H01J1/304;;H01J1/3042;;H01J2201/319,H01J1/304;;H01J9/02;;H01J7/18;;H01J29/87;;H01J29/94;;H01J31/12,,0,0,,,,EXPIRED
29,EP,A1,EP 0842526 A1,111-249-912-347-751,1998-05-20,1998,EP 96925901 A,1996-08-02,GB 9601858 W;;GB 9515988 A;;GB 9606816 A,1995-08-04,FIELD ELECTRON EMISSION MATERIALS AND DEVICES,,PRINTABLE FIELD EMITTERS LIMIT,TUCK RICHARD ALLEN;;LATHAM RODNEY VAUGHAN;;TAYLOR WILLIAM,,https://lens.org/111-249-912-347-751,Patent Application,yes,0,0,17,23,0,H01J1/304;;H01J1/3042;;H01J2201/319;;H01J1/30;;H01J1/304;;H01J1/3042;;H01J2201/319,H01J1/304;;H01J7/18;;H01J9/02;;H01J29/87;;H01J29/94;;H01J31/12,,0,0,,,,EXPIRED
30,EP,B1,EP 0842526 B1,164-787-843-611-555,2000-03-22,2000,EP 96925901 A,1996-08-02,GB 9601858 W;;GB 9515988 A;;GB 9606816 A,1995-08-04,FIELD ELECTRON EMISSION MATERIALS AND DEVICES,,PRINTABLE FIELD EMITTERS LIMIT,TUCK RICHARD ALLEN;;LATHAM RODNEY VAUGHAN;;TAYLOR WILLIAM,,https://lens.org/164-787-843-611-555,Granted Patent,yes,1,0,17,23,0,H01J1/304;;H01J1/3042;;H01J2201/319;;H01J1/30;;H01J1/304;;H01J1/3042;;H01J2201/319,H01J1/304;;H01J9/02;;H01J7/18;;H01J29/87;;H01J29/94;;H01J31/12,,3,0,,,"JOURNAL OF PHYSICS D APPLIED PHYSICS., vol. 21, 1988, LETCHWORTH GB, pages 200-204, XP002017628 S BAJIC ET AL.: ""Enhanced cold-cathode emission using composite resin-carbon coatings"" cited in the application;;JOURNAL OF PHYSICS D APPLIED PHYSICS., vol. 26, 1993, LETCHWORTH GB, pages 1776-1780, XP002017629 N S XU ET AL.: ""Similarities in the 'cold' electron emission characteristics of diamond coated molybdenum electrodes and polished bulk graphite surfaces"";;ELECTRONICS LETTERS, vol. 29, no. 18, 2 September 1993, page 1596/1597 XP000395178 XU N S ET AL: ""FIELD-DEPENDENCE OF THE AREA-DENSITY OF 'COLD' ELECTRON EMISSION SITES ON BROAD-AREA CVD DIAMOND FILMS"" cited in the application",EXPIRED
31,DE,D1,DE 69607356 D1,143-966-101-294-564,2000-04-27,2000,DE 69607356 T,1996-08-02,GB 9515988 A;;GB 9606816 A;;GB 9601858 W,1995-08-04,FELDELEKTRONENEMITTERENDE MATERIALEN UND VORRICHTUNGEN,,PRINTABLE FIELD EMITTERS LTD,TUCK RICHARD ALLEN;;LATHAM RODNEY VAUGHAN;;TAYLOR WILLIAM,,https://lens.org/143-966-101-294-564,Granted Patent,no,0,0,17,23,0,H01J1/304;;H01J1/3042;;H01J2201/319;;H01J1/30;;H01J1/304;;H01J1/3042;;H01J2201/319,H01J9/02;;H01J1/304;;H01J7/18;;H01J29/87;;H01J29/94;;H01J31/12,,0,0,,,,EXPIRED
32,CA,A1,CA 2603077 A1,150-830-879-664-985,2006-11-09,2006,CA 2603077 A,2005-03-31,US 2005/0010612 W,2005-03-31,BIOMETRIC CONTROL OF EQUIPMENT,,VAUGHAN JACK;;MILLER BRIAN SCOTT;;LEDRIERE OSCAR ALLEN,VAUGHAN JACK;;MILLER BRIAN SCOTT;;LEDRIERE OSCAR ALLEN,,https://lens.org/150-830-879-664-985,Patent Application,no,0,0,5,5,0,G06F21/32;;G06F21/83;;Y10T137/7759;;Y10T137/263;;Y10T137/0357;;Y10T137/2632;;Y10T137/2642;;G07C9/26;;G07C9/257;;Y10T137/7759;;Y10T137/263;;Y10T137/0357;;Y10T137/2632;;Y10T137/2642;;G06F21/83;;G06F21/32;;G07C9/257;;G07C9/26,G07C11/00;;B64F1/28,,0,0,,,,INACTIVE
33,WO,A1,WO 2006/118555 A1,175-893-968-125-698,2006-11-09,2006,US 2005/0010612 W,2005-03-31,US 2005/0010612 W,2005-03-31,BIOMETRIC CONTROL OF EQUIPMENT,"An apparatus for allowing operation of equipment by an authorized operator comprises a biometric scanner (20) receiving a biometric input from an authorized operator, and transmitting an authorization signal as long as the biometric input is received from the authorized operator. The apparatus further includes an equipment control system (18) that allows the equipment to operate substantially only while the equipment control system receives the authorization signal from the biometric scanner (20), and that prevents the equipment from operating shortly after the authorization signal is no longer received from the biometric scanner.",MILLER BRIAN SCOTT;;VAUGHAN JACK;;LEDRIERE OSCAR ALLEN,MILLER BRIAN SCOTT;;VAUGHAN JACK;;LEDRIERE OSCAR ALLEN,,https://lens.org/175-893-968-125-698,Patent Application,yes,5,1,5,5,0,G06F21/32;;G06F21/83;;Y10T137/7759;;Y10T137/263;;Y10T137/0357;;Y10T137/2632;;Y10T137/2642;;G07C9/26;;G07C9/257;;Y10T137/7759;;Y10T137/263;;Y10T137/0357;;Y10T137/2632;;Y10T137/2642;;G06F21/83;;G06F21/32;;G07C9/257;;G07C9/26,H04B7/00;;G06F17/30;;H04L9/00,,0,0,,,,PENDING
34,GB,A,GB 743346 A,039-160-325-875-082,1956-01-11,1956,GB 911153 A,1953-04-01,GB 911153 A,1953-04-01,Improvements in or relating to fluid valves,"743,346. Valves. NATIONAL RESEARCH DEVELOPMENT CORPORATION. April 1, 1954 [April 1, 1953], No. 9111/53. Class 135. A non-return valve comprises a spring - loaded closure member 16 of tubular form coacting with a resilient seat 15 and controlling ports 26 in a fixed guide element 24 which also serves as a stop to limit the degree of engagement of the closure member with the resilient seat. The latter, which is held in position by a sleeve 18, is exposed to and deformed by the fluid pressure that closes the valve so as to provide an efficient seal against the closure member. The closure member is moved beyond the ports 26 to open the valve either by fluid pressure applied to the inlet 13 or by mechanical operation of a stem 29, e.g. by a gauging device screwed on to the end 13 for measuring the pressure in a container to which the valve may be fitted.",NAT RES DEV,ALLEN GEOFFREY REX;;ROSS ANTHONY PETER;;VAUGHAN IVOR JOHN,,https://lens.org/039-160-325-875-082,Granted Patent,no,0,2,1,1,0,F16K21/04,F16K21/04,,0,0,,,,EXPIRED
35,US,B1,US 8020850 B1,016-809-909-572-164,2011-09-20,2011,US 91644610 A,2010-10-29,US 91644610 A,2010-10-29,Removable input tray assembly having a dual function roller for feeding media and separating media in an image forming device,"A removable input tray assembly for an image forming device according to one embodiment includes a media tray having a bottom surface defining a media storage location, a wall extending upward from the bottom surface and a housing having an opening therein to receive the tray. An inclined media dam having a media contact surface is formed in the wall. A channel extends the height of the wall and has a front wall, a rear wall, a bottom opening and a top opening. A separator roller is rotatably mounted below the media contact surface and has a first portion of its surface radially extending through a corresponding aperture in the media dam and a second portion radially extending through a corresponding aperture in the rear wall of the channel. A roller nip is formed in the channel within the media tray by the separator roller and an opposing backup roller.",LEXMARK INT INC,BLAIR BRIAN ALLEN;;MITCHELL STACEY VAUGHAN;;TRIPLETT EDWARD LYNN,LEXMARK INTERNATIONAL INC (2010-10-29),https://lens.org/016-809-909-572-164,Granted Patent,yes,3,5,1,1,0,B65H1/14;;B65H1/266;;B65H3/0684;;B65H3/44;;B65H3/5261;;B65H2402/10;;B65H2404/611;;B65H2405/1117;;B65H2405/1136;;B65H2405/313;;B65H2601/324;;B65H2801/06;;B65H2220/09;;B65H3/44;;B65H2405/1117;;B65H2801/06;;B65H3/0684;;B65H1/14;;B65H2402/10;;B65H2405/1136;;B65H1/266;;B65H3/5261;;B65H2404/611;;B65H2405/313;;B65H2601/324;;B65H2220/09,B65H5/26,271/9.11;;271/122;;271/9.13,0,0,,,,INACTIVE
36,FI,A,FI 763683 A,056-889-718-969-138,1977-06-24,1977,FI 763683 A,1976-12-22,GB 5252275 A,1975-12-23,FI 763683 A,,VICKERS LTD,GATES ALLEN PETER;;HINCH STEPHEN CHARLES;;WITHERS CHRISTOPHER VAUGHAN,,https://lens.org/056-889-718-969-138,Patent Application,no,0,0,34,34,0,C07C45/00;;C07C47/24;;C07C57/42;;C07C59/68;;C07C205/44;;C07C205/56;;C07C255/00;;C08F20/26;;C08F20/36;;G03F7/038;;G03F7/0388;;G03F7/0388;;C07C59/68;;C07C255/00;;C08F20/26;;C07C57/42;;C08F20/36;;C07C45/00;;C07C47/24;;C07C205/44;;C07C205/56;;G03F7/038,C07C45/00;;C08F2/00;;C07C47/24;;C07C57/42;;C07C57/60;;C07C59/68;;C07C205/56;;C08F2/46;;C08F2/48;;C08F8/00;;C08F8/14;;C08F20/26;;C08F20/36;;C08F220/26;;C08F290/00;;C08F299/00;;G03F7/038,,0,0,,,,EXPIRED
37,GB,A,GB 756162 A,137-465-435-015-075,1956-08-29,1956,GB 2278953 A,1953-08-18,GB 2278953 A,1953-08-18,Improvements in or relating to non-return fluid valves,"756,162. Non-return valves. NATIONAL RESEARCH DEVELOPMENT CORPORATION. Aug. 16, 1954 [Aug. 18, 1953], No. 22789/53. Class 135. A non-return valve comprises a non-resilient obturating member cooperating, in the closed position, with a fixed, resilient seating in such manner that the latter is non-yieldingly enclosed except for that part of its surface upon which the obturating member seats. The obturating member shown comprises a cylinder 16 with an intermediate partition carrying a depending tail 28 by which the valve can be manually opened against the pressure of its loading spring 31. The lower end of the cylinder seats, in the closed position, on a ring 15 of resilient material which is enclosed by the inner surface of the valve casing 11, a flange on the lower end of a liner 19, and a flanged cylindrical guide 26 for the tail 28 of the obturating member. When the valve is opened by fluid pressure applied at the lower end of the casing, the fluid flows through the annular space between the tail 28 and the cylindrical guide 26, through radial passages 29 in the guide, through passages 24 in the outer surface of obturator 16, and so to the outlet at the upper end of the casing. If the passages 29 are omitted, flow through the valve takes place when the obturating member clears the upper end of guide 26.",NAT RES DEV,ALLEN GEOFFREY REX;;ROSS ANTHONY PETER;;VAUGHAN IVOR JOHN,,https://lens.org/137-465-435-015-075,Granted Patent,no,0,6,1,1,0,F16K15/063,F16K15/06,F2V VV3           VV3,0,0,,,,EXPIRED
38,FI,C,FI 64863 C,050-182-603-126-491,1984-01-10,1984,FI 763683 A,1976-12-22,GB 5252275 A,1975-12-23,FOTOPOLYMERISERBART MATERIAL EN LJUSKAENSLIG TRYCKPLAOT INNEHAOLLANDE DETSAMMA SAMT ETT FOERFARANDE FOER FRAMSTAELLNING AVRYCKPLAOTEN,,VICKERS LTD,GATES ALLEN PETER;;HINCH STEPHEN CHARLES;;WITHERS CHRISTOPHER VAUGHAN,,https://lens.org/050-182-603-126-491,Granted Patent,no,0,0,34,34,0,C07C45/00;;C07C47/24;;C07C57/42;;C07C59/68;;C07C205/44;;C07C205/56;;C07C255/00;;C08F20/26;;C08F20/36;;G03F7/038;;G03F7/0388;;G03F7/0388;;C07C59/68;;C07C255/00;;C08F20/26;;C07C57/42;;C08F20/36;;C07C45/00;;C07C47/24;;C07C205/44;;C07C205/56;;G03F7/038,C07C45/00;;C08F2/00;;C07C47/24;;C07C57/42;;C07C57/60;;C07C59/68;;C07C205/56;;C08F2/46;;C08F2/48;;C08F8/00;;C08F8/14;;C08F20/26;;C08F20/36;;C08F220/26;;C08F290/00;;C08F299/00;;G03F7/038,,0,0,,,,EXPIRED
39,US,A,US 4989596 A,190-221-646-793-310,1991-02-05,1991,US 31112889 A,1989-02-14,US 31112889 A,1989-02-14,Face chamber,"A face chamber for use with a continuous positive airways pressure apparatus to treat a patient comprising a housing with a pressure chamber and a face receiving opening to fit over the patient's face, a seal to seal the patient's face to the housing so that the patient breathes into said pressure chamber, an inlet connector for connecting the output of the continuous positive airways pressure apparatus to the pressure chamber, and control valves for controlling the discharge of gases from the face chamber.",MACRIS ALLEN G;;KEZIOS STOTHE P;;VAUGHAN HARRY L,MACRIS ALLEN G;;KEZIOS STOTHE P;;VAUGHAN HARRY L,,https://lens.org/190-221-646-793-310,Granted Patent,yes,16,215,1,1,0,A61M16/06;;A61M16/0683;;A61M16/0633;;A61M16/0616;;A61M16/06;;A61M16/0683;;A61M16/0633;;A61M16/0616,A61M16/06,128/201.28;;128/206.24;;128/207.12;;128/206.28,0,0,,,,EXPIRED
40,CH,A5,CH 629314 A5,091-691-923-709-832,1982-04-15,1982,CH 1619976 A,1976-12-22,GB 5252275 A,1975-12-23,PHOTOPOLYMERISIERBARES MATERIAL FUER DRUCKPLATTEN.,,VICKERS LTD,GATES ALLEN PETER;;HINCH STEPHEN CHARLES;;WITHERS CHRISTOPHER VAUGHAN,,https://lens.org/091-691-923-709-832,Granted Patent,no,0,0,34,34,0,C07C45/00;;C07C47/24;;C07C57/42;;C07C59/68;;C07C205/44;;C07C205/56;;C07C255/00;;C08F20/26;;C08F20/36;;G03F7/038;;G03F7/0388;;G03F7/0388;;C07C59/68;;C07C255/00;;C08F20/26;;C07C57/42;;C08F20/36;;C07C45/00;;C07C47/24;;C07C205/44;;C07C205/56;;G03F7/038,C07C45/00;;C07C47/24;;C08F2/00;;C07C57/42;;C07C57/60;;C07C59/68;;C07C205/56;;C08F2/46;;C08F2/48;;C08F8/00;;C08F8/14;;C08F20/26;;C08F20/36;;C08F220/26;;C08F290/00;;C08F299/00;;G03F7/038,,0,0,,,,EXPIRED
41,KE,A,KE 3336 A,064-478-164-564-916,1983-11-04,1983,KE 333683 A,1983-10-05,GB 5252275 A,1975-12-23,PHOTOPOLYMERISABLE POLYMERS WITH FREE CARBOXYL GROUPS AND PRINTING PLATES THEREFROM,,VICKERS LTD,ALLEN PETER GATES;;STEPHEN CHARLES HINCH;;CHRISTOPHER VAUGHAN WITHERS,,https://lens.org/064-478-164-564-916,Granted Patent,no,0,0,34,34,0,C07C45/00;;C07C47/24;;C07C57/42;;C07C59/68;;C07C205/44;;C07C205/56;;C07C255/00;;C08F20/26;;C08F20/36;;G03F7/038;;G03F7/0388;;G03F7/0388;;C07C59/68;;C07C255/00;;C08F20/26;;C07C57/42;;C08F20/36;;C07C45/00;;C07C47/24;;C07C205/44;;C07C205/56;;G03F7/038,C07C45/00;;C07C47/24;;C07C57/42;;C07C57/60;;C07C59/68;;C07C205/56;;C08F2/00;;C08F2/46;;C08F2/48;;C08F8/00;;C08F8/14;;C08F20/26;;C08F20/36;;C08F220/26;;C08F290/00;;C08F299/00;;G03F7/038,,0,0,,,,EXPIRED
42,AU,A,AU 1976/020818 A,145-994-976-302-265,1978-06-29,1978,AU 1976/020818 A,1976-12-22,GB 5252275 A,1975-12-23,LIGHT-SENSITIVE MATERIALS,,VICKERS LTD,GATES ALLEN PETER;;HINCH STEPHEN CHARLES;;WITHERS CHRISTOPHER VAUGHAN,,https://lens.org/145-994-976-302-265,Patent Application,no,0,0,34,34,0,C07C45/00;;C07C47/24;;C07C57/42;;C07C59/68;;C07C205/44;;C07C205/56;;C07C255/00;;C08F20/26;;C08F20/36;;G03F7/038;;G03F7/0388;;G03F7/0388;;C07C59/68;;C07C255/00;;C08F20/26;;C07C57/42;;C08F20/36;;C07C45/00;;C07C47/24;;C07C205/44;;C07C205/56;;G03F7/038,C08F2/00;;C07C45/00;;C07C47/24;;C07C57/42;;C07C57/60;;C07C59/68;;C07C205/56;;C08F2/46;;C08F2/48;;C08F8/00;;C08F8/14;;C08F20/26;;C08F20/36;;C08F220/26;;C08F290/00;;C08F299/00;;G03F7/038,,0,0,,,,EXPIRED
43,FI,B,FI 64863 B,196-935-219-686-206,1983-09-30,1983,FI 763683 A,1976-12-22,GB 5252275 A,1975-12-23,FOTOPOLYMERISERBART MATERIAL EN LJUSKAENSLIG TRYCKPLAOT INNEHAOLLANDE DETSAMMA SAMT ETT FOERFARANDE FOER FRAMSTAELLNING AVRYCKPLAOTEN,,VICKERS LTD,GATES ALLEN PETER;;HINCH STEPHEN CHARLES;;WITHERS CHRISTOPHER VAUGHAN,,https://lens.org/196-935-219-686-206,Patent Application,no,0,0,34,34,0,C07C45/00;;C07C47/24;;C07C57/42;;C07C59/68;;C07C205/44;;C07C205/56;;C07C255/00;;C08F20/26;;C08F20/36;;G03F7/038;;G03F7/0388;;G03F7/0388;;C07C59/68;;C07C255/00;;C08F20/26;;C07C57/42;;C08F20/36;;C07C45/00;;C07C47/24;;C07C205/44;;C07C205/56;;G03F7/038,C07C45/00;;C07C47/24;;C08F2/00;;C07C57/42;;C07C57/60;;C07C59/68;;C07C205/56;;C08F2/46;;C08F2/48;;C08F8/00;;C08F8/14;;C08F20/26;;C08F20/36;;C08F220/26;;C08F290/00;;C08F299/00;;G03F7/038,,0,0,,,,EXPIRED
44,DE,A1,DE 2658272 A1,048-926-069-255-994,1977-07-14,1977,DE 2658272 A,1976-12-22,GB 5252275 A,1975-12-23,PHOTOPOLYMERISIERBARE MATERIALIEN,,VICKERS LTD,GATES ALLEN PETER;;HINCH STEPHEN CHARLES;;WITHERS CHRISTOPHER VAUGHAN,,https://lens.org/048-926-069-255-994,Patent Application,no,0,0,34,34,0,C07C45/00;;C07C47/24;;C07C57/42;;C07C59/68;;C07C205/44;;C07C205/56;;C07C255/00;;C08F20/26;;C08F20/36;;G03F7/038;;G03F7/0388;;G03F7/0388;;C07C59/68;;C07C255/00;;C08F20/26;;C07C57/42;;C08F20/36;;C07C45/00;;C07C47/24;;C07C205/44;;C07C205/56;;G03F7/038,C07C45/00;;C07C47/24;;C08F2/00;;C07C57/42;;C07C57/60;;C07C59/68;;C07C205/56;;C08F2/46;;C08F2/48;;C08F8/00;;C08F8/14;;C08F20/26;;C08F20/36;;C08F220/26;;C08F290/00;;C08F299/00;;G03F7/038,,0,0,,,,DISCONTINUED
45,US,A1,US 2016/0290283 A1,118-111-759-106-750,2016-10-06,2016,US 201514672938 A,2015-03-30,US 201514672938 A,2015-03-30,FLUID-POWERED THRUST REVERSER ACTUATION SYSTEM WITH ELECTROMECHANICAL SPEED CONTROL,A fluid-powered thrust reverser actuation system includes electromechanical speed control to implement multiple mid-stroke speeds. The system may also be configured to implement two different operational modes—a normal operational mode and a rejected take-off operational mode.,HONEYWELL INT INC,VAUGHAN RON;;CHAKKERA KEVIN K;;WAWRZYNEK JAMES;;FIZER LEROY ALLEN,HONEYWELL INTERNATIONAL INC (2015-03-25),https://lens.org/118-111-759-106-750,Patent Application,yes,4,4,1,1,0,F02K1/763;;F02K1/763,F02K1/76,,0,0,,,,DISCONTINUED
46,EP,A2,EP 3311449 A2,083-258-035-324-216,2018-04-25,2018,EP 16844829 A,2016-06-15,US 201562180421 P;;US 2016/0037666 W,2015-06-16,EFFICIENT PLANAR PHASED ARRAY ANTENNA ASSEMBLY,,KING ABDULAZIZ CITY SCI & TECH;;URTHECAST CORP,FOX PETER ALLEN;;BHATTACHARYA ABHIJIT;;CHEN YING;;VAUGHAN RODNEY GRANT,,https://lens.org/083-258-035-324-216,Patent Application,yes,0,1,10,10,0,H01Q21/064;;H01Q21/064;;H01Q5/42;;H01Q5/42;;H01Q13/18;;H01Q13/18;;H01Q21/005;;H01Q21/005;;H01Q21/30;;H01Q21/30,H01Q21/06;;H01Q1/24;;H01Q1/38;;H01Q15/00,,0,0,,,,ACTIVE
47,US,B2,US 8362873 B2,021-440-289-079-742,2013-01-29,2013,US 4116808 A,2008-03-03,US 4116808 A;;US 89231207 P,2007-03-01,Control of equipment using remote display,"An example display unit for facilitating operation of equipment includes a housing, an electronic display supported by the housing, and an electronic circuit located within the housing. The display unit may include one or more data receivers, such as a wireless receiver and/or an electrical interface. A biometric scanner, including a biometric sensor and proving an authorization signal when an authorized biometric input is detected by the biometric sensor, may be configured to electrically (and optionally mechanically) interconnect to the display unit. The example display unit receives an authorization status for operation of the equipment from the biometric scanner, and displays the authorization status and operational parameters relating to equipment use on the electronic display.",DEADMAN TECHNOLOGIES LLC;;MILLER BRIAN SCOTT;;VAUGHAN JACK;;LADRIERE OSCAR ALLEN;;DISIMONE GINO,MILLER BRIAN SCOTT;;VAUGHAN JACK;;LADRIERE OSCAR ALLEN;;DISIMONE GINO,DEADMAN TECHNOLOGIES LLC (2011-03-14),https://lens.org/021-440-289-079-742,Granted Patent,yes,60,4,2,4,0,G06F21/32;;G06F21/32,G05B19/00;;G05B23/00;;G06F7/00;;G06F7/04;;G06K19/00;;G08B29/00;;G08C19/00;;H04B1/00;;H04B3/00;;H04Q1/00;;H04Q9/00,340/5.52;;340/5.74;;340/5.8;;340/5.81;;340/5.82;;340/5.83;;340/3.1;;340/5.53,0,0,,,,INACTIVE
48,US,B2,US 7946483 B2,089-086-798-862-67X,2011-05-24,2011,US 4119408 A,2008-03-03,US 4119408 A;;US 89231307 P,2007-03-01,Biometric control of equipment,"An example apparatus for allowing operation of equipment by an authorized operator comprises a biometric scanner receiving a biometric input from an authorized operator, and transmitting an authorization signal. The apparatus may further includes a base station that allows the equipment to operate while the base station receives the authorization signal from the biometric scanner, and which prevents the equipment from operating shoortly after the authorization signal is no longer received from the biometric scanner.",DEADMAN TECHNOLOGIES LLC,MILLER BRIAN SCOTT;;VAUGHAN JACK;;LADRIERE OSCAR ALLEN;;DISIMONE GINO,DEADMAN TECHNOLOGIES LLC (2011-03-14),https://lens.org/089-086-798-862-67X,Granted Patent,yes,30,70,2,2,0,G07C9/37;;G07C9/37,G06K5/00,235/382,0,0,,,,INACTIVE
49,US,B2,US 10615513 B2,169-282-312-821-359,2020-04-07,2020,US 201615737065 A,2016-06-15,US 201615737065 A;;US 201562180421 P;;US 2016/0037666 W,2015-06-16,Efficient planar phased array antenna assembly,"A planar phased array antenna assembly includes a first face sheet with a first plurality of radiating slots for a first frequency band and a second plurality of radiating slots for a second frequency band, a second face sheet, a third face sheet, and a structure interposed between the first and second face sheets with a third plurality of radiating elements at the first frequency band and a fourth plurality of radiating elements at the second frequency band, and a first feed network for the third plurality of radiating elements and a second feed network for the fourth plurality of radiating elements, and the second face sheet interposed between the structure and the third face sheet. The planar phased array antenna assembly may form part of a synthetic aperture radar (SAR) antenna.",URTHECAST CORP;;KING ABDULAZIZ CITY OF SCIENCE AND TECH,FOX PETER ALLEN;;BHATTACHARYA ABHIJIT;;CHEN YING;;VAUGHAN RODNEY GRANT,SPACEALPHA INSIGHTS CORP (2021-02-23);;URTHECAST CORP (2017-12-07),https://lens.org/169-282-312-821-359,Granted Patent,yes,436,0,10,10,0,H01Q21/064;;H01Q21/064;;H01Q5/42;;H01Q5/42;;H01Q13/18;;H01Q13/18;;H01Q21/005;;H01Q21/005;;H01Q21/30;;H01Q21/30,H01Q13/10;;H01Q5/42;;H01Q13/18;;H01Q21/00;;H01Q21/06;;H01Q21/30,,131,40,075-884-802-969-452;;079-364-391-675-332;;035-425-898-589-791;;025-678-520-375-794;;030-433-249-025-468;;137-311-905-827-384;;043-615-516-560-377;;045-500-847-494-637;;026-939-845-853-642;;044-493-139-004-01X;;025-886-343-061-28X;;082-363-395-459-833;;085-225-432-239-279;;106-019-752-936-412;;092-314-569-272-705;;023-615-222-037-446;;099-972-770-137-23X;;091-176-727-820-158;;069-989-565-170-009;;034-189-318-810-480;;014-270-319-439-735;;076-625-449-463-484;;109-708-430-449-200;;023-013-166-096-936;;123-400-844-073-975;;027-654-788-635-557;;093-950-207-462-011;;053-912-659-259-702;;091-852-266-406-19X;;041-056-856-347-985;;088-262-502-533-185;;127-043-325-019-558;;062-839-943-509-658;;003-868-017-931-158;;129-750-250-803-828;;157-993-025-907-374;;057-121-529-703-742;;117-970-008-560-716;;059-856-300-614-039;;030-645-835-220-869,10.1109/radar.2008.4720789;;10.1109/iccce.2010.5556867;;10.1109/36.823926;;10.1109/tgrs.2004.830163;;10.1049/ip-f-2.1993.0033;;10.5772/56943;;10.1049/ip-rsn:20045122;;10.1109/tgrs.2008.2003002;;10.1109/tgrs.2007.895883;;10.1109/radar.2006.1631873;;10.1109/jrproc.1953.274491;;10.7716/aem.v1i1.12;;10.1002/9781118116104;;10.1117/12.511500;;10.1109/tgrs.2003.815399;;10.1109/tgrs.2014.2322813;;10.1109/jstars.2014.2317287;;10.5194/isprsarchives-xl-7-w3-1069-2015;;10.1109/proc.1965.4097;;10.17140/sroj-2-108;;10.1109/igarss.2011.6050222;;10.1109/tce.1958.6372696;;10.5194/isprsarchives-xl-2-w3-25-2014;;10.3390/rs6076472;;10.1109/36.898660;;10.1155/2015/182080;;10.3390/rs70302952;;10.1109/tgrs.2009.2028692;;10.1109/igarss.2015.7325733;;10.1109/tgrs.2007.905974;;10.1364/isa.2012.itu1c.5;;10.1109/icip.2010.5653982;;10.1109/iccv.2013.252;;10.1007/s10236-011-0460-1;;10.1109/igarss.2011.6049352;;10.1175/ei117.1;;10.1109/icip.2014.7025433;;10.1117/1.jei.22.1.011003;;10.1109/36.406668;;10.2991/icmmcce-15.2015.246,"Partial Supplementary Search Report issued in European Application No. 15829734.1, dated Dec. 21, 2017, 16 pages.;;Preliminary Amendment filed in Application No. PCT/US2015/043739, dated Feb. 7, 2017, 12 pages.;;International Search Report and Written Opinion issued in PCT Application No. PCT/US2015/043739, dated Nov. 11, 2015, 12 pages.;;Preliminary Amendment filed in U.S. Appl. No. 15/561,437, dated Sep. 25, 2017, 11 pages.;;International Search Report and Written Opinion issued in PCT Application No. PCT/US2016/022841, dated Jun. 3, 2016, 10 pages.;;Preliminary Amendment filed in U.S. Appl. No. 15/737,065, dated Dec. 15, 2017, 8 pages.;;European Communication issued in European Application No. 14883549.9, dated Nov. 24, 2017, 8 pages.;;Preliminary Amendment filed in U.S. Appl. No. 15/737,016, dated Dec. 15, 2017, 8 pages.;;International Search Report and Written Opinion issued in PCT Application No. PCT/US2016/037675, dated Feb. 16, 10 pages.;;International Search Report and Written Opinion issued in PCT Application No. PCT/US2016/063630, dated Feb. 13, 2017, 8 pages.;;Analog Devices, MT-085 Tutorial, “Fundamentals of Direct Digital Synthesis (DDS)”, 2008, pp. 1-9.;;Bordoni, Federica, et al.: “Calibration Error Model for Multichannel Spacebome SAR Systems Based on Digital Beamforming”, Proceedings of the 10th European Radar Conference, Oct. 9-11, 2013, pp. 184-187.;;D'Aria, D., et al.: “A Wide Swath, Full Polarimetric, L band spaceborne SAR”, IEEE, 2008, 4 pages.;;El Sanhoury, Ahmed, et al: “Performance Improvement of Pulsed OFDM UWB Systems Using ATF coding”, ICCCE, May 11-13, 2010, IEEE, 4 pages.;;Freeman: IEEE Transactions on Geoscience and Remote Sensing, vol. 38, No. 1, Jan. 1, 2000, pp. 320-324.;;Freeman, Anthony, et al.: On the Detection of Faraday Rotation in Linearly Polarized L-Band SAR Backscatter Signatures, IEEE Transactions on Geoscience and Remote Sensing, vol. 42, No. 8, Aug. 2004, pp. 1607-1616.;;Giuli, D., et al.: “Radar target scattering matrix measurement through orthogonal signals” IEE Proceedings—F, vol. 140, No. 4, Part F, Aug. 1993, pp. 233-242.;;Hossain, MD Anowar, et al.: “Multi-Frequency Image Fusion Based on MIMO UWB OFDM Synthetic Aperture Radar”, New Advances in Image Fusion, INTECH Open Science/Open Minds, 2013, 21 pages.;;Kankaku, Y., et al.: “The Overview of the L-band SAR Onboard ALOS-2”, Progress in Electromagnetics Research Symposium Proceedings, Moscow, Russia, Aug. 18-21, 2009, pp. 735-738.;;Lombardo, P., et al.: “Monitoring and surveillance potentialities obtained by splitting the antenna of the COSMO-SkyMed SAR into multiple sub-apertures”, The Institution of Engineering and Technology, IEE Proceedings, Apr. 2006, pp. 104-116.;;Meyer, Franz J., et al: “Prediction, Detection, and Correction of Faraday Rotation in Full-Polarimetric L-Band SAR Data”, IEEE Transactions on Geoscience and Remote Sensing, vol. 46, No. 10, Oct. 2008, pp. 3076-3086.;;Raney, Keith R: “Hybrid-Polarity SAR Architecture”, IEEE Transactions on Geoscience and Remote Sensing, vol. 45, No. 11, Nov. 2007, pp. 3397-3404.;;Rouse, Shane, et al.: “Swathbuckler Wide Area SAR Processing Front End”, IEEE 2006, pp. 673-678.;;Rudolf, Hans: “Increase of Information by Polarimetric Radar Systems”, Doctoral Dissertation, 2000, 5 pages.;;Sakiotis, N.G., et al.: Proceedings of the I.R.E., 1953, pp. 87-93.;;Souissi, B., et al.: “Investigation of the capabaility of the Compact Polarimetry mode to Reconstruct Full Polarimetry mode using RADARSAT2 data”, Advanced Electromagnetics, Vo. 1, No. 1, May 2012, 10 pages.;;Space Dynamics Laboratory, “RASAR”, 2013, 2 pages.;;Van Zyl, Jakob, et al.: “Synthetic Aperture Radar Polarimetry”, JPL Space Science and Technology Series, 2010, 333 pages.;;Werninghaus, Rolf, et al.: “The TerraSAR-X Mission”, 2004, 4 pages.;;Wolff: “Radar Basics—Exciter”, Radartutorial.eu, http://www.radartutorial.eu/08.transmitters/Exciter.en.html, downloaded Mar. 6, 2018, 2 pages.;;Wright, P.A., et al.: “Faraday Rotation Effects on L-Band Spaceborne SAR Data”, IEEE Transactions on Geoscience and Remote Sensing, vol. 41, No. 12, December 2003, pp. 2735-2744.;;Zhang, T., et al.: “OFDM Synthetic Aperture Radar Imaging With Sufficient Cyclic Prefix”, IEEE Transactions on Geoscience and Remote Sensing, vol. 53, No. 1, Jan. 2015, pp. 394-404.;;International Search Report and Written Opinion for PCT Patent Application No. PCT/US2016/037666, dated Mar. 27, 2017, 8 Pages.;;International Search Report and Written Opinion issued in PCT Application No. PCT/US2016/037666, dated Mar. 27, 2017, 8 pages.;;International Preliminary Report on Patentability issued in PCT Application No. PCT/US2016/037666, dated Dec. 28, 2017, 7 pages.;;International Preliminary Report on Patentability issued in PCT Application No. PCT/US2016/037675, dated Dec. 28, 2017, 9 pages.;;International Search Report and Written Opinion issued in PCT Application No. PCT/US2016/037681, dated Sep. 23, 2016, 10 pages.;;International Preliminary Report on Patentability issued in PCT Application No. PCT/US2016/037681, dated Dec. 28, 2017, 7 pages.;;Extended European Search Report issued in European Application No. 16844829.8, dated Apr. 25, 2018, 9 pages.;;Supplementary Partial Search Report issued in European Application No. 16846990.6, dated May 18, 2018, 16 pages.;;Extended European Search Report issued in European Application No. 16812363.6, dated May 14, 2018, 8 pages.;;W.J. LARSON & J.R. WERTZ (EDS.): ""Orbit Maintenance"", SPACE MISSION ANALYSIS AND DESIGN, XX, XX, 1 January 1997 (1997-01-01), XX, pages 153 - 154+177, XP002214373;;“Envi Tutorials,” Sep. 1, 2000, URL:http://heim.ifi.uio.no/″inf160/tutorial.pdf (XP055472060), 590 pages.;;International Preliminary Report on Patentability issued in PCT Application No. PCT/US2016/022841, dated Oct. 5, 2017, 8 pages.;;Extended European Search Report issued in European Application No. 16846990.6, dated Aug. 16, 2018, 16 pages.;;CALTAGIRONE FRANCESCO; CAPUZI A.; COLETTA ALESSANDRO; DE LUCA GIUSEPPE F.; SCORZAFAVA EDMONDO; LEONARDI R.; RIVOLA STEFANO; FAGIOL: ""The COSMO-SkyMed Dual Use Earth Observation Program: Development, Qualification, and Results of the Commissioning of the Overall Constellation"", IEEE JOURNAL OF SELECTED TOPICS IN APPLIED EARTH OBSERVATIONS AND REMOTE SENSING, IEEE, USA, vol. 7, no. 7, 1 July 2014 (2014-07-01), USA, pages 2754 - 2762, XP011557179, ISSN: 1939-1404, DOI: 10.1109/JSTARS.2014.2317287;;“ISR Systems and Technology,” Lincoln Laboratory, Massachusetts Institute of Technology, archived Jan. 19, 2017, URL=https://www.ll.mit.edu/mission/isr/israccomplishments.html, download date Oct. 8, 2018, 2 pages.;;“Northrop's SABR radar completes auto target cueing capability demonstration,” May 20, 2013, URL=https://www.airforce-technology.com/news/newsnorthrops-sabr-radar-completes-auto-target-cueing-capability-demonstration/, download date Oct. 8, 2018, 3 pages.;;Amendment, filed Jan. 17, 2019, for U.S. Appl. No. 15/101,336, Lopez et al., “Systems and Methods for Earth Observation,” 25 pages.;;Amendment, filed Sep. 5, 2018, for U.S. Appl. No. 15/316,469, Maciejewski et al., “Systems and Methods for Processing and Providing Terrestrial and/or Space-Based Earth Observation Video,” 9 pages.;;Beckett et al., “Systems and Methods for Enhancing Synthetic Aperture Radar Imagery,” U.S. Appl. No. 62/180,449, filed Jun. 16, 2015, 34 pages.;;Beckett, “UrtheCast Second-Generation Earth Observation Sensors,” 36th International Symposium on Remote Sensing of Environment, Berlin, Germany, May 11-15, 2015, pp. 1069-1073.;;Bickel et al., “Effects of Magneto-Ionic Propagation on the Polarization Scattering Matrix,” Proceedings of the IEEE 53(8):1089-1091, 1965.;;Bidigare, “MIMO Capacity of Radar as a Communications Channel,” Adaptive Sensor and Array Processing Workshop, Lexington, Massachusetts, USA, Mar. 11-13, 2003, 19 pages.;;Boccia, “Bathymetric Digital Elevation Model Generation from L-band and X-band Synthetic Aperture Radar Images in the Gulf of Naples, Italy: Innovative Techniques and Experimental Results,” doctoral thesis, University of Naples Federico II, Naples, Italy, 2015, 161 pages.;;Bordoni et al., “Ambiguity Suppression by Azimuth Phase Coding in Multichannel SAR Systems,” International Geoscience and Remote Sensing Symposium, Vancouver, Canada, Jul. 24-29, 2011, 16 pages.;;Brysk, “Measurement of the Scattering Matrix with an Intervening Ionosphere,” Transactions of the American Institute of Electrical Engineers 77(5):611-612, 1958.;;Di Iorio et al., “Innovation Technologies and Applications for Coastal Archaeological sites FP7—ITACA,” 36th International Symposium on Remote Sensing of Environment, Berlin, Germany, May 11-15, 2015, pp. 1367-1373.;;Evans, “Venus, Unmasked: 25 Years Since the Arrival of Magellan at Earth's Evil Twin,” Aug. 10, 2015, URL=http://www.americaspace.com/2015/08/10/venus-unmasked-25-years-since-the-arrival-of-magellan-at-earths-evil-twin/, download date Oct. 8, 2018, 4 pages.;;Extended European Search Report, dated Mar. 27, 2018, for European Application No. 15829734.1-1206, 18 pages.;;Extended European Search Report, dated Oct. 24, 2016, for European Application No. 14880012.1-1951, 10 pages.;;Extended European Search Report, dated Oct. 24, 2016, for European Application No. 14883549.9-1951, 10 pages.;;Fard et al., “Classifier Fusion of High-Resolution Optical and Synthetic Aperture Radar (SAR) Satellite Imagery for Classification in Urban Area,” 1st International Conference on Geospatial Information Research, Tehran, Iran, Nov. 15-17, 2014, 5 pages.;;Forkuor et al., “Integration of Optical and Synthetic Aperture Radar Imagery for Improving Crop Mapping in Northwestern Benin, West Africa,” Remote Sensing 6(7):6472-6499, 2014.;;Fox et al., “Apparatus and Methods for a Synthetic Aperture Radar With Multi-Aperture Antenna,” U.S. Appl. No. 62/510,182, filed May 23, 2017, 42 pages.;;Fox et al., “Apparatus and Methods for a Synthetic Aperture Radar With Self-Cueing,” U.S. Appl. No. 62/510,132, filed May 23, 2017, 39 pages.;;Fox et al., “Range Ambiguity Suppression in Digital Multibeam,” U.S. Appl. No. 62/590,153, filed Nov. 22, 2017, 19 pages.;;Fox et al., “Synthetic Aperture Radar Imaging Apparatus and Methods for Moving Targets,” U.S. Appl. No. 62/510,191, filed May 23, 2017, 24 pages.;;Fox, “Apparatus and Methods for Quad-Polarized Synthetic Aperture Radar,” U.S. Appl. No. 62/035,279, filed Aug. 8, 2014, 52 pages.;;Fox, “Apparatus and Methods for Synthetic Aperture Radar With Digital Beamforming,” U.S. Appl. No. 62/137,934, filed Mar. 25, 2015, 45 pages.;;Fox, “Synthetic Aperture Radar Imaging Apparatus and Methods,” U.S. Appl. No. 62/260,063, filed Nov. 25, 2015, 41 pages.;;Fox, “Synthetic Aperture Radar Imaging Apparatus and Methods,” U.S. Appl. No. 62/510,123, filed May 23, 2017, 74 pages.;;Hadjis, “Automatic Modulation Classification of Common Communication and Pulse Compression Radar Waveforms Using Cyclic Features,” master's thesis, Air Force Institute of Technology, Wright-Patterson Air Force Base, Ohio, USA, Mar. 2013, 96 pages.;;Heege et al., “Mapping of water depth, turbidity and sea state properties using multiple satellite sensors in aquatic systems,” Hydro 2010, Rostock, Germany, Nov. 2-5, 2010, 27 pages.;;Hoogeboom et al., “Integrated Observation Networks of the Future,” 4th Forum on Global Monitoring for Environment and Security, Baveno, Italy, Nov. 26-28, 2003, 14 pages.;;Hounam et al., “A Technique for the Identification and Localization of SAR Targets Using Encoding Transponders,” IEEE Transactions on Geoscience and Remote Sensing 39(1):3-7, 2001.;;Huang et al., “Analog Beamforming and Digital Beamforming on Receive for Range Ambiguity Suppression in Spaceborne SAR,” International Journal of Antennas and Propagation 2015:182080, 2015. (7 pages).;;Huang et al., “ASTC-MIMO-TOPS Mode with Digital Beam-Forming in Elevation for High-Resolution Wide-Swath Imaging,” Remote Sensing 7(3):2952-2970, 2015.;;International Preliminary Report on Patentability, dated Dec. 15, 2016, for International Application No. PCT/US2015/035628, 8 pages.;;International Preliminary Report on Patentability, dated Feb. 14, 2017, for International Application No. PCT/US2015/043739, 10 pages.;;International Preliminary Report on Patentability, dated Jun. 7, 2016, for International Application No. PCT/US2014/068642, 10 pages.;;International Preliminary Report on Patentability, dated Jun. 7, 2016, for International Application No. PCT/US2014/068645, 14 pages.;;International Preliminary Report on Patentability, dated May 29, 2018, for International Application No. PCT/US2016/063630, 6 pages.;;International Search Report and Written Opinion, dated Aug. 27, 2015, for International Application No. PCT/US2014/068642, 13 pages.;;International Search Report and Written Opinion, dated Sep. 13, 2018, for International Application No. PCT/US2018/033970, 15 pages.;;International Search Report and Written Opinion, dated Sep. 13, 2018, for International Application No. PCT/US2018/033971, 13 pages.;;International Search Report and Written Opinion, dated Sep. 13, 2018, for International Application No. PCT/US2018/034144, 11 pages.;;International Search Report and Written Opinion, dated Sep. 13, 2018, for International Application No. PCT/US2018/034146, 8 pages.;;International Search Report and Written Opinion, dated Sep. 2, 2015, for International Application No. PCT/US2014/068645, 16 pages.;;International Search Report and Written Opinion, dated Sep. 21, 2015, for International Application No. PCT/US2015/035628, 10 pages.;;Kimura, “Calibration of Polarimetric PALSAR Imagery Affected by Faraday Rotation Using Polarization Orientation,” IEEE Transactions on Geoscience and Remote Sensing 47(12):3943-3950, 2009.;;Krieger et al., “CEBRAS: Cross Elevation Beam Range Ambiguity Suppression for High-Resolution Wide-Swath and MIMO-SAR Imaging,” International Geoscience and Remote Sensing Symposium, Milan, Italy, Jul. 26-31, 2015, pp. 196-199.;;Krieger et al., “Multidimensional Waveform Encoding: A New Digital Beamforming Technique for Synthetic Aperture Radar Remote Sensing,” IEEE Transactions on Geoscience and Remote Sensing 46(1):31-46, 2008.;;Linne von Berg, “Autonomous Networked Multi-Sensor Imaging Systems,” Imaging Systems and Applications, Monterey, California, USA, Jun. 24-28, 2012, 2 pages.;;Linne von Berg, “Multi-Sensor Airborne Imagery Collection and Processing Onboard Small Unmanned Systems,” Proceedings of SPIE 7668(1):766807, 2010. (11 pages).;;Livingstone et al., “RADARSAT-2 System and Mode Description,” Systems Concepts and Integration Symposium, Colorado Springs, Colorado, USA, Oct. 10-12, 2005, 22 pages.;;Lopez et al., “Systems and Methods for Earth Observation,” U.S. Appl. No. 61/911,914, filed Dec. 4, 2013, 177 pages.;;Ma, “Application of RADARSAT-2 Polarimetric Data for Land Use and Land Cover Classification and Crop Monitoring in Southwestern Ontario,” master's thesis, The University of Western Ontario, Canada, 2013, 145 pages.;;Maciejewski et al., “Systems and Methods for Processing and Providing Video,” U.S. Appl. No. 62/011,935, filed Jun. 13, 2014, 52 pages.;;Makar et al., “Real-Time Video Streaming With Interactive Region-of-Interest,” Proceedings of 2010 IEEE 17thInternational Conference on Image Processing, Hong Kong, China, Sep. 26-29, 2010, pp. 4437-4440.;;Meilland et al., “A Unified Rolling Shutter and Motion Blur Model for 3D Visual Registration,” IEEE International Conference on Computer Vision, Sydney, Australia, Dec. 1-8, 2013, pp. 2016-2023.;;National Instruments, “Direct Digital Synthesis,” white paper, Dec. 30, 2016, 5 pages.;;Notice of Allowance, dated Mar. 9, 2017, for U.S. Appl. No. 15/101,344, Beckett et al., “Systems and Methods for Processing and Distributing Earth Observation Images,” 9 pages.;;Notice of Allowance, dated Oct. 18, 2018, for U.S. Appl. No. 15/316,469, Maciejewski et al., “Systems and Methods for Processing and Providing Terrestrial and/or Space-Based Earth Observation Video,” 8 pages.;;Office Action, dated Apr. 23, 2018, for U.S. Application No. 15/316,469, Maciejewski et al., “Systems and Methods for Processing and Providing Terrestrial and/or Space-Based Earth Observation Video,” 21 pages.;;Office Action, dated Aug. 6, 2018, for U.S. Appl. No. 15/101,336, Lopez et al., “Systems and Methods for Earth Observation,” 25 pages.;;Office Action, dated Feb. 11, 2019, for U.S. Appl. No. 15/502,468, Fox, “Apparatus and Methods for Quad-Polarized Synthetic Aperture Radar,” 42 pages.;;Pleskachevsky et al., “Synergy and fusion of optical and synthetic aperture radar satellite data for underwater topography estimation in coastal areas,” Ocean Dynamics 61(12):2099-2120, 2011.;;Preliminary Amendment, filed Dec. 15, 2017, for U.S. Appl. No. 15/737,044, Beckett et al., “Systems and Methods for Enhancing Synthetic Aperture Radar Imagery,” 10 pages.;;Preliminary Amendment, filed Dec. 5, 2016, for U.S. Appl. No. 15/316,469, Maciejewski et al., “Systems and Methods for Processing and Providing Terrestrial and/or Space-Based Earth Observation Video,” 9 pages.;;Preliminary Amendment, filed Jun. 2, 2016, for U.S. Appl. No. 15/101,336, Lopez et al., “Systems and Methods for Earth Observation,” 9 pages.;;Preliminary Amendment, filed Jun. 2, 2016, for U.S. Appl. No. 15/101,344, Beckett et al., “Systems and Methods for Processing and Distributing Earth Observation Images,” 11 pages.;;Preliminary Amendment, filed May 22, 2018, for U.S. Application No. 15/778,188, Fox, “Synthetic Aperture Radar Imaging Apparatus and Methods,” 9 pages.;;Raouf et al., “Integrated Use of SAR and Optical Data for Coastal Zone Management,” Proceedings of the 3rdEuropean Remote Sensing Symposium vol. 2, Florence, Italy, Mar. 14-21, 1997, pp. 1089-1094.;;Richardson, “By the Doppler's sharp stare,” Oct. 1, 2003, Armada International, URL=https://www.thefreelibrary.com/_/print/PrintArticle.aspx?id=111508265, download date Oct. 8, 2018, 7 pages.;;Rosen et al., “Techniques and Tools for Estimating Ionospheric Effects in Interferometric and Polarimetric SAR Data,” International Geoscience and Remote Sensing Symposium, Vancouver, British Columbia, Canada, Jul. 24-29, 2011, pp. 1501-1504.;;Rossler, “Adaptive Radar with Application to Joint Communication and Synthetic Aperture Radar (CoSAR),” doctoral dissertation, The Ohio State University, Columbus, Ohio, USA, 2013, 117 pages.;;Sano et al., “Synthetic Aperture Radar (L band) and Optical Vegetation Indices for Discriminating the Brazilian Savanna Physiognomies: A Comparative Analysis,” Earth Interactions 9( 15):15, 2005. (15 pages).;;{hacek over (S)}indelá{hacek over (r)} et al., “A Smartphone Application for Removing Handshake Blur and Compensating Rolling Shutter,” IEEE International Conference on Image Processing, Paris, France, Oct. 27-30, 2014, pp. 2160-2162.;;{hacek over (S)}indelá{hacek over (r)} et al., “Image deblurring in smartphone devices using built-in inertial measurement sensors,” Journal of Electronic Imaging 22(1):011003, 2013. (22 pages).;;Stofan et al., “Overview of Results of Spaceborne Imaging Radar-C, X-B and Synthetic Aperture Radar (SIR-C/X-SAR),” IEEE Transactions on Geoscience and Remote Sensing 33(4):817-828, 1995.;;Stralka, “Applications of Orthogonal Frequency-Division Multiplexing (OFDM) to Radar,” doctoral dissertaion, Johns Hopkins University, Baltimore, Maryland, USA, Mar. 2008, 196 pages.;;Tyc, “Systems and Methods for Remote Sensing of the Earth From Space,” U.S. Appl. No. 62/180,440, filed Jun. 16, 2015, 29 pages.;;Wall et al., “User Guide to the Magellan Synthetic Aperture Radar Images,” Jet Propulsion Laboratory, Pasadena, California, USA, Mar. 1995, 210 pages.;;Wu et al., “Simultaneous transmit and receive polarimetric synthetic aperture radar based on digital beamforming,” 4th International Conference on Mechatronics, Materials, Chemistry and Computer Engineering, Xi'an, China, Dec. 12-13, 2015, pp. 1283-1288.;;Xia et al., “Classification of High Resolution Optical and SAR Fusion Image Using Fuzzy Knowledge and Object-Oriented Paradigm,” Geographic Object-Based Image Analysis vol. XXXVIII-4/C7, Ghent, Belgium, Jun. 29-Jul. 2, 2010, 5 pages.;;Office Action, dated Oct. 4, 2019, for U.S. Appl. No. 15/737,044, Keith Dennis Richard Beckett et al., “System and Methods for Enhancing Synthetic Aperture Radar Imagery,” 14 pages.;;Office Action, dated Oct. 18, 2019, for U.S. Appl. No. 15/737,016, George Tyc, “Systems and Methods for Remote Sensing of the Earth From Space,” 18 pages.;;Foody, Gile M., “Status of Land Cover Classification Accuracy Assessment”, University of Southampton, Jul. 21, 2001 (Year: 2001), 17 pages.;;U.S. Office Action received in related U.S. Appl. No. 15/561,437 dated Jan. 27, 2020.;;China Office Action from related matter CN 201680045476.4 dated Jan. 6, 2020.",ACTIVE
50,EP,B1,EP 3311449 B1,048-438-381-381-562,2019-12-11,2019,EP 16844829 A,2016-06-15,US 201562180421 P;;US 2016/0037666 W,2015-06-16,EFFICIENT PLANAR PHASED ARRAY ANTENNA ASSEMBLY,,KING ABDULAZIZ CITY SCI & TECH;;URTHECAST CORP,FOX PETER ALLEN;;BHATTACHARYA ABHIJIT;;CHEN YING;;VAUGHAN RODNEY GRANT,,https://lens.org/048-438-381-381-562,Granted Patent,yes,9,0,10,10,0,H01Q21/30;;H01Q5/42;;H01Q13/18;;H01Q21/005;;H01Q21/064;;H01Q21/30;;H01Q5/42;;H01Q13/18;;H01Q21/005;;H01Q21/064,H01Q21/06;;H01Q1/24;;H01Q5/42;;H01Q13/18;;H01Q21/00;;H01Q21/30,,0,0,,,,ACTIVE
51,US,A1,US 2018/0366837 A1,111-750-125-361-393,2018-12-20,2018,US 201615737065 A,2016-06-15,US 201615737065 A;;US 201562180421 P;;US 2016/0037666 W,2015-06-16,EFFICIENT PLANAR PHASED ARRAY ANTENNA ASSEMBLY,"A planar phased array antenna assembly includes a first face sheet with a first plurality of radiating slots for a first frequency band and a second plurality of radiating slots for a second frequency band, a second face sheet, a third face sheet, and a structure interposed between the first and second face sheets with a third plurality of radiating elements at the first frequency band and a fourth plurality of radiating elements at the second frequency band, and a first feed network for the third plurality of radiating elements and a second feed network for the fourth plurality of radiating elements, and the second face sheet interposed between the structure and the third face sheet. The planar phased array antenna assembly may form part of a synthetic aperture radar (SAR) antenna.",URTHECAST CORP;;KING ABDULAZIZ CITY OF SCIENCE AND TECH,FOX PETER ALLEN;;BHATTACHARYA ABHIJIT;;CHEN YING;;VAUGHAN RODNEY GRANT,SPACEALPHA INSIGHTS CORP (2021-02-23);;URTHECAST CORP (2017-12-07),https://lens.org/111-750-125-361-393,Patent Application,yes,0,8,10,10,0,H01Q21/064;;H01Q21/064;;H01Q5/42;;H01Q5/42;;H01Q13/18;;H01Q13/18;;H01Q21/005;;H01Q21/005;;H01Q21/30;;H01Q21/30,H01Q21/06;;H01Q5/42;;H01Q13/18;;H01Q21/00;;H01Q21/30,,0,0,,,,ACTIVE
52,EP,A4,EP 3311449 A4,029-038-913-653-214,2018-05-23,2018,EP 16844829 A,2016-06-15,US 201562180421 P;;US 2016/0037666 W,2015-06-16,EFFICIENT PLANAR PHASED ARRAY ANTENNA ASSEMBLY,,KING ABDULAZIZ CITY SCI & TECH;;URTHECAST CORP,FOX PETER ALLEN;;BHATTACHARYA ABHIJIT;;CHEN YING;;VAUGHAN RODNEY GRANT,,https://lens.org/029-038-913-653-214,Search Report,no,4,2,10,10,0,H01Q21/064;;H01Q21/064;;H01Q5/42;;H01Q5/42;;H01Q13/18;;H01Q13/18;;H01Q21/005;;H01Q21/005;;H01Q21/30;;H01Q21/30,H01Q21/06;;H01Q1/24;;H01Q5/42;;H01Q13/18;;H01Q21/00;;H01Q21/30,,0,0,,,,ACTIVE
53,CA,A1,CA 2990063 A1,179-236-856-099-582,2017-03-16,2017,CA 2990063 A,2016-06-15,US 201562180421 P;;US 2016/0037666 W,2015-06-16,EFFICIENT PLANAR PHASED ARRAY ANTENNA ASSEMBLY,"A planar phased array antenna assembly includes a first face sheet with a first plurality of radiating slots for a first frequency band and a second plurality of radiating slots for a second frequency band, a second face sheet, a third face sheet, and a structure interposed between the first and second face sheets with a third plurality of radiating elements at the first frequency band and a fourth plurality of radiating elements at the second frequency band, and a first feed network for the third plurality of radiating elements and a second feed network for the fourth plurality of radiating elements, and the second face sheet interposed between the structure and the third face sheet. The planar phased array antenna assembly may form part of a synthetic aperture radar (SAR) antenna.",KING ABDULAZIZ CITY OF SCIENCE AND TECH;;URTHECAST CORP,FOX PETER ALLEN;;BHATTACHARYA ABHIJIT;;CHEN YING;;VAUGHAN RODNEY GRANT,,https://lens.org/179-236-856-099-582,Patent Application,no,0,0,10,10,0,H01Q21/30;;H01Q5/42;;H01Q13/18;;H01Q21/005;;H01Q21/064;;H01Q21/30;;H01Q5/42;;H01Q13/18;;H01Q21/005;;H01Q21/064,H01Q21/06;;H01Q1/24;;H01Q1/38;;H01Q15/00,,0,0,,,,PENDING
54,US,B2,US 8674804 B2,181-516-670-907-068,2014-03-18,2014,US 201313753094 A,2013-01-29,US 201313753094 A;;US 4116808 A;;US 89231207 P,2007-03-01,Control of equipment using remote display,"A wireless deadman system for controlling operation of equipment from a portable device includes a base station with an equipment control system, the base station wirelessly transmitting operational parameters for the equipment. A portable display unit has a housing, an electronic display, an electronic circuit, and a data receiver. A portable authorization device includes a liveness sensor and transmits an authorization signal when the sensor detects a liveness input. The display unit receives an authorization status for operation of the equipment from the portable authorization device and receives the operational parameters from the base station, the display displaying the authorization status and the operational parameters of the equipment on the electronic display. The equipment control system allows the equipment to operate when the authorization signal is provided and prevents the equipment from operating after the authorization signal is no longer provided.",DEADMAN TECHNOLOGIES LLC,MILLER BRIAN SCOTT;;VAUGHAN JACK;;LADRIERE OSCAR ALLEN;;DISIMONE GINO,DEADMAN TECHNOLOGIES LLC (2013-01-23),https://lens.org/181-516-670-907-068,Granted Patent,yes,60,10,2,4,0,G06F21/32;;G06F2221/2139;;H04L63/0853;;H04L63/0861;;H04W12/065;;H04W12/082;;G06V40/45;;G05B1/00;;G06F21/32;;G06F2221/2139;;H04L63/0853;;H04L63/0861;;H04W12/065;;H04W12/082;;G06V40/45,G05B19/00,340/5.52;;340/5.74;;340/5.8;;340/5.81;;340/5.82;;340/5.83;;340/3.1;;340/906;;235/462.01;;235/380;;235/449;;382/115;;382/124;;382/126;;382/181,0,0,,,,INACTIVE
55,US,A1,US 2013/0200997 A1,019-503-721-703-721,2013-08-08,2013,US 201313753094 A,2013-01-29,US 201313753094 A;;US 4116808 A;;US 89231207 P,2007-03-01,CONTROL OF EQUIPMENT USING REMOTE DISPLAY,"A wireless deadman system for controlling operation of equipment from a portable device includes a base station with an equipment control system, the base station wirelessly transmitting operational parameters for the equipment. A portable display unit has a housing, an electronic display, an electronic circuit, and a data receiver. A portable authorization device includes a liveness sensor and transmits an authorization signal when the sensor detects a liveness input. The display unit receives an authorization status for operation of the equipment from the portable authorization device and receives the operational parameters from the base station, the display displaying the authorization status and the operational parameters of the equipment on the electronic display. The equipment control system allows the equipment to operate when the authorization signal is provided and prevents the equipment from operating after the authorization signal is no longer provided.",DEADMAN TECHNOLOGIES LLC;;DEADMAN TECHNOLOGIES LLC,MILLER BRIAN SCOTT;;LADRIERE OSCAR ALLEN;;VAUGHAN JACK;;DISIMONE GINO,DEADMAN TECHNOLOGIES LLC (2013-01-23),https://lens.org/019-503-721-703-721,Patent Application,yes,34,38,2,4,0,G06F21/32;;G06F2221/2139;;H04L63/0853;;H04L63/0861;;H04W12/065;;H04W12/082;;G06V40/45;;G05B1/00;;G06F21/32;;G06F2221/2139;;H04L63/0853;;H04L63/0861;;H04W12/065;;H04W12/082;;G06V40/45,G05B1/00,340/5.52,0,0,,,,INACTIVE
56,CN,A,CN 108432049 A,153-425-523-732-73X,2018-08-21,2018,CN 201680045476 A,2016-06-15,US 201562180421 P;;US 2016/0037666 W,2015-06-16,EFFICIENT PLANAR PHASED ARRAY ANTENNA ASSEMBLY,"A planar phased array antenna assembly includes a first face sheet with a first plurality of radiating slots for a first frequency band and a second plurality of radiating slots for a second frequencyband, a second face sheet, a third face sheet, and a structure interposed between the first and second face sheets with a third plurality of radiating elements at the first frequency band and a fourth plurality of radiating elements at the second frequency band, and a first feed network for the third plurality of radiating elements and a second feed network for the fourth plurality of radiating elements, and the second face sheet interposed between the structure and the third face sheet. The planar phased array antenna assembly may form part of a synthetic aperture radar (SAR) antenna.",KING ABDULAZIZ CITY OF SCIENCE AND TECH;;URTHECAST CORP,FOX PETER ALLEN;;BHATTACHARYA ABHIJIT;;CHEN YING;;VAUGHAN RODNEY GRANT,,https://lens.org/153-425-523-732-73X,Patent Application,no,41,6,10,10,0,H01Q21/064;;H01Q21/064;;H01Q5/42;;H01Q5/42;;H01Q13/18;;H01Q13/18;;H01Q21/005;;H01Q21/005;;H01Q21/30;;H01Q21/30,H01Q21/06;;H01Q1/24;;H01Q1/38;;H01Q15/00,,0,0,,,,ACTIVE
57,GB,A,GB 941056 A,087-149-443-078-539,1963-11-06,1963,GB 413861 A,1961-02-03,GB 413861 A,1961-02-03,Heavy duty electrically insulated flooring,"941,056. Laminates. H. H. ROBERTSON (HOLDINGS) Ltd. May 2, 1962 [Feb. 3, 1961], No. 4138/61. Heading B5N. [Also in Division E1] Rectangular floor units 12, supported on pedestals 11, each comprise a metal frame 12a and a core of laminated birch 12b bonded on to a metal sheet 12c and covered with a layer of synthetic resin or vinyl tiling 12e.",H H ROBERTSON HOLDINGS LTD,ALLEN ALEXANDER;;PAYNE HAROLD JAMES WILLIAM;;VAUGHAN COLIN;;WHALLEY CHARLES ALBERT,,https://lens.org/087-149-443-078-539,Granted Patent,no,0,4,1,1,0,E04F15/02405;;E04F15/02447;;E04F15/02452,E04F15/024,B5S S17X;;B5S S17Y;;B5S S172;;B5S S184;;B5S S199;;B5S S222;;B5S S222;;B5S S25Y;;B5S S25Y;;B5S S252;;B5S S252;;B5S S254;;B5S S254;;B5S S423;;B5S S423;;B5S S424;;B5S S424;;B5S S436;;B5S S436;;B5S S439;;B5S S439;;B5S S579;;B5S S579;;B5S S634;;B5S S634;;B5S S638;;B5S S638;;B5S S648;;B5S S648;;B5S S65X;;B5S S65X;;B5S S65Y;;B5S S65Y;;B5S S668;;B5S S668;;B5S S71X;;B5S S71X;;B5S S716;;B5S S716;;B5S S72X;;B5S S72X;;B5S S72Y;;B5S S72Y;;B5S S790;;B5S S790;;E1W W4X4          1;;F1B BBA           BA06;;F1B BB106         BA06;;F1B BB228         BA06;;F1B BB234         BA06;;F1B BB242         BA06,0,0,,,,EXPIRED
58,DE,T2,DE 69514661 T2,192-004-900-410-242,2000-08-03,2000,DE 69514661 T,1995-06-21,US 26553294 A;;US 41314095 A;;US 9507909 W,1994-06-24,"POLYMERISATIONSKATALYSATORSYSTEM, IHRE HERSTELLUNG UND GEBRAUCH","This invention is generally directed toward a supported catalyst system useful for polymerizing olefins. The method for supporting the catalyst system of the invention provides for a metallocene catalyst and alumoxane activator supported on a porous support using a total volume of catalyst solution that is less than that of which a slurry is formed. The metallocene and alumoxane aer mixed in solution, then the solution is added to a porous support in a volume between the total pore volume of the support and the volume at which a slurry forms. The solvent is then removed, leaving an activated supported metallocene.",EXXON CHEMICAL PATENTS INC;;HOECHST AG,SPECA NICHOLAS;;BRINEN LAWRENCE;;VAUGHAN GEORGE ALLEN;;BRANT PATRICK;;BURKHARDT JOHN,,https://lens.org/192-004-900-410-242,Granted Patent,no,0,0,23,24,0,C08F4/61912;;C08F4/61916;;C08F4/61927;;C08F4/65912;;C08F4/65927;;C08F10/00;;C08F110/06;;Y10S526/943;;C08F10/00;;C08F4/61927;;C08F110/06;;C08F4/61912;;C08F4/65912;;C08F4/65927;;C08F4/61916;;Y10S526/943,B01J31/00;;B01J37/00;;C08F4/02;;C08F4/60;;C08F4/619;;C08F4/6192;;C08F4/642;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F110/06,,0,0,,,,EXPIRED
59,DE,D1,DE 69514661 D1,177-316-429-246-514,2000-02-24,2000,DE 69514661 T,1995-06-21,US 26553294 A;;US 41314095 A;;US 9507909 W,1994-06-24,"POLYMERISATIONSKATALYSATORSYSTEM, IHRE HERSTELLUNG UND GEBRAUCH","This invention is generally directed toward a supported catalyst system useful for polymerizing olefins. The method for supporting the catalyst system of the invention provides for a metallocene catalyst and alumoxane activator supported on a porous support using a total volume of catalyst solution that is less than that of which a slurry is formed. The metallocene and alumoxane aer mixed in solution, then the solution is added to a porous support in a volume between the total pore volume of the support and the volume at which a slurry forms. The solvent is then removed, leaving an activated supported metallocene.",EXXON CHEMICAL PATENTS INC;;HOECHST AG,SPECA NICHOLAS;;BRINEN LAWRENCE;;VAUGHAN GEORGE ALLEN;;BRANT PATRICK;;BURKHARDT JOHN,,https://lens.org/177-316-429-246-514,Granted Patent,no,0,0,23,24,0,C08F4/61912;;C08F4/61916;;C08F4/61927;;C08F4/65912;;C08F4/65927;;C08F10/00;;C08F110/06;;Y10S526/943;;C08F10/00;;C08F4/61927;;C08F110/06;;C08F4/61912;;C08F4/65912;;C08F4/65927;;C08F4/61916;;Y10S526/943,B01J31/00;;B01J37/00;;C08F4/02;;C08F4/60;;C08F4/619;;C08F4/6192;;C08F4/642;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F110/06,,0,0,,,,EXPIRED
60,EP,A3,EP 0252405 A3,085-065-279-861-781,1989-11-08,1989,EP 87109356 A,1987-06-30,US 88389886 A,1986-07-09,3-METHOXY-4-HYDROXYPHENYLGLYCOL FLUORESCENCE POLARIZATION IMMUNOASSAY,"The present invention is directed to a fluorescence polarization immunoassay for determining the 3-methoxy-4-hydroxyphenylglycol content in body fluids, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for preparing them. The assay is conducted by measuring the degree of polarization of plane polarized light that has been passed through a sample containing antiserum and tracer.  ",ABBOTT LABORATORIES,"ZEITVOGEL, CHRISTINE HELENE;;BETEBENNER, DAVID ALLEN;;ADAMCZYK, MACIEJ BOGDAN;;VAUGHAN, KENWARD SHAW",ABBOTT LABORATORIES (1994-01-12),https://lens.org/085-065-279-861-781,Search Report,yes,2,0,5,7,0,C07D493/10;;C07C45/30;;C07C45/67;;C07C45/71;;C07C49/84;;C07C49/86;;C07C59/64;;C07F9/12;;C07H21/00;;G01N33/542,G01N33/53;;C07C45/30;;C07C45/67;;C07C45/71;;C07C49/84;;C07C49/86;;C07C59/64;;C07D493/10;;C07F9/12;;C07H21/00;;C07K14/00;;C07K14/76;;C07K16/00;;C09B57/00;;C12Q1/34;;G01N33/542,,1,0,,,"CHEMICAL ABSTRACTS, vol. 94, no. 21, May 25, 1981, Columbus, Ohio, USA Y.OKURA ""Fluorescence substances and fluorometric determination"" page 354, Abstract-no. 170 650v & Jpn. Kokai Tokkyo Koho 81 14157",DISCONTINUED
61,AU,A,AU 1987/075344 A,093-852-068-758-656,1988-01-14,1988,AU 1987/075344 A,1987-07-08,US 88389886 A,1986-07-09,3-METHOXY-4-HYDROXY PHENYLGLYCOL FLUORESCENCE POLARIZATION IMMUNOASSAY,,ABBOTT LAB,ZEITVOGEL CHRISTINE HELENE;;ADAMCZYK MACIEJ BOGDAN;;BETEBENNER DAVID ALLEN;;VAUGHAN KENWARD SHAW,,https://lens.org/093-852-068-758-656,Patent Application,no,0,0,5,7,0,C07D493/10;;C07C45/30;;C07C45/67;;C07C45/71;;C07C49/84;;C07C49/86;;C07C59/64;;C07F9/12;;C07H21/00;;G01N33/542,G01N33/53;;C07C45/30;;C07C45/67;;C07C45/71;;C07C49/84;;C07C49/86;;C07C59/64;;C07D493/10;;C07F9/12;;C07H21/00;;C07K14/00;;C07K14/76;;C07K16/00;;C09B57/00;;C12Q1/34;;G01N33/542,,0,0,,,,EXPIRED
62,GR,T3,GR 3019541 T3,143-399-230-596-712,1996-07-31,1996,GR 960400932 T,1996-04-03,US 72300391 A;;US 89663792 A,1991-06-28,Ampholyte terpolymers providing superior conditioning properties in skin and nail care products,"Ampholyte terpolymer conditioning additives for skin and nail care products are disclosed which improve softening or lubricating (lubricity), moisture retention and attraction (moisturizing), feel, and reduction of irritation. The ampholyte terpolymers may have a weight average molecular weight of from about 10 thousand to 10 million, and comprise (a) from at least 1 to as much as 95 weight percent of a nonionic monomer, (b) from at least 5 to as much as 80 weight percent of a cationic monomer, and (c) from at least 1 to as much as 75 weight percent of an anionic monomer. The ampholyte terpolymers are added to skin and nail care product formulations in amounts ranging from 0.1-10% by weight.",CALGON CORP,SHIH-RUEY THOMAS;;MATZ GARY F;;VAUGHAN CRAIG W;;MELBY ALLEN L,,https://lens.org/143-399-230-596-712,Granted Patent,no,0,0,16,81,0,A61K8/8158;;A61K8/817;;A61K8/8182;;A61K2800/5428;;A61Q3/00;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/002;;A61Q19/007;;A61Q19/10;;C11D3/3773;;A61K8/8158;;A61K8/8182;;A61K8/817;;A61Q19/00;;A61Q19/10;;A61Q3/00;;A61Q17/04;;A61Q9/02;;C11D3/3773;;A61K2800/5422;;A61K2800/5426,A61K8/72;;A61K8/00;;A61K8/81;;A61Q3/00;;A61Q3/02;;A61Q5/02;;A61Q5/12;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/10;;C11D3/37,,0,0,,,,EXPIRED
63,AT,T1,AT E133559 T1,168-413-248-517-387,1996-02-15,1996,AT 92305922 T,1992-06-26,US 72300391 A;;US 89663792 A,1991-06-28,AMPHOLITISCHE TERPOLYMERE MIT VERBESSERTEN KONDITIONIERUNGSEIGENSCHAFTEN IN SHAMPOOZUSAMMENSETZUNGEN UND HAARPFLEGEMITTELN,"Ampholyte terpolymer conditioning additives for skin and nail care products are disclosed which improve softening or lubricating (lubricity), moisture retention and attraction (moisturizing), feel, and reduction of irritation. The ampholyte terpolymers may have a weight average molecular weight of from about 10 thousand to 10 million, and comprise (a) from at least 1 to as much as 95 weight percent of a nonionic monomer, (b) from at least 5 to as much as 80 weight percent of a cationic monomer, and (c) from at least 1 to as much as 75 weight percent of an anionic monomer. The ampholyte terpolymers are added to skin and nail care product formulations in amounts ranging from 0.1-10% by weight.",CALGON CORP,SHIH-RUEY THOMAS;;MATZ GARY F;;VAUGHAN CRAIG W;;MELBY ALLEN L,,https://lens.org/168-413-248-517-387,Granted Patent,no,0,0,16,81,0,A61K8/8158;;A61K8/817;;A61K8/8182;;A61K2800/5428;;A61Q3/00;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/002;;A61Q19/007;;A61Q19/10;;C11D3/3773;;A61K8/8158;;A61K8/8182;;A61K8/817;;A61Q19/00;;A61Q19/10;;A61Q3/00;;A61Q17/04;;A61Q9/02;;C11D3/3773;;A61K2800/5422;;A61K2800/5426,A61K8/72;;A61K8/00;;A61K8/81;;A61Q3/00;;A61Q3/02;;A61Q5/02;;A61Q5/12;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/10;;C11D3/37,,0,0,,,,PENDING
64,EP,A2,EP 0252405 A2,023-868-841-022-062,1988-01-13,1988,EP 87109356 A,1987-06-30,US 88389886 A,1986-07-09,3-methoxy-4-hydroxyphenylglycol fluorescence polarization immunoassay.,"The present invention is directed to a fluorescence polarization immunoassay for determining the 3-methoxy-4-hydroxyphenylglycol content in body fluids, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for preparing them. The assay is conducted by measuring the degree of polarization of plane polarized light that has been passed through a sample containing antiserum and tracer.  ",ABBOTT LAB,ZEITVOGEL CHRISTINE HELENE;;BETEBENNER DAVID ALLEN;;ADAMCZYK MACIEJ BOGDAN;;VAUGHAN KENWARD SHAW,ABBOTT LABORATORIES (1994-01-12),https://lens.org/023-868-841-022-062,Patent Application,yes,0,1,5,7,0,C07D493/10;;C07C45/30;;C07C45/67;;C07C45/71;;C07C49/84;;C07C49/86;;C07C59/64;;C07F9/12;;C07H21/00;;G01N33/542,G01N33/53;;C07C45/30;;C07C45/67;;C07C45/71;;C07C49/84;;C07C49/86;;C07C59/64;;C07D493/10;;C07F9/12;;C07H21/00;;C07K14/00;;C07K14/76;;C07K16/00;;C09B57/00;;C12Q1/34;;G01N33/542,,0,0,,,,DISCONTINUED
65,DE,D1,DE 69207971 D1,031-732-421-848-068,1996-03-14,1996,DE 69207971 T,1992-06-26,US 72300391 A;;US 89663792 A,1991-06-28,Ampholitische Terpolymere mit verbesserten Konditionierungseigenschaften in Shampoozusammensetzungen und Haarpflegemitteln,"Ampholyte terpolymer conditioning additives for skin and nail care products are disclosed which improve softening or lubricating (lubricity), moisture retention and attraction (moisturizing), feel, and reduction of irritation. The ampholyte terpolymers may have a weight average molecular weight of from about 10 thousand to 10 million, and comprise (a) from at least 1 to as much as 95 weight percent of a nonionic monomer, (b) from at least 5 to as much as 80 weight percent of a cationic monomer, and (c) from at least 1 to as much as 75 weight percent of an anionic monomer. The ampholyte terpolymers are added to skin and nail care product formulations in amounts ranging from 0.1-10% by weight.",CALGON CORP,SHIH-RUEY THOMAS;;MATZ GARY F;;VAUGHAN CRAIG W;;MELBY ALLEN L,,https://lens.org/031-732-421-848-068,Granted Patent,no,0,0,16,81,0,A61K8/8158;;A61K8/817;;A61K8/8182;;A61K2800/5428;;A61Q3/00;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/002;;A61Q19/007;;A61Q19/10;;C11D3/3773;;A61K8/8158;;A61K8/8182;;A61K8/817;;A61Q19/00;;A61Q19/10;;A61Q3/00;;A61Q17/04;;A61Q9/02;;C11D3/3773;;A61K2800/5422;;A61K2800/5426,A61K8/72;;A61K8/00;;A61K8/81;;A61Q3/00;;A61Q3/02;;A61Q5/02;;A61Q5/12;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/10;;C11D3/37,,0,0,,,,EXPIRED
66,ES,T3,ES 2084288 T3,079-446-227-122-866,1996-05-01,1996,ES 92305922 T,1992-06-26,US 72300391 A;;US 89663792 A,1991-06-28,TERPOLIMEROS ANFOLITOS QUE PROPORCIONAN PROPIEDADES SUPERIORES DE ACONDICIONAMIENTO EN PRODUCTOS PARA EL CUIDADO DE LA PIEL Y UÑAS.,"Ampholyte terpolymer conditioning additives for skin and nail care products are disclosed which improve softening or lubricating (lubricity), moisture retention and attraction (moisturizing), feel, and reduction of irritation. The ampholyte terpolymers may have a weight average molecular weight of from about 10 thousand to 10 million, and comprise (a) from at least 1 to as much as 95 weight percent of a nonionic monomer, (b) from at least 5 to as much as 80 weight percent of a cationic monomer, and (c) from at least 1 to as much as 75 weight percent of an anionic monomer. The ampholyte terpolymers are added to skin and nail care product formulations in amounts ranging from 0.1-10% by weight.",CALGON CORP,SHIH-RUEY THOMAS;;MATZ GARY F;;VAUGHAN CRAIG W;;MELBY ALLEN L,,https://lens.org/079-446-227-122-866,Granted Patent,no,0,0,16,81,0,A61K8/8158;;A61K8/817;;A61K8/8182;;A61K2800/5428;;A61Q3/00;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/002;;A61Q19/007;;A61Q19/10;;C11D3/3773;;A61K8/8158;;A61K8/8182;;A61K8/817;;A61Q19/00;;A61Q19/10;;A61Q3/00;;A61Q17/04;;A61Q9/02;;C11D3/3773;;A61K2800/5422;;A61K2800/5426,A61K8/72;;A61K8/00;;A61K8/81;;A61Q3/00;;A61Q3/02;;A61Q5/02;;A61Q5/12;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/10;;C11D3/37,,0,0,,,,EXPIRED
67,US,B2,US 8235376 B2,132-527-427-106-822,2012-08-07,2012,US 91633310 A,2010-10-29,US 91633310 A,2010-10-29,Removable input tray assembly having an integrated roller nip for an image forming device,A removable input tray assembly for an image forming device according to one embodiment includes a media tray having a bottom surface and a wall extending upward from the bottom surface. The bottom surface defines a media storage location for storing a stack of media sheets. The assembly further includes a housing having an opening therein to receive the media tray. An inclined media dam is formed in the wall and has a media contact surface for directing media advanced from the media storage location. A channel is provided in the wall and extends the height of the wall for directing media passing therethrough. A roller nip is formed in the channel within the media tray by a pair of rollers for advancing media through the channel.,BLAIR BRIAN ALLEN;;MITCHELL STACEY VAUGHAN;;THOMAS DANIEL LEE;;TRIPLETT EDWARD LYNN;;LEXMARK INT INC,BLAIR BRIAN ALLEN;;MITCHELL STACEY VAUGHAN;;THOMAS DANIEL LEE;;TRIPLETT EDWARD LYNN,LEXMARK INTERNATIONAL INC (2010-10-29),https://lens.org/132-527-427-106-822,Granted Patent,yes,11,4,2,2,0,B65H1/266;;B65H1/266;;B65H5/062;;B65H5/062;;B65H5/38;;B65H5/38;;B65H2404/143;;B65H2404/143;;B65H2404/611;;B65H2404/611;;B65H2405/1136;;B65H2405/1136;;B65H2405/313;;B65H2405/313;;B65H2801/06;;B65H2801/06,B65H5/26,271/9.11;;271/9.13;;271/122,0,0,,,,ACTIVE
68,EP,A1,EP 0522756 A1,105-797-425-084-288,1993-01-13,1993,EP 92305922 A,1992-06-26,US 72300391 A;;US 89663792 A,1991-06-28,Ampholyte terpolymers providing superior conditioning properties in skin and nail care products.,"Ampholyte terpolymer conditioning additives for skin and nail care products are disclosed which improve softening or lubricating (lubricity), moisture retention and attraction (moisturizing), feel, and reduction of irritation. The ampholyte terpolymers may have a weight average molecular weight of from about 10 thousand to 10 million, and comprise (a) from at least 1 to as much as 95 weight percent of a nonionic monomer, (b) from at least 5 to as much as 80 weight percent of a cationic monomer, and (c) from at least 1 to as much as 75 weight percent of an anionic monomer. The ampholyte terpolymers are added to skin and nail care product formulations in amounts ranging from 0.1-10% by weight.",CALGON CORP,SHIH-RUEY THOMAS;;MATZ GARY F;;VAUGHAN CRAIG W;;MELBY ALLEN L,CALGON CORPORATION (2007-10-15),https://lens.org/105-797-425-084-288,Patent Application,yes,6,56,16,81,0,A61K8/8158;;A61K8/817;;A61K8/8182;;A61K2800/5428;;A61Q3/00;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/002;;A61Q19/007;;A61Q19/10;;C11D3/3773;;A61K8/8158;;A61K8/8182;;A61K8/817;;A61Q19/00;;A61Q19/10;;A61Q3/00;;A61Q17/04;;A61Q9/02;;C11D3/3773;;A61K2800/5422;;A61K2800/5426,A61K8/72;;A61K8/00;;A61K8/81;;A61Q3/00;;A61Q3/02;;A61Q5/02;;A61Q5/12;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/10;;C11D3/37,,0,0,,,,EXPIRED
69,AU,B2,AU 610507 B2,180-576-134-956-374,1991-05-23,1991,AU 1987/075344 A,1987-07-08,US 88389886 A,1986-07-09,3-METHOXY-4-HYDROXY PHENYLGLYCOL FLUORESCENCE POLARIZATION IMMUNOASSAY,,ABBOTT LAB,ZEITVOGEL CHRISTINE HELENE;;ADAMCZYK MACIEJ BOGDAN;;BETEBENNER DAVID ALLEN;;VAUGHAN KENWARD SHAW,,https://lens.org/180-576-134-956-374,Granted Patent,no,2,0,5,7,0,C07D493/10;;C07C45/30;;C07C45/67;;C07C45/71;;C07C49/84;;C07C49/86;;C07C59/64;;C07F9/12;;C07H21/00;;G01N33/542,G01N33/53;;C07C45/30;;C07C45/67;;C07C45/71;;C07C49/84;;C07C49/86;;C07C59/64;;C07D493/10;;C07F9/12;;C07H21/00;;C07K14/00;;C07K14/76;;C07K16/00;;C09B57/00;;C12Q1/34;;G01N33/542,,0,0,,,,EXPIRED
70,AT,T1,AT E207085 T1,194-412-219-890-703,2001-11-15,2001,AT 95924038 T,1995-06-21,US 26553394 A;;US 41281095 A;;US 9507910 W,1994-06-24,"POLYMERISATIONSKATALYSATORSYSTEM, IHRE HERSTELLUNG UND VERWENDUNG",This invention is generally directed toward a supported catalyst system useful for polymerizing olefins. The method for supporting the catalyst system of the invention provides for a supported bulky ligand transition metal catalyst system which when utilized in a polymerization process substantially reduces the reactor fouling and sheeting particularly in a gas phase polymerization process.,EXXONMOBIL CHEM PATENTS INC,VAUGHAN GEORGE ALLEN;;SPECA ANTHONY NICHOLAS;;BRANT PATRICK;;CANICH JO ANN MARIE,,https://lens.org/194-412-219-890-703,Granted Patent,no,0,0,18,43,0,C07F17/00;;C08F4/65908;;C08F4/65912;;C08F4/6592;;C08F10/00;;C08F210/16;;Y10S526/943;;C07F17/00;;C08F4/65912;;C08F4/65908;;C08F210/16;;C08F4/6592;;C08F10/00;;Y10S526/943,C08F4/642;;C07F17/00;;C08F2/34;;C08F4/60;;C08F4/64;;C08F4/655;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F210/16,,0,0,,,,EXPIRED
71,KR,B1,KR 100216098 B1,177-418-654-323-819,1999-08-16,1999,KR 920011184 A,1992-06-26,US 72300391 A;;US 89663792 A,1991-06-28,AMPHOLYTE TERPOLYMERS PROVIDING SUPERIOR CONDITIONING PROPERTIES IN SKIN AND NAIL CARE PRODUCTS,"Ampholyte terpolymer conditioning additives for skin and nail care products are disclosed which improve softening or lubricating (lubricity), moisture retention and attraction (moisturizing), feel, and reduction of irritation. The ampholyte terpolymers may have a weight average molecular weight of from about 10 thousand to 10 million, and comprise (a) from at least 1 to as much as 95 weight percent of a nonionic monomer, (b) from at least 5 to as much as 80 weight percent of a cationic monomer, and (c) from at least 1 to as much as 75 weight percent of an anionic monomer. The ampholyte terpolymers are added to skin and nail care product formulations in amounts ranging from 0.1-10% by weight.",CALGON CORP,SHIH-RUEY THOMAS;;CRAIG W VAUGHAN;;ALLEN L MELBY;;GARY F MATZ,,https://lens.org/177-418-654-323-819,Granted Patent,no,0,0,16,81,0,A61K8/8158;;A61K8/817;;A61K8/8182;;A61K2800/5428;;A61Q3/00;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/002;;A61Q19/007;;A61Q19/10;;C11D3/3773;;A61K8/8158;;A61K8/8182;;A61K8/817;;A61Q19/00;;A61Q19/10;;A61Q3/00;;A61Q17/04;;A61Q9/02;;C11D3/3773;;A61K2800/5422;;A61K2800/5426,A61K8/00;;A61K8/72;;A61K8/81;;A61Q3/00;;A61Q3/02;;A61Q5/02;;A61Q5/12;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/10;;C11D3/37,,0,0,,,,EXPIRED
72,EP,B1,EP 0522756 B1,153-403-416-707-689,1996-01-31,1996,EP 92305922 A,1992-06-26,US 72300391 A;;US 89663792 A,1991-06-28,Ampholyte terpolymers providing superior conditioning properties in skin and nail care products,"Ampholyte terpolymer conditioning additives for skin and nail care products are disclosed which improve softening or lubricating (lubricity), moisture retention and attraction (moisturizing), feel, and reduction of irritation. The ampholyte terpolymers may have a weight average molecular weight of from about 10 thousand to 10 million, and comprise (a) from at least 1 to as much as 95 weight percent of a nonionic monomer, (b) from at least 5 to as much as 80 weight percent of a cationic monomer, and (c) from at least 1 to as much as 75 weight percent of an anionic monomer. The ampholyte terpolymers are added to skin and nail care product formulations in amounts ranging from 0.1-10% by weight.",CALGON CORP,SHIH-RUEY THOMAS;;MATZ GARY F;;VAUGHAN CRAIG W;;MELBY ALLEN L,CALGON CORPORATION (2007-10-15),https://lens.org/153-403-416-707-689,Granted Patent,yes,6,3,16,81,0,A61K8/8158;;A61K8/817;;A61K8/8182;;A61K2800/5428;;A61Q3/00;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/002;;A61Q19/007;;A61Q19/10;;C11D3/3773;;A61K8/8158;;A61K8/8182;;A61K8/817;;A61Q19/00;;A61Q19/10;;A61Q3/00;;A61Q17/04;;A61Q9/02;;C11D3/3773;;A61K2800/5422;;A61K2800/5426,A61K8/72;;A61K8/00;;A61K8/81;;A61Q3/00;;A61Q3/02;;A61Q5/02;;A61Q5/12;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/10;;C11D3/37,,0,0,,,,EXPIRED
73,ES,T3,ES 2165425 T3,030-301-430-105-089,2002-03-16,2002,ES 95924038 T,1995-06-21,US 26553394 A;;US 41281095 A,1994-06-24,"SISTEMAS CATALITICOS DE POLIMERIZACION, SU PRODUCCION Y USO.",This invention is generally directed toward a supported catalyst system useful for polymerizing olefins. The method for supporting the catalyst system of the invention provides for a supported bulky ligand transition metal catalyst system which when utilized in a polymerization process substantially reduces the reactor fouling and sheeting particularly in a gas phase polymerization process.,EXXONMOBIL CHEM PATENTS INC,VAUGHAN GEORGE ALLEN;;SPECA ANTHONY NICHOLAS;;BRANT PATRICK;;CANICH JO ANN MARIE,,https://lens.org/030-301-430-105-089,Granted Patent,no,0,0,18,43,0,C07F17/00;;C08F4/65908;;C08F4/65912;;C08F4/6592;;C08F10/00;;C08F210/16;;Y10S526/943;;C07F17/00;;C08F4/65912;;C08F4/65908;;C08F210/16;;C08F4/6592;;C08F10/00;;Y10S526/943,C07F17/00;;C08F2/34;;C08F4/642;;C08F4/60;;C08F4/64;;C08F4/655;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F210/16,,0,0,,,,EXPIRED
74,DE,T2,DE 69207971 T2,061-525-538-540-688,1996-06-27,1996,DE 69207971 T,1992-06-26,US 72300391 A;;US 89663792 A,1991-06-28,Ampholitische Terpolymere mit verbesserten Konditionierungseigenschaften in Shampoozusammensetzungen und Haarpflegemitteln,"Ampholyte terpolymer conditioning additives for skin and nail care products are disclosed which improve softening or lubricating (lubricity), moisture retention and attraction (moisturizing), feel, and reduction of irritation. The ampholyte terpolymers may have a weight average molecular weight of from about 10 thousand to 10 million, and comprise (a) from at least 1 to as much as 95 weight percent of a nonionic monomer, (b) from at least 5 to as much as 80 weight percent of a cationic monomer, and (c) from at least 1 to as much as 75 weight percent of an anionic monomer. The ampholyte terpolymers are added to skin and nail care product formulations in amounts ranging from 0.1-10% by weight.",CALGON CORP,SHIH-RUEY THOMAS;;MATZ GARY F;;VAUGHAN CRAIG W;;MELBY ALLEN L,,https://lens.org/061-525-538-540-688,Granted Patent,no,0,1,16,81,0,A61K8/8158;;A61K8/817;;A61K8/8182;;A61K2800/5428;;A61Q3/00;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/002;;A61Q19/007;;A61Q19/10;;C11D3/3773;;A61K8/8158;;A61K8/8182;;A61K8/817;;A61Q19/00;;A61Q19/10;;A61Q3/00;;A61Q17/04;;A61Q9/02;;C11D3/3773;;A61K2800/5422;;A61K2800/5426,A61K8/72;;A61K8/00;;A61K8/81;;A61Q3/00;;A61Q3/02;;A61Q5/02;;A61Q5/12;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/10;;C11D3/37,,0,0,,,,EXPIRED
75,DK,T3,DK 0522756 T3,140-526-997-741-612,1996-06-24,1996,DK 92305922 T,1992-06-26,US 72300391 A;;US 89663792 A,1991-06-28,"Amfolytiske terpolymerer, som giver overlegne konditioneringsegenskaber i hud- og negleplejeprodukter","Ampholyte terpolymer conditioning additives for skin and nail care products are disclosed which improve softening or lubricating (lubricity), moisture retention and attraction (moisturizing), feel, and reduction of irritation. The ampholyte terpolymers may have a weight average molecular weight of from about 10 thousand to 10 million, and comprise (a) from at least 1 to as much as 95 weight percent of a nonionic monomer, (b) from at least 5 to as much as 80 weight percent of a cationic monomer, and (c) from at least 1 to as much as 75 weight percent of an anionic monomer. The ampholyte terpolymers are added to skin and nail care product formulations in amounts ranging from 0.1-10% by weight.",CALGON CORP,MATZ GARY F;;SHIH-RUEY THOMAS;;VAUGHAN CRAIG W;;MELBY ALLEN L,,https://lens.org/140-526-997-741-612,Granted Patent,no,0,0,16,81,0,A61K8/8158;;A61K8/817;;A61K8/8182;;A61K2800/5428;;A61Q3/00;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/002;;A61Q19/007;;A61Q19/10;;C11D3/3773;;A61K8/8158;;A61K8/8182;;A61K8/817;;A61Q19/00;;A61Q19/10;;A61Q3/00;;A61Q17/04;;A61Q9/02;;C11D3/3773;;A61K2800/5422;;A61K2800/5426,A61K8/72;;A61K8/00;;A61K8/81;;A61Q3/00;;A61Q3/02;;A61Q5/02;;A61Q5/12;;A61Q9/02;;A61Q17/04;;A61Q19/00;;A61Q19/10;;C11D3/37,,0,0,,,,EXPIRED
76,US,A1,US 2012/0104682 A1,017-513-366-580-961,2012-05-03,2012,US 91633310 A,2010-10-29,US 91633310 A,2010-10-29,Removable Input Tray Assembly Having an Integrated Roller Nip for an Image Forming Device,A removable input tray assembly for an image forming device according to one embodiment includes a media tray having a bottom surface and a wall extending upward from the bottom surface. The bottom surface defines a media storage location for storing a stack of media sheets. The assembly further includes a housing having an opening therein to receive the media tray. An inclined media dam is formed in the wall and has a media contact surface for directing media advanced from the media storage location. A channel is provided in the wall and extends the height of the wall for directing media passing therethrough. A roller nip is formed in the channel within the media tray by a pair of rollers for advancing media through the channel.,BLAIR BRIAN ALLEN;;MITCHELL STACEY VAUGHAN;;THOMAS DANIEL LEE;;TRIPLETT EDWARD LYNN,BLAIR BRIAN ALLEN;;MITCHELL STACEY VAUGHAN;;THOMAS DANIEL LEE;;TRIPLETT EDWARD LYNN,LEXMARK INTERNATIONAL INC (2010-10-29),https://lens.org/017-513-366-580-961,Patent Application,yes,0,1,2,2,0,B65H1/266;;B65H1/266;;B65H5/062;;B65H5/062;;B65H5/38;;B65H5/38;;B65H2404/143;;B65H2404/143;;B65H2404/611;;B65H2404/611;;B65H2405/1136;;B65H2405/1136;;B65H2405/313;;B65H2405/313;;B65H2801/06;;B65H2801/06,B65H3/06;;B65H1/04,271/117;;271/162,0,0,,,,ACTIVE
77,EP,B1,EP 0766702 B1,106-149-981-666-909,2001-10-17,2001,EP 95924038 A,1995-06-21,US 9507910 W;;US 26553394 A;;US 41281095 A,1994-06-24,"POLYMERIZATION CATALYST SYSTEMS, THEIR PRODUCTION AND USE",This invention is generally directed toward a supported catalyst system useful for polymerizing olefins. The method for supporting the catalyst system of the invention provides for a supported bulky ligand transition metal catalyst system which when utilized in a polymerization process substantially reduces the reactor fouling and sheeting particularly in a gas phase polymerization process.,EXXONMOBIL CHEM PATENTS INC,VAUGHAN GEORGE ALLEN;;SPECA ANTHONY NICHOLAS;;BRANT PATRICK;;CANICH JO ANN MARIE,EXXONMOBIL CHEMICAL PATENTS INC. (2001-05-30),https://lens.org/106-149-981-666-909,Granted Patent,yes,4,0,18,43,0,C07F17/00;;C08F4/65908;;C08F4/65912;;C08F4/6592;;C08F10/00;;C08F210/16;;Y10S526/943;;C07F17/00;;C08F4/65912;;C08F4/65908;;C08F210/16;;C08F4/6592;;C08F10/00;;Y10S526/943,C08F4/642;;C07F17/00;;C08F2/34;;C08F4/60;;C08F4/64;;C08F4/655;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F210/16,,0,0,,,,EXPIRED
78,DE,D1,DE 3681589 D1,109-286-082-434-506,1991-10-24,1991,DE 3681589 T,1986-09-09,EP 86306938 A,1986-09-09,"ZEOLITH MIT HOHEM SILIZIUMGEHALT (ECR-17), DIESES ZEOLITH ENTHALTENDER KATALYSATOR UND UMWANDLUNG VON KOHLENWASSERSTOFFEN MIT EINEM SOLCHEN KATALYSATOR.","(A) Zeolite (''ECR-17'') has the compsn. (aH, bCs)2O:Al2O3:xSiO2 (I), where a = 0.6-1; b = 0-0.4; a + b = 1.0 +/- 0.05; x = 7 or more; and a specified CuK alpha X-ray diffraction pattern (d) (Angstrom, I/IO): where the 3 highest are 14.1-13.8, 100 +/- 20; 12.3-12.0, 15 +/- 10; and 8.7-8.47, 30 +/- 10. (B) Hydrocarbon conversion catalyst comprises a zeolite defined as in (A). (C) Hydrocarbon conversion, pref. cracking, process comprises contacting a hydrocarbon with the catalyst of (B) under conversion conditions. In formula (I), pref. x = about 8-2,000. The H, Cs and Na ions in the zeolite may be at least partly replaced by cations of metal(s) from Gps. I-VIII and NH4. The catalyst pref. also contains a matrix component, comprising Al2O3, clay or other inorganic oxide. ECR-17's structure seems to be very similar to that of CSZ-1 (US 4,309,313).",EXXON RESEARCH ENGINEERING CO,BEYERLEIN ROBERT ALLEN;;KUGLER EDWIN LEE;;TUNISON MAFER EUGENE;;VAUGHAN DAVID EVAN WILLIAM,,https://lens.org/109-286-082-434-506,Granted Patent,no,0,0,5,5,0,B01J29/08;;C10G11/05,B01J29/00;;B01J29/08;;B01J29/70;;C01B39/00;;C01B39/06;;C01B39/20;;C01B39/26;;C01B39/36;;C01B39/38;;C01B39/42;;C10G11/05,,0,0,,,,EXPIRED
79,EP,A1,EP 0259526 A1,120-250-573-835-885,1988-03-16,1988,EP 86306938 A,1986-09-09,EP 86306938 A,1986-09-09,"A high silica zeolite (ECR-17), a catalyst containing that zeolite, and a hydrocarbon conversion process using that catalyst.","The present invention relates to a zeolite, designated as ECR-17, having a structure similar to CSZ-1 and a silica to alumina ratio greater than about 7. The invention also relates to a catalyst containing that zeolite or hydrocarbon conversion process, notably catalytic cracking, using that catalyst.  ",EXXON RESEARCH ENGINEERING CO,BEYERLEIN ROBERT ALLEN;;KUGLER EDWIN LEE;;TUNISON MAFER EUGENE;;VAUGHAN DAVID EVAN WILLIAM,,https://lens.org/120-250-573-835-885,Patent Application,yes,4,17,5,5,0,B01J29/08;;C10G11/05,B01J29/00;;B01J29/08;;B01J29/70;;C01B39/00;;C01B39/06;;C01B39/20;;C01B39/26;;C01B39/36;;C01B39/38;;C01B39/42;;C10G11/05,,0,0,,,,EXPIRED
80,US,B1,US 7280342 B1,189-357-306-069-120,2007-10-09,2007,US 63979606 A,2006-12-15,US 63979606 A;;US 33427106 A,2006-01-18,Low inductance high ESR capacitor,"A low inductance multi-layer capacitor. The capacitor comprises interleaved parallel internal electrode plates with dielectric there between. Each internal electrode plate comprises two lead-out tabs and is generally T shaped. A first external electrode terminal is electrically connected to the lead-out tabs of the even internal electrode plates, and a second external electrode terminal is electrically connected to the lead-out tabs of the odd internal electrode plates. The external electrode terminals are on a common first exterior surface and a common opposing second exterior surface of the capacitor.",KEMET ELECTRONICS CORP,RANDALL MICHAEL S;;HILL ALLEN;;BLAIS PETER;;RENNER GARRY;;VAUGHAN RANDAL;;TAJUDDIN AZIZUDDIN,KEMET ELECTRONIC CORPORATION (2006-12-09),https://lens.org/189-357-306-069-120,Granted Patent,yes,13,27,5,5,0,H01G4/232;;H01G4/232;;H01G4/30;;H01G4/30,H01G4/005;;H01G4/06;;H01G4/228,361/303;;361/311;;361/306.3,0,0,,,,ACTIVE
81,AT,T1,AT E67467 T1,022-642-904-172-554,1991-10-15,1991,AT 86306938 T,1986-09-09,EP 86306938 A,1986-09-09,"ZEOLITH MIT HOHEM SILIZIUMGEHALT (ECR-17), DIESES ZEOLITH ENTHALTENDER KATALYSATOR UND UMWANDLUNG VON KOHLENWASSERSTOFFEN MIT EINEM SOLCHEN KATALYSATOR.","The present invention relates to a zeolite, designated as ECR-17, having a structure similar to CSZ-1 and a silica to alumina ratio greater than about 7. The invention also relates to a catalyst containing that zeolite or hydrocarbon conversion process, notably catalytic cracking, using that catalyst.",EXXON RESEARCH ENGINEERING CO,BEYERLEIN ROBERT ALLEN;;KUGLER EDWIN LEE;;TUNISON MAFER EUGENE;;VAUGHAN DAVID EVAN WILLIAM,,https://lens.org/022-642-904-172-554,Granted Patent,no,0,0,5,5,0,B01J29/08;;C10G11/05,C01B39/00;;B01J29/00;;B01J29/08;;B01J29/70;;C01B39/06;;C01B39/20;;C01B39/26;;C01B39/36;;C01B39/38;;C01B39/42;;C10G11/05,,0,0,,,,DISCONTINUED
82,EP,B1,EP 0259526 B1,100-516-998-078-138,1991-09-18,1991,EP 86306938 A,1986-09-09,EP 86306938 A,1986-09-09,"A HIGH SILICA ZEOLITE (ECR-17), A CATALYST CONTAINING THAT ZEOLITE, AND A HYDROCARBON CONVERSION PROCESS USING THAT CATALYST","The present invention relates to a zeolite, designated as ECR-17, having a structure similar to CSZ-1 and a silica to alumina ratio greater than about 7. The invention also relates to a catalyst containing that zeolite or hydrocarbon conversion process, notably catalytic cracking, using that catalyst.",EXXON RESEARCH AND ENGINEERING COMPANY,"BEYERLEIN, ROBERT ALLEN;;KUGLER, EDWIN LEE;;TUNISON, MAFER EUGENE;;VAUGHAN, DAVID EVAN WILLIAM",,https://lens.org/100-516-998-078-138,Granted Patent,yes,4,2,5,5,0,B01J29/08;;C10G11/05,B01J29/00;;B01J29/08;;B01J29/70;;C01B39/00;;C01B39/06;;C01B39/20;;C01B39/26;;C01B39/36;;C01B39/38;;C01B39/42;;C10G11/05,,0,0,,,,EXPIRED
83,JP,A,JP S6385013 A,041-697-934-094-398,1988-04-15,1988,JP 22636786 A,1986-09-26,EP 86306938 A,1986-09-09,"HIGH SILICA ZEOLITE (ECR-17), CATALYST CONTAINING SAME AND CONVERSION OF HYDROCARBONS","The present invention relates to a zeolite, designated as ECR-17, having a structure similar to CSZ-1 and a silica to alumina ratio greater than about 7. The invention also relates to a catalyst containing that zeolite or hydrocarbon conversion process, notably catalytic cracking, using that catalyst.",EXXON RESEARCH ENGINEERING CO,BEYERLEIN ROBERT ALLEN;;KUGLER EDWIN LEE;;TUNISON MAFER EUGENE;;VAUGHAN DAVID EVAN WILLIAM,,https://lens.org/041-697-934-094-398,Patent Application,no,0,3,5,5,0,B01J29/08;;C10G11/05,B01J29/00;;B01J29/08;;B01J29/70;;C01B39/06;;C01B39/00;;C01B39/20;;C01B39/26;;C01B39/36;;C01B39/38;;C01B39/42;;C10G11/05,,0,0,,,,DISCONTINUED
84,US,A1,US 2007/0165361 A1,072-095-917-802-07X,2007-07-19,2007,US 63979606 A,2006-12-15,US 63979606 A;;US 33427106 A,2006-01-18,Low inductance high ESR capacitor,"A low inductance multi-layer capacitor. The capacitor comprises interleaved parallel internal electrode plates with dielectric there between. Each internal electrode plate comprises two lead-out tabs and is generally T shaped. A first external electrode terminal is electrically connected to the lead-out tabs of the even internal electrode plates, and a second external electrode terminal is electrically connected to the lead-out tabs of the odd internal electrode plates. The external electrode terminals are on a common first exterior surface and a common opposing second exterior surface of the capacitor.",RANDALL MICHAEL S;;HILL ALLEN;;BLAIS PETER;;RENNER GARRY;;VAUGHAN RANDAL;;TAJUDDIN AZIZUDDIN,RANDALL MICHAEL S;;HILL ALLEN;;BLAIS PETER;;RENNER GARRY;;VAUGHAN RANDAL;;TAJUDDIN AZIZUDDIN,KEMET ELECTRONIC CORPORATION (2006-12-09),https://lens.org/072-095-917-802-07X,Patent Application,yes,3,39,5,5,0,H01G4/232;;H01G4/232;;H01G4/30;;H01G4/30,H01G4/228,361/306.3,0,0,,,,ACTIVE
85,US,S,US D0607349 S,006-023-343-304-146,2010-01-05,2010,US 32697108 F,2008-10-28,US 32697108 F,2008-10-28,Sensor and LED enclosure,,HEWLETT PACKARD DEVELOPMENT CO,VAUGHAN BROOKS;;MORRISON ALLEN T;;NGUYEN HOANG THANH;;MOORE DAVID A;;FELCMAN CHRIS F,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2008-10-28),https://lens.org/006-023-343-304-146,Design Right,no,0,0,1,1,0,,,1004;;D10/57,0,0,,,,EXPIRED
86,EP,B1,EP 0766700 B1,092-647-766-692-798,2000-01-19,2000,EP 95924037 A,1995-06-21,US 9507909 W;;US 26553294 A;;US 41314095 A,1994-06-24,"POLYMERIZATION CATALYST SYSTEMS, THEIR PRODUCTION AND USE","This invention is generally directed toward a supported catalyst system useful for polymerizing olefins. The method for supporting the catalyst system of the invention provides for a metallocene catalyst and alumoxane activator supported on a porous support using a total volume of catalyst solution that is less than that of which a slurry is formed. The metallocene and alumoxane aer mixed in solution, then the solution is added to a porous support in a volume between the total pore volume of the support and the volume at which a slurry forms. The solvent is then removed, leaving an activated supported metallocene.",EXXON CHEMICAL PATENTS INC;;HOECHST AG,SPECA ANTHONY NICHOLAS;;BRINEN JEFFREY LAWRENCE;;VAUGHAN GEORGE ALLEN;;BRANT PATRICK;;BURKHARDT TERRY JOHN,,https://lens.org/092-647-766-692-798,Granted Patent,yes,3,0,23,24,0,C08F4/61912;;C08F4/61916;;C08F4/61927;;C08F4/65912;;C08F4/65927;;C08F10/00;;C08F110/06;;Y10S526/943;;C08F10/00;;C08F4/61927;;C08F110/06;;C08F4/61912;;C08F4/65912;;C08F4/65927;;C08F4/61916;;Y10S526/943,B01J31/00;;B01J37/00;;C08F4/02;;C08F4/60;;C08F4/619;;C08F4/6192;;C08F4/642;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F110/06,,0,0,,,,EXPIRED
87,US,B1,US 11874822 B1,195-362-636-503-245,2024-01-16,2024,US 202217854419 A,2022-06-30,US 202217854419 A,2022-06-30,Multi-stream transactional event processing in a distributed log-based append-only datastore,"Techniques for multi-stream transactional event processing under ACID semantics in a distributed log-based append-only datastore are described. A transaction coordinator writes events that are part of a transaction to a transaction buffer, where the events can be made visible to clients involved in the transaction while other clients are not aware. Upon committing the transaction, an optimistic concurrency control based technique is utilized to attempt to obtain locks on all events involved in the transaction across one or multiple shards by one or multiple designated writer nodes. When all involved writer nodes indicate that they are able to commit their events, the transaction can be committed.",AMAZON TECH INC,SINGH ABHIRAM KUMAR HARE RAM;;CARROLL THEODORE ALLEN;;LANGMAN NATHANIAL VAUGHAN;;SCISCENTI MICHAEL ANTHONY,AMAZON TECHNOLOGIES INC (2022-06-28),https://lens.org/195-362-636-503-245,Granted Patent,yes,3,0,1,1,0,G06F16/2365;;G06F9/466;;G06F16/2308;;G06F16/2379;;G06F9/542;;G06F16/2358;;G06F16/2365;;G06F16/1805;;G06F16/2315,G06F16/23;;G06F16/18,,0,0,,,,ACTIVE
88,ES,T3,ES 2143636 T3,172-077-370-509-772,2000-05-16,2000,ES 95924037 T,1995-06-21,US 26553294 A;;US 41314095 A,1994-06-24,"SISTEMAS DE CATALIZADORES DE POLIMERIZACION, SU PRODUCCION Y USO.","This invention is generally directed toward a supported catalyst system useful for polymerizing olefins. The method for supporting the catalyst system of the invention provides for a metallocene catalyst and alumoxane activator supported on a porous support using a total volume of catalyst solution that is less than that of which a slurry is formed. The metallocene and alumoxane aer mixed in solution, then the solution is added to a porous support in a volume between the total pore volume of the support and the volume at which a slurry forms. The solvent is then removed, leaving an activated supported metallocene.",EXXON CHEMICAL PATENTS INC;;HOECHST AG,SPECA ANTHONY NICHOLAS;;BRINEN JEFFREY LAWRENCE;;VAUGHAN GEORGE ALLEN;;BRANT PATRICK;;BURKHARDT TERRY JOHN,,https://lens.org/172-077-370-509-772,Granted Patent,no,0,0,23,24,0,C08F4/61912;;C08F4/61916;;C08F4/61927;;C08F4/65912;;C08F4/65927;;C08F10/00;;C08F110/06;;Y10S526/943;;C08F10/00;;C08F4/61927;;C08F110/06;;C08F4/61912;;C08F4/65912;;C08F4/65927;;C08F4/61916;;Y10S526/943,B01J31/00;;B01J37/00;;C08F4/02;;C08F4/60;;C08F4/619;;C08F4/6192;;C08F4/642;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F110/06,,0,0,,,,EXPIRED
89,AT,T1,AT E188972 T1,127-060-911-699-757,2000-02-15,2000,AT 95924037 T,1995-06-21,US 26553294 A;;US 41314095 A;;US 9507909 W,1994-06-24,"POLYMERISATIONSKATALYSATORSYSTEM, IHRE HERSTELLUNG UND GEBRAUCH","This invention is generally directed toward a supported catalyst system useful for polymerizing olefins. The method for supporting the catalyst system of the invention provides for a metallocene catalyst and alumoxane activator supported on a porous support using a total volume of catalyst solution that is less than that of which a slurry is formed. The metallocene and alumoxane aer mixed in solution, then the solution is added to a porous support in a volume between the total pore volume of the support and the volume at which a slurry forms. The solvent is then removed, leaving an activated supported metallocene.",EXXON CHEMICAL PATENTS INC;;HOECHST AG,SPECA ANTHONY NICHOLAS;;BRINEN JEFFREY LAWRENCE;;VAUGHAN GEORGE ALLEN;;BRANT PATRICK;;BURKHARDT TERRY JOHN,,https://lens.org/127-060-911-699-757,Granted Patent,no,0,0,23,24,0,C08F4/61912;;C08F4/61916;;C08F4/61927;;C08F4/65912;;C08F4/65927;;C08F10/00;;C08F110/06;;Y10S526/943;;C08F10/00;;C08F4/61927;;C08F110/06;;C08F4/61912;;C08F4/65912;;C08F4/65927;;C08F4/61916;;Y10S526/943,B01J31/00;;B01J37/00;;C08F4/02;;C08F4/60;;C08F4/619;;C08F4/6192;;C08F4/642;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F110/06,,0,0,,,,DISCONTINUED
90,US,B2,US 6550758 B2,055-425-201-954-206,2003-04-22,2003,US 77336001 A,2001-01-31,US 77336001 A,2001-01-31,Finisher with frictional sheet mover,"
    Sheets (  57  ) exit printer (  1  ) into finisher (  3  ) where they are moved against perpendicular reference walls (  61, 69  ) by frictional fingers (  21, 23  ). The fingers are rotated away while a sheet is moved downward. Since the fingers are near their reference surface, buckling of the sheets normally does not occur, so the sheet stays in place. In an embodiment, the fingers move with a resilient force selected to be low enough so that the fingers stop when the sheet contacts the reference wall. 
",LEXMARK INT INC,ARDERY JEFFREY ALLEN;;GORDON MICHAEL KURT;;GREER DAVID EMERSON;;MITCHELL STACEY VAUGHAN;;WESTHOFF DANIEL JOSEPH,LEXMARK INTERNATIONAL INC (2001-01-30),https://lens.org/055-425-201-954-206,Granted Patent,yes,28,21,4,4,0,B65H31/26;;B65H31/26;;B65H31/34;;B65H31/34;;B65H2301/3621;;B65H2301/3621;;B65H2404/1114;;B65H2404/1114;;B65H2801/27;;B65H2801/27,B65H31/26;;B65H31/34,270/58.12;;271/220;;271/236,0,0,,,,EXPIRED
91,WO,A1,WO 2002/060798 A1,176-716-296-357-443,2002-08-08,2002,US 0202882 W,2002-01-31,US 77336001 A,2001-01-31,FINISHER WITH FRICTIONAL SHEET MOVER,"Sheets (57) exit printer (1) into finisher (3) where they are moved against perpendicular reference walls (61, 69) by frictional fingers (21,23). The fingers are rotated away while a sheet is moved downward. Since the fingers are near their reference surface, buckling of the sheets normally does not occur, so the sheet stays in place. In an embodiment, the fingers move with a resilient force selected to be low enough so that the fingers stop when the sheet contacts the reference wall.",LEXMARK INT INC,ARDERY JEFFREY ALLEN;;GORDON MICHAEL KURT;;GREER DAVID EMERSON;;MITCHELL STACEY VAUGHAN;;WESTHOFF DANIEL JOSEPH,,https://lens.org/176-716-296-357-443,Patent Application,yes,3,0,4,4,0,B65H31/26;;B65H31/26;;B65H31/34;;B65H31/34;;B65H2301/3621;;B65H2301/3621;;B65H2404/1114;;B65H2404/1114;;B65H2801/27;;B65H2801/27,B65H31/26;;B65H31/34,,0,0,,,,PENDING
92,US,A1,US 2005/0015493 A1,003-921-980-130-922,2005-01-20,2005,US 71696803 A,2003-11-19,US 71696803 A;;US 47065003 P,2003-05-15,Session and application level bandwidth and/or QoS modification,"Methods, systems and/or computer program products are provided for managing Quality of Service (QoS) and/or bandwidth allocation in a Regional/Access Network (RAN) having a broadband access server (BRAS) that facilitates differentiated end-to-end data transport between a Network Service Provider (NSP) and/or an Application Service Provider (ASP), and a Customer Premises Network (CPN) that includes a Routing Gateway (RG). In particular embodiments of the present invention, a modify QoS and/or bandwidth allocation message including updated QoS and/or bandwidth information from the NSP and/or ASP is received at the RAN. The BRAS is updated with the QoS and/or bandwidth information and the RG is also updated with the QoS and/or bandwidth information.",ANSCHUTZ THOMAS ARNOLD;;CASSANOVA JEFFREY PATRICK;;SHRUM EDGAR VAUGHAN;;WRIGHT STEVEN ALLEN;;ZHANG LI,ANSCHUTZ THOMAS ARNOLD;;CASSANOVA JEFFREY PATRICK;;SHRUM EDGAR VAUGHAN JR;;WRIGHT STEVEN ALLEN;;ZHANG LI,BELLSOUTH INTELLECTUAL PROPERTY CORPORATION (2003-11-07),https://lens.org/003-921-980-130-922,Patent Application,yes,4,53,2,51,0,H04L12/1485;;H04L47/2408;;H04L47/762;;H04L47/2408;;H04L41/0896;;H04L12/1485;;H04L47/762,G06F15/173,709/226,0,0,,,,EXPIRED
93,US,A1,US 2002/0101029 A1,164-909-737-249-567,2002-08-01,2002,US 77336001 A,2001-01-31,US 77336001 A,2001-01-31,Finisher with frictional sheet mover,"
    Sheets ( 57 ) exit printer ( 1 ) into finisher ( 3 ) where they are moved against perpendicular reference walls ( 61, 69 ) by frictional fingers ( 21, 23 ). The fingers are rotated away while a sheet is moved downward. Since the fingers are near their reference surface, buckling of the sheets normally does not occur, so the sheet stays in place. In an embodiment, the fingers move with a resilient force selected to be low enough so that the fingers stop when the sheet contacts the reference wall. 
",ARDERY JEFFREY ALLEN;;GORDON MICHAEL KURT;;GREER DAVID EMERSON;;MITCHELL STACEY VAUGHAN;;WESTHOFF DANIEL JOSEPH,ARDERY JEFFREY ALLEN;;GORDON MICHAEL KURT;;GREER DAVID EMERSON;;MITCHELL STACEY VAUGHAN;;WESTHOFF DANIEL JOSEPH,LEXMARK INTERNATIONAL INC (2001-01-30),https://lens.org/164-909-737-249-567,Patent Application,yes,0,3,4,4,0,B65H31/26;;B65H31/26;;B65H31/34;;B65H31/34;;B65H2301/3621;;B65H2301/3621;;B65H2404/1114;;B65H2404/1114;;B65H2801/27;;B65H2801/27,B65H31/26;;B65H31/34,271/207,0,0,,,,EXPIRED
94,TW,B,TW 555679 B,024-985-741-669-810,2003-10-01,2003,TW 91101836 A,2002-01-31,US 77336001 A,2001-01-31,Finisher with frictional sheet mover,"Sheets (57) exit printer (1) into finisher (3) where they are moved against perpendicular reference walls (61, 69) by frictional fingers (21, 23). The fingers are rotated away while a sheet is moved downward. Since the fingers are near their reference surface, buckling of the sheets normally does not occur, so the sheet stays in place. In an embodiment, the fingers move with a resilient force selected to be low enough so that the fingers stop when the sheet contacts the reference wall.",LEXMARK INT INC,ARDERY JEFFREY ALLEN;;GORDON MICHAEL KURT;;GREER DAVID EMERSON;;MITCHELL STACEY VAUGHAN;;WESTHOFF DANIEL JOSEPH,,https://lens.org/024-985-741-669-810,Granted Patent,no,0,0,4,4,0,B65H31/26;;B65H31/26;;B65H31/34;;B65H31/34;;B65H2301/3621;;B65H2301/3621;;B65H2404/1114;;B65H2404/1114;;B65H2801/27;;B65H2801/27,B65H31/26;;B65H31/34,,0,0,,,,EXPIRED
95,US,B2,US 7536460 B2,189-849-178-992-180,2009-05-19,2009,US 71696803 A,2003-11-19,US 71696803 A;;US 47065003 P,2003-05-15,Session and application level bandwidth and/or QoS modification,"Methods, systems and/or computer program products are provided for managing Quality of Service (QoS) and/or bandwidth allocation in a Regional/Access Network (RAN) having a broadband access server (BRAS) that facilitates differentiated end-to-end data transport between a Network Service Provider (NSP) and/or an Application Service Provider (ASP), and a Customer Premises Network (CPN) that includes a Routing Gateway (RG). In particular embodiments of the present invention, a modify QoS and/or bandwidth allocation message including updated QoS and/or bandwidth information from the NSP and/or ASP is received at the RAN. The BRAS is updated with the QoS and/or bandwidth information and the RG is also updated with the QoS and/or bandwidth information.",AT & T IP I LP,ANSCHUTZ THOMAS ARNOLD;;CASSANOVA JEFFREY PATRICK;;SHRUM EDGAR VAUGHAN JR;;WRIGHT STEVEN ALLEN;;ZHANG LI,BELLSOUTH INTELLECTUAL PROPERTY CORPORATION (2003-11-07),https://lens.org/189-849-178-992-180,Granted Patent,yes,4,13,2,51,0,H04L12/1485;;H04L47/2408;;H04L47/762;;H04L47/2408;;H04L41/0896;;H04L12/1485;;H04L47/762,G06F15/173,709/226,10,1,079-187-850-007-743,10.1109/90.986522,"Cobb, Jorge. ""Preserving Quality of Service Guarantees in Spite of Flow Aggregation"". IEEE/ACM Transactions on Networking vol. 10, No. 1, Feb. 2002.;;Blake et al., ""An Architecture for Differentiated Services,"" The Internet Society (Dec. 1998).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Proposed Draft: PD-00X, Revision 1 (Aug. 2002).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Revision 4 (Dec. 2002).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Revision 5 (Feb. 2003).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Revision 6 (Mar. 2003).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Straw Ballot Revision (7) (Mar. 2003).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Straw Ballot Revision (8) (Mar. 2003).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Letter Ballot Revision (9) (Jun. 2003).;;Anschutz et al., DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Technical Report: TR-059 (Sep. 2003).",ACTIVE
96,US,S,US D0953081 S,194-209-676-058-943,2022-05-31,2022,US 202029747046 F,2020-08-19,US 202029747046 F,2020-08-19,Table,,STEELCASE INC,RAMOS RYAN JEROME;;SNYDER BRIAN K;;VAUGHAN RYAN D;;ALLEN JOHN MARK;;THOMAS THEODORE;;CARRAL O'GORMAN SANTIAGO,STEELCASE INC (2020-07-27),https://lens.org/194-209-676-058-943,Design Right,no,100,0,1,1,0,,,0603;;D 66962,10,0,,,"Elbrook Table Collection by Steelcase, first available: Unknown. Steelcase.com [online], [site visited Feb. 7, 2022], Internet URL: https://www.steelcase.com/products/education-desks-tables/elbrook-table-collection/?drawer_main=images&drawer_sub=on-white (Year: 2021).;;Elbrook Tables by Steelcase, first available: 2021. Studiomurmur.com [online], [site visited Feb. 5, 2022], Internet URL: https://www.studiomurmur.net/steelcase-elbrook (Year: 2022).;;Danish Vintage Organic Shaped Coffee Table by LANOBA Design Balderskilde, first available: Unknown. Aptdeco.com [online], [site visited: Feb. 5, 2022], Internet URL: https://www.aptdeco.com/product/danish-vintage-organic-shaped-coffee-table (Year: 2022).;;MOHD—Mollura Home Design, Ligne Roset Pebble Concave Table, downloaded on Jun. 26, 2020 at https://shop.mohd.it/en-gb/pebbte-tavolino-concavo-d16121.html.;;Article, Amoeba Wild Walnut 42.5″ Wide Coffee Table, downloaded on Jun. 25, 2020 from https://www.article.com/pla/1289/amoeba-wild-walnut-42-5-wide-coffee-table?artcl_campignID=900506311&artcl_network=g&artcl_adgroupid=44470072225&artcl_keyword=&artcl_source=google&gclid=CjwKCAjwqpP2BRBTEiwAfpiD-yOvukBSccluHHofxymNAruv7JDS17wBvV_Crr_iYuxAq3o9PdEXZRoC9foQAvD_BwE.;;Pinterest, downloaded on Aug. 19, 2020, from https://www.pinterest.com/pin/100345897916897678/?nic_v1=1aqlqsfgjlgAl2Wjs7lgJFzeRaRPzWKFR%2BhTaTJdKQqPjT9u2s1Gzn%2BsH%2B36M2eP9F.;;1STDIBS, downloaded on June 25, 2020, from https://www.pinterest.com/pin/97108935704984793/?nic_v1=1auNFKGczfEevW1Bxyb0e%2B7DrCc4wswqAlbhVA5Sk3u4mxslMs2xnkYxdf90D3Vbay.;;CF Interiors, Trent Coffee Table, downloaded on June 25, 2020, from https://cfinteriorsonline.com/products/trent-coffee-table.;;Ultra Modern, Otto Dining Table, downloaded on Jun. 25, 2020 from https://www.pinterest.com/pin/338051515780748851/?nic_v1=1aEerS43iEtoMbSO4FFN%2BtZwScgeZOazzzuckuqaM5b7E7IJoulZYIRSrCJfS5bV%2F9.;;Knoll by Jens Risom, Risom Amoeba Coffee Table downloaded on Jun. 25. 2020, from https://www.knoll.com/product/risom-amoeba-coffee-table.",ACTIVE
97,US,A1,US 2015/0078879 A1,005-986-308-602-071,2015-03-19,2015,US 201314063247 A,2013-10-25,US 201314063247 A;;US 201361878194 P,2013-09-16,AIRCRAFT ENGINE COWL DOOR MOVEMENT CONTROL SYSTEM AND METHOD,"A system and method are provided for controlling the movement of an aircraft engine cowl door between an open position and a closed position. The system includes an electric motor, at least one actuator, and an electrically operated brake. The actuator is coupled to the motor and is operable to move the cowl door between the closed and the open position. The electrically operated brake is coupled to the electric motor and the at least one actuator and is configured, upon being energized, to supply a unidirectional resisting torque load to the electric motor that does not prevent motor rotation.",HONEYWELL INT INC,VAUGHAN RON;;FIZER LEROY ALLEN;;WAWRZYNEK JAMES;;CHAKKERA KEVIN K;;SALAM MOHAMED A;;WARR WILLIAM;;BIRN STEPHEN,HONEYWELL INTERNATIONAL INC (2013-10-14),https://lens.org/005-986-308-602-071,Patent Application,yes,11,10,2,2,0,B64D29/06;;B64D29/06;;F16H25/2204,B64D29/08,415/1;;415/201,0,0,,,,ACTIVE
98,US,S,US D0950284 S,091-306-688-108-207,2022-05-03,2022,US 202029747037 F,2020-08-19,US 202029747037 F,2020-08-19,Table,,STEELCASE INC,RAMOS RYAN JEROME;;SNYDER BRIAN K;;VAUGHAN RYAN D;;ALLEN JOHN MARK;;THOMAS THEODORE;;CARRAL O'GORMAN SANTIAGO,STEELCASE INC (2020-07-27),https://lens.org/091-306-688-108-207,Design Right,no,102,0,1,1,0,,,0603;;D 66962,10,0,,,"Elbrook Table Collection by Steelcase, first available: Unknown. Steelcase.com [online], [site visited Feb. 7, 2022], Internet URL: https://www.steelcase.com/products/education-desks-tables/elbrook-table-collection/?drawer_main=images&drawer_sub=on-white (Year: 2021).;;Overbed Table with Swivel Wheels by Carex, first available: Unknown. Walmart.com [online], [site visited Feb. 8, 2022], Internet URL : https://www.walmart.com/ip/Carex-Overbed-Table-with-Swivel-Wheels-Hospital-Bed-Table-Adjustable-Height-Extra-Large-Surface-Cup-Holder-and-Unique-C-Base/6537518 (Year: 2022).;;Swivel TV Tray Table by Cozy Space, first available: Sep. 1, 2020. Amazon.com [online], [site visited Feb. 8, 2022], Internet URL: https://www.amazon.com/dp/B0881LWKZQ/ref=sspa_dk_detail_3?th=1 (Year: 2020).;;MOHD—Mollura Home Design, Ligne Roset Pebble Concave Table, downloaded on Jun. 26, 2020 at https://shop.mohd.it/en-gb/pebble-tavolino-concavo-d16121.html.;;Article, Amoeba Wild Walnut 42.5″ Wide Coffee Table, downloaded on Jun. 25, 2020 from https:/www.article.com/pla/1289/amoeba-wild-walnut-42-5-wide-coffee-table?artcl_campignID=900506311&artcl_network=g&artcl_adgroupid=44470072225&artcl_keyword=&artcl_source=google&gclid=CjwKCAjwqpP2BRBTEiwAfpiD-yOvukBSccluHHofxymNAruv7JDS17wBvV_Crr_jYuxAg3o9PdEXZRoC9foQAvD_BwE.;;Pinterest, downloaded on Aug. 19, 2020, from https://www.pinterest.com/pin/100345897916897678/?nic_v1=1aqlqsfgjlgAl2Wjs7lgJFzeRaRPzWKFR%2BhTaTJdKQqPjT9u2s1Gzn%2BsH%2B36M2eP9F.;;1STDIBS, downloaded on Jun. 25, 2020, from https://www.pinterest.com/pin/97108935704984793/?nic_v1=1auNFKGczfEevW1Bxyb0e%2B7DrCc4wswqAlbhVA5Sk3u4mxslMs2xnkYxdf90D3Vbay.;;CF Interiors, Trent Coffee Table, downloaded on Jun. 25, 2020, from https://cfinteriorsonline.com/products/trent-coffee-table.;;Ultra Modern, Otto Dining Table, downloaded on Jun. 25, 2020 from https://www.pinterest.com/pin/338051515780748851/?nic_v1=1aEerS43iEtoMbSO4FFN%2BtZwScgeZOazzzuckuqaM5b7E7IJoulZYIRSrCJfS5bV%2F9.;;Knoll by Jens Risom, Risom Amoeba Coffee Table downloaded on Jun. 25, 2020, from https://www.knoll.com/product/risom-amoeba-coffee-table.",ACTIVE
99,US,S,US D0950283 S,063-742-879-769-652,2022-05-03,2022,US 202029747050 F,2020-08-19,US 202029747050 F,2020-08-19,Table,,STEELCASE INC,RAMOS RYAN JEROME;;SNYDER BRIAN K;;VAUGHAN RYAN D;;ALLEN JOHN MARK;;THOMAS THEODORE;;CARRAL O'GORMAN SANTIAGO,STEELCASE INC (2020-07-27),https://lens.org/063-742-879-769-652,Design Right,no,104,1,1,1,0,,,0603;;D 66961,10,0,,,"Elbrook Table Collection by Steelcase, first available: Unknown. Steelcase.com [online], [site visited Feb. 7, 2022], Internet URL: https://www.steelcase.com/products/education-desks-tables/elbrook-table-collection/?drawer_main=images&drawer_sub=on-white (Year: 2021).;;Elbrook Tables by Steelcase, first available: 2021. Studiomurmur.com [online], [site visited Feb. 5, 2022], Internet URL: https://www.studiomurmur.net/steelcase-elbrook (Year: 2022).;;Hana Shape Coffee & Side Table, first available: Unknown. Propertyfurniture.com [online], [site visited: Feb. 5, 2022], Internet URL: https://propertyfurniture.com/product/hana-shape-coffee-side-table-quickship/ (Year: 2022).;;Mohd—Mollura Home Design, Ligne Reset Pebble Concave Table, downloaded on Jun. 26, 2020 at https:// shop.mohd.it/en-gb/pebble-tavolino-concavo-d16121.html.;;Article, Amoeba Wild Walnut 42.5″ Wide Coffee Table, downloaded on Jun. 25, 2020, from https://www.article.com/pla/1289/amoeba-wild-walnut-42-5-wide-coffee-table?artcl_campignID=900506311&artcl_network=g&artcl_adgroupid=44470072225&artcl_keyword=&artcl_source=google&gclid=CjwKCAjwpP2BRBTEiwAfpiD-yOvukBSccluHHofxymNAruv7JDS17wBvV_Crr_iYuxAq3o9PdEXZRoC9foQAvD_BwE.;;Pinterest, downloaded on Aug. 19, 2020, from https://www.pinterest.com/pin/100345897916897678/?nic_v1=1aqIqsfgjIgAI2Wjs7IgJFzeRaRPzWKFR%2BhTaTJdKQqPjT9u2s1Gzn%2BsH%2B36M2eP9F.;;1STDIBS, downloaded on Jun. 25, 2020, from https://www.pinterest.com/pin/97108935704984793/?nic_v1=1auNFKGczfEevW1Bxyb0e%2B7DrCc4wswqAIbhVA5Sk3u4mxslMs2xnkYxdf90D3Vbay.;;CF Interiors, Trent Coffee Table, downloaded on Jun. 25, 2020, from https://cfinteriorsonline.com/products/trent-coffee-table.;;Ultra Modern, Otto Dining Table, downloaded on Jun. 25, 2020 from https://www.pinterest.com/pin/338051515780748851/?nic_v1=1aEerS43iEtoMbSO4FFN%2BtZwScgeZOazzzuckuqaM5b7E7IJoulZYIRSrCJfS5bV%2F9;;Knoll by Jens Risom, Risom Amoeba Coffee Table downloaded on Jun. 25, 2020, from https://www.knoll.com/product/risom-amoeba-coffee-table.",ACTIVE
100,US,S,US D0949611 S,050-336-534-543-409,2022-04-26,2022,US 202029747059 F,2020-08-19,US 202029747059 F,2020-08-19,Table,,STEELCASE INC,RAMOS RYAN JEROME;;SNYDER BRIAN K;;VAUGHAN RYAN D;;ALLEN JOHN MARK;;THOMAS THEODORE;;CARRAL O'GORMAN SANTIAGO,STEELCASE INC (2020-07-27),https://lens.org/050-336-534-543-409,Design Right,no,101,0,1,1,0,,,0603;;D 66962,11,0,,,"Elbrook Table Collection by Steelcase, first available: Unknown. Steelcase.com [online], [site visited Feb. 7, 2022], Internet URL: https://www.steelcase.com/products/education-desks-tables/elbrook-table-collection/?drawer_main=images&drawer_sub=on-white (Year: 2021).;;Elbrook Tables by Steelcase, first available: 2021. Studiomurmur.com [online], [site visited Feb. 5, 2022], Internet URL: https://www.studiomurmur.net/steelcase-elbrook (Year: 2022).;;Danish Vintage Organic Shaped Coffee Table by LANOBA Design Balderskilde, first available: Unknown. Aptdeco.com [online], [site visited: Feb. 5, 2022], Internet URL: https://www.aptdeco.com/product/danish-vintage-organic-shaped-coffee-table (Year: 2022).;;Large Vintage Laauser Organic Kidney—Shaped Coffee Table by Svante Skogh, first available: Unknown. Design-mkt.com [online], [site visited: Feb. 5, 2022], Internet URL: https://www.design-mkt.com/164354-large-vintage-laauser-organic-kidney-shaped-coffee-table-by-svante-skogh-1960s.html (Year: 2022).;;MOHD—Mollura Home Design, Ligne Reset Pebble Concave Table, downloaded on Jun. 26, 2020 at https://shop.mohd.it/en-gb/pebble-tavolino-concavo-d16121.html.;;Article, Amoeba Wild Walnut 42.5″ Wide Coffee Table, downloaded on Jun. 25, 2020 from https:/wwww.article.com/pla/1289/amoeba-wild-walnut-42-5-wide-coffee-table?artcl_campignID=900506311&artcl_network=g&artcl_adgroupid=44470072225&artcl_keyword=&artcl_source=google&gclid=CjwKCAjwqpP2BRBTEiwAfpiD-yOvukBSccluHHofxymNAruv7JDS17wBvV_Crr_jYuxAq3o9PdEXZRoC9foQAvD_BwE.;;Pinterest, downloaded on Aug. 19, 2020, from https://www.pinterest.com/pin/100345897916897678/?nic_v1=1aqlqsfgjlgAI2Wjs7lgJFzeRaRPzWKFR%2BhTaTJdKQqPjT9u2s1Gzn%2BsH%2B36M2eP9F.;;1STDIBS, downloaded on Jun. 25, 2020, from https://www.pinterest.com/pin/97108935704984793/?nic_v1=1auNFKGczfEevW1Bxyb0e%2B7DrCc4wswqAlbhVA5Sk3u4mxslMs2xnkYxdf90D3Vbay.;;CF Interiors, Trent Coffee Table, downloaded on Jun. 25, 2020, from https://cfinteriorsonline.com/products/trent-coffee-table.;;Ultra Modern, Otto Dining Table, downloaded on Jun. 25, 2020 from https://www.pinterest.com/pin/338051515780748851/?nic_v1=1aEerS43iEtoMbSO4FFN%2BtZwScgeZOazzzuckuqaM5b7E7IJoulZYlRSrCJfS5bV%2F9.;;Knoll by Jens Risom, Risom Amoeba Coffee Table downloaded on Jun. 25, 2020, from https://www.knoll.com/product/risom-amoeba-coffee-table.",ACTIVE
101,US,B2,US 9701414 B2,030-604-058-530-975,2017-07-11,2017,US 201314063247 A,2013-10-25,US 201314063247 A;;US 201361878194 P,2013-09-16,Aircraft engine cowl door movement control system and method,"A system and method are provided for controlling the movement of an aircraft engine cowl door between an open position and a closed position. The system includes an electric motor, at least one actuator, and an electrically operated brake. The actuator is coupled to the motor and is operable to move the cowl door between the closed and the open position. The electrically operated brake is coupled to the electric motor and the at least one actuator and is configured, upon being energized, to supply a unidirectional resisting torque load to the electric motor that does not prevent motor rotation.",HONEYWELL INT INC,VAUGHAN RON;;FIZER LEROY ALLEN;;WAWRZYNEK JAMES;;CHAKKERA KEVIN K;;SALAM MOHAMED A;;WARR WILLIAM;;BIRN STEPHEN,HONEYWELL INTERNATIONAL INC (2013-10-14),https://lens.org/030-604-058-530-975,Granted Patent,yes,16,2,2,2,0,B64D29/06;;B64D29/06;;F16H25/2204,B64D29/06;;B64D27/00,,0,0,,,,ACTIVE
102,US,S,US D0949610 S,088-534-091-006-511,2022-04-26,2022,US 202029747056 F,2020-08-19,US 202029747056 F,2020-08-19,Table,,STEELCASE INC,RAMOS RYAN JEROME;;SNYDER BRIAN K;;VAUGHAN RYAN D;;ALLEN JOHN MARK;;THOMAS THEODORE;;CARRAL O'GORMAN SANTIAGO,STEELCASE INC (2020-07-27),https://lens.org/088-534-091-006-511,Design Right,no,101,1,1,1,0,,,0603;;D 66962,11,0,,,"Elbrook Table Collection by Steelcase, first available: Unknown. Steelcase.com [online], [site visited Feb. 7, 2022], Internet URL: https://www.steelcase.com/products/education-desks-tables/elbrook-table-collection/?drawer_main=images&drawer_sub=on-white (Year: 2021).;;Elbrook Tables by Steelcase, first available: 2021. Studiomurmur.com [online], [site visited Feb. 5, 2022], Internet URL: https://www.studiomurmur.net/steelcase-elbrook (Year: 2022).;;Danish Vintage Organic Shaped Coffee Table by LANOBA Design Balderskilde, first available: Unknown. Aptdeco.com [online], [site visited: Feb. 5, 2022], Internet URL: https://www.aptdeco.com/product/danish-vintage-organic-shaped-coffee-table (Year: 2022).;;Large Vintage Laauser Organic Kidney—Shaped Coffee Table by Svante Skogh, first available: Unknown. Design-mkt.com [online], [site visited: Feb. 5, 2022], Internet URL: https://www.design-mkt.com/164354-large-vintage-laauser-organic-kidney-shaped-coffee-table-by-svante-skogh-1960s.html (Year: 2022).;;MOHD—Mollura Home Design, Ligne Reset Pebble Concave Table, downloaded on Jun. 26, 2020 at https://shop.mohd.it/en-gb/pebble-tavolino-concavo-d16121.html.;;Article, Amoeba Wild Walnut 42.5″ Wide Coffee Table, downloaded on Jun. 25, 2020 from https://www.article.com/pla/1289/amoeba-wild-walnut-42-5-wide-coffee-table?artcl_campignID-900506311&artcl_network=g&artcl_adgroupid=44470072225&artcl_keywords&artcl_source=google&gclid=CjwKCAjwqpP2BRBTEiwAfpiD-yOvukBSccluHHofxymNAruv7JDS17wBvV_Crr_iYuxAq3o9PdEXZRoC9foQAvD_BwE.;;Pinterest, downloaded on Aug. 19, 2020, from https://www.pinterest.com/pin/100345897916897678/?nic_v1=1aqlqsfgjlgAI2Wjs7lgJFzeRaRPzWKFR%2BhTaTJdKQqPjT9u2s1Gzn%2BsH%2B36M2eP9F.;;1stdibs, downloaded on Jun. 25, 2020, from https://www.pinterest.com/pin/97108935704984793/?nic_v1=1 auNFKGczfEevW1Bxyb0e%2B7DrCc4wswqAlbhVA5Sk3u4mxslMs2xnkYxdf90D3Vbay.;;CF Interiors, Trent Coffee Table, downloaded on Jun. 25, 2020, from https://cfinteriorsoniine.com/products/trent-coffee-table.;;Ultra Modern, Otto Dining Table, downloaded on Jun. 25, 2020 from https://www.pinferest.com/pin/338051515780748851/?nic_v1=1aEerS43iEtoMbSO4FFN%2BtZwScgeZOazzzuckuqaM5b7E7IJoulZYIRSrCJfS5bV%2F9.;;Knoll by Jens Risom, Risom Amoeba Coffee Table downloaded on Jun. 25, 2020, from https://www.knoll.com/product/risom-amoeba-coffee-table.",ACTIVE
103,US,A1,US 2012/0103118 A1,194-429-547-046-764,2012-05-03,2012,US 91639710 A,2010-10-29,US 91639710 A,2010-10-29,Detachable Reversible Pick Mechanism for Feeding Media From a Media Tray of an Image Forming Device,"A detachable reversible pick mechanism for a media input tray. The pick mechanism comprises a reversible drive transmission having a drive shaft gear operatively connected to a pick axle gear, the drive shaft gear slidably engageable onto a cantilevered drive shaft extending from a housing, a pick axle having a pick wheel at each end, the pick axle operatively connected to the pick axle gear; and a transmission housing consisting of a top, a bottom, and a side surface defining a cavity therein for containing the reversible drive transmission, an opening in a front portion and in a rear portion of the transmission housing through which the pick axle and drive shaft, respectively, pass, the front portion dimensioned so that the pick wheels each extend beyond the top and the bottom of the front portion, and a releasable latch mounted on the side surface for rotatably engaging a free end of the cantilevered drive shaft to axially position the pick mechanism on the drive shaft, the latch allowing a user to readily dismount the pick mechanism for service or replacement.",BLAIR BRIAN ALLEN;;FICHTER DUSTIN DANIEL;;INOUYE DEREK MASAMI;;MITCHELL STACEY VAUGHAN;;SHANOR MICHAEL JAMES;;TONGES JEFFREY LAWRENCE;;TRIPLETT EDWARD LYNN,BLAIR BRIAN ALLEN;;FICHTER DUSTIN DANIEL;;INOUYE DEREK MASAMI;;MITCHELL STACEY VAUGHAN;;SHANOR MICHAEL JAMES;;TONGES JEFFREY LAWRENCE;;TRIPLETT EDWARD LYNN,LEXMARK INTERNATIONAL INC (2010-10-29),https://lens.org/194-429-547-046-764,Patent Application,yes,6,0,2,2,0,G03G15/6511;;G03G15/6511;;Y10T74/19605;;Y10T74/19605,F16H57/00,74/404,0,0,,,,ACTIVE
104,US,B2,US 8371572 B2,064-281-325-649-613,2013-02-12,2013,US 91639710 A,2010-10-29,US 91639710 A,2010-10-29,Detachable reversible pick mechanism for feeding media from a media tray of an image forming device,"A detachable reversible pick mechanism for a media input tray. The pick mechanism comprises a reversible drive transmission having a drive shaft gear operatively connected to a pick axle gear, the drive shaft gear slidably engageable onto a cantilevered drive shaft extending from a housing, a pick axle having a pick wheel at each end, the pick axle operatively connected to the pick axle gear; and a transmission housing consisting of a top, a bottom, and a side surface defining a cavity therein for containing the reversible drive transmission, an opening in a front portion and in a rear portion of the transmission housing through which the pick axle and drive shaft, respectively, pass, the front portion dimensioned so that the pick wheels each extend beyond the top and the bottom of the front portion, and a releasable latch mounted on the side surface for rotatably engaging a free end of the cantilevered drive shaft to axially position the pick mechanism on the drive shaft, the latch allowing a user to readily dismount the pick mechanism for service or replacement.",LEXMARK INT INC;;BLAIR BRIAN ALLEN;;FICHTER DUSTIN DANIEL;;INOUYE DEREK MASAMI;;MITCHELL STACEY VAUGHAN;;SHANOR MICHAEL JAMES;;TONGES JEFFREY LAWRENCE;;TRIPLETT EDWARD LYNN,BLAIR BRIAN ALLEN;;FICHTER DUSTIN DANIEL;;INOUYE DEREK MASAMI;;MITCHELL STACEY VAUGHAN;;SHANOR MICHAEL JAMES;;TONGES JEFFREY LAWRENCE;;TRIPLETT EDWARD LYNN,LEXMARK INTERNATIONAL INC (2010-10-29),https://lens.org/064-281-325-649-613,Granted Patent,yes,6,8,2,2,0,G03G15/6511;;G03G15/6511;;Y10T74/19605;;Y10T74/19605,B65H3/06,271/117,0,0,,,,ACTIVE
105,US,A,US 5907021 A,181-919-271-371-362,1999-05-25,1999,US 4829398 A,1998-03-26,US 4829398 A;;US 76919196 A;;US 54597395 A;;US 889395 P,1995-10-20,High temperature olefin polymerization process,"A polymerization process for olefinically or acetylenically unsaturated monomers is disclosed. The process comprises contacting the one or more of the monomers with a suitable ionic catalyst system in the presence of a long-chain, linear alkyl ligand-containing organo aluminum compound. Preferred ionic catalysts are derived from 1) bridged hafnium compounds, 2) silicon bridged monocyclopentadienyl titanium compounds and 3) unbridged, bulky Group 15 containing, bulky monocyclopentadienyl titanium compounds, and a non-coordinating anion precursor compound. A class of preferred anion precursors consists of hydrated salts comprising a Group 1 or 2 cation and a non-coordinating anion. Using the preferred ionic catalysts high temperature processes, e.g., at or above 90.degree. C. can be conducted to prepare polyolefins, particularly ethylene copolymers, of both high molecular weight and high comonomer content.",EXXON CHEMICAL PATENTS INC,TURNER HOWARD WILLIAM;;SPEED CHARLES STANLEY;;FOLIE BERNARD JEAN;;CROWTHER DONNA JEAN;;VAUGHAN GEORGE ALAN;;FISHER RICHARD ALLEN;;WALZER JR JOHN FLEXER,,https://lens.org/181-919-271-371-362,Granted Patent,yes,20,70,2,19,0,C08F210/16;;C08F210/16;;C08F4/65908;;C08F4/65908;;C08F4/65912;;C08F4/65912;;C08F4/6592;;C08F4/6592;;C08F4/65922;;C08F4/65922;;C08F10/00;;C08F10/00;;C08F210/18;;C08F210/18;;Y02P20/582;;Y02P20/582,C08F2/04;;C08F4/642;;C08F4/643;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F210/16;;C08F210/18,526/160;;526/127;;526/132;;526/133;;526/151;;526/152;;526/348.2;;526/348.6,2,0,,,"Production of Polyacetylene , Patent Abstracts of Japan, Matsushita Electric Ind. Co., Ltd., vol. 14, No. 475, (C 0770), Oct. 17, 1990.;;High Temperature Olefin Polymerization Process , Research Disclosures, vol. 388, No. 035, Aug. 10, 1996.",EXPIRED
106,US,A,US 5767208 A,099-178-840-259-710,1998-06-16,1998,US 76919196 A,1996-12-18,US 76919196 A;;US 54597395 A;;US 889395 P,1995-10-20,High temperature olefin polymerization process,"A polymerization process for olefinically or acetylenically unsaturated monomers is disclosed. The process comprises contacting the one or more of the monomers with a suitable ionic catalyst system in the presence of a long-chain, linear alkyl ligand-containing organo aluminum compound. Preferred ionic catalysts are derived from 1) bridged hafnium compounds, 2) silicon bridged monocyclopentadienyl titanium compounds and 3) unbridged, bulky Group 15 containing, bulky monocyclopentadienyl titanium compounds, and a non-coordinating anion precursor compound. A class of preferred anion precursors consists of hydrated salts comprising a Group 1 or 2 cation and a non-coordinating anion. Using the preferred ionic catalysts high temperature processes, e.g., at or above 90.degree. C. can be conducted to prepare polyolefins, particularly ethylene copolymers, of both high molecular weight and high comonomer content.",EXXON CHEMICAL PATENTS INC,TURNER HOWARD WILLIAM;;VAUGHAN GEORGE ALAN;;FISHER RICHARD ALLEN;;WALZER JR JOHN FLEXER;;SPEED CHARLES STANLEY;;FOLIE BERNARD JEAN;;CROWTHER DONNA JEAN,EXXON CHEMICAL PATENTS INC (1997-03-20),https://lens.org/099-178-840-259-710,Granted Patent,yes,18,111,2,19,0,C08F210/16;;C08F210/16;;C08F4/65908;;C08F4/65908;;C08F4/65912;;C08F4/65912;;C08F4/6592;;C08F4/6592;;C08F4/65922;;C08F4/65922;;C08F10/00;;C08F10/00;;C08F210/18;;C08F210/18;;Y02P20/582;;Y02P20/582,C08F2/04;;C08F4/642;;C08F4/643;;C08F4/659;;C08F4/6592;;C08F10/00;;C08F210/16;;C08F210/18,526/160;;526/127;;526/132;;526/133;;526/134;;526/151;;526/152;;526/348.2;;526/348.6,2,0,,,"Production of Polyacetylene , Patent Abstracts of Japan, Matsushita Electric Ind. Co., Ltd., vol. 14, No. 475, (C 0770), Oct. 17, 1990.;;High Temperature Olefin Polymerization Process , Research Disclosures, vol. 388, No. 035, Aug. 10, 1996.",EXPIRED
107,DE,I1,DE 122004000004 I1,030-184-561-296-030,2004-08-12,2004,DE 122004000004 C,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Humane Antikörper welche an Humanen TNFalpha binden.,,ABOTT BIOTECHNOLOGY LTD,SALFELD JOCHEN;;ALLEN DEBORAH;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN;;MCGUINESS BRIAN;;ROBERTS ANDREW;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS;;SCHOENHAUT DAVID;;VAUGHAN J;;WILTON J,,https://lens.org/030-184-561-296-030,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
108,BG,B1,BG 66509 B1,080-972-447-637-795,2015-11-30,2015,BG 11070310 A,2010-07-12,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,"ЧОВЕШКО АНТИТЯЛО ИЛИ АНТИГЕН-СВЪРЗВАЩА ЧАСТ ОТ НЕГО, ФАРМАЦЕВТИЧЕН СЪСТАВ, КОЙТО ГИ СЪДЪРЖА И ТЯХНОТО ИЗПОЛЗВАНЕ","Изобретението се отнася до фармацевтични състави, включващи изолирани човешки антитела или тяхна антиген-свързваща част, които свързват човешки TNFaлфа, и до тяхното приложение за производство на медикамент за лечение на нарушения, при които TNFaлфа активността е с вредно действие.",ABBVIE BIOTECHNOLOGY LTD,WILTON ALISON;;ROBERTS ANDREW;;LABKOVSKY BORIS;;SCHOENHAUT DAVID;;ALLEN DEBORAH;;HOOGENBOOM HENDRICUS;;SALFELD JOCHEN;;MANKOVICH JOHN;;WHITE MICHAEL;;SAKORAFAS PAUL;;VAUGHAN TRISTAN;;KAYMAKCALAN ZEHRA;;MCGUINESS BRIAN,,https://lens.org/080-972-447-637-795,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
109,BG,B1,BG 64776 B1,105-281-168-572-784,2006-03-31,2006,BG 10753798 A,1998-09-08,US 59922696 A;;US 3147696 P,1996-02-09,INHIBITION OF HUMAN TNF ALPHA ACTIVITY,The invention relates to a method for the inhibition of human TNFalpha activity by using isolated human antibody or its antigen-connection part. This property to inhibit TNFalpha finds application to produce medicaments for the treatment of diseases wherein the hTHFalpha activity is detrimental.,BASF AG,SALFELD JOCHEN;;ALLEN DEBORAH;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN;;MCGUINNESS BRIAN;;ROBERTS ANDREW;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN;;WHITE MICHAEL;;WILTON ALISON,,https://lens.org/105-281-168-572-784,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/26;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/14;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
110,BG,B1,BG 64564 B1,146-158-185-433-798,2005-07-29,2005,BG 10275598 A,1998-09-08,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES BINDING HUMAN TUMOUR NECROTIC FACTOR ALPHA,"The invention relates to human antibodies, preferably recombinant human antibodies which are specifically bound to human tumour necrotic factor alpha(TNFalpha). The antibodies have high afinity to hTNFalpha, e.g. Kd = 10-8 M or less, low hTNFalpha dissociate velocity, e.g. Koff = 10-3sec-1 or less, and neutralize the hTNFalpha activity in vitro and in vivo. Antibody of this invention can be an antibody with its full length or its antigene-binding part. The antibodies or parts thereof are applicable for the detection of hTNFalpha and for the inhibition of hTNFalpha activity, for example in patients suffering from indispositions where the hTNFalpha activity is harmfull. The invention also relates to nucleinic acids, vectors and host cells for the expression of recombinant human antibodies and to methods for their synthetization.",BASF AG,SALFELD JOCHEN;;ALLEN DEBORAH;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN;;MCGUINNESS BRIAN;;ROBERTS ANDREW;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN;;WHITE MICHAEL;;WILTON ALISON,,https://lens.org/146-158-185-433-798,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
111,CN,A,CN 103275221 A,072-228-414-768-558,2013-09-04,2013,CN 201310141436 A,1997-02-10,CN 97193635 A;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human tnf alpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha (hTNF alpha ) are disclosed. These antibodies have high affinity for hTNF alpha (e.g., K[d]=1X10<-8> M or less), a slow off rate for hTNF alpha dissociation (e.g., K[off] = 1X10<-3>s<-1> or less) and neutralize hTNF alpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF alpha and for inhibiting hTNF alpha activity, e.g., in a human subject suffering from a disorder in which hTNF alpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN;;ALLEN DEBORAH;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN;;MCGUINNESS BRIAN;;ROBERTS ANDREW;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN;;WHITE MICHAEL;;WILTON ALISON,,https://lens.org/072-228-414-768-558,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
112,CN,A,CN 102070715 A,034-927-027-124-597,2011-05-25,2011,CN 201010552509 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNF alpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFalpha) are disclosed. These antibodies have high affinity for hTNFalpha (e.g., Kd=1x10-8 M or less), a slow off rate for hTNFalpha dissociation (e.g., Koff=1x10-3 sec-1 or less) and neutralize hTNFalpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFalpha and for inhibiting hTNFalpha activity, e.g., in a human subject suffering from a disorder in which hTNFalpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,JOCHEN SALFELD;;DEBORAH ALLEN;;ZEHRA KAYMAKCALAN;;BORIS LABKOVSKY;;JOHN MANKOVICH;;BRIAN MCGUINNESS;;ANDREW ROBERTS;;PAUL SAKORAFAS;;HENDRICUS HOOGENBOOM;;DAVID SCHOENHAUT;;TRISTAN VAUGHAN;;MICHAEL WHITE;;ALISON WILTON,,https://lens.org/034-927-027-124-597,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/18;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P3/04;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
113,CN,C,CN 100429232 C,095-010-782-279-670,2008-10-29,2008,CN 03100958 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,,ABBOTT BIOTECH LTD,SALFELD JOCHEN;;ALLEN DEBORAH;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN;;MCGUINNESS BRIAN;;ROBERTS ANDREW;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN;;WHITE MICHAEL;;WILTON ALISON,ABBVIE BIOTECHNOLOGY LTD. (2013-08-14),https://lens.org/095-010-782-279-670,Granted Patent,no,4,1,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/577;;G01N33/68,,1,1,072-378-691-723-546,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990,"Human anti-self antibodies with high specifity fom phagedisplay libraries. GRIFFITH ET AL.EMBO J.,Vol.12 No.2. 1993",EXPIRED
114,DE,T2,DE 69721548 T2,020-258-205-284-013,2004-04-01,2004,DE 69721548 T,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN,,ABBOTT LAB BERMUDA LTD,SALFELD G;;ALLEN J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH A;;MCGUINESS T;;ROBERTS J;;SAKORAFAS PAUL;;HOOGENBOOM R;;SCHOENHAUT DAVID;;VAUGHAN J;;WHITE MICHAEL;;WILTON J,,https://lens.org/020-258-205-284-013,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
115,BG,A,BG 109311 A,098-889-503-263-422,2006-03-31,2006,BG 10931100 A,2000-01-01,US 59922696 A;;US 3147696 P,1996-02-09,PHARMACEUTICAL COMPOSITION INCLUDING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha AND THE APPLICATION THEREOF,"The invention relates to pharmaceutical compositions including isolated human antibodies or their antigen binding part which bind the human TNFalpha, and to their application for the preparation of amedicament for the treatment of disorders wherein the TNFalpha activity is detrimental.",ABBOTT BIOTECH LTD,SALFELD JOCHEN;;ALLEN DEBORAH;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN;;MCGUINNESS BRIAN;;ROBERTS ANDREW;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN;;WHITE MICHAEL;;WILTON ALISON,,https://lens.org/098-889-503-263-422,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
116,BG,B1,BG 66195 B1,126-711-123-416-656,2012-01-31,2012,BG 10931105 A,2005-09-30,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,PHARMACEUTICAL COMPOSITION INCLUDING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha AND THE APPLICATION THEREOF,"The invention relates to pharmaceutical compositions including isolated human antibodies or their antigen binding part which bind the human TNFalpha, and to their application for the preparation of amedicament for the treatment of disorders wherein the TNFalpha activity is detrimental.",ABBOTT BIOTECH LTD,SALFELD JOCHEN;;ALLEN DEBORAH;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN;;MCGUINNESS BRIAN;;ROBERTS ANDREW;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN;;WHITE MICHAEL;;WILTON ALISON,,https://lens.org/126-711-123-416-656,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
117,CN,C,CN 1300173 C,123-777-825-106-436,2007-02-14,2007,CN 97193635 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind huma TNF 'alpha',,ABBOTT BIOTECH LTD,SALFELD JOCHEN;;ALLEN DEBORAH;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN;;MCGUINNESS BRIAN;;ROBERTS ANDREW;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN;;WHITE MICHAEL;;WILTON ALISON,"ABBVIE BIOTECHNOLOGY LTD. (2013-08-14);;ROOM #, AIBOTESHIYAN   BERMUDA   CO., LTD. (2003-09-22);;ABBOT BIOISYSTECH CO., LTD. (2006-03-10)",https://lens.org/123-777-825-106-436,Granted Patent,no,3,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
118,CN,A,CN 1504752 A,058-504-475-695-090,2004-06-16,2004,CN 03100958 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,公开了特异性与人肿瘤坏死因子α(hTNFα)结合的人抗体，最好为重组人抗体。这些抗体对hTNFα具有高亲和性(例如，K#-[d]不高于1×10#+[-8]M)和低解离速率(例如，K#-[off]不高于1×10#+[-3]s#+[-1])并在体外和体内中和hTNFα活性。本发明的抗体可以是全长抗体或是其抗原结合部分。本发明的抗体或抗体部分可以用于检测hTNFα并例如在患有其中hTNFα活性是有害的紊乱的人类受治疗者中抑制hTNFα活性。本发明亦包括表达本发明重组人抗体的核酸、载体和宿主细胞、以及合成所述重组人抗体的方法。,ABBOTT BIOTECH LTD,SALFELD JOCHEN;;ALLEN DEBORAH;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN;;MCGUINNESS BRIAN;;ROBERTS ANDREW;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN;;WHITE MICHAEL;;WILTON ALISON,ABBVIE BIOTECHNOLOGY LTD. (2013-08-14),https://lens.org/058-504-475-695-090,Patent Application,no,0,1,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
119,BG,A,BG 112042 A,098-663-135-437-713,2015-10-30,2015,BG 11204215 A,2015-06-24,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,HUMAN ANTIBODIES BINDING HUMAN TUMOR NECROSIS FACTOR ALPHA (TNF ALPHA),"The human antibodies described are preferably recombinant human antibodies which bind specifically to human tumor necrosis factor (TNF alpha). These antibodies possess high affinity to hTNF alpha (e.g. Kd = 10-8 M or less), low rate of dissociation of hTNF alpha (e.g. Koff = 10-3 sес-1 М or less) and neutralize the hTNF alpha activity in vitro and in vivo. An antibody, according to the invention, can be an antibody in its full length or its antigen-binding portion. The antibodies or a portion of the antibodies of the invention are applicable for detecting hTNF alpha and for inhibiting hTNF alpha activity. The invention also encompasses nucleic acids, vectors, and host cells for expression of recombinant human antibodies, according to the invention.",ABBVIE BIOTECHNOLOGY LTD,WILTON ALISON;;ROBERTS ANDREW;;LABKOVSKY BORIS;;SCHOENHAUT DAVID;;ALLEN DEBORAH;;HOOGENBOOM HENDRICUS;;SALFELD JOCHEN;;MANKOVICH JOHN;;WHITE MICHAEL;;SAKORAFAS PAUL;;VAUGHAN TRISTAN;;KAYMAKCALAN ZEHRA;;MCGUINESS BRIAN,,https://lens.org/098-663-135-437-713,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
120,BG,A,BG 110703 A,008-215-409-287-49X,2010-10-29,2010,BG 11070310 A,2010-07-12,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,PHARMACEUTICAL COMPOSITION COMPRISING HUMAN ANTIBODIES THAT BIND HUMAN TNF-ALPHA AND APPLICATION OF THIS COMPOSITION,The invention relates to pharmaceutical compositions comprising isolated human antibodies or their antigen-binding component which bind human TNF-alpha and to their application in the production of amedication for the treatment of disorders where TNF-alpha activity has adverse effects.,ABBOTT BIOTECH LTD,SALFELD JOCHEN;;ALLEN DEBORAH;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN;;MCGUINNESS BRIAN;;ROBERTS ANDREW;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN;;WHITE MICHAEL;;WILTON ALISON,,https://lens.org/008-215-409-287-49X,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
121,US,A1,US 2005/0050301 A1,173-268-124-260-64X,2005-03-03,2005,US 65237903 A,2003-08-29,US 65237903 A,2003-08-29,Extensible user interface,"A method, apparatus, computer system and computer program product that enable a server to provide information and control the display of the information at a client dynamically without being persistently connected to the client. Functionality of the user interface can be changed without changing a client application displaying the information, installing a new application on the client computer system, or maintaining a persistent network connection between the client computer system and the server computer system. A control program running on the client computer system is configured to operate according to instructions provided by the server. The instructions provide information such as particular modules to present within the user interface and the layout of windows that provide access to the modules. The server also provides instructions for responses to be performed upon receiving events.",YAHOO INC,WHITTLE DERRICK WANG;;SOLLICITO VINCENT LOUIS;;SEITZ EDWARD F;;DAVIS BROCKTON SCOTT;;OWENS STEPHEN KENT;;VAUGHAN RICHARD GEORGE;;BOLLAS JAMES ZACHARY;;GUE ROBERT S;;BIDDY JAMES BRADFORD;;WOLFORD MICHAEL R;;DOWDS STEVEN ALLEN,OATH INC (2017-12-31);;YAHOO! INC (2003-08-28);;YAHOO HOLDINGS INC (2017-06-13),https://lens.org/173-268-124-260-64X,Patent Application,yes,18,170,1,20,0,G06F9/451;;G06F9/451,G06F9/44;;G06F15/00;;G06F17/00,712/32;;X7071,0,0,,,,DISCONTINUED
122,WO,A2,WO 2005/022337 A2,064-743-658-039-948,2005-03-10,2005,US 2004/0027874 W,2004-08-25,US 65237903 A;;US 65260703 A;;US 65192303 A,2003-08-29,EXTENSIBLE USER INTERFACE,"A method, apparatus, computer system and computer program product that enable a server to provide information and control the display of the information at a client dynamically without being persistently connected to the client. Functionality of the user interface can be changed without changing a client application displaying the information, installing a new application on the client computer system, or maintaining a persistent network connection between the client computer system and the server computer system. A control program running on the client computer system is configured to operate according to instructions provided by the server. The instructions provide information such as particular modules to present within the user interface and the layout of windows that provide access to the modules. The server also provides instructions for responses to be performed upon receiving events.",YAHOO INC;;WHITLE DERRICK WANG;;SOLLICITO VINCENT LOUIS;;SEITZ EDWARD F;;DAVIS BROCKTON SCOTT;;OWENS STEPHEN KENT;;VAUGHAN RICHARD GEORGE;;BOLLAS JAMES ZACHARY;;GUE ROBERT S;;BIDDY JAMES BRADFORD;;WOLFORD MICHAEL R;;DOWDS STEVEN ALLEN,WHITLE DERRICK WANG;;SOLLICITO VINCENT LOUIS;;SEITZ EDWARD F;;DAVIS BROCKTON SCOTT;;OWENS STEPHEN KENT;;VAUGHAN RICHARD GEORGE;;BOLLAS JAMES ZACHARY;;GUE ROBERT S;;BIDDY JAMES BRADFORD;;WOLFORD MICHAEL R;;DOWDS STEVEN ALLEN,,https://lens.org/064-743-658-039-948,Patent Application,yes,0,4,2,20,0,G06F3/04855;;G06F3/04842;;G06F3/0482;;G06F8/34;;G06F8/38,G06F/,,0,0,,,,PENDING
123,WO,A3,WO 2005/022337 A3,119-181-428-729-021,2006-05-11,2006,US 2004/0027874 W,2004-08-25,US 65237903 A;;US 65260703 A;;US 65192303 A,2003-08-29,EXTENSIBLE USER INTERFACE,"A method, apparatus, computer system and computer program product that enable a server to provide information and control the display of the information at a client dynamically without being persistently connected to the client. Functionality of the user interface can be changed without changing a client application displaying the information, installing a new application on the client computer system, or maintaining a persistent network connection between the client computer system and the server computer system. A control program running on the client computer system is configured to operate according to instructions provided by the server. The instructions provide information such as particular modules to present within the user interface and the layout of windows that provide access to the modules. The server also provides instructions for responses to be performed upon receiving events.",YAHOO INC;;WHITLE DERRICK WANG;;SOLLICITO VINCENT LOUIS;;SEITZ EDWARD F;;DAVIS BROCKTON SCOTT;;OWENS STEPHEN KENT;;VAUGHAN RICHARD GEORGE;;BOLLAS JAMES ZACHARY;;GUE ROBERT S;;BIDDY JAMES BRADFORD;;WOLFORD MICHAEL R;;DOWDS STEVEN ALLEN,WHITLE DERRICK WANG;;SOLLICITO VINCENT LOUIS;;SEITZ EDWARD F;;DAVIS BROCKTON SCOTT;;OWENS STEPHEN KENT;;VAUGHAN RICHARD GEORGE;;BOLLAS JAMES ZACHARY;;GUE ROBERT S;;BIDDY JAMES BRADFORD;;WOLFORD MICHAEL R;;DOWDS STEVEN ALLEN,,https://lens.org/119-181-428-729-021,Search Report,yes,3,0,2,20,0,G06F3/04855;;G06F3/04842;;G06F3/0482;;G06F8/34;;G06F8/38,G06F/,,0,0,,,,PENDING
124,US,A1,US 2007/0249813 A1,105-088-587-833-278,2007-10-25,2007,US 78790107 A,2007-04-17,US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNFa,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1998-11-18);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/105-088-587-833-278,Patent Application,yes,60,32,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/18;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,530/387.1,0,0,,,,EXPIRED
125,DE,I1,DE 122004000003 I1,138-700-117-757-261,2004-09-23,2004,DE 122004000003 C,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Humane antikörper welche an humanen TNFalpha Binden.,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN J;;WHITE MICHAEL;;WILTON J,,https://lens.org/138-700-117-757-261,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
126,DE,D1,DE 69721548 D1,027-507-907-553-221,2003-06-05,2003,DE 69721548 T,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN J;;WHITE MICHAEL;;WILTON J,,https://lens.org/027-507-907-553-221,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
127,BG,A,BG 107537 A,006-394-503-592-558,2003-09-30,2003,BG 10753703 A,1998-09-08,US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,METHOD FOR THE INHIBITION OF HUMAN TNF ALPHA ACTIVITY AND ITS APPLICATION,"The invention relates to a method for the inhibition of human TNFalpha activity by using isolated human antibody or its antigen-connection part. This property to inhibit TNFalpha finds application to produce medicaments for the treatment of diseases wherein the hTHFalpha activity is detrimental. 99 claims, 9 figures",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/006-394-503-592-558,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
128,US,A1,US 2006/0024293 A1,156-737-413-683-182,2006-02-02,2006,US 23325205 A,2005-09-21,US 23325205 A;;US 30235602 A;;US 54001800 A;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/156-737-413-683-182,Patent Application,yes,47,50,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;A61K39/395;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/130.1;;424/78.27;;424/145.1,0,0,,,,EXPIRED
129,BG,A,BG 102755 A,187-117-457-807-412,1999-05-31,1999,BG 10275598 A,1998-09-08,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN TNF ALPHA BINDING HUMAN ANTIBODIES,"The invention relates to human antibodies, preferablyrecombinant human antibodies which are specifically bound to humantumour necrotic factor (TNF). The antibodies have high afinity tohTNF, e.g. Kd = 10-8 M or less, low hTNF dissociate velocity, e.g.Koff = 10-3sec-1 or less, and neutralize the hTNF activity invitro and in vivo. Antibody of this invention can be an antibodywith its full length or its antigene-binding part. The antibodiesor parts thereof are applicable for the detection of hTNF and forthe inhibition of hTNF activity, for example in patients sufferingfrom indispositions where the hTNF activity is harmfull. Theinvention also relates to nucleinic acids, vectors and host cellsfor the expression of recombinant human antibodies and to methodsfor their synthetization.77 claims",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MC GUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/187-117-457-807-412,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
130,US,A1,US 2005/0002335 A1,069-950-539-765-297,2005-01-06,2005,US 83694104 A,2004-04-30,US 83694104 A;;US 70474003 A;;US 71605103 A;;US 71696703 A;;US 71927003 A;;US 72219403 A;;US 71696803 A;;US 47065003 P,2003-05-15,"Methods of implementing dynamic QoS and/or bandwidth provisioning and related data networks, data service providers, routing gateways, and computer program products","A method of operating a data network may include establishing a data path through the data network between a routing gateway for a subscriber of the data network and a service provider providing a data service. Moreover, the data service may be provided for use at the routing gateway over the data path during a data session. A request may be received from the service provider wherein the request defines a data flow characteristic for the data path between the routing gateway and the service provider providing the data service during the data session. The data flow characteristic may then be transmitted to a node along the data path between the routing gateway and the service provider for enforcement of the data flow characteristic for the data path at the node. More particularly, the data session may be a point-to-point protocol data session. Related methods, data networks, data service providers, routing gateways, and computer program products are also discussed.",ADAMCZYK MARIA;;ANSCHUTZ THOMAS ARNOLD;;BLACKBURN ALAN RYAN;;CASSANOVA JEFFREY PATRICK;;HILL SAMMIE WALTER;;HOLT SCOTT CRANDALL;;HUSLAK NICHOLAS STEVEN;;MCQUAIDE ARNOLD CHESTER;;SHRUM EDGAR VAUGHAN;;STILLMAN SCOTT TRAYNHAM;;WRIGHT STEVEN ALLEN;;ZHANG LI,ADAMCZYK MARIA;;ANSCHUTZ THOMAS ARNOLD;;BLACKBURN ALAN RYAN;;CASSANOVA JEFFREY PATRICK;;HILL SAMMIE WALTER;;HOLT SCOTT CRANDALL;;HUSLAK NICHOLAS STEVEN;;MCQUAIDE ARNOLD CHESTER;;SHRUM EDGAR VAUGHAN JR;;STILLMAN SCOTT TRAYNHAM;;WRIGHT STEVEN ALLEN;;ZHANG LI,AT&T INTELLECTUAL PROPERTY I L.P (2011-04-11);;BELLSOUTH INTELLECTUAL PROPERTY CORPORTION (2004-04-19),https://lens.org/069-950-539-765-297,Patent Application,yes,99,154,10,51,0,H04L63/029;;H04L63/083;;H04L12/2859;;H04L47/2458;;H04L47/2408;;H04L47/2416;;H04L47/2441;;H04L63/102;;H04L63/029;;H04L63/083;;H04L12/2859;;H04L47/2458;;H04L47/2408;;H04L47/2416;;H04L47/2441;;H04L63/102;;H04L47/24;;H04W72/0446,H04L12/66;;H04L47/2416;;H04L47/31,37023,0,0,,,,EXPIRED
131,EP,A1,EP 2357200 A1,194-352-674-750-014,2011-08-17,2011,EP 10184643 A,1997-02-10,EP 02022788 A;;EP 97906572 A;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα ( e.g ., K d  = 10 -8  M or less), a slow off rate for hTNFα dissociation ( e.g.,  K off  = 10 -3  sec -1  or less) and neutralize hTNFα activity  in vitro  and  in vivo.  An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity,  e.g ., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVKSY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBVIE BIOTECHNOLOGY LTD (2014-01-01),https://lens.org/194-352-674-750-014,Patent Application,yes,42,1,45,181,2,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,105,80,072-378-691-723-546;;040-701-579-915-050;;074-871-884-454-68X;;016-907-020-918-983;;011-796-204-010-792;;117-499-681-530-662;;006-117-436-368-816;;046-939-287-004-026;;085-191-504-989-317;;041-591-849-635-094;;054-329-283-530-645;;002-495-006-719-164;;021-113-833-013-619;;015-584-716-307-216;;092-412-882-661-570;;072-438-011-112-832;;006-342-252-521-899;;057-954-116-868-246;;072-378-691-723-546;;003-907-950-634-854;;041-956-664-134-903;;035-071-534-473-573;;071-901-988-318-434;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;066-749-017-721-197;;001-467-559-709-949;;143-467-932-790-298;;123-171-555-829-362;;071-707-020-428-907;;168-113-989-624-417;;044-369-216-298-341;;092-023-577-402-127;;022-179-293-052-569;;030-630-100-818-462;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;100-049-580-404-573;;033-797-614-829-293;;072-378-691-723-546;;005-119-615-003-591;;034-331-211-704-877;;025-395-146-381-464;;011-962-497-035-168;;065-145-385-150-339;;033-459-816-867-43X;;098-513-251-868-998;;063-873-022-003-842;;044-317-656-227-593;;011-114-894-374-225;;037-795-266-129-616;;048-153-224-318-923;;008-835-817-825-32X;;075-878-183-554-694;;004-001-063-582-854;;079-192-394-643-91X;;000-065-369-829-300;;128-904-140-606-949;;077-369-546-251-682;;032-821-336-726-761;;050-094-719-890-440;;070-452-766-365-174;;110-232-737-639-142;;028-469-508-809-412;;044-217-982-536-908;;012-422-300-553-121;;033-522-835-476-708;;097-358-265-091-151;;041-043-853-736-19X;;085-885-495-910-537;;167-234-008-883-687;;061-475-814-399-439;;031-974-874-348-471;;054-469-226-992-186;;007-667-472-783-358;;023-473-383-533-503;;063-233-860-095-920;;052-159-696-111-105,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7521646;;10.1038/nbt0994-899;;2413547;;10.1126/science.2413547;;10.1146/annurev.bi.57.070188.002445;;3052281;;10.1146/annurev.biochem.57.1.505;;10.1146/annurev.immunol.7.1.625;;10.1146/annurev.iy.07.040189.003205;;2540776;;1590993;;10.1146/annurev.iy.10.040192.002211;;10.1146/annurev.immunol.10.1.411;;0001590993;;10.1146/annurev.med.45.1.491;;8198398;;3889916;;pmc397878;;10.1073/pnas.82.11.3814;;3729942;;10.1016/0006-291x(86)91157-5;;3805735;;10.1016/0022-1759(87)90367-x;;10.1089/hyb.1987.6.359;;2442093;;10.1016/0161-5890(93)90106-l;;8232330;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1016/s0140-6736(94)90628-9;;7934491;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1016/0022-1759(91)90361-i;;2040812;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7703831;;10.1038/312724a0;;6392892;;3552045;;10.1021/bi00379a018;;2922046;;2922050;;10.1038/338225a0;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;8597629;;10.3233/hab-1995-6303;;10.1016/0161-5890(94)90100-7;;7935496;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;1804254;;7541226;;10.1002/jmr.300080122;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;10.1038/348552a0;;2247164;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;1385989;;10.3233/hab-1992-3204;;2531466;;10.1126/science.2531466;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;pmc52428;;10.1073/pnas.88.18.7978;;1896445;;8216416;;10.1002/art.1780360907;;8907592;;10.1007/bf02265123;;10.1097/00001756-199604260-00023;;8817534;;8619098;;10.1016/s0889-857x(21)00466-x;;10.1016/0958-1669(93)90055-2;;7764470;;10.1002/art.1780380202;;7848304;;pmc1534244;;8222316;;10.1111/j.1365-2249.1993.tb03441.x;;10.1093/rheumatology/34.4.334;;7788147;;10.1097/00007890-199409000-00007;;7940686;;10.1097/00007890-199501000-00025;;10.1097/00007890-199501270-00025;;7839455;;7832839;;10.1056/nejm199408113310606;;10.1126/science.3764421;;3764421;;10.1172/jci113459;;pmc442560;;3366898;;pmc1535044;;2117510;;10.1111/j.1365-2249.1990.tb03334.x;;7797011;;10.1016/0016-5085(95)90277-5;;10.1038/319516a0;;3511389;;10.1002/jbmr.5650030607;;3266953;;8442433;;10.1002/jbmr.5650080205;;7512360;;10.1016/8756-3282(93)90317-4;;2920991;;10.1002/hep.1840090302;;10.1111/j.1530-0277.1990.tb00482.x;;2190492;;10.1002/hep.1840200228;;8045508;;10.1016/0270-9139(94)90200-3;;10.1016/0168-8278(91)90945-8;;2051003;;pmc502205;;10.1136/jcp.47.12.1112;;7876386;;2188129;;10.1056/nejm199006073222302;;1924431;;10.1152/ajpheart.1994.267.1.h118;;8048575;;8148074;;10.1016/0305-4179(94)90104-x;;10.1152/ajpgi.1994.267.6.g1122;;7810659;;7992355;;10.1097/00007890-199412150-00003;;10.1016/0300-9572(95)00831-d;;7659869;;10.1007/bf00918154;;1512303;;pmc453150;;1721867;;10.1002/j.1460-2075.1991.tb04978.x,"GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"", EMBO J., vol. 12, no. 2, 1993, pages 725 - 734, XP000645476;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899 - 903, XP000572619, ISSN: 0733-222X;;OLD, L., SCIENCE, vol. 230, 1985, pages 630 - 632;;BEUTLER, B.; CERAMI, A., ANNU. REV. BIOCHEM., vol. 57, 1988, pages 505 - 518;;BEUTLER, B.; CERAMI, A., ANNU. REV. IMMUNOL., vol. 7, 1989, pages 625 - 655;;MOELLER, A. ET AL., CYTOKINE, vol. 2, 1990, pages 162 - 169;;VASILLI, P., ANNU. REV. IMMUNOL., vol. 10, 1992, pages 411 - 452;;TRACEY, K.J.; CERAMI, A., ANNU. REV. MED., vol. 45, 1994, pages 491 - 503;;HAHN T ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3814 - 3818;;LIANG, C-M. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 137, 1986, pages 847 - 854;;HIRAI, M. ET AL., J. IMMUNOL. METHODS, vol. 96, 1987, pages 57 - 62;;FENDLY, B.M. ET AL., HYBRIDOMA, vol. 6, 1987, pages 359 - 370;;KNIGHT, D.M ET AL., MOL. IMMUNOL., vol. 30, 1993, pages 1443 - 1453;;ELLIOTT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1125 - 1127;;ELLIOT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1105 - 1110;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 556 - 568;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 569 - 581;;FOMSGAARD, A. ET AL., SCAND. J. IMMUNOL., vol. 30, 1989, pages 219 - 223;;BENDTZEN, K. ET AL., PROG. LEUKOCYTE BIOL., vol. 10B, 1990, pages 447 - 452;;LEUSCH, H-G. ET AL., J. IMMUNOL. METHOD, vol. 139, 1991, pages 145 - 147;;GRIFFITHS, A.D. ET AL., EMBO J., vol. 12, 1993, pages 725 - 734;;LIDBURY, A. ET AL., BIOTECHNOL. THER., vol. 5, 1994, pages 27 - 45;;PENNICA, D. ET AL., NATURE, vol. 312, 1984, pages 724 - 729;;DAVIS, J.M. ET AL., BIOCHEMISTRY, vol. 26, 1987, pages 1322 - 1326;;JONES, E.Y. ET AL., NATURE, vol. 338, 1989, pages 225 - 228;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;KIPRIYANOV, S.M. ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101;;KIPRIYANOV, S.M. ET AL., MOL. IMMUNOL., vol. 31, 1994, pages 1047 - 1058;;TAYLOR, L.D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295;;J6NSSON, U. ET AL., ANN. BIOL. CLIN., vol. 5, no. 1, 1993, pages 19 - 26;;JÖNSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627;;JOHNSSON, B. ET AL., J. MOL. RECOGNIT., vol. 8, 1995, pages 125 - 131;;JOHNNSON, B. ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages 268 - 277;;""Molecular Cloning; A Laboratory Manual"", 1989;;""Current Protocols in Molecular Biology"", 1989, GREENE PUBLISHING ASSOCIATES;;KABAT, E.A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;TOMLINSON, I.M. ET AL.: ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COX, J.P.L. ET AL.: ""A Directory of Human Germ-line V K Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;GOEDDEL: ""Gene Expression Technology: Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;BOSS, M.A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R.J. KAUFMAN; P.A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;FUCHS ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1370 - 1372;;HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., JMOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;GARRAD ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;ARTHRITIS & RHEUMATISM, vol. 37, 1994, pages S295;;J. INVEST. MED., vol. 44, 1996, pages 235A;;ARTHRITIS & RHEUMATISM, vol. 38, 1995, pages 5185;;ARTHRITIS & RHEUMATISM, vol. 36, 1993, pages 1223;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S284;;AMER. J. PHYSIOL. - HEART AND CIRCULATORY PHYSIOLOGY, vol. 268, 1995, pages 37 - 42;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S282;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S81;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S82;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S131;;INFLAMMATION RESEARCH, vol. 45, 1996, pages 103 - 107;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 5280;;NEURO REPORT, vol. 7, 1996, pages 1209 - 1213;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S281;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S296;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S308;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 5120;;DELUCA ET AL., RHEUM. DIS. CLIN. NORTH AM., vol. 21, 1995, pages 759 - 777;;RUSSELL, D; THOMPSON, R.C., CURR. OPIN. BIOTECH., vol. 4, 1993, pages 714 - 721;;AREND, W.P.; DAYER, J-M., ARTH. RHEUM., vol. 38, 1995, pages 151 - 160;;FAVA, R.A. ET AL., CLIN. EXP. IMMUNOL., vol. 94, 1993, pages 261 - 266;;RANKIN, E.C. ET AL., BR. J. RHEUMATOL., vol. 34, 1995, pages 334 - 342;;FIETZE, E. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 675 - 680;;EASON, J.D. ET AL., TRANSPLANTATION, vol. 59, 1995, pages 300 - 305;;SUTHANTHIRAN, M.; STROM, T.B., NEW ENGL. J. MED., vol. 331, 1994, pages 365 - 375;;TRACY, K.J. ET AL., SCIENCE, vol. 234, 1986, pages 470 - 474;;SUN, X-M. ET AL., J. CLIN. INVEST., vol. 81, 1988, pages 1328 - 133 1;;MACDONALD, T.T. ET AL., CLIN. EXP. IMMUNOL., vol. 81, 1990, pages 301 - 305;;VAN DULLEMEN, H.M. ET AL., GASTROENTEROLOGY, vol. 109, 1995, pages 129 - 135;;BERTOLINI, D.R. ET AL., NATURE, vol. 319, 1986, pages 516 - 518;;KONIG, A. ET AL., J. BONE MINER. RES., vol. 3, 1988, pages 621 - 627;;LERNER, U.H.; OHLIN, A., J. BONE MINER. RES., vol. 8, 1993, pages 147 - 155;;SHANKAR, G.; STERN, P.H., BONE, vol. 14, 1993, pages 871 - 876;;MCCLAIN, C.J.; COHEN, D.A., HEPATOLOGY, vol. 2, 1989, pages 349 - 351;;FELVER, M.E. ET AL., ALCOHOL. CLIN. EXP. RES., vol. 14, 1990, pages 255 - 259;;HANSEN, J. ET AL., HEPATOLOGY, vol. 20, 1994, pages 461 - 474;;SHERON, N. ET AL., J. HEPATOL., vol. 12, 1991, pages 241 - 245;;HUSSAIN, M.J. ET AL., J. CLIN. PATHOL., vol. 47, 1994, pages 1112 - 1115;;VAN DER POLL, T. ET AL., N. ENGL. J. MED., vol. 322, 1990, pages 1622 - 1627;;VAN DER POLL, T. ET AL., PROG. CLIN. BIOL. RES., vol. 367, 1991, pages 55 - 60;;GIROIR, B.P. ET AL., AM. J. PHYSIOL., vol. 267, 1994, pages H118 - 124;;LIU, X.S. ET AL., BURNS, vol. 20, 1994, pages 40 - 44;;SCALES, W.E. ET AL., AM. J. PHYSIOL., vol. 267, 1994, pages G1122 - 1127;;SERRICK, C. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 1158 - 1162;;YAO, Y.M. ET AL., RESUSCITATION, vol. 29, 1995, pages 157 - 168;;MCCAULEY, R.L. ET AL., J. CLIN. IMMUNOL., vol. 12, 1992, pages 300 - 308;;EMBO J, vol. 10, 1991, pages 4025 - 4031",EXPIRED
132,UA,C2,UA 82823 C2,069-883-757-554-909,2008-05-26,2008,UA 2002097761 A,2002-09-30,US 3147696 P;;US 59922696 A,1996-02-09,"METHOD FOR THE INHIBITION OF HUMAN TNF-?? ACTIVITY, APPLICATION OF ISOLATED HUMAN ANTIBODY IN PPRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF DISORDER IN WHICH HTNF? ACTIVITY IS DETRIMENTAL, ISOLATED HUMAN ANTIBODY THAT SPECIFICALLY BINDS TO TNF-?? AND PHARMACEUTICAL COMPOUND CONTAINING THEREOF","The invention relates to a method for the inhibition of human TNF?? activity involves interaction of TNF-?? with antibody inhibiting human TNF? activity. These antibodies have high affinity for hTNF? ( Kd of 10-8 M or less), a slow off rate for hTNF? dissociation (Koff of 10-3 sec-1 or less) and neutralize hTNF??cytotoxicity in a standard in vitro L929 assay with an IC50 of 10-7M or less. The antibodies, or antibody portions may be useful for inhibiting hTNF? activity in a human subject suffering from a disorder in which hTNF? activity is detrimental. The invention relates as well to the isolated human antibody that specifically binds to TNF-?? and pharmaceutical compound containing thereof.",,SALFELD JOCHEN G;;ALLEN DEBORAH DEBORA G;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW G;;SAKOFARAS PAUL;;HOOGENBOOM HENDRIKUS R;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON G,,https://lens.org/069-883-757-554-909,Limited Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
133,HK,A1,HK 1066860 A1,131-443-794-815-95X,2005-04-01,2005,HK 04109765 A,1999-10-15,US 59922696 A;;US 3147696 P;;HK 99104584 A,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF ALPHA,,ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/131-443-794-815-95X,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K/;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K/;;C07K16/24;;C12N/;;C12N1/21;;C12N5/10;;C12P21/08;;G01N/;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
134,EP,B1,EP 2357200 B1,168-837-409-693-517,2016-11-16,2016,EP 10184643 A,1997-02-10,EP 02022788 A;;EP 97906572 A;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNFalpha,,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVKSY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBVIE BIOTECHNOLOGY LTD (2014-01-01),https://lens.org/168-837-409-693-517,Granted Patent,yes,5,2,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,2,0,,,"GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"", EMBO J., vol. 12, no. 2, 1993, pages 725-734, XP000645476,;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899-903, XP000572619, ISSN: 0733-222X",EXPIRED
135,HU,B1,HU 230515 B1,001-758-441-519-365,2016-10-28,2016,HU P1500179 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,The use of human tnf-alpha binding antibodies,,ABBVIE BIOTECHNOLOGY LTD,ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SALFELD JOCHEN G;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/001-758-441-519-365,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
136,AU,A1,AU 2006/241387 A1,121-069-414-643-771,2006-12-14,2006,AU 2006/241387 A,2006-11-24,AU 2004/202769 A;;AU 2006/241387 A,2004-06-23,Human antibodies that bind human TNFalpha,,ABBOTT BIOTECH LTD,MANKOVICH JOHN A;;VAUGHAN TRISTAN J;;SALFELD JOCHEN G;;HOOGENBOOM HENDRICUS R J M;;ALLEN DEBORAH J;;MCGUINESS BRIAN T;;KAYMAKCALAN ZEHR;;SCHOENHAUT DAVID;;ROBERTS ANDREW J;;LABKOVSKY BORIS;;WHITE MICHAEL;;WILTON ALISON J;;SAKORAFAS PAUL,,https://lens.org/121-069-414-643-771,Patent Application,no,0,0,5,5,0,A61K2039/505;;C07K16/241;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/622;;C07K2317/76;;C07K2317/92;;G01N2333/525;;G01N2800/10;;G01N2800/102,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
137,BR,B8,BR PI9707379 B8,146-871-891-744-618,2015-07-07,2015,BR 9707379 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,"Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.",,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBOTT BIOTECHNOLOGY LTD. (BM) (2006-09-05);;ABBOTT LABORATORIES (BERMUDA) LTD (BM) (2003-12-16);;ABBVIE BIOTECHNOLOGY LTD. (BM) (2015-06-09),https://lens.org/146-871-891-744-618,Amended Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
138,NO,B1,NO 316711 B1,004-246-809-319-717,2004-04-13,2004,NO 983627 A,1998-08-07,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,"Isolert human-antistoff eller antigen-bindingsdel derav som binder human TNF<alfa>, rekombinant human-antistoff eller antigen-bindingsdel derav, isolert nukleinsyre som koder for en lett eller tungkjede av antistoffet, eventuelt en region derav, rekombina",,ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNES BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON JANE,"ABBVIE BIOTECHNOLOGY LTD, BM (2013-10-14)",https://lens.org/004-246-809-319-717,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
139,HK,A1,HK 1214609 A1,020-361-107-128-274,2016-07-29,2016,HK 16102509 A,2016-03-04,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA TNF,,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/020-361-107-128-274,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K/;;A61K/;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N/;;C12N1/21;;C12N5/10;;C12P21/08;;G01N/;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
140,US,B2,US 8372400 B2,022-711-393-166-086,2013-02-12,2013,US 57848709 A,2009-10-13,US 57848709 A;;US 36945109 A;;US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,Methods of treating disorders using human antibodies that bind human TNFα,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD;;SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBOTT BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/022-711-393-166-086,Granted Patent,yes,102,51,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K39/395;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/142.1;;424/145.1;;424/158.1;;424/810;;530/868,85,73,005-321-867-106-932;;082-560-368-073-508;;092-412-882-661-570;;072-438-011-112-832;;064-048-827-826-930;;101-630-891-707-104;;022-179-293-052-569;;077-341-362-901-551;;026-408-993-198-966;;024-854-471-494-140;;003-185-616-989-105;;006-342-252-521-899;;033-261-430-402-230;;072-378-691-723-546;;005-119-615-003-591;;036-413-156-723-523;;033-797-614-829-293;;040-701-579-915-050;;030-874-783-814-532;;017-529-128-038-946;;057-954-116-868-246;;015-761-810-001-488;;020-855-322-534-259;;010-916-105-450-247;;061-726-307-774-867;;074-932-950-939-666;;053-341-149-236-635;;004-601-819-239-79X;;030-323-674-660-051;;087-599-254-199-807;;003-841-586-111-459;;098-176-334-504-327;;022-384-366-455-012;;019-030-524-959-069;;092-023-577-402-127;;021-641-900-032-887;;006-117-436-368-816;;145-140-396-707-208;;042-623-879-457-954;;074-817-300-512-106;;031-729-641-207-089;;022-133-574-143-973;;116-193-705-533-609;;028-677-787-189-119;;032-820-729-763-323;;041-315-340-063-133;;027-477-313-726-928;;088-851-255-233-972;;137-274-595-200-649;;026-144-631-995-304;;010-327-392-460-003;;006-911-122-969-908;;006-626-799-687-686;;021-113-833-013-619;;038-613-711-274-229;;025-395-146-381-464;;085-277-440-303-853;;012-897-611-427-172;;050-836-464-727-069;;032-071-991-081-664;;035-939-173-669-143;;077-815-816-621-813;;002-495-006-719-164;;043-108-278-056-872;;046-104-560-723-30X;;048-379-681-038-232;;016-219-576-017-946;;001-900-209-379-77X;;020-753-772-581-741;;040-981-641-449-302;;003-595-371-167-198;;053-289-310-577-642;;088-581-950-418-154,7884952;;10.1001/jama.1995.03520360048038;;10.1001/jama.273.12.934;;7735957;;10.1097/00024382-199404000-00001;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1038/nrd984;;12509759;;10.1097/00003246-199609000-00002;;8797612;;10.1002/eji.1830240409;;8149953;;7935497;;10.1016/0161-5890(94)90101-5;;18240199;;10.1002/art.23362;;10.1146/annurev.immunol.19.1.163;;11244034;;10.1006/jmbi.1994.1351;;8196048;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;1560463;;10.1016/0022-2836(92)91010-m;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;7620183;;10.1182/blood.v86.3.890.890;;2531466;;10.1126/science.2531466;;7521646;;10.1038/nbt0994-899;;pmc1766613;;11053087;;10.1136/ard.59.suppl_1.i44;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;8757799;;10.1006/jmbi.1996.0406;;1748994;;10.1016/0022-2836(91)90498-u;;10.1038/nbt0792-779;;1368267;;7765558;;10.1038/nbt1194-1134;;10.1016/1043-4666(90)90011-h;;1716486;;10.1016/0959-440x(95)80028-x;;8528760;;15848075;;10.1016/j.ymeth.2005.01.006;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;10.1097/00003246-199605000-00003;;8706447;;8364031;;10.1021/bi00085a016;;11730333;;10.1006/abio.2001.5380;;10.1016/1043-4666(92)90072-y;;1381227;;8609615;;10.1006/jmbi.1996.0069;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1146/annurev.med.45.1.491;;8198398;;7697917;;pmc1534281;;10.1111/j.1365-2249.1995.tb03598.x;;9624683;;10.1038/nbt0698-535;;10.1038/341544a0;;2677748;;8397764;;10.1016/0167-5699(93)90039-n;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1038/nbt0595-475;;9634788;;8159246;;10.1038/368856a0;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.3.co;2-y;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.0.co;2-l;;8727325;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1423650;;10.3109/07388559209114235;;10.1111/j.1365-2249.1994.tb05522.x;;7994916;;pmc1534487;;10.3233/hab-1995-6206;;7492754;;9180069;;10.1126/science.276.5319.1665;;8783501;;10.1016/0167-5699(96)10025-6;;9265725;;10.1016/s0958-1669(97)80068-7;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/ng0594-13;;8075633;;pmc395221;;10.1002/j.1460-2075.1994.tb06626.x;;8045255;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;10.1016/0022-2836(92)90894-p;;1404359;;10.1111/j.1365-2141.1992.tb08212.x;;1379467;;7579668;;10.1016/0958-1669(95)80093-x;;10.1016/0161-5890(93)90106-l;;8232330;;7494109;;10.3109/08830189509061738;;10.1016/s0021-9258(18)41952-7;;1644788;;7764095;;10.1038/nbt1093-1145;;10.1038/ng0297-146;;9020839;;9052775;;10.1038/386025a0;;10.1093/intimm/6.4.579;;8018598;;7957560;;10.1002/eji.1830241116;;8190629;;pmc307995;;10.1093/nar/22.8.1389;;10.1096/fasebj.10.10.8751726;;8751726;;10.4049/jimmunol.164.3.1432;;10640759,"Abraham, Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor a in Patients With Sepsis Syndrome (1995) JAMA, vol. 273(12):934-941.;;Barbuto, Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes (1993) Proc. Am. Assoc. Cancer Res. 34:48.;;Bendtzen, Auto-antibodies to IL-1alpha and TNFalpha in Normal Individuals and in Infectious and Immunoinflammatory Disorders (1990) The Physiological and Pathological Effects of Cytokines (Wiely-Liss, Inc., 1990) 447-52.;;Boekstegers, Repeated administration of F(ab')2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels (1994) Shock, vol. 1(4):237-245.;;Boyle, A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor-alpha (1993) Cell. Immunol. 152:556-68.;;Boyle, The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFalpha on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope (1993) Cell. Immunol. 152:569-81.;;Brekke, Therapeutic Antibodies for Human Diseases at the Dawn of the Twenty-First Century (2003) Nature, vol. 2:52-62.;;Chow, Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFalpha, IL-1beta, and IL-6 levels in patients with sepsis syndrome (1994) Clinical Research 42:2 299A.;;Cohen, INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis (1996) Critical Care Medicine, vol. 24(9):1431-1440.;;Cox, A directory of human germ-line Vx segments reveals a strong bias in their usage (1994) Eur. J. Immunol. 24(2):827-36.;;Department of Surgery, University of Toronto Annual Report. Jul. 1, 1998-Jun. 30, 1999 http://www.surg.med.utoronto.ca/AnnRep/AR98-99/index.html.;;Doring, E., Identification and Characterization of a TNFa Antagonist Derived from a Monoclonal Antibody (1994) Mol Immunol 31(14): 1059-1067.;;Elliot, Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha (1993) Arthritis & Rheumatism 36(12):1681-90.;;Feldmann, Anti-TNF-alpha Therapy of Rheumatoid Arthritis: What Have We Learned? (2001) Annu. Rev. Immunol., vol. 19:163-196.;;Figini, In Vitro assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation (1994) J. Mol. Biol., vol. 239:68-78.;;Fomsgaard, Auto-antibodies to Tumor Necrosis Factor alpha in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections (1989) Scand. J. Immunol. 30:219-23.;;Foote, J., Antibody framework residues affecting the conformation of the hypervariable loops (1992) J Mol Biol, vol. 224(2):487-499.;;Griffiths, Human anti-self antibodies with high specificity from phage display libraries (1993) The EMBO J. 12(2):725-34.;;Hawkins, Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation (1992) J. Mol. Biol., vol. 226:889-896.;;Holler, Modulation of Acute Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation by Tumor Necrosis Factor -alpha (TNF-alpha) Release in the Course of Pretransplant Conditioning: Role of Conditioning Regimens and Prophylactic Application of a Monoclonal Antibody Neutralizing Human TNF-alpha (MAK 195F) (1995) Blood, vol. 86(3):890-899.;;Hoogenboom, Converting rodent into human antibodies by guided selection (1996) Antibody Engineering, Oxford University Press, pp. 169-185.;;Huse, Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda (1989) Science 246:1275-81.;;Jespers, Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen (1994) Bio/Technology, vol. 12:899-903.;;Kempeni, Update on D2E7: a fully human anti-tumour necrosis factor -alpha monoclonal antibody (2000) Ann. Rheum. Dis., vol. 59(Suppl. I):144-145.;;Lerner, Antibodies without immunization (1992) Science 258:1313-14.;;Leusch, Failure to demonstrate TNFalpha-specific autoantibodies in human sera by ELISA and Western blot (1991) J. Immunol. Methods 139:145-47.;;Lewis, Use of alanine scanning mutagenesis to improve the affinity of an anti gp120 (HIV) antibody (1994) J. Cell. Biochem. 18D:215.;;Low, Nigel Low: thesis extract (1996) Cambridge University.;;Low, Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain (1996) J. Mol. Biol., vol. 260:359-368.;;Marks, By-passing immunization: Human antibodies from V-gene libraries displayed on phage (1991) J. Mol. Biol. 222:581-97.;;Marks, JD., By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling (1992) Biotechnology, vol. 10:779-783.;;Medynski, Phage Display: All Dressed Up and Ready to Role (1994) Bio/Technology, vol. 12:1134-1136.;;Möller, Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and vivo application (1990) Cytokine 2(3):162-69.;;Nilsson, Antibody engineering (1995) Current Opinion in Structural Biology, vol. 5:450-456.;;Osbourn, From rodent reagents to human therapeutics using antibody guided selection (2005) Methods, vol. 36(1):61-68.;;Queen, C., A humanized antibody that binds to the interleukin 2 receptor (1989) Proc Natl Acad Sci USA, vol. 86(24):10029-10033.;;Reinhart, Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study (1996) Crit. Care Med., vol. 24(5):733-742.;;Riechmann, Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement (1993) Biochemistry, vol. 32(34):8848-8855 (1993).;;Santora, Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BlAcore (2001) Analytical Biochemistry, vol. 299:119-129.;;Thorp, Tumour Necrosis Factor Induction of ELAM-1 and ICAM-1 on Human Umbilical Vein Endothelial Cells-Analysis of Tumour Necrosis Factor Receptor Interaction (1992) Cytokine 4(4): 313.;;Thompson, Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity (1996) J. Mol. Biol., vol. 256(1):77-88.;;Tomlinson, The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops (1992) J. Mol. Biol. 227:776-98.;;Tomlinson, The structural repertoire of the human Vk domain (1995) The EMBO J. 14(18):4628-38.;;Tracey, Tumor necrosis factor: A pleiotropic cytokine and therapeutic target (1994) Annu. Rev. Med. 45:491-503.;;Van Der Poll, Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees (1995) Clin. Exp. Immunol., vol. 100:21-25.;;Vaughan, Human antibodies by design (1998) Nature Biotechnology, vol. 16:535-539.;;Ward, Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli (1989) Nature, vol. 341:544-546.;;Winter, Humanized antibodies (1993) Immunol. Today 14(6):243-46.;;Winter, Making antibodies by phage display technology (1994) Annu. Rev. Immunol., vol. 12:433-455.;;Rader et al. ""A phage display approach to rapid antibody humanization: Designed combinatorial V gene libraries"" Proc Natl Acad Sci USA 95:8910-8915 (1998).;;Davies et al., ""Antibody VH domains as small recognition units."" Biotechnology, 13:475-479 (1995).;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications."" Nature, 368:856-859 (1994).;;Martin, A.C.R. ""Accessing the Kabat antibody sequence database by computer."" Proteins: Structure, Function and Genetics, 25:130-133 (1996).;;Rudikoff, et al., Single amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci. USA, 70:1979-1983 (1982).;;Sandhu, J. ""Protein engineering of antibodies."" Critical Reviews in Biotechnology, 12:437-462 (1992).;;Sioud et al., ""Characterization of naturally occurring autoantibodies against tumour necrosis factor-alpha (TNF-alpha): in vitro function and precise epitope mapping by phage epitope library."" Clin Exp Immunol, 98:520-525 (1994).;;Teichmann, S. Declaration dated Dec. 7, 2010 from opposition proceedings in EP 0929578.;;Tsuchiyama et al., ""Comparison of anti-TNF alpha autoantibodies in plasma and from EBV transformed lymphocytes of autoimmune and normal individuals."" Hum. Antibod. Hybridomas 6(2):73-76 (1995).;;Wedemayer et al., ""Structural insights into the evolution of an antibody combining site."" Science 276:1665-1669 (1997).;;Bruggemann, M., Neuberger, M.S., ""Strategies for expressing human antibody repertoires in transgenic mice, "" Immunol. Today 17:391-397 (1996).;;Bruggemann et al. ""Production of human antibody repertoires in transgenic mice"" Cur. Op. Biotechnol. 8:455-458 (1997).;;Cambridge Antibody Technology, advertisement of phage display services, Science vol. 253, No. 5018 (1991).;;Elliot et al., ""Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis,"" Lancet 344:1125-1127 (1994).;;Fishwild et al., ""High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice,"" Nature Biotechnology 14:845-851 (1996).;;Gram et al., ""In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library,"" PNAS 89:3576-3580 (1992).;;Green et al., ""Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,"" Nature Genetics 7:13-21 (1994).;;Griffiths et al., ""Isolation of high affinity human antibodies directly from large synthetic repertoires,"" EMBO J. 13:3245-3260 (1994).;;Harding et al., ""Class switching in human immunoglobulin transgenic mice,"" Ann. NY Acad. Sci. 764:536-547 (1995).;;Hoogenboom et al., ""By-passing immunisation : Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro,"" J. Mol. Biol. 227:381-388 (1992).;;Huang et al. ""Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia,"" Br. J. Haematol 81(2):231-234 (1992).;;Jakobovits, A., ""Production of fully human antibodies by transgenic mice,"" Curr. Op. Biotechnol. 6:561-566 (1995).;;The Kennedy Institute of Rheumatology, 1995 Annual Scientific Report, ""Anti-TNF trials and studies of mechanisms of action"".;;Knight et al., ""Construction and initial characterization of a mouse-human chimeric anti-TNF antibody,"" Mol. Immunol. 30(16):1443-1453 (1993).;;Lonberg et al., ""Human Antibodies from Transgenic Mice,"" Int. Rev. Immunol. 13:65-93 (1995).;;Marks et al., ""Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system,"" J. Biol. Chem. 267:16007-16010 (1992).;;Marks et al., ""Human antibody fragments specific for human blood group antigens from a phage display library,"" Bio/Technology 11:1145-1150 (1993).;;Marks, ""Human Monoclonal Antibodies from V-gene Repertoires Expressed on Bacteriophage."" In Antibody Engineering, Second Edition, edited by Carl A.K. Borrebaeck.(1995), pp. 53-88. New York: Oxford Univ. Press.;;Mendez et al., ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice,"" Nature Genetics 15:146-156 (1997).;;Neuberger M., et al., ""Mice perform a human repertoire"", Nature 386: 25-26 (1997).;;Salfeld, ""Development of a Fully Human Antibody to TNF by Phage Display Technology"", IBC Conference, Antibody Engineering, San Diego (Dec. 1996), pp. 1-36.;;Taylor et al.,""Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,"" Int. Immunol. 6:579-591 (1994).;;Wagner et al., ""The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human immunoglobulin gene miniloci,"" Eur. J. Immunol. 24:2672-2681 (1994).;;Wagner et al., ""Antibodies generated from human immunoglobulin miniloci in transgenic mice,"" Nucl. Acids Res. 22:1389-1393 (1994).;;Zou et al., ""Dominant expression of a 1.3 Mb human Ig kappa locus replacing mouse light chain production,"" FASEB J 10:1227-1232 (1996).;;Tamura et al., ""Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only,"" J. Immunology (2000) vol. 164, pp. 1432-1441.",EXPIRED
141,NO,L,NO 20040154 L,047-460-086-226-337,1998-10-07,1998,NO 20040154 A,2004-01-13,US 3147696 P;;US 59922696 A;;US 9702219 W,1996-02-09,"Farmasoytisk blanding omfattende human-antistoffer som binder TNF<alfa>, samt anvendelser derav",,ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON JANE;;MCGUINESS BRIAN T,"ABBVIE BIOTECHNOLOGY LTD, BM (2013-10-14)",https://lens.org/047-460-086-226-337,Abstract,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
142,EP,A1,EP 2930187 A1,058-254-545-534-892,2015-10-14,2015,EP 15165138 A,1997-02-10,US 59922696 A;;US 3147696 P;;EP 10184662 A;;EP 02022788 A;;EP 97906572 A,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα ( e.g.,  K d  = 10 -8  M or less), a slow off rate for hTNFα dissociation  (e.g.,  K off = 10 -3  sec -1  or less) and neutralize hTNFα activity  in vitro  and  in vivo.  An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity,  e.g.,  in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/058-254-545-534-892,Patent Application,yes,42,0,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,105,83,072-378-691-723-546;;040-701-579-915-050;;074-871-884-454-68X;;016-907-020-918-983;;011-796-204-010-792;;117-499-681-530-662;;006-117-436-368-816;;046-939-287-004-026;;085-191-504-989-317;;041-591-849-635-094;;054-329-283-530-645;;002-495-006-719-164;;021-113-833-013-619;;015-584-716-307-216;;092-412-882-661-570;;072-438-011-112-832;;006-342-252-521-899;;057-954-116-868-246;;072-378-691-723-546;;003-907-950-634-854;;041-956-664-134-903;;035-071-534-473-573;;071-901-988-318-434;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;066-749-017-721-197;;001-467-559-709-949;;143-467-932-790-298;;123-171-555-829-362;;071-707-020-428-907;;026-012-929-845-355;;168-113-989-624-417;;044-369-216-298-341;;092-023-577-402-127;;022-179-293-052-569;;030-630-100-818-462;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;035-872-873-163-027;;100-049-580-404-573;;033-797-614-829-293;;072-378-691-723-546;;005-119-615-003-591;;034-331-211-704-877;;025-395-146-381-464;;174-783-722-981-415;;011-962-497-035-168;;065-145-385-150-339;;033-459-816-867-43X;;098-513-251-868-998;;063-873-022-003-842;;044-317-656-227-593;;011-114-894-374-225;;037-795-266-129-616;;048-153-224-318-923;;008-835-817-825-32X;;075-878-183-554-694;;004-001-063-582-854;;079-192-394-643-91X;;000-065-369-829-300;;128-904-140-606-949;;077-369-546-251-682;;032-821-336-726-761;;050-094-719-890-440;;070-452-766-365-174;;110-232-737-639-142;;028-469-508-809-412;;044-217-982-536-908;;012-422-300-553-121;;033-522-835-476-708;;097-358-265-091-151;;041-043-853-736-19X;;085-885-495-910-537;;167-234-008-883-687;;061-475-814-399-439;;031-974-874-348-471;;054-469-226-992-186;;007-667-472-783-358;;023-473-383-533-503;;063-233-860-095-920;;052-159-696-111-105,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7521646;;10.1038/nbt0994-899;;2413547;;10.1126/science.2413547;;10.1146/annurev.bi.57.070188.002445;;3052281;;10.1146/annurev.biochem.57.1.505;;10.1146/annurev.immunol.7.1.625;;10.1146/annurev.iy.07.040189.003205;;2540776;;1590993;;10.1146/annurev.iy.10.040192.002211;;10.1146/annurev.immunol.10.1.411;;0001590993;;10.1146/annurev.med.45.1.491;;8198398;;3889916;;pmc397878;;10.1073/pnas.82.11.3814;;3729942;;10.1016/0006-291x(86)91157-5;;3805735;;10.1016/0022-1759(87)90367-x;;10.1089/hyb.1987.6.359;;2442093;;10.1016/0161-5890(93)90106-l;;8232330;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1016/s0140-6736(94)90628-9;;7934491;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1016/0022-1759(91)90361-i;;2040812;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7703831;;10.1038/312724a0;;6392892;;3552045;;10.1021/bi00379a018;;2922046;;2922050;;10.1038/338225a0;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;8597629;;10.3233/hab-1995-6303;;10.1016/0161-5890(94)90100-7;;7935496;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;8338253;;1804254;;7541226;;10.1002/jmr.300080122;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;10.1038/348552a0;;2247164;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;1367769;;10.1038/nbt1291-1369;;1385989;;10.3233/hab-1992-3204;;2531466;;10.1126/science.2531466;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/nbt1291-1373;;1369462;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;pmc52428;;10.1073/pnas.88.18.7978;;1896445;;8216416;;10.1002/art.1780360907;;8907592;;10.1007/bf02265123;;10.1097/00001756-199604260-00023;;8817534;;8619098;;10.1016/s0889-857x(21)00466-x;;10.1016/0958-1669(93)90055-2;;7764470;;10.1002/art.1780380202;;7848304;;pmc1534244;;8222316;;10.1111/j.1365-2249.1993.tb03441.x;;10.1093/rheumatology/34.4.334;;7788147;;10.1097/00007890-199409000-00007;;7940686;;10.1097/00007890-199501000-00025;;10.1097/00007890-199501270-00025;;7839455;;7832839;;10.1056/nejm199408113310606;;10.1126/science.3764421;;3764421;;10.1172/jci113459;;pmc442560;;3366898;;pmc1535044;;2117510;;10.1111/j.1365-2249.1990.tb03334.x;;7797011;;10.1016/0016-5085(95)90277-5;;10.1038/319516a0;;3511389;;10.1002/jbmr.5650030607;;3266953;;8442433;;10.1002/jbmr.5650080205;;7512360;;10.1016/8756-3282(93)90317-4;;2920991;;10.1002/hep.1840090302;;10.1111/j.1530-0277.1990.tb00482.x;;2190492;;10.1002/hep.1840200228;;8045508;;10.1016/0270-9139(94)90200-3;;10.1016/0168-8278(91)90945-8;;2051003;;pmc502205;;10.1136/jcp.47.12.1112;;7876386;;2188129;;10.1056/nejm199006073222302;;1924431;;10.1152/ajpheart.1994.267.1.h118;;8048575;;8148074;;10.1016/0305-4179(94)90104-x;;10.1152/ajpgi.1994.267.6.g1122;;7810659;;7992355;;10.1097/00007890-199412150-00003;;10.1016/0300-9572(95)00831-d;;7659869;;10.1007/bf00918154;;1512303;;pmc453150;;1721867;;10.1002/j.1460-2075.1991.tb04978.x,"GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"", EMBO J., vol. 12, no. 2, 1993, pages 725 - 734, XP000645476;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899 - 903, XP000572619, ISSN: 0733-222X;;OLD, L., SCIENCE, vol. 230, 1985, pages 630 - 632;;BEUTLER, B.; CERAMI, A., ANNU. REV. BIOCHEM., vol. 57, 1988, pages 505 - 518;;BEUTLER, B.; CERAMI, A., ANNU. REV. IMMUNOL., vol. 7, 1989, pages 625 - 655;;MOELLER, A. ET AL., CYTOKINE, vol. 2, 1990, pages 162 - 169;;VASILLI, P., ANNU. REV. IMMUNOL., vol. 10, 1992, pages 411 - 452;;TRACEY, K.J.; CERAMI, A., ANNU. REV. MED., vol. 45, 1994, pages 491 - 503;;HAHN T ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3814 - 3818;;LIANG, C-M. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 137, 1986, pages 847 - 854;;HIRAI, M. ET AL., J. IMMUNOT. METHODS, vol. 96, 1987, pages 57 - 62;;FENDLY, B.M. ET AL., HYBRIDOMA, vol. 6, 1987, pages 359 - 370;;KNIGHT, D.M ET AL., MOL. IMMUNOL., vol. 30, 1993, pages 1443 - 1453;;ELLIOTT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1125 - 1127;;ELLIOT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1105 - 1110;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 556 - 568;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 569 - 581;;FOMSGAARD, A. ET AL., SCAND. J. IMMUNOL., vol. 30, 1989, pages 219 - 223;;BENDTZEN, K. ET AL., PROG. LEUKOCYTE BIOL., vol. 10B, 1990, pages 447 - 452;;LEUSCH, H-G. ET AL., J. IMMUNOL. METHODS, vol. 139, 1991, pages 145 - 147;;GRIFFITHS, A.D. ET AL., EMBO J., vol. 12, 1993, pages 725 - 734;;LIDBURY, A. ET AL., BIOTECHNOL. THER., vol. 5, 1994, pages 27 - 45;;PENNICA, D. ET AL., NATURE, vol. 312, 1984, pages 724 - 729;;DAVIS, J.M. ET AL., BIOCHEMISTRY, vol. 26, 1987, pages 1322 - 1326;;JONES, E.Y. ET AL., NATURE, vol. 338, 1989, pages 225 - 228;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;KIPRIYANOV, S.M. ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101;;KIPRIYANOV, S.M. ET AL., MOL. IMMUNOL., vol. 31, 1994, pages 1047 - 1058;;TAYLOR, L.D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295;;JONSSON, U. ET AL., ANN. BIOL. CLIN., vol. 51, 1993, pages 19 - 26;;JONSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627;;JOHNSSON, B. ET AL., J. MOT. RECOGNIT., vol. 8, 1995, pages 125 - 131;;JOHNNSON, B. ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages 268 - 277;;SAMBROOK, FRITSCH AND MANIATIS: ""Molecular Cloning; A Laboratory Manual, Second Edition,"", 1989, COLD SPRING HARBOR;;AUSUBEL, F.M. ET AL.: ""Current Protocols in Molecular Biology"", 1989, GREENE PUBLISHING ASSOCIATES;;KABAT, E.A. ET AL.: ""Sequences of Proteins of Immunological Interest, Fifth Edition,"", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES;;TOMLINSON, I.M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups of V Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798, XP024020607, DOI: doi:10.1016/0022-2836(92)90223-7;;COX, J.P.L. ET AL.: ""A Directory of Human Germ-line V Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;GOEDDEL: ""Gene Expression Technology: Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;BOSS, M.A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R.J. KAUFMAN; P.A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;FUCHS ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1370 - 1372;;HAY ET AL., HUM ANTIBODHYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., JMOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;GARRAD ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;ARTHRITIS & RHEUMATISM, vol. 37, 1994, pages 295;;J. INVEST. MED., vol. 44, 1996, pages 235A;;ARTHRITIS & RHEUMATISM, vol. 38, 1995, pages I85;;ARTHRITIS & RHEUMATISM, vol. 36, 1993, pages 1223;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 284;;AMER. J. PHYSIOL. - HEART AND CIRCULATORY PHYSIOLOGY, vol. 268, 1995, pages 37 - 42;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 282;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 81;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 82;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 131;;INFLAMMATION RESEARCH, vol. 45, 1996, pages 103 - 107;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 280;;NEURO REPORT, vol. 7, 1996, pages 1209 - 1213;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 281;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 296;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 308;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 120;;DELUCA ET AL., RHEUM. DIS. CLIN. NORTH AM., vol. 21, 1995, pages 759 - 777;;RUSSELL, D; THOMPSON, R.C., CURR. OPIN. BIOTECH., vol. 4, 1993, pages 714 - 721;;AREND, W.P.; DAYER, J-M., ARTH. RHEUM., vol. 38, 1995, pages 151 - 160;;FAVA, R.A. ET AL., CLIN. EXP. IMMUNOL., vol. 94, 1993, pages 261 - 266;;RANKIN, E.C. ET AL., BR. J. RHEUMATOL., vol. 34, 1995, pages 334 - 342;;FIETZE, E. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 675 - 680;;EASON, J.D. ET AL., TRANSPLANTATION, vol. 59, 1995, pages 300 - 305;;SUTHANTHIRAN, M.; STROM, T.B., NEW ENGL. J. MED., vol. 331, 1994, pages 365 - 375;;TRACY, K.J. ET AL., SCIENCE, vol. 234, 1986, pages 470 - 474;;SUN, X-M. ET AL., J. CLIN. INVEST., vol. 81, 1988, pages 1328 - 1331;;MACDONALD, T.T. ET AL., CLIN. EXP. IMMUNOL., vol. 81, 1990, pages 301 - 305;;VAN DULLEMEN, H.M. ET AL., GASTROENTEROLOGY, vol. 109, 1995, pages 129 - 135;;BERTOLINI, D.R. ET AL., NATURE, vol. 319, 1986, pages 516 - 518;;KONIG, A. ET AL., J. BONE MINER. RES., vol. 3, 1988, pages 621 - 627;;LERNER, U.H.; OHLIN, A., J. BONE MINER. RES., vol. 8, 1993, pages 147 - 155;;SHANKAR, G.; STERN, P.H., BONE, vol. 14, 1993, pages 871 - 876;;MCCLAIN, C.J.; COHEN, D.A., HEPATOLOGY, vol. 9, 1989, pages 349 - 351;;FELVER, M.E. ET AL., ALCOHOL. CLIN. EXP. RES., vol. 14, 1990, pages 255 - 259;;HANSEN, J. ET AL., HEPATOLOGY, vol. 20, 1994, pages 461 - 474;;SHERON, N. ET AL., J. HEPATOL., vol. 12, 1991, pages 241 - 245;;HUSSAIN, M.J. ET AL., J. CLIN. PATHOL., vol. 47, 1994, pages 1112 - 1115;;VAN DER POLL, T. ET AL., N. ENGL. J. MED., vol. 322, 1990, pages 1622 - 1627;;VAN DER POLL, T. ET AL., PROG. CLIN. BIOL. RES., vol. 367, 1991, pages 55 - 60;;GIROIR, B.P. ET AL., AM. J. PHYSIOL., vol. 267, 1994, pages H118 - 124;;LIU, X.S. ET AL., BURNS, vol. 20, 1994, pages 40 - 44;;SCALES, W.E. ET AL., AM. J. PHYSIOL., vol. 267, 1994, pages G1122 - 1127;;SERRICK, C. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 1158 - 1162;;YAO, Y.M. ET AL., RESUSCITATION, vol. 29, 1995, pages 157 - 168;;MCCAULEY, R.L. ET AL., J. CLIN. IMMUNOL., vol. 12, 1992, pages 300 - 308;;EMBO J, vol. 10, 1991, pages 4025 - 4031",DISCONTINUED
143,BR,A,BR 9707379 A,051-072-222-724-155,1999-04-13,1999,BR 9707379 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Anticorpo humano isolado ácido nucleico isolado vetor recombinante de expressão célula hospedeira processo para sintetizar um anticorpo humano que se liga á TNF Alfa humano composição farmacéutica processo para inibir á atividade do TNF humano e uso do anticorpo,,BASF AG,SALFELD JOCHEN G;;WILTON ALISON J;;WHITE MICHAEL;;VAUGHAN TRISTAN J;;SCHOENHAUT DAVID;;HOOGENBOOM HENDRICUS R J M;;SAKORAFAS PAUL;;ROBERTS ANDREW J;;MCGUINESS BRIAN T;;MANKOVICH JOHN A;;LABROVSKY BORIS;;KAYMAKCALAN ZEHRA;;ALLEN DEBORAH J,ABBOTT BIOTECHNOLOGY LTD. (BM) (2006-09-05);;ABBOTT LABORATORIES (BERMUDA) LTD (BM) (2003-12-16);;ABBVIE BIOTECHNOLOGY LTD. (BM) (2015-06-09),https://lens.org/051-072-222-724-155,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
144,AU,A1,AU 2004/202769 A1,073-810-339-412-374,2004-07-15,2004,AU 2004/202769 A,2004-06-23,AU 2004/202769 A;;AU 2000/066649 A,2000-10-20,Human antibodies that bind human TNFalpha,,ABBOTT LAB BERMUDA LTD,KAYMAKCALAN ZEHR;;ALLEN DEBORAH J;;SALFELD JOCHEN G;;SCHOENHAUT DAVID;;WILTON ALISON J;;WHITE MICHAEL;;VAUGHAN TRISTAN J;;HOOGENBOOM HENDRICUS R J M;;SAKORAFAS PAUL;;ROBERTS ANDREW J;;MCGUINESS BRIAN T;;MANKOVICH JOHN A;;LABKOVSKY BORIS,ABBOTT BIOTECHNOLOGY LTD (2005-12-01),https://lens.org/073-810-339-412-374,Patent Application,no,0,0,2,2,0,Y02A50/30,A61K39/395;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,EXPIRED
145,HK,A1,HK 1214608 A1,152-973-340-701-173,2016-07-29,2016,HK 16102500 A,2016-03-04,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA TNF,,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/152-973-340-701-173,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K/;;A61K/;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N/;;C12N1/21;;C12N5/10;;C12P21/08;;G01N/;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
146,HU,A2,HU P9901874 A2,154-995-453-242-241,1999-09-28,1999,HU P9901874 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFALFA,"A találmány lényegében tűmőr nekrózis faktőra (TNFa) aktivitást gátlóantitestekre vőnatkőzik. A találmány szerinti legelőnyösebb antitestetgéntechnőlógiai módszerekkel állítják elő őlyan nűkleinsav szekvenciákhasználatával, amelyek az antitestnek a TNFa kötéséhez szükségesrészeit kódőlják. A találmány szerinti anti-TNFa antitesttel végzettkísérletekben azt találták, hőgy a TNFa különböző aktivitásaitmegfelelően gátőlja. A találmány szerinti TNFa elleni antitestetszámős őlyan betegség megelőzésére, kezelésére és kiegészítőterápiájában alkalmazható gyógyszerkészítmény előállításáhőzalkalmasnak találták, amelyekben a TNFa aktivitás kárős hatásafennáll. ŕ",BASF AG,ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SALFELD JOCHEN G;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBOTT LABORATORIES (BERMUDA) LTD., BM (2003-06-28);;ABBOTT BIOTECHNOLOGY LTD., BM (2005-02-28);;ABBVIE BIOTECHNOLOGY LTD, BM (2014-07-28)",https://lens.org/154-995-453-242-241,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
147,EP,A3,EP 1285930 A3,157-188-525-716-388,2007-05-30,2007,EP 02022788 A,1997-02-10,EP 97906572 A;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα ( e.g ., K d  = 10 -8  M or less), a slow off rate for hTNFα dissociation ( e.g ., K off  = 10 -3  sec -1  or less) and neutralize hTNFα activity  in vitro  and  in vivo . An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity,  e.g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBVIE BIOTECHNOLOGY LTD (2014-01-01);;ABBOTT LABORATORIES (BERMUDA) LTD. (2003-08-13);;ABBOTT BIOTECHNOLOGY LTD (2004-03-31),https://lens.org/157-188-525-716-388,Search Report,yes,5,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;C07K16/24;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,3,2,072-378-691-723-546;;040-701-579-915-050,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7521646;;10.1038/nbt0994-899,"GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"", EMBO J., vol. 12, no. 2, 1993, pages 725 - 734, XP000645476;;CHOW ET AL.: ""Effect of monoclonal antibody to human TNF on TNFalpha, IL-1beta and IL-6 levels in patients with sepsis syndrome"", CLINICAL RESEARCH, vol. 42, no. 2, April 1994 (1994-04-01), pages 299a, XP002032300;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899 - 903, XP000572619, ISSN: 0733-222X",DISCONTINUED
148,US,B2,US 8197813 B2,165-905-958-164-717,2012-06-12,2012,US 40146909 A,2009-03-10,US 40146909 A;;US 23325205 A;;US 30235602 A;;US 54001800 A;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFα,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/165-905-958-164-717,Granted Patent,yes,101,53,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/142.1;;424/145.1;;424/158.1;;530/388.15;;530/388.23,91,78,116-193-705-533-609;;005-321-867-106-932;;082-560-368-073-508;;092-412-882-661-570;;072-438-011-112-832;;064-048-827-826-930;;101-630-891-707-104;;022-179-293-052-569;;026-408-993-198-966;;024-854-471-494-140;;003-185-616-989-105;;006-342-252-521-899;;033-261-430-402-230;;072-378-691-723-546;;005-119-615-003-591;;036-413-156-723-523;;033-797-614-829-293;;040-701-579-915-050;;030-874-783-814-532;;017-529-128-038-946;;057-954-116-868-246;;015-761-810-001-488;;010-916-105-450-247;;020-855-322-534-259;;061-726-307-774-867;;074-932-950-939-666;;053-341-149-236-635;;004-601-819-239-79X;;030-323-674-660-051;;003-841-586-111-459;;087-599-254-199-807;;098-176-334-504-327;;019-030-524-959-069;;092-023-577-402-127;;021-641-900-032-887;;006-117-436-368-816;;145-140-396-707-208;;042-623-879-457-954;;074-817-300-512-106;;031-729-641-207-089;;022-133-574-143-973;;028-677-787-189-119;;077-341-362-901-551;;032-820-729-763-323;;041-315-340-063-133;;027-477-313-726-928;;088-851-255-233-972;;137-274-595-200-649;;022-384-366-455-012;;026-144-631-995-304;;010-327-392-460-003;;006-911-122-969-908;;006-626-799-687-686;;021-113-833-013-619;;038-613-711-274-229;;025-395-146-381-464;;085-277-440-303-853;;072-378-691-723-546;;012-897-611-427-172;;050-836-464-727-069;;005-119-615-003-591;;032-071-991-081-664;;035-939-173-669-143;;077-815-816-621-813;;040-701-579-915-050;;002-495-006-719-164;;043-108-278-056-872;;020-855-322-534-259;;010-916-105-450-247;;046-104-560-723-30X;;048-379-681-038-232;;016-219-576-017-946;;074-932-950-939-666;;001-900-209-379-77X;;020-753-772-581-741;;040-981-641-449-302;;003-595-371-167-198;;053-289-310-577-642,9671778;;pmc21176;;10.1073/pnas.95.15.8910;;7884952;;10.1001/jama.1995.03520360048038;;10.1001/jama.273.12.934;;7735957;;10.1097/00024382-199404000-00001;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1038/nrd984;;12509759;;10.1097/00003246-199609000-00002;;8797612;;10.1002/eji.1830240409;;8149953;;18240199;;10.1002/art.23362;;10.1146/annurev.immunol.19.1.163;;11244034;;10.1006/jmbi.1994.1351;;8196048;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;1560463;;10.1016/0022-2836(92)91010-m;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;7620183;;10.1182/blood.v86.3.890.890;;2531466;;10.1126/science.2531466;;7521646;;10.1038/nbt0994-899;;pmc1766613;;11053087;;10.1136/ard.59.suppl_1.i44;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;8757799;;10.1006/jmbi.1996.0406;;10.1038/nbt0792-779;;1368267;;1748994;;10.1016/0022-2836(91)90498-u;;7765558;;10.1038/nbt1194-1134;;10.1016/1043-4666(90)90011-h;;1716486;;10.1016/0959-440x(95)80028-x;;8528760;;15848075;;10.1016/j.ymeth.2005.01.006;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;8364031;;10.1021/bi00085a016;;10.1097/00003246-199605000-00003;;8706447;;11730333;;10.1006/abio.2001.5380;;8609615;;10.1006/jmbi.1996.0069;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1146/annurev.med.45.1.491;;8198398;;7697917;;pmc1534281;;10.1111/j.1365-2249.1995.tb03598.x;;9624683;;10.1038/nbt0698-535;;10.1038/341544a0;;2677748;;8397764;;10.1016/0167-5699(93)90039-n;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;10.1038/nbt0595-475;;9634788;;7935497;;10.1016/0161-5890(94)90101-5;;8159246;;10.1038/368856a0;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.3.co;2-y;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.0.co;2-l;;8727325;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1423650;;10.3109/07388559209114235;;10.1111/j.1365-2249.1994.tb05522.x;;7994916;;pmc1534487;;10.1016/1043-4666(92)90072-y;;1381227;;10.3233/hab-1995-6206;;7492754;;9180069;;10.1126/science.276.5319.1665;;8783501;;10.1016/0167-5699(96)10025-6;;9265725;;10.1016/s0958-1669(97)80068-7;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/ng0594-13;;8075633;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;pmc395221;;10.1002/j.1460-2075.1994.tb06626.x;;8045255;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;10.1016/0022-2836(92)90639-2;;1507232;;10.1016/0022-2836(92)90894-p;;1404359;;10.1111/j.1365-2141.1992.tb08212.x;;1379467;;7579668;;10.1016/0958-1669(95)80093-x;;7521646;;10.1038/nbt0994-899;;10.1016/0161-5890(93)90106-l;;8232330;;7494109;;10.3109/08830189509061738;;1748994;;10.1016/0022-2836(91)90498-u;;10.1038/nbt0792-779;;1368267;;10.1016/s0021-9258(18)41952-7;;1644788;;7764095;;10.1038/nbt1093-1145;;10.1038/ng0297-146;;9020839;;10.1016/1043-4666(90)90011-h;;1716486;;9052775;;10.1038/386025a0;;10.1093/intimm/6.4.579;;8018598;;7957560;;10.1002/eji.1830241116;;8190629;;pmc307995;;10.1093/nar/22.8.1389;;10.1096/fasebj.10.10.8751726;;8751726,"Rader et al. ""A phage display approach to rapid antibody humanization: Designed combinatorial V gene libraries"" Proc Natl Acad Sci USA 95:8910-8915 (1998).;;Abraham et al., ""Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor alpha in Patients with Sepsis Syndrome,"" JAMA, vol. 273(12):934-941 (1995).;;Barbuto et al., ""Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes"" Proc. Am. Assoc. Cancer Res,. 34:487, Abstr. 2904 (1993).;;Bendtzen et al., ""Auto-antibodies to IL-1alpha and TNFalpha in Normal Individuals and in Infectious and Immunoinflammatory Disorders"" The Physiological and Pathological Effects of Cytokines, 447-52 (1990).;;Boekstegers et al., ""Repeated administration of a F(ab')2 fragment of an anti-tumor recrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,"" Shock, vol. 1(4):237-245 (1994) (abstract from Pub Med).;;Boyle et al., ""A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor-alpha"" Cell. Immunol., 152:556-68 (1993).;;Boyle et al., ""The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF.alpha. on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope"", Cell. Immunol., vol. 152, pp. 569-581, (1993).;;Brekke et al., ""Therapeutic antibodies for human diseases at the dawn of the twenty-first century,"" Nature Reviews/Drug Discovery, vol. 2:52-62 (2003).;;Chow et al.,""Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFalpha, IL-1beta, and IL-6 levels in patients with sepsis syndrome"" Clinical Research, vol. 42, No. 2 p. 299A (1994).;;Cohen et al.,""Intersept: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis,"" Crit Care Med, vol. 24(9):1431-1440 (1996).;;Cox et al., ""A directory of human germ-line Vkappasegments reveals a strong bias in their usage"" Eur. J. Immunol., 24(2):827-36 (1994).;;Department of Surgery, University of Toronto Annual Report, Jul. 1, 1998-Jun. 30, 1999-found online at http://www.surg.med.utoronto.ca/AnnRep/AR98-99/index.html.;;Elliot et al., ""Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha"" Arthritis & Rheumatism, 36(12):1681-90 (1993).;;Feldman et al., ""Anti-TNFalpha Therapy of Rheumatoid Arthritis: What Have We Learned?"" Annu. Rev. Immunol., vol. 19:163-196 (2001).;;Figini et al., ""In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation,"" J. Mol. Biol., vol. 239:68-78 (1994).;;Fomsgaard et al., ""Auto-antibodies to Tumour Necrosis Factor alpha in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections"" Scand. J. Immunol., 30:219-23 (1989).;;Foote et al. ""Antibody framework residues affecting the conformation of the hypervariable loops,"" J Mol Biol 224(2):487 (1992).;;Griffiths et al., ""Human anti-self antibodies with high specificity from phage display libraries"" The EMBO J., 12(2):725-34 (1993).;;Hawkins et al., ""Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,"" J. Mol. Biol., vol. 226:889-896 (1992).;;Holler et al., ""Modulation of acute graft-versus-host-disease after allogeneic bone marrow ransplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F),"" Blood, vol. 86(3):890-899 (1995) (abstract from Pub Med).;;Hoogenboom et al., ""Converting rodent into human antibodies by guided selection,"" Antibody Engineering, Oxford University Press, pp. 169-185 (1996).;;Huse et al., ""Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda"" Science, 246:1275-81 (1989).;;Jespers et al., ""Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen,"" Bio/Technology, vol. 12:899-903 (1994).;;Kempeni, ""Update on D2E7: a fully human anti-tumor necrosis factor alpha monoclonal antibody,"" Ann Rheum Dis, vol. 59(Suppl. 1)144-145 (2000).;;Lerner et al., ""Antibodies without immunization"" Science, 258:1313-14 (1992).;;Leusch et al., ""Failure to demonstrate TNFalpha-specific autoantibodies in human sera by ELISA and Western blot"" J. lmmunol. Methods, 139:145-47 (1991).;;Lewis et al., ""Use of alanine scanning mutagenesis to improve the affinity of an anti gp120 (HIV) antibody."" J. Cell. Biochem., 18D:215 (1994).;;Low, thesis extract, Cambridge University (1996).;;Low et al., ""Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,"" J. Mol. Biol., vol. 260:359-368 (1996).;;Marks et al., ""By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,"" Biotechnology 10:779-783 (1992).;;Marks et al. ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"" J. Mol. Biol. 222:581-97 (1991).;;Medynski, ""Phage Display: All Dressed Up and Ready to Role,"" Bio/Technology, vol. 12:1134-1136 (1994).;;Möller et al., ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and vivo application"" Cytokine, 2(3):162-69 (1990).;;Nilsson, ""Antibody engineering,"" Current Opinion in Structural Biology, vol. 5:450-456 (1995).;;Osbourn et al., ""From rodent reagents to human therapeutics using antibody guided selection,"" Methods 36(1):61 (2005).;;Queen et al., ""A humanized antibody that binds to the interleukin 2 receptor,"" PNAS USA, 86(24):10029 (1989).;;Riechmann et al., ""Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement,"" Biochemistry, vol. 32(34):8848-8855 (1993) (abstract from Pub Med).;;Reinhart et al., ""Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study."" 1996 Crit. Care. Med., vol. 24(5):733-742.;;Santora et al., ""Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIA core,"" Analytical Biochemistry, vol. 299:119-129 (2001).;;Thompson et al., ""Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity,"" J. Mol. Biol., vol. 256(1):77-88 (1996) (abstract from Pub Med).;;Tomlinson et al., ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,"" J. Mol. Biol., vol. 227:776-798 (1992).;;Tomlinson et al., ""The structural repertoire of the human Vkappadomain,"" The EMBO Journal, vol. 14(18):4628-4638 (1995).;;Tracey et al., ""Tumor Necrosis Factor: A Pleiotropic Cytokine and Therapeutic Target,"" Annu. Rev. Med., vol. 45:491-503 (1994).;;Van Der Poll et al., ""Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees,"" Clin Exp Immunol, vol. 100:21-25 (1995).;;Vaughan et al., ""Human antibodies by design,"" Nature Biotechnology, vol. 16:535-539 (1998).;;Ward et al., ""Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli,"" Nature, vol. 341(6242):544-546 (1989).;;Winter et al, ""Humanized antibodies,"" Immunology Today, vol. 14(6):243-246 (1993).;;Winter et al., ""Making antibodies by phage display technology,"" Annu. Rev. Immunol., vol.12:433-455 (1994).;;Davies et al., ""Antibody VH domains as small recognition units."" Biotechnology, 13:475-479 (1995).;;Doring, E., Identification and Characterization of a TNFa Antagonist Derived from a Monoclonal Antibody (1994) Mol Immunol 31(14): 1059-1067.;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications."" Nature, 368:856-859 (1994).;;Martin, A.C.R. ""Accessing the Kabat antibody sequence database by computer."" PROTEINS: Structure, Function and Genetics, 25:130-133 (1996).;;Rudikoff, et al., Single amino acid substitution altering antigen-binding specificity. Proc. NaNatl.Acad. Sci. USA, 70:1979-1983 (1982).;;Sandhu, J. ""Protein engineering of antibodies."" Critical Reviews in Biotechnology, 12:437-462 (1992).;;Sioud et al., ""Characterization of naturally occurring autoantibodies against tumour necrosis factor-alpha (TNF-alpha): in vitro function and precise epitope mapping by phage epitope library."" Clin Exp Immunol, 98:520-525 (1994).;;Teichmann, S. Declaration dated Dec. 7, 2010 from opposition appeal proceedings in EP 0929578.;;Thorp et al., Tumour Necrosis Factor Induction of ELAM-1 and ICAM-1 on Human Umbilical Vein Endothelial Cells-Analysis of Tumour Necrosis Factor Receptor Interaction (1992) Cytokine 4(4): 313.;;Tsuchiyama et al., ""Comparison of anti-TNF alpha autoantibodies in plasma and from EBV transformed lymphocytes of autoimmune and normal individuals."" Hum. Antibod. Hybridomas 6(2):73-76 (1995).;;Wedemayer et al., ""Structural insights into the evolution of an antibody combining site."" Science 276:1665-1669 (1997).;;Bruggemann, M., Neuberger, M.S., ""Strategies for expressing human antibody repertoires in transgenic mice, "" Immunol. Today 17:391-397 (1996).;;Bruggemann et al. ""Production of human antibody repertoires in transgenic mice"" Cur. Op. Biotechnol. 8:455-458 (1997).;;Cambridge Antibody Technology, advertisement of phage display services, Science vol. 253, No. 5018 (1991).;;Elliot et al., ""Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis,"" Lancet 344:1125-1127 (1994).;;Fishwild et al., ""High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice,"" Nature Biotechnology 14:845-851 (1996).;;Gram et al., ""In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library,"" PNAS 89:3576-3580 (1992).;;Green et al., ""Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,"" Nature Genetics 7:13-21 (1994).;;Griffiths et al., ""Human anti-self antibodies with high specificity from phage display libraries,"" EMBO J. 12:725-734 (1993).;;Griffiths et al., ""Isolation of high affinity human antibodies directly from large synthetic repertoires,"" EMBO J. 13:3245-3260 (1994).;;Harding et al., ""Class switching in human immunoglobulin transgenic mice,"" Ann. NY Acad. Sci. 764:536-547 (1995).;;Hawkins et al., ""Selection of phage antibodies by binding affinity. Mimicking affinity maturation,"" J. Mol. Biol. 226:889-896 (1992).;;Hoogenboom et al., ""By-passing immunisation: Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro, "" J. Mol. Biol. 227:381-388.(1992).;;Huang et al. ""Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia,"" Br. J. Haematol 81(2):231-234 (1992).;;Jakobovits, A., ""Production of fully human antibodies by transgenic mice,"" Curr. Op. Biotechnol. 6:561-566 (1995).;;Jespers et al.,""Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen,"" Nature Biotechnology 12:899-903 (1994).;;The Kennedy Institute of Rheumatology, 1995 Annual Scientific Report, ""Anti-TNF trials and studies of mechanisms of action"".;;Knight et al., ""Construction and initial characterization of a mouse-human chimeric anti-TNF antibody,"" Mol. Immunol. 30(16):1443-1453 (1993).;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications,"" Nature 368:856-859 (1994).;;Lonberg et al., ""Human Antibodies from Transgenic Mice,"" Int. Rev. Immunol. 13:65-93 (1995).;;Marks et al., ""Bypassing immunization Human antibodies from V-gene libraries displayed on phage,"" J. Mol. Biol. 222:581-597 (1991).;;Marks et al., ""Bypassing immunization: High affinity human antibodies by chain shuffling,"".Bio/Technology 10:779-783 (1992).;;Marks et al., ""Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system,"" J. Biol. Chem. 267:16007-16010 (1992).;;Marks et al., ""Human antibody fragments specific for human blood group antigens from a phage display library,"" Bio/Technology 11:1145-1150 (1993).;;Marks, ""Human Monoclonal Antibodies from V-gene Repertoires Expressed on Bacteriophage."" In Antibody Engineering , Second Edition, edited by Carl A.K. Borrebaeck (1995), pp. 53-88. New York: Oxford Univ. Press.;;Mendez et al., ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice,"" Nature Genetics 15:146-156 (1997).;;Moller et al., ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and in vivo application,"" Cytokine 2(3):162-169 (1990).;;Neuberger M., et al., ""Mice perform a human repertoire"", Nature 386: 25-26 (1997).;;Salfeld, ""Development of a Fully Human Antibody to TNF by Phage Display Technology""IBC Conference, Antibody Engineering, San Diego (1996).;;Taylor et al., ""Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,"" Int. Immunol.6:579-591 (1994).;;Wagner et al., ""The diversity of antigen-specific monoclonal antibodies from transgenic mice.bearing human immunoglobulin gene miniloci,"" Eur. J. Immunol. 24:2672-2681 (1994).;;Wagner et al., ""Antibodies generated from human immunoglobulin miniloci in transgenic.mice,"" Nucl. Acids Res. 22:1389-1393 (1994).;;Zou et al., ""Dominant expression of a 1.3 Mb human Ig kappa locus replacing mouse light chain production,"" FASEB J 10:1227-1232 (1996).",EXPIRED
149,US,A,US 6090382 A,010-349-401-937-393,2000-07-18,2000,US 59922696 A,1996-02-09,US 59922696 A,1996-02-09,Human antibodies that bind human TNF alpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha. (e.g., K.sub.d =10.sup.-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K.sub.off =10.sup.-3 sec.sup.-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/010-349-401-937-393,Granted Patent,yes,18,789,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/133.1;;424/135.1;;424/142.1;;424/145.1;;530/387.3;;530/388.15;;530/388.23,18,15,092-412-882-661-570;;072-438-011-112-832;;022-179-293-052-569;;058-666-530-378-058;;006-342-252-521-899;;033-797-614-829-293;;017-529-128-038-946;;057-954-116-868-246;;020-855-322-534-259;;074-932-950-939-666;;021-641-900-032-887;;092-023-577-402-127;;006-117-436-368-816;;031-729-641-207-089;;072-378-691-723-546,7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1002/eji.1830240409;;8149953;;8250987;;10.1002/art.1780361206;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;2531466;;10.1126/science.2531466;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;1748994;;10.1016/0022-2836(91)90498-u;;10.1016/1043-4666(90)90011-h;;1716486;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;1404388;;10.1016/0022-2836(92)90223-7;;10.1146/annurev.med.45.1.491;;8198398;;8397764;;10.1016/0167-5699(93)90039-n;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990,"Barbuto, J.A.M., et al. Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor Infiltrating B Lymphocytes , Abstract 2904, Proc. Am. Assoc. Cancer Res., vol. 34, p. 487, Mar. 1993.;;Bendtzen, K. et al. Auto Antibodies to IL 1 and TNF in Nornal Individuals and in Infectious and Immunoinflammatory Disorders , in The Physiological and Pathological Effects of Cytokines, pp. 447 452, Wiley Liss, Inc., 1990.;;Boyle, P. et al. A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor , Cell. Immunol., vol. 152, pp. 556 568, (1993).;;Boyle, P. et al. The B5 Monoclonal Human Autoanitibody Binds to Cell Surface TNF on Human Lymphoid Cells and Cell Lines and Aappears to Recognize a Novel Epitope , Cell. Immunol., vol. 152, pp. 569 581, (1993).;;Cox, J.P.L. et al., A directory of human germ line V x segments reveals a strong bias in their usage , Eur. J. Immunol., vol. 24, pp. 827 836 (1994).;;Elliot, M.J. et al., Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor , Arthritis & Rheumatism, vol. 36, No. 12, pp. 1681 1690 (1993).;;Fomsgaard, A. et al. Auto antibodies to Tumor Necrosis Factor in Healthy Humans and Patients with Inflammatory Diseases and Gram Negative Bacterial Infections , Scand. J. Immunol., vol. 30, pp. 219 223, (1989).;;Huse, W.D. et al., Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda , Science, vol. 246, pp. 1275 1281 (1989).;;Lerner, R.A. et al., Antibodies without immunization , Science, vol. 258, pp. 1313 1314 (1992).;;Leusch, H G. et al. Failure to demonstrate TNF specific autoantibodies in human sera by ELISA and Western blot , J. Immunol. Methods, vol. 139, pp. 145 147, (1991).;;Marks, J.D. et al., By passing immunization: Human antibodies from V gene libraries displayed on phage , J. Mol. Biol., vol. 222, pp. 581 597 (1991).;;M o ller, et al., Monoclonal antibodies to human tumor necrosis factor : in vitro and in vivo application , Cytokine, vol. 2, No. 3, pp. 162 169 (1990).;;Tomlinson, I.M. et al., The structural repertoire of the human V k domain , EMBO, vol. 14, No. 18, pp. 4628 4638 (1995).;;Tomlinson, I.M. et al., The repertoire of human germline V H sequences reveals about fifty groups of V H segments with different hypervariable loops , J. Mol. Biol., vol. 227, pp. 776 698 (1992).;;Tracey, K.J. et al., Tumor necrosis factor: A pleiotropic cytokine and therapuetic target , Annu. Rev. Med., vol. 45, pp. 491 503 (1994).;;Winter, G. et al., Humanized antibodies , Immunology Today, vol. 14, No. 6, pp. 243 246 (1993).;;Griffiths et al., The EMBO J. 12(2):725, 1993.;;Lewis et al., J. Cell. Biochem., 18D:215, 1994.",EXPIRED
150,CA,A1,CA 2596476 A1,029-142-338-844-531,1997-08-14,1997,CA 2596476 A,1997-02-10,US 59922696 A;;US 3147696 P;;CA 2389943 A,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF .ALPHA.,,ABBOTT BIOTECH LTD,WILTON ALISON J;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;SAKORAFAS PAUL;;LABKOVSKY BORIS;;HOOGENBOOM HENDRICUS R J M;;SALFELD JOCHEN G;;KAYMAKCALAN ZEHRA;;WHITE MICHAEL;;SCHOENHAUT DAVID;;ALLEN DEBORAH J;;ROBERTS ANDREW J;;VAUGHAN TRISTAN J,,https://lens.org/029-142-338-844-531,Patent Application,no,0,0,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K19/00;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C07K16/46;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
151,US,A1,US 2013/0122018 A1,031-809-991-568-482,2013-05-16,2013,US 201313738432 A,2013-01-10,US 201313738432 A;;US 201213466892 A;;US 40146909 A;;US 23325205 A;;US 30235602 A;;US 54001800 A;;US 59922696 A,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD BERMUDA;;ABBOTT BIOTECH LTD BERMUDA,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/031-809-991-568-482,Patent Application,yes,4,14,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/158.1;;530/389.2;;530/387.3,4,4,013-880-541-901-494;;089-788-839-300-179;;000-335-858-105-765;;058-354-982-149-667,1356177;;10.1016/0140-6736(92)92294-p;;12949252;;10.1093/rheumatology/keg424;;10.1016/s0021-9258(19)39314-7;;2108155;;9631034;;10.1038/nbt0896-975,"Isaacs et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 1992 Sep 26;340(8822):748-52.;;Lockwood et al. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford). 2003 Dec;42(12):1539-44. Epub 2003 Aug 29.;;Smith et al. Transfer and expression of a murine UDP-Gal:beta-D-Gal-alpha 1,3-galactosyltransferase gene in transfected Chinese hamster ovary cells. Competition reactions between the alpha 1,3-galactosyltransferase and the endogenous alpha 2,3-sialyltransferase. J Biol Chem. 1990 Apr 15;265(11):6225-34.;;Jenkins et al. Getting the glycosylation right: implications for the biotechnology industry. Nat Biotechnol. 1996 Aug;14(8):975-81.",DISCONTINUED
152,US,B2,US 8372401 B2,127-001-833-598-554,2013-02-12,2013,US 201213466892 A,2012-05-08,US 201213466892 A;;US 40146909 A;;US 23325205 A;;US 30235602 A;;US 54001800 A;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFα,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD;;SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBOTT BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/127-001-833-598-554,Granted Patent,yes,99,51,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;A61K39/395;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/00;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/142.1;;424/145.1;;424/158.1;;530/388.15;;530/388.23,86,74,005-321-867-106-932;;082-560-368-073-508;;092-412-882-661-570;;072-438-011-112-832;;064-048-827-826-930;;101-630-891-707-104;;022-179-293-052-569;;026-408-993-198-966;;024-854-471-494-140;;003-185-616-989-105;;006-342-252-521-899;;033-261-430-402-230;;072-378-691-723-546;;005-119-615-003-591;;036-413-156-723-523;;033-797-614-829-293;;040-701-579-915-050;;030-874-783-814-532;;017-529-128-038-946;;057-954-116-868-246;;015-761-810-001-488;;010-916-105-450-247;;020-855-322-534-259;;061-726-307-774-867;;074-932-950-939-666;;053-341-149-236-635;;004-601-819-239-79X;;030-323-674-660-051;;003-841-586-111-459;;087-599-254-199-807;;098-176-334-504-327;;019-030-524-959-069;;092-023-577-402-127;;021-641-900-032-887;;006-117-436-368-816;;145-140-396-707-208;;042-623-879-457-954;;074-817-300-512-106;;031-729-641-207-089;;022-133-574-143-973;;077-341-362-901-551;;022-384-366-455-012;;088-581-950-418-154;;028-677-787-189-119;;041-315-340-063-133;;027-477-313-726-928;;088-851-255-233-972;;137-274-595-200-649;;026-144-631-995-304;;010-327-392-460-003;;032-820-729-763-323;;006-911-122-969-908;;006-626-799-687-686;;021-113-833-013-619;;038-613-711-274-229;;025-395-146-381-464;;085-277-440-303-853;;012-897-611-427-172;;050-836-464-727-069;;035-939-173-669-143;;077-815-816-621-813;;040-701-579-915-050;;002-495-006-719-164;;043-108-278-056-872;;046-104-560-723-30X;;048-379-681-038-232;;016-219-576-017-946;;001-900-209-379-77X;;020-753-772-581-741;;040-981-641-449-302;;003-595-371-167-198;;053-289-310-577-642;;032-071-991-081-664;;116-193-705-533-609,7884952;;10.1001/jama.1995.03520360048038;;10.1001/jama.273.12.934;;7735957;;10.1097/00024382-199404000-00001;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1038/nrd984;;12509759;;10.1097/00003246-199609000-00002;;8797612;;10.1002/eji.1830240409;;8149953;;18240199;;10.1002/art.23362;;10.1146/annurev.immunol.19.1.163;;11244034;;10.1006/jmbi.1994.1351;;8196048;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;1560463;;10.1016/0022-2836(92)91010-m;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;7620183;;10.1182/blood.v86.3.890.890;;2531466;;10.1126/science.2531466;;7521646;;10.1038/nbt0994-899;;pmc1766613;;11053087;;10.1136/ard.59.suppl_1.i44;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;8757799;;10.1006/jmbi.1996.0406;;10.1038/nbt0792-779;;1368267;;1748994;;10.1016/0022-2836(91)90498-u;;7765558;;10.1038/nbt1194-1134;;10.1016/1043-4666(90)90011-h;;1716486;;10.1016/0959-440x(95)80028-x;;8528760;;15848075;;10.1016/j.ymeth.2005.01.006;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;8364031;;10.1021/bi00085a016;;10.1097/00003246-199605000-00003;;8706447;;11730333;;10.1006/abio.2001.5380;;8609615;;10.1006/jmbi.1996.0069;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1146/annurev.med.45.1.491;;8198398;;7697917;;pmc1534281;;10.1111/j.1365-2249.1995.tb03598.x;;9624683;;10.1038/nbt0698-535;;10.1038/341544a0;;2677748;;8397764;;10.1016/0167-5699(93)90039-n;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;7935497;;10.1016/0161-5890(94)90101-5;;10.1016/1043-4666(92)90072-y;;1381227;;10.4049/jimmunol.164.3.1432;;10640759;;10.1038/nbt0595-475;;9634788;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.3.co;2-y;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.0.co;2-l;;8727325;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1423650;;10.3109/07388559209114235;;10.1111/j.1365-2249.1994.tb05522.x;;7994916;;pmc1534487;;10.3233/hab-1995-6206;;7492754;;9180069;;10.1126/science.276.5319.1665;;8159246;;10.1038/368856a0;;8783501;;10.1016/0167-5699(96)10025-6;;9265725;;10.1016/s0958-1669(97)80068-7;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/ng0594-13;;8075633;;pmc395221;;10.1002/j.1460-2075.1994.tb06626.x;;8045255;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;10.1111/j.1365-2141.1992.tb08212.x;;1379467;;7579668;;10.1016/0958-1669(95)80093-x;;7521646;;10.1038/nbt0994-899;;10.1016/0161-5890(93)90106-l;;8232330;;7494109;;10.3109/08830189509061738;;10.1016/s0021-9258(18)41952-7;;1644788;;7764095;;10.1038/nbt1093-1145;;10.1038/ng0297-146;;9020839;;9052775;;10.1038/386025a0;;10.1093/intimm/6.4.579;;8018598;;7957560;;10.1002/eji.1830241116;;8190629;;pmc307995;;10.1093/nar/22.8.1389;;10.1096/fasebj.10.10.8751726;;8751726;;10.1016/0022-2836(92)90894-p;;1404359;;9671778;;pmc21176;;10.1073/pnas.95.15.8910,"Abraham et al., ""Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor alpha in Patients with Sepsis Syndrome,"" JAMA, vol. 273(12):934-941 (1995).;;Barbuto et al., ""Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes"" Proc. Am. Assoc. Cancer Res,. 34:487, Abstr. 2904 (1993).;;Bendtzen et al., ""Auto-antibodies to IL-1alpha and TNFalpha in Normal Individuals and in Infectious and Immunoinflammatory Disorders"" The Physiological and Pathological Effects of Cytokines, 447-52 (1990).;;Boekstegers et al., ""Repeated administration of a F(ab')2 fragment of an anti-tumor recrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,"" Shock, vol. 1(4):237-245 (1994) (abstract from Pub Med).;;Boyle et al., ""A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- alpha"" Cell. Immunol., 152:556-68 (1993).;;Boyle et al., ""The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF.alpha. on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope"", Cell. Immunol., vol. 152, pp. 569-581, (1993).;;Brekke et al., ""Therapeutic antibodies for human diseases at the dawn of the twenty-first century,"" Nature Reviews/Drug Discovery, vol. 2:52-62 (2003).;;Chow et al., ""Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFalpha, IL-1beta, and IL-6 levels in patients with sepsis syndrome"" Clinical Research, vol. 42, No. 2 p. 299A (1994).;;Cohen et al.,""Intersept: An international, multicenter, placebo-controlled trial of monoclonal anitbody to human tumor necrosis factor-alpha in patients with sepsis,"" Crit Care Med, vol. 24(9):1431-1440 (1996).;;Cox et al., ""A directory of human germ-line Vkappasegments reveals a strong bias in their usage"" Eur. J. Immunol., 24(2):827-36 (1994).;;Department of Surgery, University of Toronto Annual Report, Jul. 1, 1998 Jun. 30, 1999-found online at http://www.surg.med.utoronto.ca/AnnRep/AR98-99/index.html.;;Elliot et al., ""Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha"" Arthritis & Rheumatism, 36(12):1681-90 (1993).;;Feldman et al., ""Anti-TNFalpha Therapy of Rheumatoid Arthritis: What Have We Learned?"" Annu. Rev. Immunol., vol. 19:163-196 (2001).;;Figini et al., ""In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation,"" J. Mol. Biol., vol. 239:68-78 (1994).;;Fomsgaard et al., ""Auto-antibodies to Tumour Necrosis Factor alpha in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections"" Scand. J. Immunol., 30:219-23 (1989).;;Foote et al. ""Antibody framework residues affecting the conformation of the hypervariable loops,"" J Mol Biol 224(2):487 (1992).;;Griffiths et al., ""Human anti-self antibodies with high specificity from phage display libraries"" The EMBO J., 12(2):725-34 (1993).;;Hawkins et al., ""Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,"" J. Mol. Biol., vol. 226:889-896 (1992).;;Holler et al., ""Modulation of acute graft-versus-host-disease after allogeneic bone marrow ransplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F),"" Blood, vol. 86(3):890-899 (1995) (abstract from Pub Med).;;Hoogenboom et al., ""Converting rodent into human antibodies by guided selection,"" Antibody Engineering, Oxford University Press, pp. 169-185 (1996).;;Huse et al., ""Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda"" Science, 246:1275-81 (1989).;;Jespers et al., ""Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen,"" Bio/Technology, vol. 12:899-903 (1994).;;Kempeni, ""Update on D2E7: a fully human anti-tumor necrosis factor alpha monoclonal antibody,"" Ann Rheum Dis, vol. 59(Suppl. I):144-145 (2000).;;Lerner et al., ""Antibodies without immunization"" Science, 258:1313-14 (1992).;;Leusch et al., ""Failure to demonstrate TNFalpha-specific autoantibodies in human sera by ELISA and Western blot"" J. Immunol. Methods, 139:145-47 (1991).;;Lewis et al., ""Use of alanine scanning mutagenesis to improve the affinity of an anti gp120 (HIV) antibody."" J. Cell. Biochem., 18D:215 (1994).;;Low, thesis extract, Cambridge University (1996).;;Low et al., ""Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,"" J. Mol. Biol., vol. 260:359-368 (1996).;;Marks et al., ""By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,"" Biotechnology 10:779-783 (1992).;;Marks et al. ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"" J. Mol. Biol. 222:581-97 (1991).;;Medynski, ""Phage Display: All Dressed Up and Ready to Role,"" Bio/Technology, vol. 12:1134-1136 (1994).;;Möller et al., ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and vivo application"" Cytokine, 2(3):162-69 (1990).;;Nilsson, ""Antibody engineering,"" Current Opinion in Structural Biology, vol. 5:450-456 (1995).;;Osbourn et al., ""From rodent reagents to human therapeutics using antibody guided selection,"" Methods 36(1):61 (2005).;;Queen et al., ""A humanized antibody that binds to the interleukin 2 receptor,"" PNAS USA, 86(24):10029 (1989).;;Riechmann et al., ""Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement,"" Biochemistry, vol. 32(34):8848-8855 (1993) (abstract from Pub Med).;;Reinhart et al., ""Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study."" 1996 Crit. Care. Med., vol. 24(5):733-742.;;Santora et al., ""Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIA core,"" Analytical Biochemistry, vol. 299:119-129 (2001).;;Thompson et al., ""Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity,"" J. Mol. Biol., vol. 256(1):77-88 (1996) (abstract from Pub Med).;;Tomlinson et al., ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,"" J. Mol. Biol., vol. 227:776-798 (1992).;;Tomlinson et al., ""The structural repertoire of the human Vkappa domain,"" The EMBO Journal, vol. 14(18):4628-4638 (1995).;;Tracey et al., ""Tumor Necrosis Factor: A Pleiotropic Cytokine and Therapeutic Target,"" Annu. Rev. Med., vol. 45:491-503 (1994).;;Van Der Poll et al., ""Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees,"" Clin Exp Immunol, vol. 100:21-25 (1995).;;Vaughan et al., ""Human antibodies by design,"" Nature Biotechnology, vol. 16:535-539 (1998).;;Ward et al., ""Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli,"" Nature, vol. 341(6242):544-546 (1989).;;Winter et al, ""Humanized antibodies,"" Immunology Today, vol. 14(6):243-246 (1993).;;Winter et al., ""Making antibodies by phage display technology,"" Annu. Rev. Immunol., vol. 12:433-455 (1994).;;Doring, E., Identification and Characterization of a TNFa Antagonist Derived from a Monoclonal Antibody (1994) Mol Immunol 31(14): 1059-1067.;;Thorp et al., Tumour Necrosis Factor Induction of ELAM-1 and ICAM-1 on Human Umbilical Vein Endothelial Cells-Analysis of Tumour Necrosis Factor Receptor Interaction (1992) Cytokine 4(4): 313.;;Tamura, M. et al. ""Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only"" Journal of Immunology (2000) vol. 164, pp. 1432-1441.;;Davies et al., ""Antibody VH domains as small recognition units."" Biotechnology, 13:475-479 (1995).;;Martin, A.C.R. ""Accessing the Kabat antibody sequence database by computer."" Proteins: Structure, Function and Genetics, 25:130-133 (1996).;;Rudikoff, et al., Single amino acid substitution altering antigen-binding specificity. Proc. Natl. Acad. Sci. USA, 70:1979-1983 (1982).;;Sandhu, J. ""Protein engineering of antibodies."" Critical Reviews in Biotechnology, 12:437-462 (1992).;;Sioud et al., ""Characterization of naturally occurring autoantibodies against tumour necrosis factor-alpha (TNF-alpha): in vitro function and precise epitope mapping by phage epitope library."" Clin Exp Immunol, 98:520-525 (1994).;;Teichmann, S. Declaration dated Dec. 7, 2010 from opposition appeal proceedings in EP 0929578.;;Tsuchiyama et al., ""Comparison of anti-TNF alpha autoantibodies in plasma and from EBV transformed lymphocytes of autoimmune and normal individuals."" Hum. Antibod. Hybridomas 6(2):73-76 (1995).;;Wedemayer et al., ""tructural insights into the evolution of an antibody combining site."" Science 276:1665-1669 (1997).;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications."" Nature, 368:856-859 (1994).;;Bruggemann, M., Neuberger, M.S., ""Strategies for expressing human antibody repertoires in transgenic mice,"" Immunol. Today 17:391-397 (1996).;;Bruggemann et al. ""Production of human antibody repertoires in transgenic mice"" Cur. Op. Biotechnol. 8:455-458 (1997).;;Cambridge Antibody Technology, advertisement of phage display services, Science vol. 253, No. 5018 (1991).;;Elliot et al., ""Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis,"" Lancet 344:1125-1127 (1994).;;Fishwild et al., ""High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice,"" Nature Biotechnology 14:845-851 (1996).;;Gram et al., ""In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library,"" PNAS 89:3576-3580 (1992).;;Green et al., ""Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,"" Nature Genetics 7:13-21 (1994).;;Griffiths et al., ""Isolation of high affinity human antibodies directly from large synthetic repertoires,"" EMBO J. 13:3245-3260 (1994).;;Harding et al., ""Class switching in human immunoglobulin transgenic mice,"" Ann. NY Acad. Sci. 764:536-547 (1995).;;Huang et al. ""Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia,"" Br. J. Haematol 81(2):231-234 (1992).;;Jakobovits, A., ""Production of fully human antibodies by transgenic mice,"" Curr. Op. Biotechnol. 6:561-566 (1995).;;Jespers et al.,""Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen,"" Nature Biotechnology 12:899-903 (1994).;;The Kennedy Institute of Rheumatology, 1995 Annual Scientific Report, ""Anti-TNF trials and studies of mechanisms of action"".;;Knight et al., ""Construction and initial characterization of a mouse-human chimeric anti-TNF antibody,"" Mol. Immunol. 30(16):1443-1453 (1993).;;Lonberg et al., ""Human Antibodies from Transgenic Mice,"" Int. Rev. Immunol. 13:65-93 (1995).;;Marks et al., ""Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system,"" J. Biol. Chem. 267:16007-16010 (1992).;;Marks et al., ""Human antibody fragments specific for human blood group antigens from a phage display library,"" Bio/Technology 11:1145-1150 (1993).;;Marks, ""Human Monoclonal Antibodies from V-gene Repertoires Expressed on Bacteriophage."" In Antibody Engineering, Second Edition, edited by Carl A.K. Borrebaeck (1995), pp. 53-88. New York: Oxford Univ. Press.;;Mendez et al., ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice,"" Nature Genetics 15:146-156 (1997).;;Neuberger M., et al., ""Mice perform a human repertoire"", Nature 386: 25-26 (1997).;;Salfeld, ""Development of a Fully Human Antibody to TNF by Phage Display Technology"", IBC Conference, Antibody Engineering, San Diego (1996).;;Taylor et al., ""Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,"" Int. Immunol. 6:579-591 (1994).;;Wagner et al., ""The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human immunoglobulin gene miniloci,"" Eur. J. Immunol. 24:2672-2681 (1994).;;Wagner et al., ""Antibodies generated from human immunoglobulin miniloci in transgenic mice,"" Nucl. Acids Res. 22:1389-1393 (1994).;;Zou et al., ""Dominant expression of a 1.3 Mb human Ig kappa locus replacing mouse light chain production,"" FASEB J 10:1227-1232 (1996).;;Hoogenboom et al., ""By-passing immunisation: Human antibodies from synthetic repertoires of germline V.sub.H gene segments rearranged in vitro,"" J. Mol. Biol. 227:381-388.(1992).;;Rader et al., ""A phage display approach to rapid antibody humanization: Designed combinatorial V gene libraries"" Proc Natl Acad Sci USA 95:8910-8915 (1998).",EXPIRED
153,AU,C1,AU 2009/202707 C1,118-093-853-028-190,2013-09-05,2013,AU 2009/202707 A,2009-07-03,AU 2006/241387 A;;AU 2009/202707 A,2006-11-24,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kd= 10-8 M or less), a slow off rate for hTNFa dissociation (e.g., Kof~1 0 3 sec-1 or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/118-093-853-028-190,Amended Patent,no,1,0,5,5,0,A61K2039/505;;C07K16/241;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/622;;C07K2317/76;;C07K2317/92;;G01N2333/525;;G01N2800/10;;G01N2800/102,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
154,NZ,A,NZ 587678 A,028-400-383-138-735,2012-04-27,2012,NZ 58767897 A,1997-02-10,US 59922696 A;;US 3147696 P;;NZ 57671697 A,1996-02-09,Rheumatoid Arthritis treatment by Human Antibodies that Bind Human TNFa,"Provided is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFá with a Kd of 1 x 10-8 M or less and a Koff rate constant of 1 x 10-3 s-1 or less, both determined by surface plasmon resonance, and neutralizes human TNFá cytotoxicity in a standard in vitro L929 assay with an IC50 of 1 x 10-7 M or less; in combination with a non-steroidal anti-inflammatory drug, which can be used for the treatment of rheumatoid arthritis. Further provided are amino acid sequences of suitable antibodies and their CDRs.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/028-400-383-138-735,Patent Application,no,0,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;C12N15/09;;A61K31/40;;C12N15/13;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
155,NZ,A,NZ 536216 A,045-178-679-436-311,2006-08-31,2006,NZ 53621697 A,1997-02-10,US 3147696 P;;US 59922696 A,1996-02-09,Use of an isolated antibody D2E7 for the treatment of a disorder in which TNF(alpha) activity is detrimental,The use of an isolated antibody D2E7 in the manufacture of a medicament for the treatment of a disorder in which TNFalpha activity is detrimental.,ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/045-178-679-436-311,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;C12N15/09;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
156,CY,B1,CY 2463 B1,106-585-619-508-87X,2005-06-03,2005,CY 0400052 A,2004-06-24,US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human tnfalpha.,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/106-585-619-508-87X,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,ACTIVE
157,NZ,A,NZ 576716 A,111-081-182-777-170,2011-02-25,2011,NZ 57671697 A,1997-02-10,US 3147696 P;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFalpha,Provided is the combination of TNF alpha antibody and methotrexate to be used in combination for the treatment of rheumatoid arthritis. The antibody can comprise specified CDR domains.,ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;ROBERTS ANDREW J;;MCGUINESS BRIAN T;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/111-081-182-777-170,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;C12N15/13;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
158,CA,C,CA 2243459 C,157-412-726-007-098,2002-09-17,2002,CA 2243459 A,1997-02-10,US 3147696 P;;US 59922696 A;;US 9702219 W,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF.ALPHA.,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. The se antibodies have high affinity for hTNF.alpha.(e.g., Kd = 10-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., Koff = 10-3sec-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereo f. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing t he recombinant human antibodies, are also encompassed by the invention.",BASF AG,VAUGHAN TRISTAN J;;ALLEN DEBORAH J;;SALFELD JOCHEN G;;WHITE MICHAEL;;HOOGENBOOM HENDRICUS R J M;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;KAYMAKCALAN ZEHRA;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;WILTON ALISON J;;LABKOVSKY BORIS,,https://lens.org/157-412-726-007-098,Granted Patent,no,0,2,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
159,DK,T3,DK 0929578 T3,160-007-351-136-684,2003-08-25,2003,DK 97906572 T,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,"Humane antistoffer, der binder human TNFalfa",,ABBOTT LAB BERMUDA LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/160-007-351-136-684,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
160,UA,C2,UA 57726 C2,182-483-856-604-581,2003-07-15,2003,UA 98094737 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Human antibodies binding to human tumor necrosis factor alpha,"Human antibodies, preferably recombinant human antibodies that specifically bind to human tumor necrosis factor alpha (hTNF alpha) are disclosed. These antibodies have high affinity for hTNF alpha (e. g., Kd = 10-8 M or less), a slow off rate for hTNF alpha dissociation (e. g., Koff = 10-3 sec.-1 or less) and neutralize hTNF alpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF alpha and for inhibiting hTNF alpha activity, e.g., in a human subject suffering from a disorder in which hTNF alpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/182-483-856-604-581,Limited Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
161,AU,A1,AU 2014/202726 A1,174-950-831-076-532,2014-06-12,2014,AU 2014/202726 A,2014-05-19,AU 2013/203420 A;;AU 2014/202726 A,2013-04-10,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kd = 10-8 M or less), a slow off rate for hTNFa dissociation (e.g., Koff~1Osec-1 or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/174-950-831-076-532,Patent Application,no,0,0,3,3,0,,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,DISCONTINUED
162,US,A1,US 2012/0178107 A1,194-714-537-586-68X,2012-07-12,2012,US 201113340805 A,2011-12-30,US 201113340805 A;;US 40146909 A;;US 23325205 A;;US 30235602 A;;US 54001800 A;;US 59922696 A,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/194-714-537-586-68X,Patent Application,yes,3,11,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;C12N15/09;;A61K31/40;;G01N33/566;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N9/96;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,435/7.92;;435/188;;436/501;;530/389.2;;530/391.3;;530/391.7,0,0,,,,EXPIRED
163,EP,A1,EP 2305712 A1,005-713-626-605-135,2011-04-06,2011,EP 10184662 A,1997-02-10,EP 02022788 A;;EP 97906572 A;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d  = 10 -8  M or less), a slow off rate for hTNFα dissociation  (e.g.,  K off  = 10 -3  sec -1  or less) and neutralize hTNFα activity  in vitro  and  in vivo.  An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBVIE BIOTECHNOLOGY LTD (2014-01-01),https://lens.org/005-713-626-605-135,Patent Application,yes,42,6,45,181,2,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,106,80,072-378-691-723-546;;040-701-579-915-050;;074-871-884-454-68X;;016-907-020-918-983;;011-796-204-010-792;;117-499-681-530-662;;006-117-436-368-816;;046-939-287-004-026;;085-191-504-989-317;;041-591-849-635-094;;054-329-283-530-645;;002-495-006-719-164;;021-113-833-013-619;;015-584-716-307-216;;092-412-882-661-570;;072-438-011-112-832;;006-342-252-521-899;;057-954-116-868-246;;072-378-691-723-546;;003-907-950-634-854;;041-956-664-134-903;;035-071-534-473-573;;071-901-988-318-434;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;066-749-017-721-197;;001-467-559-709-949;;143-467-932-790-298;;123-171-555-829-362;;071-707-020-428-907;;168-113-989-624-417;;044-369-216-298-341;;092-023-577-402-127;;022-179-293-052-569;;030-630-100-818-462;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;100-049-580-404-573;;033-797-614-829-293;;072-378-691-723-546;;005-119-615-003-591;;034-331-211-704-877;;025-395-146-381-464;;011-962-497-035-168;;065-145-385-150-339;;033-459-816-867-43X;;098-513-251-868-998;;063-873-022-003-842;;044-317-656-227-593;;011-114-894-374-225;;037-795-266-129-616;;048-153-224-318-923;;008-835-817-825-32X;;075-878-183-554-694;;004-001-063-582-854;;079-192-394-643-91X;;000-065-369-829-300;;128-904-140-606-949;;077-369-546-251-682;;032-821-336-726-761;;050-094-719-890-440;;070-452-766-365-174;;110-232-737-639-142;;028-469-508-809-412;;044-217-982-536-908;;012-422-300-553-121;;033-522-835-476-708;;097-358-265-091-151;;041-043-853-736-19X;;085-885-495-910-537;;167-234-008-883-687;;061-475-814-399-439;;031-974-874-348-471;;054-469-226-992-186;;007-667-472-783-358;;023-473-383-533-503;;063-233-860-095-920;;052-159-696-111-105,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7521646;;10.1038/nbt0994-899;;2413547;;10.1126/science.2413547;;10.1146/annurev.bi.57.070188.002445;;3052281;;10.1146/annurev.biochem.57.1.505;;10.1146/annurev.immunol.7.1.625;;10.1146/annurev.iy.07.040189.003205;;2540776;;1590993;;10.1146/annurev.iy.10.040192.002211;;10.1146/annurev.immunol.10.1.411;;0001590993;;10.1146/annurev.med.45.1.491;;8198398;;3889916;;pmc397878;;10.1073/pnas.82.11.3814;;3729942;;10.1016/0006-291x(86)91157-5;;3805735;;10.1016/0022-1759(87)90367-x;;10.1089/hyb.1987.6.359;;2442093;;10.1016/0161-5890(93)90106-l;;8232330;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1016/s0140-6736(94)90628-9;;7934491;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1016/0022-1759(91)90361-i;;2040812;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7703831;;10.1038/312724a0;;6392892;;3552045;;10.1021/bi00379a018;;2922046;;2922050;;10.1038/338225a0;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;8597629;;10.3233/hab-1995-6303;;10.1016/0161-5890(94)90100-7;;7935496;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;1804254;;7541226;;10.1002/jmr.300080122;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;10.1038/348552a0;;2247164;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;1385989;;10.3233/hab-1992-3204;;2531466;;10.1126/science.2531466;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;pmc52428;;10.1073/pnas.88.18.7978;;1896445;;8216416;;10.1002/art.1780360907;;8907592;;10.1007/bf02265123;;10.1097/00001756-199604260-00023;;8817534;;8619098;;10.1016/s0889-857x(21)00466-x;;10.1016/0958-1669(93)90055-2;;7764470;;10.1002/art.1780380202;;7848304;;pmc1534244;;8222316;;10.1111/j.1365-2249.1993.tb03441.x;;10.1093/rheumatology/34.4.334;;7788147;;10.1097/00007890-199409000-00007;;7940686;;10.1097/00007890-199501000-00025;;10.1097/00007890-199501270-00025;;7839455;;7832839;;10.1056/nejm199408113310606;;10.1126/science.3764421;;3764421;;10.1172/jci113459;;pmc442560;;3366898;;pmc1535044;;2117510;;10.1111/j.1365-2249.1990.tb03334.x;;7797011;;10.1016/0016-5085(95)90277-5;;10.1038/319516a0;;3511389;;10.1002/jbmr.5650030607;;3266953;;8442433;;10.1002/jbmr.5650080205;;7512360;;10.1016/8756-3282(93)90317-4;;2920991;;10.1002/hep.1840090302;;10.1111/j.1530-0277.1990.tb00482.x;;2190492;;10.1002/hep.1840200228;;8045508;;10.1016/0270-9139(94)90200-3;;10.1016/0168-8278(91)90945-8;;2051003;;pmc502205;;10.1136/jcp.47.12.1112;;7876386;;2188129;;10.1056/nejm199006073222302;;1924431;;10.1152/ajpheart.1994.267.1.h118;;8048575;;8148074;;10.1016/0305-4179(94)90104-x;;10.1152/ajpgi.1994.267.6.g1122;;7810659;;7992355;;10.1097/00007890-199412150-00003;;10.1016/0300-9572(95)00831-d;;7659869;;10.1007/bf00918154;;1512303;;pmc453150;;1721867;;10.1002/j.1460-2075.1991.tb04978.x,"GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"", EMBO J., vol. 12, no. 2, 1993, pages 725 - 734, XP000645476;;CHOW ET AL.: ""Effect of monoclonal antibody to human TNF on TNFalpha, IL-1beta and IL-6 levels in patients with sepsis syndrome"", CLINICAL RESEARCH, vol. 42, no. 2, April 1994 (1994-04-01), pages 299A, XP002032300;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899 - 903, XP000572619, ISSN: 0733-222X;;OLD, L., SCIENCE, vol. 230, 1985, pages 630 - 632;;BEUTLER, B.; CERAMI, A., ANNU. REV. BIOCHEM., vol. 57, 1988, pages 505 - 518;;BEUTLER, B.; CERAMI, A., ANNU. REV. IMMUNOL., vol. 7, 1989, pages 625 - 655;;MOELLER, A. ET AL., CYTOKINE, vol. 2, 1990, pages 162 - 169;;VASILLI, P., ANNU. REV. IMMUNOL., vol. 10, 1992, pages 411 - 452;;TRACEY, K.J.; CERAMI, A., ANNU. REV. MED., vol. 45, 1994, pages 491 - 503;;HAHN T ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3814 - 3818;;LIANG, C-M. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 137, 1986, pages 847 - 854;;HIRAI, M. ET AL., J. IMMUNOL. METHODS, vol. 96, 1987, pages 57 - 62;;FENDLY, B.M. ET AL., HYBRIDOMA, vol. 6, 1987, pages 359 - 370;;KNIGHT, D.M ET AL., MOL. IMMUNOL., vol. 30, 1993, pages 1443 - 1453;;ELLIOTT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1125 - 1127;;ELLIOT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1105 - 1110;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 556 - 568;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 569 - 581;;FOMSGAARD, A. ET AL., SCAND. J. IMMUNOL., vol. 30, 1989, pages 219 - 223;;BENDTZEN, K. ET AL., PROG. LEUKOCYTE BIOL., vol. 10B, 1990, pages 447 - 452;;LEUSCH, H-G. ET AL., J. IMMUNOL. METHODS, vol. 139, 1991, pages 145 - 147;;GRIFFITHS, A.D. ET AL., EMBO J., vol. 12, 1993, pages 725 - 734;;LIDBURY, A. ET AL., BIOTECHNOL. THER., vol. 5, 1994, pages 27 - 45;;PENNICA, D. ET AL., NATURE, vol. 312, 1984, pages 724 - 729;;DAVIS, J.M. ET AL., BIOCHEMISTRY, vol. 26, 1987, pages 1322 - 1326;;JONES, E.Y. ET AL., NATURE, vol. 338, 1989, pages 225 - 228;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;KIPRIYANOV, S.M. ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101;;KIPRIYANOV, S.M. ET AL., MOL. IMMUNOL., vol. 31, 1994, pages 1047 - 1058;;TAYLOR, L.D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295;;JÖNSSON, U. ET AL., ANN. BIOL. CLIN., vol. 5, no. 1, 1993, pages 19 - 26;;JÖNSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627;;JOHNSSON, B. ET AL., J. MOL. RECOGNIT., vol. 8, 1995, pages 125 - 131;;JOHNNSON, B. ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages 268 - 277;;""Molecular Cloning; A Laboratory Manual"", 1989, COLD SPRING HARBOR;;""Current Protocols in Molecular Biology"", 1989, GREENE PUBLISHING ASSOCIATES;;KABAT, E.A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;TOMLINSON, I.M. ET AL.: ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COX, J.P.L. ET AL.: ""A Directory of Human Germ-line V K Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;GOEDDEL: ""Gene Expression Technology: Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;BOSS, M.A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R.J. KAUFMAN; P.A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;FUCHS ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1370 - 1372;;HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., J MOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;GARRAD ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;ARTHRITIS & RHEUMATISM, vol. 37, 1994, pages 295;;J. INVEST. MED., vol. 44, 1996, pages 235A;;ARTHRITIS & RHEUMATISM, vol. 38, 1995, pages 5185;;ARTHRITIS & RHEUMATISM, vol. 36, 1993, pages 1223;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 284;;AMER. J. PHYSIOL. - HEART AND CIRCULATORY PHYSIOLOGY, vol. 268, 1995, pages 37 - 42;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 282;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 81;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 82;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 131;;INFLAMMATION RESEARCH, vol. 45, 1996, pages 103 - 107;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 280;;NEURO REPORT, vol. 7, 1996, pages 1209 - 1213;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 281;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 296;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 308;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 120;;DELUCA ET AL., RHEUM. DIS. CLIN. NORTH AM., vol. 21, 1995, pages 759 - 777;;RUSSELL, D; THOMPSON, R.C., CURR. OPIN. BIOTECH., vol. 4, 1993, pages 714 - 721;;AREND, W.P.; DAYER, J-M., ARTH. RHEUM., vol. 38, 1995, pages 151 - 160;;FAVA, R.A. ET AL., CLIN. EXP. IMMUNOL., vol. 94, 1993, pages 261 - 266;;RANKIN, E.C. ET AL., BR. J. RHEUMATOL., vol. 34, 1995, pages 334 - 342;;FIETZE, E. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 675 - 680;;EASON, J.D. ET AL., TRANSPLANTATION, vol. 59, 1995, pages 300 - 305;;SUTHANTHIRAN, M.; STROM, T.B., NEW ENGL. J. MED., vol. 331, 1994, pages 365 - 375;;TRACY, K.J. ET AL., SCIENCE, vol. 234, 1986, pages 470 - 474;;SUN, X-M. ET AL., J. CLIN. INVEST., vol. 81, 1988, pages 1328 - 133 1;;MACDONALD, T.T. ET AL., CLIN. EXP. IMMUNOL., vol. 81, 1990, pages 301 - 305;;VAN DULLEMEN, H.M. ET AL., GASTROENTEROLOGY, vol. 109, 1995, pages 129 - 135;;BERTOLINI, D.R. ET AL., NATURE, vol. 319, 1986, pages 516 - 518;;KONIG, A. ET AL., J. BONE MINER. RES., vol. 3, 1988, pages 621 - 627;;LERNER, U.H.; OHLIN, A., J. BONE MINER. RES., vol. 8, 1993, pages 147 - 155;;SHANKAR, G.; STERN, P.H., BONE, vol. 14, 1993, pages 871 - 876;;MCCLAIN, C.J.; COHEN, D.A., HEPATOLOGY, vol. 2, 1989, pages 349 - 351;;FELVER, M.E. ET AL., ALCOHOL. CLIN. EXP. RES., vol. 14, 1990, pages 255 - 259;;HANSEN, J. ET AL., HEPATOLOGY, vol. 20, 1994, pages 461 - 474;;SHERON, N. ET AL., J. HEPATOL., vol. 12, 1991, pages 241 - 245;;HUSSAIN, M.J. ET AL., J. CLIN. PATHOL., vol. 47, 1994, pages 1112 - 1115;;VAN DER POLL, T. ET AL., N. ENGL. J. MED., vol. 322, 1990, pages 1622 - 1627;;VAN DER POLL, T. ET AL., PROG. CLIN. BIOL. RES., vol. 367, 1991, pages 55 - 60;;GIROIR, B.P. ET AL., AM. J. PHYSIOL., vol. 267, 1994, pages H118 - 124;;LIU, X.S. ET AL., BURNS, vol. 20, 1994, pages 40 - 44;;SCALES, W.E. ET AL., AM. J. PHYSIOL., vol. 267, 1994, pages 1122 - 1127;;SERRICK, C. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 1158 - 1162;;YAO, Y.M. ET AL., RESUSCITATION, vol. 29, 1995, pages 157 - 168;;MCCAULEY, R.L. ET AL., J. CLIN. IMMUNOL., vol. 12, 1992, pages 300 - 308;;EMBO J, vol. 10, 1991, pages 4025 - 4031",DISCONTINUED
164,BR,C8,BR PI9715219 C8,049-404-807-733-66X,2017-12-12,2017,BR PI9715219 A,1997-02-10,US 9702219 W;;US 59922696 A;;US 3147696 P;;BR PI9707379 A,1996-02-09,"vetor recombinante de expressão, e célula hospedeira procariótica.",,ABBOTT BIOTECH LTD;;ABBVIE BIOTECHNOLOGY LTD;;ABBOTT LABORATORIES BERMUDA LTD;;BASF AG,ALISON J WILTON;;ANDREW J ROBERTS;;BORIS LABROVSKY;;BRIAN T MCGUINNESS;;DAVID SCHOENHAUT;;DEBORAH J ALLEN;;HENDRICUS R J M HOOGENBOOM;;JOCHEN G SALFELD;;JOHN A MANKOVICH;;MICHAEL WHITE;;PAUL SAKORAFAS;;TRISTAN J VAUGHAN;;ZEHRA KAYMAKCALAN,,https://lens.org/049-404-807-733-66X,Amended Patent,no,0,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K39/395;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
165,UA,C2,UA 102988 C2,062-570-647-389-461,2013-09-10,2013,UA A200805824 A,1997-02-10,US 59922696 A,1996-02-09,"ISOLATED HUMAN ANTIBODY, OR AN ANTIGEN-BINDING PORTION THEREOF THAT SPECIFICALLY BINDS TO HUMAN TNFα, PHARMACEUTICAL COMPOSITION COMPRISING THEREOF AND METHOD FOR TREATING A DISORDER IN WHICH TNFα ACTIVITY IS DETRIMENTAL","The invention relates to an antigen-binding portion of antibody that specifically binds to human TNFα, dAb fragment of isolated human antibody binding human TNFα, isolated human antibody, pharmaceutical composition, method for treating disease, isolated nucleic acid, recombinant expression vector, host cell, method of synthesizing the antibody.",BASF AG,JOCHEN G SALFELD;;DEBORAH J ALLEN;;ZEHRA KAYMAKCALAN;;BORIS LABKOVSKY;;JOHN A MANKOVICH;;BRIAN T MCGUINESS;;ANDREW J ROBERTS;;PAIUL SAKORAFAS;;HENDRIKUS R J M HOOGENBOOM;;DAVID SCHOENHAUT;;TRISTAN J VAUGHAN;;MICHAEL WHITE;;ALISON J WILTON,,https://lens.org/062-570-647-389-461,Limited Patent,no,0,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N15/28;;C12N15/64;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
166,AU,A1,AU 2014/202728 A1,090-043-327-206-41X,2014-06-12,2014,AU 2014/202728 A,2014-05-19,AU 2012/261708 A;;AU 2014/202728 A,2012-12-07,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kg= 10~ M or less), a slow off rate for hTNFa dissociation (e.g., K,~ 10~3sec' or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/090-043-327-206-41X,Patent Application,no,0,0,3,3,0,,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,DISCONTINUED
167,NZ,A,NZ 614727 A,144-143-816-922-914,2015-03-27,2015,NZ 61472797 A,1997-02-10,US 3147696 P;;US 59922696 A;;NZ 59848797 A,1996-02-09,Human antibodies that bind human tnfa,"Disclosed is an isolated human anti-human TNF-alpha antibody comprising: - a light chain variable region (LCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3 (QRYNRAPYT/A), a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5 (AASTLQS), and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7 (RASQGIRNYLA); and - a heavy chain variable region (HCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4 (VSYLSTASSLDY/N), a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6 (AITWNSGHIDYADSVEG), and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8 (DYAMH), wherein the antibody comprises an IgG1 heavy chain constant region and a kappa light chain constant region.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/144-143-816-922-914,Patent Application,no,0,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;C12N15/13;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
168,HK,A1,HK 1214607 A1,148-182-970-194-764,2016-07-29,2016,HK 16102499 A,2016-03-04,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA TNF,,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/148-182-970-194-764,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K/;;C07K/;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N/;;C12N1/21;;C12N5/10;;C12P21/08;;G01N/;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
169,NZ,A,NZ 331579 A,008-973-890-087-197,2001-06-29,2001,NZ 33157997 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Human antibodies that bind human TNF(alpha) and use in medicaments,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumour necrosis factor a (hTNFa) are provided. These antibodies have high affinity for hTNFa ( Kd of 10-8 M or less), a slow off rate for hTNFa dissociation (Koff of 10-3 sec-1 or less) and neutralize hTNFa cytotoxicity in a standard in vitro L929 assay with an IC50 of 10-7M or less. The antibodies, or antibody portions may be useful for inhibiting hTNFa activity in a human subject suffering from a disorder in which hTNFa activity is detrimental. Such disorders include sepsis, autoimmune diseases, infectious diseases, transplant rejection, malignancy, pulmonary disorder, intestinal disorder, cardiac disorder and inflammatory bone disorders.",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBOTT BIOTECHNOLOGY LIMITED, BM (2005-02-25)",https://lens.org/008-973-890-087-197,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;C12N15/09;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
170,SI,B,SI 9720020 B,027-022-675-658-108,2001-12-31,2001,SI 9720020 A,1997-02-10,US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNF alpha,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBOTT BIOTECHNOLOGY LTD.; BM (2005-03-10);;ABBVIE BIOTECHNOLOGY LTD.; BM (2014-04-08),https://lens.org/027-022-675-658-108,Amended Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;C12N15/09;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
171,EP,A1,EP 2930186 A1,062-115-040-311-436,2015-10-14,2015,EP 15165134 A,1997-02-10,US 59922696 A;;US 3147696 P;;EP 10184662 A;;EP 02022788 A;;EP 97906572 A,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα ( e.g ., K d  = 10 -8  M or less), a slow off rate for hTNFα dissociation ( e.g ., K off = 10 -3  sec -1  or less) and neutralize hTNFα activity  in vitro  and  in vivo.  An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity,  e.g ., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/062-115-040-311-436,Patent Application,yes,42,0,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,107,80,072-378-691-723-546;;040-701-579-915-050;;074-871-884-454-68X;;016-907-020-918-983;;011-796-204-010-792;;117-499-681-530-662;;006-117-436-368-816;;046-939-287-004-026;;085-191-504-989-317;;041-591-849-635-094;;054-329-283-530-645;;002-495-006-719-164;;021-113-833-013-619;;015-584-716-307-216;;092-412-882-661-570;;072-438-011-112-832;;006-342-252-521-899;;057-954-116-868-246;;072-378-691-723-546;;003-907-950-634-854;;041-956-664-134-903;;035-071-534-473-573;;071-901-988-318-434;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;066-749-017-721-197;;001-467-559-709-949;;143-467-932-790-298;;123-171-555-829-362;;071-707-020-428-907;;044-369-216-298-341;;092-023-577-402-127;;022-179-293-052-569;;030-630-100-818-462;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;035-872-873-163-027;;100-049-580-404-573;;033-797-614-829-293;;072-378-691-723-546;;005-119-615-003-591;;034-331-211-704-877;;025-395-146-381-464;;174-783-722-981-415;;011-962-497-035-168;;065-145-385-150-339;;033-459-816-867-43X;;098-513-251-868-998;;063-873-022-003-842;;044-317-656-227-593;;011-114-894-374-225;;037-795-266-129-616;;008-835-817-825-32X;;075-878-183-554-694;;004-001-063-582-854;;079-192-394-643-91X;;000-065-369-829-300;;128-904-140-606-949;;077-369-546-251-682;;032-821-336-726-761;;050-094-719-890-440;;070-452-766-365-174;;110-232-737-639-142;;028-469-508-809-412;;044-217-982-536-908;;012-422-300-553-121;;033-522-835-476-708;;097-358-265-091-151;;041-043-853-736-19X;;085-885-495-910-537;;167-234-008-883-687;;061-475-814-399-439;;031-974-874-348-471;;054-469-226-992-186;;007-667-472-783-358;;023-473-383-533-503;;063-233-860-095-920;;052-159-696-111-105,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7521646;;10.1038/nbt0994-899;;2413547;;10.1126/science.2413547;;10.1146/annurev.bi.57.070188.002445;;3052281;;10.1146/annurev.biochem.57.1.505;;10.1146/annurev.immunol.7.1.625;;10.1146/annurev.iy.07.040189.003205;;2540776;;1590993;;10.1146/annurev.iy.10.040192.002211;;10.1146/annurev.immunol.10.1.411;;0001590993;;10.1146/annurev.med.45.1.491;;8198398;;3889916;;pmc397878;;10.1073/pnas.82.11.3814;;3729942;;10.1016/0006-291x(86)91157-5;;3805735;;10.1016/0022-1759(87)90367-x;;10.1089/hyb.1987.6.359;;2442093;;10.1016/0161-5890(93)90106-l;;8232330;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1016/s0140-6736(94)90628-9;;7934491;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1016/0022-1759(91)90361-i;;2040812;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7703831;;10.1038/312724a0;;6392892;;3552045;;10.1021/bi00379a018;;2922046;;2922050;;10.1038/338225a0;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;8597629;;10.3233/hab-1995-6303;;10.1016/0161-5890(94)90100-7;;7935496;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;7541226;;10.1002/jmr.300080122;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;10.1038/348552a0;;2247164;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;1367769;;10.1038/nbt1291-1369;;1385989;;10.3233/hab-1992-3204;;2531466;;10.1126/science.2531466;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/nbt1291-1373;;1369462;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;pmc52428;;10.1073/pnas.88.18.7978;;1896445;;8216416;;10.1002/art.1780360907;;8907592;;10.1007/bf02265123;;10.1097/00001756-199604260-00023;;8817534;;8619098;;10.1016/s0889-857x(21)00466-x;;10.1016/0958-1669(93)90055-2;;7764470;;10.1002/art.1780380202;;7848304;;10.1093/rheumatology/34.4.334;;7788147;;10.1097/00007890-199409000-00007;;7940686;;10.1097/00007890-199501000-00025;;10.1097/00007890-199501270-00025;;7839455;;7832839;;10.1056/nejm199408113310606;;10.1126/science.3764421;;3764421;;10.1172/jci113459;;pmc442560;;3366898;;pmc1535044;;2117510;;10.1111/j.1365-2249.1990.tb03334.x;;7797011;;10.1016/0016-5085(95)90277-5;;10.1038/319516a0;;3511389;;10.1002/jbmr.5650030607;;3266953;;8442433;;10.1002/jbmr.5650080205;;7512360;;10.1016/8756-3282(93)90317-4;;2920991;;10.1002/hep.1840090302;;10.1111/j.1530-0277.1990.tb00482.x;;2190492;;10.1002/hep.1840200228;;8045508;;10.1016/0270-9139(94)90200-3;;10.1016/0168-8278(91)90945-8;;2051003;;pmc502205;;10.1136/jcp.47.12.1112;;7876386;;2188129;;10.1056/nejm199006073222302;;1924431;;10.1152/ajpheart.1994.267.1.h118;;8048575;;8148074;;10.1016/0305-4179(94)90104-x;;10.1152/ajpgi.1994.267.6.g1122;;7810659;;7992355;;10.1097/00007890-199412150-00003;;10.1016/0300-9572(95)00831-d;;7659869;;10.1007/bf00918154;;1512303;;pmc453150;;1721867;;10.1002/j.1460-2075.1991.tb04978.x,"GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"", EMBO J., vol. 12, no. 2, 1993, pages 725 - 734, XP000645476;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899 - 903, XP000572619, ISSN: 0733-222X;;OLD, L., SCIENCE, vol. 230, 1985, pages 630 - 632;;BEUTLER, B.; CERAMI, A., ANNU. REV. BIOCHEM., vol. 57, 1988, pages 505 - 518;;BEUTLER, B.; CERAMI, A., ANNU. REV. IMMUNOL., vol. 7, 1989, pages 625 - 655;;MOELLER, A. ET AL., CYTOKINE, vol. 2, 1990, pages 162 - 169;;VASILLI, P., ANNU. REV. IMMUNOL., vol. 10, 1992, pages 411 - 452;;TRACEY, K.J.; CERAMI, A., ANNU. REV. MED., vol. 45, 1994, pages 491 - 503;;HAHN T ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3814 - 3818;;LIANG, C-M. ET AL., BIOCHENI. BIOPHYS. RES. COMMUN., vol. 137, 1986, pages 847 - 854;;HIRAI, M. ET AL., J. IMMUNOL. METHODS, vol. 96, 1987, pages 57 - 62;;FENDLY, B.M. ET AL., HYBRIDOMA, vol. 6, 1987, pages 359 - 370;;KNIGHT, D.M ET AL., OL. IMMUNOL., vol. 30, 1993, pages 1443 - 1453;;ELLIOTT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1125 - 1127;;ELLIOT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1105 - 1110;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 556 - 568;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 569 - 581;;FOMSGAARD, A. ET AL., SCAND. J. IMMUNOL., vol. 30, 1989, pages 219 - 223;;BENDTZEN, K. ET AL., PROG. LEUKOCYTE BIOL., vol. 1OB, 1990, pages 447 - 452;;LEUSCH, H-G. ET AL., J. IMMUNOL. METHODS, vol. 139, 1991, pages 145 - 147;;GRIFFITHS, A.D. ET AL., EMBO J., vol. 12, 1993, pages 725 - 734;;LIDBURY, A. ET AL., BIOTECHNOL. THER, vol. 5, 1994, pages 27 - 45;;PENNICA, D. ET AL., NATURE, vol. 312, 1984, pages 724 - 729;;DAVIS, J.M. ET AL., BIOCHEMISTRY, vol. 26, 1987, pages 1322 - 1326;;JONES, E.Y. ET AL., NATURE, vol. 338, 1989, pages 225 - 228;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;KIPRIYANOV, S.M. ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101;;KIPRIYANOV, S.M. ET AL., M /. IMMUNOL., vol. 31, 1994, pages 1047 - 1058;;TAYLOR, L.D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295;;J6NSSON, U. ET AL., ANN. BIOL. CLIN., vol. 51, 1993, pages 19 - 26;;J6NSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627;;JOHNSSON, B. ET AL., J. MOT. RECOGNIT., vol. 8, 1995, pages 125 - 131;;JOHNNSON, B. ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages 268 - 277;;SAMBROOK, FRITSCH AND MANIATIS: ""Molecular Cloning; A Laboratory Manual, 2nd ed."", 1989, COLD SPRING HARBOR;;AUSUBEL, F.M. ET AL.: ""Current Protocols in Molecular Biology"", 1989, GREENE PUBLISHING ASSOCIATES;;KABAT, E.A. ET AL.: ""Sequences of Proteins of Immunological Interest, 5th ed."", 1991, NIH PUBLICATION NO. 91-3242;;TOMLINSON, I.M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups ofV Segments with Different Hypervariable Loops"", MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COX, J.P.L. ET AL.: ""A Directory of Human Germ-line V K Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;KABAT, E.A. ET AL.: ""Sequences ofP oteinS of Immunological Interest, 5th ed."", 1991, NIH PUBLICATION NO. 91-3242;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;GOEDDEL: ""Gene Expression Technology: Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;BOSS, M.A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R.J. KAUFMAN; P.A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;FUCHS ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1370 - 1372;;HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., JMOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;GARRAD ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982;;J.R. ROBINSON: ""Sustained and Controlled Release Drug Delivery Systenis"", 1978, MARCEL DEKKER, INC.;;ARTHRITIS & RHEUMATISM, vol. 37, 1994, pages S295;;J. INVEST. MED., vol. 44, 1996, pages 235A;;ARTHRITIS & RHEUMATISM, vol. 38, 1995, pages SI85;;ARTHRITIS & RHEUMATISM, vol. 36, 1993, pages 1223;;RHEUMATISM, ARTHRITIS, vol. 39, no. 9, 1996, pages S284;;AMER. J. PHYSIOL. - HEART AND CIRCULATORY PHYSIOLOGY, vol. 268, 1995, pages 37 - 42;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S282;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S81;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S82;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S131;;INFLAMMATION RESEARCH, vol. 45, 1996, pages 103 - 107;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S284;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S280;;NEURO REPORT, vol. 7, 1996, pages 1209 - 1213;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S281;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S296;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S308;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S120;;DELUCA ET AL., RHEUNI. DIS. CLIN. NORTH AM., vol. 21, 1995, pages 759 - 777;;RUSSELL, D; THOMPSON, R.C., CURRO OPIN. BIOTECH., vol. 4, 1993, pages 714 - 721;;AREND, W.P.; DAYER, J-M., ARTH. RHEUNI., vol. 38, 1995, pages 151 - 160;;FAVA, R.A. ET AL., CLIN. EXP. IMM UNO, vol. 94, 1993, pages 261 - 266;;RANKIN, E.C. ET AL., BR. J. RHEUMATOL., vol. 34, 1995, pages 334 - 342;;FIETZE, E. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 675 - 680;;EASON, J.D. ET AL., TRANSPLANTATION, vol. 59, 1995, pages 300 - 305;;STROM, T.B., NEWENGL. J. MED., vol. 331, 1994, pages 365 - 375;;TRACY, K.J. ET AL., SCIENCE, vol. 234, 1986, pages 470 - 474;;SUN, X-M. ET AL., CLIN. INVEST., vol. 81, 1988, pages 1328 - 1331;;MACDONALD, T.T. ET AL., CLIN. EXP. IMMUNOL., vol. 81, 1990, pages 301 - 305;;VAN DULLEMEN, H.M. ET AL., GASTROENTEROLOGY, vol. 109, 1995, pages 129 - 135;;BERTOLINI, D.R. ET AL., NATURE, vol. 319, 1986, pages 516 - 518;;KONIG, A. ET AL., J. BONE MINER. RES., vol. 3, 1988, pages 621 - 627;;LEMER, U.H.; OHLIN, A., J. BONE MINER. RES., vol. 8, 1993, pages 147 - 155;;SHANKAR, G.; STERN, P.H., BONE, vol. 14, 1993, pages 871 - 876;;MCCLAIN, C.J.; COHEN, D.A., HEPATOLOGY, vol. 9, 1989, pages 349 - 351;;FELVER, M.E. ET AL., ALCOHOL. CLIN.. EXP. RES., vol. 14, 1990, pages 255 - 259;;HANSEN, J. ET AL., HEPATOLOGY, vol. 20, 1994, pages 461 - 474;;SHERON, N. ET AL., J. HEPATOL., vol. 12, 1991, pages 241 - 245;;HUSSAIN, M.J. ET AL., J. CLIN. PATHOL, vol. 47, 1994, pages 1112 - 1115;;VAN DER POLL, T. ET AL., N. ENGL. J. MED., vol. 322, 1990, pages 1622 - 1627;;VAN DER POLL, T. ET AL., PROG. CLIN. BIOL. RES., vol. 367, 1991, pages 55 - 60;;GIROIR, B.P. ET AL., AM. J PHYSIOL., vol. 267, 1994, pages H118 - 124;;LIU, X.S. ET AL., BURNS, vol. 20, 1994, pages 40 - 44;;SCALES, W.E. ET AL., AM. J PHYSIOL., vol. 267, 1994, pages 1122 - 1127;;SERRICK, C. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 1158 - 1162;;YAO, Y.M. ET AL., RESUSCITATION, vol. 29, 1995, pages 157 - 168;;MCCAULEY, R.L. ET AL., J. CLIN. IMMUNO ., vol. 12, 1992, pages 300 - 308;;EMBO J, vol. 10, 1991, pages 4025 - 4031",DISCONTINUED
172,US,A1,US 2013/0330356 A1,064-587-203-244-29X,2013-12-12,2013,US 201313965152 A,2013-08-12,US 201313965152 A;;US 201313736931 A;;US 57848709 A;;US 36945109 A;;US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/064-587-203-244-29X,Patent Application,yes,12,13,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;C07K16/24;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/158.1;;530/389.2,12,9,095-334-545-560-259;;014-113-432-888-031;;027-477-313-726-928;;045-942-104-775-903;;051-707-000-800-833;;031-100-076-670-370;;001-779-867-387-972;;013-142-717-038-23X;;026-618-359-490-391,10.1006/jmbi.1996.0548;;8876650;;12218124;;10.4049/jimmunol.169.6.3076;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;12850000;;10.1016/s0006-291x(03)01131-8;;12079396;;10.1016/s0022-2836(02)00264-4;;16989900;;10.1016/j.molimm.2006.08.001;;10.1006/jmbi.1999.3192;;10543973;;10556035;;10.1006/jmbi.1999.3141;;12102646;;10.2165/00063030-200216030-00003,"U. S. Application No. 13965155, filed 08/12/2013;;U. S. Application No. 10623318, filed 07/18/2013;;U. S. Application No. 10622932, filed 07/18/2003;;MacCallum et al. Journal of Molecular. Biology, 1996, Vol 262, pp. 732-745.;;De Pascalis et al. Journal of Immunology, 2002, Vol. 169, pp. 3076-3084.;;Rudikoff et al. Proc Natl Acad Sci USA 1982 Vol 79 pp 1979-1983.;;Casset et al. Biochemical and Biophysical Research Communications, 2003, Vol. 307, pp. 198-205.;;Vajdos et al. Journal of Molecular biology, 2002, Vol. 320, pp. 415-428.;;Holm et al. Molecular Immunology, 2007, Vol. 44, pp. 1075-1084.;;Chen et al. Journal of Molecular Biology, 1999, Vol. 293, pp. 865-881.;;Wu et al. Journal of Molecular Biology, 1999, Vol. 294, pp. 151-162.;;Wiendl et al. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs. 2002;16(3):183-200.",DISCONTINUED
173,US,B2,US 8753633 B2,121-331-296-771-115,2014-06-17,2014,US 201213524525 A,2012-06-15,US 201213524525 A;;US 36945109 A;;US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNFα,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/121-331-296-771-115,Granted Patent,yes,105,18,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;C07K16/24;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/142.1;;424/145.1;;424/158.1;;424/130.1;;530/388.15;;530/388.23;;530/387.1,99,76,005-321-867-106-932;;082-560-368-073-508;;092-412-882-661-570;;072-438-011-112-832;;064-048-827-826-930;;101-630-891-707-104;;022-179-293-052-569;;077-341-362-901-551;;026-408-993-198-966;;024-854-471-494-140;;003-185-616-989-105;;006-342-252-521-899;;033-261-430-402-230;;072-378-691-723-546;;005-119-615-003-591;;036-413-156-723-523;;033-797-614-829-293;;040-701-579-915-050;;030-874-783-814-532;;017-529-128-038-946;;057-954-116-868-246;;015-761-810-001-488;;010-916-105-450-247;;020-855-322-534-259;;061-726-307-774-867;;074-932-950-939-666;;053-341-149-236-635;;004-601-819-239-79X;;030-323-674-660-051;;116-193-705-533-609;;003-841-586-111-459;;087-599-254-199-807;;027-477-313-726-928;;098-176-334-504-327;;019-030-524-959-069;;022-384-366-455-012;;092-023-577-402-127;;021-641-900-032-887;;006-117-436-368-816;;145-140-396-707-208;;042-623-879-457-954;;074-817-300-512-106;;031-729-641-207-089;;022-133-574-143-973;;006-911-122-969-908;;006-626-799-687-686;;028-677-787-189-119;;021-113-833-013-619;;038-613-711-274-229;;025-395-146-381-464;;085-277-440-303-853;;072-378-691-723-546;;012-897-611-427-172;;050-836-464-727-069;;005-119-615-003-591;;032-071-991-081-664;;035-939-173-669-143;;077-815-816-621-813;;002-495-006-719-164;;032-820-729-763-323;;043-108-278-056-872;;046-104-560-723-30X;;048-379-681-038-232;;041-315-340-063-133;;016-219-576-017-946;;074-932-950-939-666;;001-900-209-379-77X;;088-851-255-233-972;;137-274-595-200-649;;088-581-950-418-154;;020-753-772-581-741;;026-144-631-995-304;;040-981-641-449-302;;003-595-371-167-198;;010-327-392-460-003;;053-289-310-577-642,7884952;;10.1001/jama.1995.03520360048038;;10.1001/jama.273.12.934;;7735957;;10.1097/00024382-199404000-00001;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1038/nrd984;;12509759;;10.1097/00003246-199609000-00002;;8797612;;10.1002/eji.1830240409;;8149953;;7935497;;10.1016/0161-5890(94)90101-5;;18240199;;10.1002/art.23362;;10.1146/annurev.immunol.19.1.163;;11244034;;10.1006/jmbi.1994.1351;;8196048;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;1560463;;10.1016/0022-2836(92)91010-m;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;7620183;;10.1182/blood.v86.3.890.890;;2531466;;10.1126/science.2531466;;7521646;;10.1038/nbt0994-899;;pmc1766613;;11053087;;10.1136/ard.59.suppl_1.i44;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;8757799;;10.1006/jmbi.1996.0406;;10.1038/nbt0792-779;;1368267;;1748994;;10.1016/0022-2836(91)90498-u;;7765558;;10.1038/nbt1194-1134;;10.1016/1043-4666(90)90011-h;;1716486;;10.1016/0959-440x(95)80028-x;;8528760;;15848075;;10.1016/j.ymeth.2005.01.006;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;8364031;;10.1021/bi00085a016;;10.1097/00003246-199605000-00003;;8706447;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;11730333;;10.1006/abio.2001.5380;;8609615;;10.1006/jmbi.1996.0069;;10.1016/1043-4666(92)90072-y;;1381227;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1146/annurev.med.45.1.491;;8198398;;7697917;;pmc1534281;;10.1111/j.1365-2249.1995.tb03598.x;;9624683;;10.1038/nbt0698-535;;10.1038/341544a0;;2677748;;8397764;;10.1016/0167-5699(93)90039-n;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;8783501;;10.1016/0167-5699(96)10025-6;;9265725;;10.1016/s0958-1669(97)80068-7;;10.1038/nbt0595-475;;9634788;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/ng0594-13;;8075633;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;pmc395221;;10.1002/j.1460-2075.1994.tb06626.x;;8045255;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;10.1016/0022-2836(92)90639-2;;1507232;;10.1016/0022-2836(92)90894-p;;1404359;;10.1111/j.1365-2141.1992.tb08212.x;;1379467;;7579668;;10.1016/0958-1669(95)80093-x;;10.1016/0161-5890(93)90106-l;;8232330;;8159246;;10.1038/368856a0;;7494109;;10.3109/08830189509061738;;10.1016/s0021-9258(18)41952-7;;1644788;;7764095;;10.1038/nbt1093-1145;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.3.co;2-y;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.0.co;2-l;;8727325;;10.1038/ng0297-146;;9020839;;10.1016/1043-4666(90)90011-h;;1716486;;9052775;;10.1038/386025a0;;1423650;;10.3109/07388559209114235;;10.1111/j.1365-2249.1994.tb05522.x;;7994916;;pmc1534487;;10.4049/jimmunol.164.3.1432;;10640759;;10.1093/intimm/6.4.579;;8018598;;10.3233/hab-1995-6206;;7492754;;7957560;;10.1002/eji.1830241116;;8190629;;pmc307995;;10.1093/nar/22.8.1389;;9180069;;10.1126/science.276.5319.1665;;10.1096/fasebj.10.10.8751726;;8751726,"U.S. Appl. No. 13/965,152, filed Aug. 12, 2013.;;U.S. Appl. No. 13/965,155, filed Aug. 12, 2013.;;Abraham et al., ""Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor alpha in Patients with Sepsis Syndrome,"" JAMA, vol. 273(12):934-941 (1995).;;Barbuto et al. ""Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes"" Proc. Am. Assoc. Cancer Res,. 34:487, Abstr. 2904 (1993).;;Bendtzen et al. ""Auto-antibodies to IL-1alpha and TNFalpha in Normal Individuals and in Infectious and Immunoinflammatory Disorders"" The Physiological and Pathological Effects of Cytokines, 447-52 (1990).;;Boekstegers et al., ""Repeated administration of a F(ab')2 fragment of an anti-tumor recrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,"" Shock, vol. 1(4):237-245 (1994) (abstract from Pub Med).;;Boyle et al. ""A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- alpha"" Cell. Immunol., 152:556-68 (1993).;;Boyle et al. ""The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF.alpha. on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope"", Cell. Immunol., vol. 152, pp. 569-581, (1993).;;Brekke et al., ""Therapeutic antibodies for human diseases at the dawn of the twenty-first century,"" Nature Reviews/Drug Discovery, vol. 2:52-62 (2003).;;Chow et al. ""Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFalpha, IL-1beta, and IL-6 levels in patients with sepsis syndrome"" Clinical Research, vol. 42, No. 2 p. 299A (1994).;;Cohen et al., ""Intersept: An international, multicenter, placebo-controlled trial of monoclonal anitbody to human tumor necrosis factor-alpha in patients with sepsis,"" Crit Care Med, vol. 24(9):1431-1440 (1996).;;Cox et al. ""A directory of human germ-line VKsegments reveals a strong bias in their usage"" Eur. J. Immunol., 24(2):827-36 (1994).;;Department of Surgery, University of Toronto Annual Report, Jul. 1, 1998-Jun. 30, 1999-found online at http://www.surg.med.utoronto.ca/AnnRep/AR98-99/index.html.;;Doring et al. ""Identification and Characterization of a TNFa antagonist derived from a monoclonal antibody"" Mol Immunol 31:1059-1067 (1994).;;Elliot et al. ""Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha"" Arthritis & Rheumatism, 36(12):1681-90 (1993).;;Feldman et al., ""Anti-TNFalpha Therapy of Rheumatoid Arthritis: What Have We Learned?"" Annu. Rev. Immunol., vol. 19:163-196 (2001).;;Figini et al., ""In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation,"" J. Mol. Biol., vol. 239:68-78 (1994).;;Fomsgaard. et al. ""Auto-antibodies to Tumour Necrosis Factor alpha in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections"" Scand. J. Immunol., 30:219-23 (1989).;;Foote et al. ""Antibody framework residues affecting the conformation of the hypervariable loops,"" J Mol Biol 224(2):487 (1992).;;Griffiths et al. ""Human anti-self antibodies with high specificity from phage display libraries"" The EMBO J., 12(2):725-34 (1993).;;Hawkins et al., ""Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,"" J. Mol. Biol., vol. 226:889-896 (1992).;;Holler et al., ""Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F),"" Blood, vol. 86(3):890-899 (1995) (abstract from Pub Med).;;Hoogenboom et al., ""Converting rodent into human antibodies by guided selection,"" Antibody Engineering, Oxford University Press, pp. 169-185 (1996).;;Huse et al. ""Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda"" Science, 246:1275-81 (1989).;;Jespers, Laurent S., et al., ""Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen,"" Nature Biotechnology, vol. 12:899-903 (1994).;;Kempeni ""Update on D2E7: a fully human anti-tumor necrosis factor alpha monoclonal antibody,"" Ann Rheum Dis, vol. 59(Suppl. I):144-145 (2000).;;Lerner et al. ""Antibodies without immunization"" Science, 258:1313-14 (1992).;;Leusch et al. ""Failure to demonstrate TNFalpha-specific autoantibodies in human sera by ELISA and Western blot"" J. Immunol. Methods, 139:145-47 (1991).;;Lewis et al. ""Use of alanine scanning mutagenesis to improve the affinity of an anti gp120 (HIV) antibody."" J. Cell. Biochem., 18D:215 (1994).;;Low, Nigel M., thesis extract, Cambridge University (1996).;;Low, Nigel M., et al., ""Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,"" J. Mol. Biol., vol. 260:359-368 (1996).;;Marks et al., ""By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,"" Biotechnology 10:779-783 (1992).;;Marks et al. ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"" J. Mol. Biol. 222:581-97 (1991).;;Medynski ""Phage Display: All Dressed Up and Ready to Role,"" Bio/Technology, vol. 12:1134-1136 (1994).;;Möller et al. ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and vivo application"" Cytokine, 2(3):162-69 (1990).;;Nilsson ""Antibody engineering,"" Current Opinion in Structural Biology, vol. 5:450-456 (1995).;;Osbourn et al. ""From rodent reagents to human therapeutics using antibody guided selection,"" Methods 36(1):61 (2005).;;Queen et al., ""A humanized antibody that binds to the interleukin 2 receptor,"" PNAS USA, 86(24):10029 (1989).;;Rader et al. ""A phage display approach to rapid antibody humanization: Designed combinatorial V gene libraries"" Proc Natl Acad Sci USA 95:8910-8915 (1998).;;Riechmann et al., ""Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement,"" Biochemistry, vol. 32(34):8848-8855 (1993) (abstract from Pub Med).;;Reinhart et al., ""Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment , MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study,"" Crit Care Med, vol. 24(5):1608 (1996) (abstract from Pub Med).;;Rudikoff et al. ""Single Amino Acid Substitution Altering Antigen-Binding Specificity"" Proc Natl Acad Sci USA 79:1979-1983 (1982).;;Santora et al., ""Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIA core,"" Analytical Biochemistry, vol. 299:119-129 (2001).;;Thompson et al., ""Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity,"" J. Mol. Biol., vol. 256(1):77-88 (1996) (abstract from Pub Med).;;Thorp et. al. ""Tumour Necrosis Factor Induction of ELAM-1 and ICAM-1 on Human Umbilical Vein Endothelial Cells-Analysis of Tumour Necrosis Factor Receptor Interactions"" Cytokine 4:313-319 (1992).;;Tomlinson et al., ""The Repertoire of Human Germline VHSequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,"" J. Mol. Biol., vol. 227:776-798 (1992).;;Tomlinson et al., ""The structural repertoire of the human Vkappa domain,"" The EMBO Journal, vol. 14(18):4628-4638 (1995).;;Tracey et al., ""Tumor Necrosis Factor: A Pleiotropic Cytokine and Therapeutic Target,"" Annu. Rev. Med., vol. 45:491-503 (1994).;;Van Der Poll et al., ""Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees,"" Clin Exp Immunol, vol. 100:21-25 (1995).;;Vaughan et al., ""Human antibodies by design,"" Nature Biotechnology, vol. 16:535-539 (1998).;;Ward et al., ""Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli,"" Nature, vol. 341(6242):544-546 (1989).;;Winter et al, ""Humanized antibodies,"" Immunology Today, vol. 14(6):243-246 (1993).;;Winter et al., ""Making antibodies by phage display technology,"" Annu. Rev. Immunol., vol. 12:433-455 (1994).;;Bruggemann, M., Neuberger, M.S., ""Strategies for expressing human antibody repertoires in transgenic mice,"" Immunol. Today 17:391-397 (1996).;;Bruggemann et al., ""Production of human antibody repertoires in transgenic mice"" Cur. Op. Biotechnol. ;455-458 (1997).;;Cambridge Antibody Technology, advertisement of phage display services, Science vol. 253, No. 5018 (1991).;;Davies et al., ""Antibody VH domains as small recognition units."" Biotechnology, 13:475-479 (1995).;;Elliot et al., ""Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis,"" Lancet 344:1125-1127 (1994).;;Fishwild et al., ""High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice,"" Nature Biotechnology 14:845-851 (1996).;;Gram et al., ""In vitro selection and affinity maturation of antibodies from a naïve combinatorial immunoglobulin library"", PNAS 89:3576-3580 (1992).;;Green et al., ""Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,"" Nature Genetics 7:13-21 (1994).;;Griffiths et al., ""Human anti-self antibodies with high specificity from phage display libraries,"" EMBO J. 12:725-734 (1993).;;Griffiths et al., ""Isolation of high affinity human antibodies directly from large synthetic repertoires,"" EMBO J. 13:3245-3260 (1994).;;Harding et al., ""Class switching in human immunoglobulin transgenic mice,"" Ann. NY Acad. Sci. 764:536-547 (1995).;;Hawkins et al., ""Selection of phage antibodies by binding affinity, Mimicking affinity maturation,"" J. Mol. Biol. 226:889-896 (1992).;;Hoogenboom et al., ""By-passing immunisation: Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro,"" J. Mol. Biol. 227:381-388 (1992).;;Huang et al., ""Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia,"" Br. J. Haematol 81(2):231-234 (1992).;;Jakobovits, A., ""Production of fully human antibodies by transgenic mice,"" Curr. Op. Biotechnol. 6:561-566 (1995).;;Knight et al., ""Construction and initial characterization of a mouse-human chimeric anti-TNF antibody,"" Mol. Immunol. 30(16):1443-1453 (1993).;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications,"" Nature 368:856-859 (1994).;;Lonberg et al., ""Human Antibodies from Transgenic Mice,"" Int. Rev. Immunol. 13:65-93 (1995).;;Marks et al., ""Molecular evolution of proteins on filamentous phage, Mimicking the strategy of the immune system,"" J. Biol. Chem. 267:16007-16010 (1992).;;Marks et al., ""Human antibody fragments specific for human blood group antigens from a phage display library,"" Bio/Technology 11:1145-1150 (1993).;;Marks et al., ""Human Monoclonal Antibodies from V-gene Repertoires Expressed on Bacteriophage."" In Antiody Engineering, Second Edition, edited by Carl A.K. Borrebaeck (1995), pp. 53-88, New York:Oxford Univ. Press.;;Martin, A.C.R. ""Accessing the Kabat antibody sequence database by computer"", Proteins: Structure, Function and Genetics, 25:130-133 (1996).;;Mendez et al., ""Functional transplant of megabase human immunoglobulin loci recapitulates human antobidy response in mice,"" Nature Genetics 15:146-156 (1997).;;Möller et al., ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and in vivo application,"" Cytokine 2(3):162-169 (1990).;;Neuberger M., et al., ""Mice perform a human repertoire"", Nature 386:25-26 (1997).;;Salfeld, ""Development of a Fully Human Antibody to TNF by Phage Display Technology,"" IBC Confence, Antibody Engineering, San Diego (1996), Part 1 of 4.;;Salfeld, ""Development of a Fully Human Antibody to TNF by Phage Display Technology,"" IBC Confence, Antibody Engineering, San Diego (1996), Part 2 of 4.;;Salfeld, ""Development of a Fully Human Antibody to TNF by Phage Display Technology,"" IBC Confence, Antibody Engineering, San Diego (1996), Part 3 of 4.;;Salfeld, ""Development of a Fully Human Antibody to TNF by Phage Display Technology,"" IBC Confence, Antibody Engineering, San Diego (1996), Part 4 of 4.;;Sandhu, J. ""Protein engineering of antibodies,"" Critical Reviews in Biotechnology, 12:437-462 (1992).;;Sioud et al., ""Characterization of naturally occurring autoantibodies against tumor necrosis factor-alpha (TNF-alpha): in vitro function and precise epitope mapping by phage epitope library"" Clin Exp Immunol., 98:520-525 (1994).;;Tamura, M. et al., ""Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRS) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only"" Journal Immunology (2000) vol. 164, pp. 1432-1441.;;Taylor et al., ""Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,"" Int. Immunol 6:579-591 (1994).;;Teichmann, S. Declaration dated Dec. 7, 2010 from opposition proceedings in EP 0929578.;;Tsuchiyama et al., ""Comparision of anti-TNF alpha autoantibodies in plasma and from EVB transformed lymphocytes of autoimmune and normal individual."" Hum. Antibod. Hybridomas 6(2):73-76 (1995).;;Wagner et al., ""The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human immunoglobulin gene miniloci,"" Eur. J. Immunol. 24:2672-2681 (1994).;;Wagner et al., ""Antibodies generated from human immunoglobulin miniloci in transgenic mice,"" Nucl. Acids Res. 22:1389-1393 (1994).;;Wedemayer et al., ""Structural insights into the evolution of an antibody combining site."" Science 276:1665-1669 (1997).;;Zou et al., ""Dominant expression of a 1.3 Mb human iG kappa locus replacing mouse light chain production,"" FASEB J 10:1227-1232 (1996).;;""Plaintiffs' Memorandum in Support of Their Motion for Partial Summary Judgment"", dated Aug. 1, 2013 and submitted by plaintiff in Civil Action No. 09-40089-FDS.;;""Plaintiffs' Rule 56.1 Statement of Undisputed Material Facts in Support of Their Motion for Partial Summary Judgment"", dated Aug. 1, 2013 and submitted by plaintiff in Civil Action No. 09-40089-FDS.;;""Memorandum in Support of Centocor's Motion for Summary Judgment No. 1 that All Asserted Claims Are Invalid for Lack of Written Description"", dated Aug. 1, 2013 and submitted by defendant in Civil Action No. 09-40089-FDS.;;""Memorandum in Support of Centocor's Motion for Summary Judgment No. 2 that All Asserted Claims are Invalid for Lack of Enablement"", dated Aug. 1, 2013 and submitted by defendant in Civil Action No. 09-40089-FDS.;;""Memorandum in Support of Centocor's Motion No. 3 for Summary Judgment that the 394 and 031 Patents are Invalid for Under 35 U.S.C. §102(f) for Failing to Name the Proper Inventors"", dated Aug. 1, 2013 and submitted by defendant in Civil Action No. 09-40089-.;;""Memorandum in Support of Centocor's Motion for Summary Judgment No. 4 that Claims Encompassing Non-recombinant Human Antibodies Are Invalid for Failing to Meet the Requirement of 35 U.S.C. §112"", dated Aug. 1, 2013 and submitted by defendant in Civil Action No. 09-40089-FDS.;;""Memorandum in Support of Centocor's Motion No. 6 for Summary Judgment that References Dated Before Feb. 10, 1997 Qualify as Prior Art to the 394 and 031 Patents"", dated Aug. 1, 2013 and submitted by defendant in Civil Action No. 09-40089-.",EXPIRED
174,SK,A3,SK 106298 A3,137-607-730-758-243,1999-03-12,1999,SK 106298 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF'ALPHA',,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBVIE BIOTECHNOLOGY LTD., HAMILTON, BM (2013-10-14)",https://lens.org/137-607-730-758-243,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;C12N15/09;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
175,MX,B,MX 336813 B,182-007-891-703-73X,2016-02-02,2016,MX 12010598 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF ALPHA.,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha (hTNF alpha ) are disclosed. These antibodies have high affinity for hTNF alpha (e.g., Kd = 10<-8> M or less), a slow off rate for hTNF alpha dissociation (e.g., Koff = 10<-3>sec<-1> or less) and neutralize hTNF alpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF alpha and for inhibiting hTNF alpha activity, e.g., in a human subject suffering from a disorder in which hTNF alpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;ALFELD JOCHEN G,,https://lens.org/182-007-891-703-73X,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
176,BR,B1,BR 9707379 B1,187-246-964-775-110,2009-08-11,2009,BR 9707379 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,"composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.",,,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABROVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBOTT BIOTECHNOLOGY LTD. (BM) (2006-09-05);;ABBOTT LABORATORIES (BERMUDA) LTD (BM) (2003-12-16);;ABBVIE BIOTECHNOLOGY LTD. (BM) (2015-06-09),https://lens.org/187-246-964-775-110,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
177,AU,A1,AU 2013/257402 A1,005-672-076-159-100,2013-11-28,2013,AU 2013/257402 A,2013-11-11,AU 2013/203420 A;;AU 2013/257402 A,2013-04-10,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kd= 10~8 M or less), a slow off rate for hTNFa dissociation (e.g., K ~ff10- 3 sec~' or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/005-672-076-159-100,Patent Application,no,0,0,3,3,0,,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
178,HU,B1,HU 228630 B1,009-801-998-731-63X,2013-04-29,2013,HU P0204115 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,USE OF HUMAN ANTI BODIES THAT BIND HUMAN TNF-ALPHA AND PROCESS FOR INHIBITING OF HUMAN TNF-ALPHA ACTIVITY,,ABBOTT BIOTECH LTD,ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SALFELD JOCHEN G;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBVIE BIOTECHNOLOGY LTD., BM (2014-06-30)",https://lens.org/009-801-998-731-63X,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
179,MX,B,MX 343996 B,121-703-905-832-775,2016-12-02,2016,MX 13008395 A,1998-08-06,US 59922696 A;;US 3147696 P;;US 3147696 A,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFA.,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha (hTNFalpha) are disclosed. These antibodies have high affinity for hTNFalpha (e.g., Kd=10-8 M or less), a slow off rate for hTNFalpha dissociation (e.g., Koff=10-3 sec-1 or less) and neutralize hTNFalpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFalpha and for inhibiting hTNFalpha activity, e.g., in a human subject suffering from a disorder in which hTNFalpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,JOCHEN G SALFELD;;DEBORAH J ALLEN;;ZEHRA KAYMAKCALAN;;BORIS LABKOVSKY;;JOHN A MANKOVICH;;BRIAN T MCGUINESS;;ANDREW J ROBERTS;;PAUL SAKORAFAS;;HENDRICUS R J M HOOGENBOOM;;DAVID SCHOENHAUT;;TRISTAN J VAUGHAN;;MICHAEL WHITE;;ALISON J WILTON,,https://lens.org/121-703-905-832-775,Granted Patent,no,0,0,1,181,0,,A61K39/395;;A61K38/04;;C07K16/24,,0,0,,,,EXPIRED
180,NO,L,NO 20026202 L,128-931-340-074-637,1998-10-07,1998,NO 20026202 A,2002-12-23,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,"Fremgangsmåte for inhibering av TNF<alfa>-aktivitet in vitro, anvendelse avhuman antistoff som binder human TNF<alfa>, rekombinant humanantistoff som binder TNF<alfa>, nukleinsyre, ekspresjonsvektor, vertscelle ogfremgangsmåte for åsyntetise",,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNES BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON JANE,"ABBOTT BIOTECHNOLOGY LTD, BM (2013-10-07);;ABBVIE BIOTECHNOLOGY LTD, BM (2013-10-14)",https://lens.org/128-931-340-074-637,Abstract,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
181,HK,A1,HK 1019452 A1,149-084-556-555-250,2000-02-11,2000,HK 99104584 A,1999-10-15,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Human antibodies that bind human tnf,,ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE CHAEL;;WILTON ALISON J,,https://lens.org/149-084-556-555-250,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K/;;A61K/;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N/;;C12N1/21;;C12N5/10;;C12P21/08;;G01N/;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
182,US,A1,US 2009/0155205 A1,169-856-308-951-839,2009-06-18,2009,US 36945109 A,2009-02-11,US 36945109 A;;US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFa,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/169-856-308-951-839,Patent Application,yes,99,80,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K38/20;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K38/21;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/85.2;;424/158.1;;424/133.1;;424/145.1;;424/85.6,0,0,,,,EXPIRED
183,EP,A1,EP 2933267 A1,172-880-523-850-676,2015-10-21,2015,EP 15165123 A,1997-02-10,US 59922696 A;;US 3147696 P;;EP 10184662 A;;EP 02022788 A;;EP 97906572 A,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα ( e.g. , K d  = 10 -8  M or less), a slow off rate for hTNFα dissociation ( e.g.,  K off  = 10 -3  sec -1  or less) and neutralize hTNFα activity  in vitro  and  in vivo.  An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/172-880-523-850-676,Patent Application,yes,42,0,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,107,80,072-378-691-723-546;;040-701-579-915-050;;074-871-884-454-68X;;016-907-020-918-983;;011-796-204-010-792;;117-499-681-530-662;;006-117-436-368-816;;046-939-287-004-026;;085-191-504-989-317;;041-591-849-635-094;;054-329-283-530-645;;002-495-006-719-164;;021-113-833-013-619;;015-584-716-307-216;;092-412-882-661-570;;072-438-011-112-832;;006-342-252-521-899;;057-954-116-868-246;;072-378-691-723-546;;003-907-950-634-854;;041-956-664-134-903;;035-071-534-473-573;;071-901-988-318-434;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;066-749-017-721-197;;001-467-559-709-949;;143-467-932-790-298;;123-171-555-829-362;;071-707-020-428-907;;044-369-216-298-341;;092-023-577-402-127;;022-179-293-052-569;;030-630-100-818-462;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;035-872-873-163-027;;100-049-580-404-573;;033-797-614-829-293;;072-378-691-723-546;;005-119-615-003-591;;034-331-211-704-877;;025-395-146-381-464;;174-783-722-981-415;;011-962-497-035-168;;065-145-385-150-339;;033-459-816-867-43X;;098-513-251-868-998;;063-873-022-003-842;;044-317-656-227-593;;011-114-894-374-225;;037-795-266-129-616;;008-835-817-825-32X;;075-878-183-554-694;;004-001-063-582-854;;079-192-394-643-91X;;000-065-369-829-300;;128-904-140-606-949;;077-369-546-251-682;;032-821-336-726-761;;050-094-719-890-440;;070-452-766-365-174;;110-232-737-639-142;;028-469-508-809-412;;044-217-982-536-908;;012-422-300-553-121;;033-522-835-476-708;;097-358-265-091-151;;041-043-853-736-19X;;085-885-495-910-537;;167-234-008-883-687;;061-475-814-399-439;;031-974-874-348-471;;054-469-226-992-186;;007-667-472-783-358;;023-473-383-533-503;;063-233-860-095-920;;052-159-696-111-105,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7521646;;10.1038/nbt0994-899;;2413547;;10.1126/science.2413547;;10.1146/annurev.bi.57.070188.002445;;3052281;;10.1146/annurev.biochem.57.1.505;;10.1146/annurev.immunol.7.1.625;;10.1146/annurev.iy.07.040189.003205;;2540776;;1590993;;10.1146/annurev.iy.10.040192.002211;;10.1146/annurev.immunol.10.1.411;;0001590993;;10.1146/annurev.med.45.1.491;;8198398;;3889916;;pmc397878;;10.1073/pnas.82.11.3814;;3729942;;10.1016/0006-291x(86)91157-5;;3805735;;10.1016/0022-1759(87)90367-x;;10.1089/hyb.1987.6.359;;2442093;;10.1016/0161-5890(93)90106-l;;8232330;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1016/s0140-6736(94)90628-9;;7934491;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1016/0022-1759(91)90361-i;;2040812;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7703831;;10.1038/312724a0;;6392892;;3552045;;10.1021/bi00379a018;;2922046;;2922050;;10.1038/338225a0;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;8597629;;10.3233/hab-1995-6303;;10.1016/0161-5890(94)90100-7;;7935496;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;7541226;;10.1002/jmr.300080122;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;10.1038/348552a0;;2247164;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;1367769;;10.1038/nbt1291-1369;;1385989;;10.3233/hab-1992-3204;;2531466;;10.1126/science.2531466;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/nbt1291-1373;;1369462;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;pmc52428;;10.1073/pnas.88.18.7978;;1896445;;8216416;;10.1002/art.1780360907;;8907592;;10.1007/bf02265123;;10.1097/00001756-199604260-00023;;8817534;;8619098;;10.1016/s0889-857x(21)00466-x;;10.1016/0958-1669(93)90055-2;;7764470;;10.1002/art.1780380202;;7848304;;10.1093/rheumatology/34.4.334;;7788147;;10.1097/00007890-199409000-00007;;7940686;;10.1097/00007890-199501000-00025;;10.1097/00007890-199501270-00025;;7839455;;7832839;;10.1056/nejm199408113310606;;10.1126/science.3764421;;3764421;;10.1172/jci113459;;pmc442560;;3366898;;pmc1535044;;2117510;;10.1111/j.1365-2249.1990.tb03334.x;;7797011;;10.1016/0016-5085(95)90277-5;;10.1038/319516a0;;3511389;;10.1002/jbmr.5650030607;;3266953;;8442433;;10.1002/jbmr.5650080205;;7512360;;10.1016/8756-3282(93)90317-4;;2920991;;10.1002/hep.1840090302;;10.1111/j.1530-0277.1990.tb00482.x;;2190492;;10.1002/hep.1840200228;;8045508;;10.1016/0270-9139(94)90200-3;;10.1016/0168-8278(91)90945-8;;2051003;;pmc502205;;10.1136/jcp.47.12.1112;;7876386;;2188129;;10.1056/nejm199006073222302;;1924431;;10.1152/ajpheart.1994.267.1.h118;;8048575;;8148074;;10.1016/0305-4179(94)90104-x;;10.1152/ajpgi.1994.267.6.g1122;;7810659;;7992355;;10.1097/00007890-199412150-00003;;10.1016/0300-9572(95)00831-d;;7659869;;10.1007/bf00918154;;1512303;;pmc453150;;1721867;;10.1002/j.1460-2075.1991.tb04978.x,"GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"", EMBO J., vol. 12, no. 2, 1993, pages 725 - 734, XP000645476;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899 - 903, XP000572619, ISSN: 0733-222X;;OLD, L., SCIENCE, vol. 230, 1985, pages 630 - 632;;BEUTLER, B.; CERAMI, A., ANNU. REV. BIOCHEM., vol. 57, 1988, pages 505 - 518;;BEUTLER, B.; CERAMI, A., ANNU. REV. IMMUNOL., vol. 7, 1989, pages 625 - 655;;MOELLER, A. ET AL., CYTOKINE, vol. 2, 1990, pages 162 - 169;;VASILLI, P., ANNU. REV. IMMUNOL., vol. 10, 1992, pages 411 - 452;;TRACEY, K.J.; CERAMI, A., ANNU. REV. MED., vol. 45, 1994, pages 491 - 503;;HAHN T ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3814 - 3818;;LIANG, C-M. ET AL., BIOCHENI. BIOPHYS. RES. COMMUN., vol. 137, 1986, pages 847 - 854;;HIRAI, M. ET AL., J. IMMUNOL. METHODS, vol. 96, 1987, pages 57 - 62;;FENDLY, B.M. ET AL., HYBRIDOMA, vol. 6, 1987, pages 359 - 370;;KNIGHT, D.M, ET AL., OL. IMMUNOL., vol. 30, 1993, pages 1443 - 1453;;ELLIOTT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1125 - 1127;;ELLIOT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1105 - 1110;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 556 - 568;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 569 - 581;;FOMSGAARD, A. ET AL., SCAND. J. IMMUNOL., vol. 30, 1989, pages 219 - 223;;BENDTZEN, K. ET AL., PROG. LEUKOCYTE BIOL., vol. 1OB, 1990, pages 447 - 452;;LEUSCH, H-G. ET AL., J. IMMUNOL. METHODS, vol. 139, 1991, pages 145 - 147;;GRIFFITHS, A.D. ET AL., EMBO J., vol. 12, 1993, pages 725 - 734;;LIDBURY, A. ET AL., BIOTECHNOL. THER., vol. 5, 1994, pages 27 - 45;;PENNICA, D. ET AL., NATURE, vol. 312, 1984, pages 724 - 729;;DAVIS, J.M. ET AL., BIOCHEMISTRY, vol. 26, 1987, pages 1322 - 1326;;JONES, E.Y. ET AL., NATURE, vol. 338, 1989, pages 225 - 228;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;KIPRIYANOV, S.M. ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101;;KIPRIYANOV, S.M. ET AL., M /. IMMUNOL., vol. 31, 1994, pages 1047 - 1058;;TAYLOR, L.D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295;;J6NSSON, U., ET AL., ANN. BIOL. CLIN., vol. 51, 1993, pages 19 - 26;;J6NSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627;;JOHNSSON, B. ET AL., J. MOT. RECOGNIT., vol. 8, 1995, pages 125 - 131;;JOHNNSON, B. ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages 268 - 277;;SAMBROOK, FRITSCH AND MANIATIS: ""Molecular Cloning; A Laboratory Manual, Second Edition,"", 1989, COLD SPRING HARBOR;;AUSUBEL, F.M. ET AL.: ""Current Protocols in Molecular Biology"", 1989, GREENE PUBLISHING ASSOCIATES;;KABAT, E.A. ET AL.: ""Sequences of Proteins of Immunological Interest, Fifth Edition,"", 1991, NIH PUBLICATION NO. 91-3242;;TOMLINSON, I.M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups ofV Segments with Different Hypervariable Loops"", , MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COX, J.P.L. ET AL.: ""A Directory of Human Germ-line V K Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;KABAT, E.A. ET AL.: ""Sequences ofP oteinS of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;GOEDDEL: ""Gene Expression Technology: Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;BOSS, M.A.; WOOD, C. R, IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R.J. KAUFMAN; P.A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;PHARMACIA RECOMBINANT PHAGE ANTIBODY SYSTEM;;FUCHS ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1370 - 1372;;HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., JMOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;GARRAD ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982;;J.R. ROBINSON,: ""Sustained and Controlled Release Drug Delivery Systenis"", 1978, MARCEL DEKKER, INC.;;ARTHRITIS & RHEUMATISM, vol. 37, 1994, pages S295;;J. INVEST. MED., vol. 44, 1996, pages 235A;;ARTHRITIS & RHEUMATISM, vol. 38, 1995, pages SI85;;ARTHRITIS & RHEUMATISM, vol. 36, 1993, pages 1223;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S284;;AMER. J. PHYSIOL. - HEART AND CIRCULATORY PHYSIOLOGY, vol. 268, 1995, pages 37 - 42;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S282;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S81;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S82;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S131;;INFLAMMATION RESEARCH, vol. 45, 1996, pages 103 - 107;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S280;;NEURO REPORT, vol. 7, 1996, pages 1209 - 1213;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S281;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S296;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S308;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S120;;DELUCA ET AL., RHEUNI. DIS. CLIN. NORTH AM., vol. 21, 1995, pages 759 - 777;;RUSSELL, D; THOMPSON, R.C, CURRO OPIN. BIOTECH., vol. 4, 1993, pages 714 - 721;;AREND, W.P.; DAYER, J-M., ARTH. RHEUNI., vol. 38, 1995, pages 151 - 160;;FAVA, R.A. ET AL., CLIN. EXP. IMM UNO, vol. 94, 1993, pages 261 - 266;;RANKIN, E.C. ET AL., BR. J. RHEUMATOL., vol. 34, 1995, pages 334 - 342;;FIETZE, E. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 675 - 680;;EASON, J.D. ET AL., TRANSPLANTATION, vol. 59, 1995, pages 300 - 305;;SUTHANTHIRAN, M.; STROM, T.B., NEWENGL. J. MED., vol. 331, 1994, pages 365 - 375;;TRACY, K.J. ET AL., SCIENCE, vol. 234, 1986, pages 470 - 474;;SUN, X-M. ET AL., CLIN. INVEST., vol. 81, 1988, pages 1328 - 1331;;MACDONALD, T.T. ET AL., CLIN. EXP. IMMUNOL., vol. 81, 1990, pages 301 - 305;;VAN DULLEMEN, H.M. ET AL., GASTROENTEROLOGY, vol. 109, 1995, pages 129 - 135;;BERTOLINI, D.R. ET AL., NATURE, vol. 319, 1986, pages 516 - 518;;KONIG, A. ET AL., J. BONE MINER. RES., vol. 3, 1988, pages 621 - 627;;LEMER, U.H.; OHLIN, A., J. BONE MINER. RES., vol. 8, 1993, pages 147 - 155;;SHANKAR, G.; STERN, P.H, BONE, vol. 14, 1993, pages 871 - 876;;MCCLAIN, C.J.; COHEN, D.A., HEPATOLOGY, vol. 9, 1989, pages 349 - 351;;FELVER, M.E. ET AL., ALCOHOL. CLIN.. EXP. RES., vol. 14, 1990, pages 255 - 259;;HANSEN, J. ET AL., HEPATOLOGY, vol. 20, 1994, pages 461 - 474;;SHERON, N. ET AL., J. HEPATOL., vol. 12, 1991, pages 241 - 245;;HUSSAIN, M.J. ET AL., J. CLIN. PATHOL., vol. 47, 1994, pages 1112 - 1115;;VAN DER POLL, T. ET AL., N. ENGL. J. MED., vol. 322, 1990, pages 1622 - 1627;;VAN DER POLL, T. ET AL., PROG. CLIN. BIOL. RES., vol. 367, 1991, pages 55 - 60;;GIROIR, B.P. ET AL., AM. J PHYSIOL., vol. 267, 1994, pages H118 - 124;;LIU, X.S. ET AL., BURNS, vol. 20, 1994, pages 40 - 44;;SCALES, W.E. ET AL., AM. J PHYSIOL., vol. 267, 1994, pages G1122 - 1127;;SERRICK, C. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 1158 - 1162;;YAO, Y.M. ET AL., RESUSCITATION, vol. 29, 1995, pages 157 - 168;;MCCAULEY, R.L. ET AL., J. CLIN. IMMUNO ., vol. 12, 1992, pages 300 - 308;;EMBO J, vol. 10, 1991, pages 4025 - 4031",DISCONTINUED
184,NO,B1,NO 319955 B1,026-951-733-302-696,2005-10-03,2005,NO 20026202 A,2002-12-23,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,"Anvendelse av isolert human-antistoff som binder human-TNF-alfa, fremgangsmate for inhibering av TNF-alfa-aktivitet in vitro, samt isolert human-antistoff som binder human-TNF-alfa og farmasoytisk blanding som omfatter nevnte antistoff.",,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNES BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON JANE,"ABBOTT BIOTECHNOLOGY LTD, BM (2013-10-07);;ABBVIE BIOTECHNOLOGY LTD, BM (2013-10-14)",https://lens.org/026-951-733-302-696,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;C12N15/09;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
185,AU,B2,AU 775499 B2,056-344-909-471-439,2004-08-05,2004,AU 2000/066649 A,2000-10-20,AU 2000/066649 A;;AU 1997/021229 A,1997-02-10,Human antibodies that bind human TNFalpha',,ABBOTT LAB BERMUDA LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBOTT LABORATORIES (BERMUDA) LTD (2003-06-19),https://lens.org/056-344-909-471-439,Granted Patent,no,0,0,2,2,0,Y02A50/30,A61K39/395;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,EXPIRED
186,US,A1,US 2010/0016557 A1,124-277-173-223-64X,2010-01-21,2010,US 40146909 A,2009-03-10,US 40146909 A;;US 23325205 A;;US 30235602 A;;US 54001800 A;;US 59922696 A,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d=10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/124-277-173-223-64X,Patent Application,yes,89,58,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;C07K16/24;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07H21/04;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,530/387.3;;530/388.15;;536/23.53,0,0,,,,EXPIRED
187,AU,A1,AU 2009/202707 A1,142-101-799-030-35X,2009-07-23,2009,AU 2009/202707 A,2009-07-03,AU 2006/241387 A;;AU 2009/202707 A,2006-11-24,Human antibodies that bind human TNFa,,ABBOTT BIOTECH LTD,VAUGHAN TRISTAN J;;SALFELD JOCHEN G;;MCGUINESS BRIAN T;;HOOGENBOOM HENDRICUS R J M;;LABKOVSKY BORIS;;SCHOENHAUT DAVID;;SAKORAFAS PAUL;;MANKOVICH JOHN A;;ALLEN DEBORAH J;;WILTON ALISON J;;KAYMAKCALAN ZEHR;;WHITE MICHAEL;;ROBERTS ANDREW J,,https://lens.org/142-101-799-030-35X,Patent Application,no,0,0,5,5,0,A61K2039/505;;C07K16/241;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/622;;C07K2317/76;;C07K2317/92;;G01N2333/525;;G01N2800/10;;G01N2800/102,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
188,AU,A1,AU 2013/203420 A1,136-934-698-124-25X,2013-05-02,2013,AU 2013/203420 A,2013-04-10,AU 2012/261708 A;;AU 2013/203420 A,2012-12-07,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., K= 10-8 M or less), a slow off rate for hTNFa dissociation (e.g., Koir ~10-3sec 1 or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/136-934-698-124-25X,Patent Application,no,0,1,3,3,0,,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
189,AU,B2,AU 2013/257402 B2,137-669-165-643-841,2014-02-20,2014,AU 2013/257402 A,2013-11-11,AU 2013/203420 A;;AU 2013/257402 A,2013-04-10,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kd= 10~8 M or less), a slow off rate for hTNFa dissociation (e.g., K ~ff10- 3 sec~' or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/137-669-165-643-841,Granted Patent,no,2,0,3,3,0,,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
190,PL,B1,PL 193499 B1,141-013-918-216-688,2007-02-28,2007,PL 36523797 A,1997-02-10,US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,"ISOLATED HUMAN ANTIBODY, RECOMBINED HUMAN ANTIBODY, PHARMACEUTICAL COMPOUND, METHOD FOR THE INHIBITION OF ACTIVITY OF HUMAN TNFALPHA IN VITRO, APPLICATION OF THESE ISOLATED HUMAN ANTIBODIES AND ISOLATED NUCLEIC ACID",,ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/141-013-918-216-688,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
191,PL,B1,PL 188192 B1,155-763-977-001-645,2004-12-31,2004,PL 32841197 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,HUMAN ANTIBODIES CAPABLE TO BOND HUMAN TNF ALPHA,,ABBOTT LAB BERMUDA LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/155-763-977-001-645,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
192,CA,A1,CA 2389943 A1,194-924-419-674-086,1997-08-14,1997,CA 2389943 A,1997-02-10,CA 2243459 A;;US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF.ALPHA.,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha. (e.g., K d = 10 -8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K off = 10 -3sec -1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full- length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions; of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",BASF AG,WILTON ALISON J;;WHITE MICHAEL;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;ALLEN DEBORAH J;;SCHOENHAUT DAVID;;MCGUINNESS BRIAN T;;KAYMAKCALAN ZEHRA;;SALFELD JOCHEN G;;ROBERTS ANDREW J,,https://lens.org/194-924-419-674-086,Patent Application,no,0,0,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
193,AU,A1,AU 2012/261708 A1,008-658-493-114-622,2013-01-10,2013,AU 2012/261708 A,2012-12-07,AU 2009/202707 A;;AU 2012/261708 A,2009-07-03,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kd = 10~8 M or less), a slow off rate for hTNFa dissociation (e.g., Korr~10~3sec-' or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/008-658-493-114-622,Patent Application,no,0,0,2,2,0,,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
194,BR,C8,BR PI9707379 C8,036-643-843-936-938,2017-12-12,2017,BR PI9707379 A,1997-02-10,US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,"composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.","""anticorpo humano isolado, ácido nucléico isolado, vetor recombinante de expressão, célula hospedeira, processo para sintetizar um anticorpo humano que se liga a tnf<244> humano, composição farmacêutica, processo para inibir a atividade do tnf humano, e, uso do anticorpo"". são apresentados os anticorpos dos seres humanos, preferivelmente os anticorpos recombinantes dos seres humanos, que especificamente se ligam ao fator <244> de necrose tumoral humana (htnf<244>). estes anticorpos tem alta afinidade por htnf<244> (por exemplo, k~ d~ = 10^ -8^ m ou menos), um índice muito lento para dissociação do htnf<244> (por exemplo, k~ off~ = 10^ -3^seg^ 1^ ou menos) e neutraliza a atividade do htnf<244> in vitro e in vivo. um anticorpo da invenção pode ser um anticorpo de comprimento de comprimento completo ou uma porção deste de ligação de antígeno. os anticorpos, ou as porções dos anticorpos, da invenção, são úteis para detectar htnf<244> e para inibir a atividade do htnf<244>, por exemplo em um indivíduo humano sofrendo de um distúrbio em que a atividade do htnf<244> seja prejudicial. os ácidos nucleicos, vetores e células hospedeiras para expressar os anticorpos recombinantes de seres humanos da invenção, e os processos de sintetização dos anticorpos recombinantes de seres humanos, são também abrangidos pela invenção.",ABBOTT BIOTECH LTD;;ABBVIE BIOTECHNOLOGY LTD;;ABBOTT LABORATORIES BERMUDA LTD;;BASF AG,ALISON J WILTON;;ANDREW J ROBERTS;;BORIS LABKOVSKY;;BRIAN T MCGUINNESS;;DAVID SCHOENHAUT;;DEBORAH J ALLEN;;HENDRICUS R J M HOOGENBOOM;;JOCHEN G SALFELD;;JOHN A MANKOVICH;;MICHAEL WHITE;;PAUL SAKORAFAS;;TRISTAN J VAUGHAN;;ZEHRA KAYMAKCALAN,,https://lens.org/036-643-843-936-938,Amended Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
195,NO,L,NO 20040052 L,046-594-402-797-05X,1998-10-07,1998,NO 20040052 A,2004-01-07,US 3147696 P;;US 59922696 A;;US 9702219 W,1996-02-09,Farmasoytisk blanding og fremgangsmate for inhibering av Human TNF<alfa>-aktivitet,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNES BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON JANE,"ABBOTT BIOTECHNOLOGY LTD, BM (2013-10-07);;ABBVIE BIOTECHNOLOGY LTD, BM (2013-10-14)",https://lens.org/046-594-402-797-05X,Abstract,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
196,CZ,B6,CZ 292465 B6,071-431-453-231-638,2003-09-17,2003,CZ 247698 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind to human TNF alpha,"Human antibodies, preferably recombinant human antibodies that specifically bind to human tumor necrosis factor alpha (hTNF alpha) are described. These antibodies have high affinity for hTNF alpha (e.g., Kid = =10e-3se-1 or less), a slow off rate for hTNF alpha dissociation (e.g., Koff = 10<-3>sec<-1> or less) and neutralize hTNF alpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF alpha and for inhibiting hTNF alpha activity, e.g., in a human subject suffering from a disorder in which hTNF alpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT LAB BERMUDA LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/071-431-453-231-638,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
197,NO,D0,NO 20026202 D0,087-372-761-299-363,2002-12-23,2002,NO 20026202 A,2002-12-23,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,"Fremgangsmåte for inhibering av TNF<alfa>-aktivitet in vitro, anvendelse avhuman antistoff som binder human TNF<alfa>, rekombinant humanantistoff som binder TNF<alfa>, nukleinsyre, ekspresjonsvektor, vertscelle ogfremgangsmåte for åsyntetise",,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNES BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON JANE,"ABBOTT BIOTECHNOLOGY LTD, BM (2013-10-07);;ABBVIE BIOTECHNOLOGY LTD, BM (2013-10-14)",https://lens.org/087-372-761-299-363,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
198,EP,A1,EP 2930185 A1,143-527-688-952-719,2015-10-14,2015,EP 15165128 A,1997-02-10,US 59922696 A;;US 3147696 P;;EP 10184662 A;;EP 02022788 A;;EP 97906572 A,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d  = 10 -8  M or less), a slow off rate for hTNFα dissociation  (e.g.,  K off = 10 -3  sec -1  or less) and neutralize hTNFα activity  in vitro  and  in vivo.  An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/143-527-688-952-719,Patent Application,yes,42,0,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,104,78,072-378-691-723-546;;040-701-579-915-050;;074-871-884-454-68X;;016-907-020-918-983;;011-796-204-010-792;;117-499-681-530-662;;006-117-436-368-816;;046-939-287-004-026;;085-191-504-989-317;;041-591-849-635-094;;054-329-283-530-645;;002-495-006-719-164;;021-113-833-013-619;;015-584-716-307-216;;092-412-882-661-570;;072-438-011-112-832;;006-342-252-521-899;;057-954-116-868-246;;072-378-691-723-546;;003-907-950-634-854;;041-956-664-134-903;;035-071-534-473-573;;071-901-988-318-434;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;066-749-017-721-197;;001-467-559-709-949;;143-467-932-790-298;;123-171-555-829-362;;071-707-020-428-907;;044-369-216-298-341;;092-023-577-402-127;;022-179-293-052-569;;030-630-100-818-462;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;100-049-580-404-573;;033-797-614-829-293;;072-378-691-723-546;;005-119-615-003-591;;034-331-211-704-877;;025-395-146-381-464;;174-783-722-981-415;;011-962-497-035-168;;065-145-385-150-339;;033-459-816-867-43X;;098-513-251-868-998;;063-873-022-003-842;;044-317-656-227-593;;011-114-894-374-225;;037-795-266-129-616;;008-835-817-825-32X;;075-878-183-554-694;;004-001-063-582-854;;079-192-394-643-91X;;000-065-369-829-300;;128-904-140-606-949;;077-369-546-251-682;;032-821-336-726-761;;050-094-719-890-440;;070-452-766-365-174;;110-232-737-639-142;;028-469-508-809-412;;044-217-982-536-908;;012-422-300-553-121;;033-522-835-476-708;;097-358-265-091-151;;041-043-853-736-19X;;085-885-495-910-537;;167-234-008-883-687;;031-974-874-348-471;;054-469-226-992-186;;007-667-472-783-358;;023-473-383-533-503;;063-233-860-095-920;;052-159-696-111-105,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7521646;;10.1038/nbt0994-899;;2413547;;10.1126/science.2413547;;10.1146/annurev.bi.57.070188.002445;;3052281;;10.1146/annurev.biochem.57.1.505;;10.1146/annurev.immunol.7.1.625;;10.1146/annurev.iy.07.040189.003205;;2540776;;1590993;;10.1146/annurev.iy.10.040192.002211;;10.1146/annurev.immunol.10.1.411;;0001590993;;10.1146/annurev.med.45.1.491;;8198398;;3889916;;pmc397878;;10.1073/pnas.82.11.3814;;3729942;;10.1016/0006-291x(86)91157-5;;3805735;;10.1016/0022-1759(87)90367-x;;10.1089/hyb.1987.6.359;;2442093;;10.1016/0161-5890(93)90106-l;;8232330;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1016/s0140-6736(94)90628-9;;7934491;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1016/0022-1759(91)90361-i;;2040812;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7703831;;10.1038/312724a0;;6392892;;3552045;;10.1021/bi00379a018;;2922046;;2922050;;10.1038/338225a0;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;8597629;;10.3233/hab-1995-6303;;10.1016/0161-5890(94)90100-7;;7935496;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;7541226;;10.1002/jmr.300080122;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;10.1038/348552a0;;2247164;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;1385989;;10.3233/hab-1992-3204;;2531466;;10.1126/science.2531466;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/nbt1291-1373;;1369462;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;pmc52428;;10.1073/pnas.88.18.7978;;1896445;;8216416;;10.1002/art.1780360907;;8907592;;10.1007/bf02265123;;10.1097/00001756-199604260-00023;;8817534;;8619098;;10.1016/s0889-857x(21)00466-x;;10.1016/0958-1669(93)90055-2;;7764470;;10.1002/art.1780380202;;7848304;;10.1093/rheumatology/34.4.334;;7788147;;10.1097/00007890-199409000-00007;;7940686;;10.1097/00007890-199501000-00025;;10.1097/00007890-199501270-00025;;7839455;;7832839;;10.1056/nejm199408113310606;;10.1126/science.3764421;;3764421;;10.1172/jci113459;;pmc442560;;3366898;;pmc1535044;;2117510;;10.1111/j.1365-2249.1990.tb03334.x;;7797011;;10.1016/0016-5085(95)90277-5;;10.1038/319516a0;;3511389;;10.1002/jbmr.5650030607;;3266953;;8442433;;10.1002/jbmr.5650080205;;7512360;;10.1016/8756-3282(93)90317-4;;2920991;;10.1002/hep.1840090302;;10.1111/j.1530-0277.1990.tb00482.x;;2190492;;10.1002/hep.1840200228;;8045508;;10.1016/0270-9139(94)90200-3;;10.1016/0168-8278(91)90945-8;;2051003;;pmc502205;;10.1136/jcp.47.12.1112;;7876386;;2188129;;10.1056/nejm199006073222302;;1924431;;8148074;;10.1016/0305-4179(94)90104-x;;10.1152/ajpgi.1994.267.6.g1122;;7810659;;7992355;;10.1097/00007890-199412150-00003;;10.1016/0300-9572(95)00831-d;;7659869;;10.1007/bf00918154;;1512303;;pmc453150;;1721867;;10.1002/j.1460-2075.1991.tb04978.x,"GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"", EMBO J., vol. 12, no. 2, 1993, pages 725 - 734, XP000645476;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899 - 903, XP000572619, ISSN: 0733-222X;;OLD, L, SCIENCE, vol. 230, 1985, pages 630 - 632;;BEUTLER, B.; CERAMI, A., ANNU. REV. BIOCHEM., vol. 57, 1988, pages 505 - 518;;BEUTLER, B.; CERAMI, A., ANNU. REV. IMMUNOL., vol. 7, 1989, pages 625 - 655;;MOELLER, A. ET AL., CYTOKINE, vol. 2, 1990, pages 162 - 169;;VASILLI, P., ANNU. REV. IMMUNOT., vol. 10, 1992, pages 411 - 452;;TRACEY, K.J.; CERAMI, A., ANNU. REV. MED., vol. 45, 1994, pages 491 - 503;;HAHN T ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3814 - 3818;;LIANG, C-M. ET AL., BIOCHENI. BIOPHYS. RES. COMMUN., vol. 137, 1986, pages 847 - 854;;HIRAI, M. ET AL., J. IMMUNOL. METHODS, vol. 96, 1987, pages 57 - 62;;FENDLY, B.M. ET AL., HYBRIDOMA, vol. 6, 1987, pages 359 - 370;;KNIGHT, D.M, ET AL., OL. IMMUNOL., vol. 30, 1993, pages 1443 - 1453;;ELLIOTT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1125 - 1127;;ELLIOT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1105 - 1110;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 556 - 568;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 569 - 581;;FOMSGAARD, A. ET AL., SCAND. J. IMMUNOL., vol. 30, 1989, pages 219 - 223;;BENDTZEN, K. ET AL., PROG. LEUKOCYTE BIOL., vol. LOB, 1990, pages 447 - 452;;LEUSCH, H-G. ET AL., J. IMMUNOL. METHODS, vol. 139, 1991, pages 145 - 147;;GRIFFITHS, A.D. ET AL., EMBO J., vol. 12, 1993, pages 725 - 734;;LIDBURY, A. ET AL., BIOTECHNOL. THER., vol. 5, 1994, pages 27 - 45;;PENNICA, D. ET AL., NATURE, vol. 312, 1984, pages 724 - 729;;DAVIS, J.M. ET AL., BIOCHEMISTRY, vol. 26, 1987, pages 1322 - 1326;;JONES, E.Y. ET AL., NATURE, vol. 338, 1989, pages 225 - 228;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;KIPRIYANOV, S.M. ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101;;KIPRIYANOV, S.M. ET AL., MO/. IMMMUNOLL., vol. 31, 1994, pages 1047 - 1058;;TAYLOR, L.D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295;;J6NSSON, U. ET AL., ANN. BIOL. CLIN., vol. 51, 1993, pages 19 - 26;;J6NSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627;;JOHNSSON, B. ET AL., J. MOT. RECOGNIT., vol. 8, 1995, pages 125 - 131;;JOHNNSON, B. ET AL., ANAL. BIOCHENI, vol. 198, 1991, pages 268 - 277;;SAMBROOK, FRITSCH AND MANIATIS: ""Molecular Cloning; A Laboratory Manual, Second Edition"", 1989, COLD SPRING HARBOR;;AUSUBEL, F.M. ET AL.: ""Current Protocols in Molecular Biology"", 1989, GREENE PUBLISHING ASSOCIATES;;TOMLINSON, I.M. ET AL.: ""The Repertoire of Human Germline V Sequences Reveals about Fifty Groups ofV Segments with Different Hypervariable Loops"", MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COX, J.P.L. ET AL.: ""A Directory of Human Germ-line V K Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836, XP003004702, DOI: doi:10.1002/eji.1830240409;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;GOEDDEL: ""Gene Expression Technology: Methods in Enzymo o"", 1990, ACADEMIC PRESS, pages: 185;;BOSS, M.A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R.J. KAUFMAN; P.A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;FUCHS ET AL., BIO/TECHNOLOGY, vol. 2, 1991, pages 1370 - 1372;;HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., JMOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;GARRAD ET AL., BIO/TECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982;;J.R. ROBINSON,: ""Sustained and Controlled Release Drug Delivery Systenis"", 1978, MARCEL DEKKER, INC.;;ARTHRITIS & RHEUMATISM, vol. 37, 1994, pages S295;;J. INVEST. MED., vol. 44, 1996, pages 235A;;ARTHRITIS & RHEUMATISM, vol. 38, 1995, pages SI85;;ARTHRITIS & RHEUMATISM, vol. 36, 1993, pages 1223;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S284;;AMER. J. PHYSIOL. - HEART AND CIRCULATORY PHYSIOLOGY, vol. 268, 1995, pages 37 - 42;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S282;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S81;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S82;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S131;;INFLAMMATION RESEARCH, vol. 45, 1996, pages 103 - 107;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S280;;NEURO REPORT, vol. 7, 1996, pages 1209 - 1213;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S281;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S296;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S308;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S120;;DELUCA ET AL., RHEUNI. DIS. CLIN. NORTH AM., vol. 21, 1995, pages 759 - 777;;RUSSELL, D; THOMPSON, R.C., CURRO OPIN. BIOTECH., vol. 4, 1993, pages 714 - 721;;AREND, W.P.; DAYER, J-M., ARTH. RHEUNI., vol. 38, 1995, pages 151 - 160;;FAVA, R.A. ET AL., CLIN. EXP. IMM UNO, vol. 94, 1993, pages 261 - 266;;RANKIN, E.C. ET AL., BR. J. RHEUMATOL, vol. 34, 1995, pages 334 - 342;;FIETZE, E. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 675 - 680;;EASON, J.D. ET AL., TRANSPLANTATION, vol. 59, 1995, pages 300 - 305;;SUTHANTHIRAN, M.; STROM, T.B., NEWENGL. J. MED., vol. 331, 1994, pages 365 - 375;;TRACY, K.J. ET AL., SCIENCE, vol. 234, 1986, pages 470 - 474;;SUN, X-M. ET AL., J. CLIN. INVEST., vol. 81, 1988, pages 1328 - 1331;;MACDONALD, T.T. ET AL., CLIN. EXP. IMMUNO ., vol. 81, 1990, pages 301 - 305;;VAN DULLEMEN, H.M. ET AL., GASTROENTEROLOGY, vol. 109, 1995, pages 129 - 135;;BERTOLINI, D.R. ET AL., NATURE, vol. 319, 1986, pages 516 - 518;;KONIG, A. ET AL., J. BONE MINER. RES., vol. 3, 1988, pages 621 - 627;;LERNER, U.H.; OHLIN, A., J. BONE MINER. RES., vol. 8, 1993, pages 147 - 155;;SHANKAR, G.; STERN, P.H., BONE, vol. 14, 1993, pages 871 - 876;;MCCLAIN, C.J.; COHEN, D.A., HEPATOLOGY, vol. 9, 1989, pages 349 - 351;;FELVER, M.E. ET AL., ALCOHOL. CLIN.. EXP. RES., vol. 14, 1990, pages 255 - 259;;HANSEN, J. ET AL., HEPATOLOGY, vol. 20, 1994, pages 461 - 474;;SHERON, N. ET AL., J. HEPATOL., vol. 12, 1991, pages 241 - 245;;HUSSAIN, M.J. ET AL., J. CLIN. PATHOL., vol. 47, 1994, pages 1112 - 1115;;VAN DER POLL, T ET AL., N. ENGL. I MED., vol. 322, 1990, pages 1622 - 1627;;VAN DER POLL, T. ET AL., PROG. CLIN. BIOL. RES., vol. 367, 1991, pages 55 - 60;;GIROIR, B.P. ET AL., AM. J PHYSIOL., vol. 267, 1994, pages HI18 - 124;;LIU, X.S. ET AL., BURNS, vol. 20, 1994, pages 40 - 44;;SCALES, W.E. ET AL., AM. J PHYSIOL., vol. 267, 1994, pages G1122 - 1127;;SERRICK, C. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 1158 - 1162;;YAO, Y.M. ET AL., RESUSCITATION, vol. 29, 1995, pages 157 - 168;;MCCAULEY, R.L. ET AL., CLIN. IMMUNOL., vol. 12, 1992, pages 300 - 308;;EMBO J, vol. 10, 1991, pages 4025 - 4031",DISCONTINUED
199,US,A1,US 2013/0115224 A1,190-501-431-308-994,2013-05-09,2013,US 201313736931 A,2013-01-08,US 201313736931 A;;US 57848709 A;;US 36945109 A;;US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/190-501-431-308-994,Patent Application,yes,3,17,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;C07K16/24;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/158.1;;530/389.2;;530/387.3,5,4,013-880-541-901-494;;089-788-839-300-179;;000-335-858-105-765;;058-354-982-149-667,1356177;;10.1016/0140-6736(92)92294-p;;12949252;;10.1093/rheumatology/keg424;;10.1016/s0021-9258(19)39314-7;;2108155;;9631034;;10.1038/nbt0896-975,"Isaacs et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 1992 Sep 26;340(8822):748-52.;;Lockwood et al. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford). 2003 Dec;42(12):1539-44. Epub 2003 Aug 29.;;Smith et al. Transfer and expression of a murine UDP-Gal:beta-D-Gal-alpha 1,3-galactosyltransferase gene in transfected Chinese hamster ovary cells. Competition reactions between the alpha 1,3-galactosyltransferase and the endogenous alpha 2,3-sialyltransferase. J Biol Chem. 1990 Apr 15;265(11):6225-34.;;Jenkins et al. Getting the glycosylation right: implications for the biotechnology industry. Nat Biotechnol. 1996 Aug;14(8):975-81.;;U. S. Application No. 14183845, filed 02/19/2014.",DISCONTINUED
200,AU,B2,AU 2006/241387 B2,031-572-112-605-361,2009-07-23,2009,AU 2006/241387 A,2006-11-24,AU 2004/202769 A;;AU 2006/241387 A,2004-06-23,Human antibodies that bind human TNFalpha,,ABBVIE BIOTECHNOLOGY LTD,MANKOVICH JOHN A;;VAUGHAN TRISTAN J;;SALFELD JOCHEN G;;HOOGENBOOM HENDRICUS R J M;;ALLEN DEBORAH J;;MCGUINESS BRIAN T;;KAYMAKCALAN ZEHR;;SCHOENHAUT DAVID;;ROBERTS ANDREW J;;LABKOVSKY BORIS;;WHITE MICHAEL;;WILTON ALISON J;;SAKORAFAS PAUL,,https://lens.org/031-572-112-605-361,Granted Patent,no,0,0,5,5,0,A61K2039/505;;C07K16/241;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/622;;C07K2317/76;;C07K2317/92;;G01N2333/525;;G01N2800/10;;G01N2800/102,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
201,HK,A1,HK 1125972 A1,029-649-733-518-309,2009-08-21,2009,HK 09104315 A,2009-05-12,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF,,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/029-649-733-518-309,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N/;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K/;;C07K16/24;;C12N1/21;;C12N5/10;;C12P/;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
202,NZ,A,NZ 598487 A,051-345-670-967-178,2014-01-31,2014,NZ 59848797 A,1997-02-10,US 3147696 P;;US 59922696 A;;NZ 58767897 A,1996-02-09,Human antibodies that bind human tnfa,"NZ 598487 Disclosed is a method for inhibiting human TNFα activity in vitro comprising contacting human TNFα with an antibody such that human TNFα activity is inhibited, wherein the antibody is an isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNFα with a Kd of 1 x 10-8 M or less and a Koff rate constant of 1 x 10-3 s-1 or less, both determined by surface plasmon resonance, and neutralises human TNFα cytotoxicity in a standard in vitro L929 assay with an IC50 of 1 x 10-7 M or less.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/051-345-670-967-178,Patent Application,no,0,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;C12N15/13;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
203,NO,L,NO 983627 L,067-404-938-695-002,1998-10-07,1998,NO 983627 A,1998-08-07,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Human-antistoffer som binder human TNF<alfa>,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNES BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBVIE BIOTECHNOLOGY LTD, BM (2013-10-14)",https://lens.org/067-404-938-695-002,Abstract,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
204,AU,B2,AU 2013/203420 B2,068-978-888-247-330,2014-02-20,2014,AU 2013/203420 A,2013-04-10,AU 2012/261708 A;;AU 2013/203420 A,2012-12-07,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., K= 10-8 M or less), a slow off rate for hTNFa dissociation (e.g., Koir ~10-3sec 1 or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/068-978-888-247-330,Granted Patent,no,2,0,3,3,0,,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
205,US,B2,US 7588761 B2,093-365-926-768-773,2009-09-15,2009,US 23325205 A,2005-09-21,US 23325205 A;;US 30235602 A;;US 54001800 A;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/093-365-926-768-773,Granted Patent,yes,79,137,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/142.1;;424/145.1;;424/158.1;;424/484;;424/486;;424/810;;530/388.15;;530/388.23;;530/868,49,40,005-321-867-106-932;;082-560-368-073-508;;092-412-882-661-570;;072-438-011-112-832;;064-048-827-826-930;;101-630-891-707-104;;022-179-293-052-569;;026-408-993-198-966;;024-854-471-494-140;;003-185-616-989-105;;006-342-252-521-899;;072-378-691-723-546;;005-119-615-003-591;;036-413-156-723-523;;033-797-614-829-293;;040-701-579-915-050;;030-874-783-814-532;;017-529-128-038-946;;057-954-116-868-246;;015-761-810-001-488;;020-855-322-534-259;;061-726-307-774-867;;074-932-950-939-666;;053-341-149-236-635;;087-599-254-199-807;;003-841-586-111-459;;098-176-334-504-327;;019-030-524-959-069;;021-641-900-032-887;;092-023-577-402-127;;006-117-436-368-816;;145-140-396-707-208;;042-623-879-457-954;;074-817-300-512-106;;022-133-574-143-973;;033-261-430-402-230;;004-601-819-239-79X;;030-323-674-660-051;;031-729-641-207-089;;010-916-105-450-247,7884952;;10.1001/jama.1995.03520360048038;;10.1001/jama.273.12.934;;7735957;;10.1097/00024382-199404000-00001;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1038/nrd984;;12509759;;10.1097/00003246-199609000-00002;;8797612;;10.1002/eji.1830240409;;8149953;;18240199;;10.1002/art.23362;;10.1146/annurev.immunol.19.1.163;;11244034;;10.1006/jmbi.1994.1351;;8196048;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;7620183;;10.1182/blood.v86.3.890.890;;2531466;;10.1126/science.2531466;;7521646;;10.1038/nbt0994-899;;pmc1766613;;11053087;;10.1136/ard.59.suppl_1.i44;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;8757799;;10.1006/jmbi.1996.0406;;1748994;;10.1016/0022-2836(91)90498-u;;7765558;;10.1038/nbt1194-1134;;10.1016/1043-4666(90)90011-h;;1716486;;10.1016/0959-440x(95)80028-x;;8528760;;10.1097/00003246-199605000-00003;;8706447;;8364031;;10.1021/bi00085a016;;11730333;;10.1006/abio.2001.5380;;8609615;;10.1006/jmbi.1996.0069;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;1404388;;10.1016/0022-2836(92)90223-7;;10.1146/annurev.med.45.1.491;;8198398;;7697917;;pmc1534281;;10.1111/j.1365-2249.1995.tb03598.x;;9624683;;10.1038/nbt0698-535;;10.1038/341544a0;;2677748;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;1560463;;10.1016/0022-2836(92)91010-m;;15848075;;10.1016/j.ymeth.2005.01.006;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;8397764;;10.1016/0167-5699(93)90039-n;;10.1038/nbt0792-779;;1368267,"Abraham, Edward et al, ""Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor alpha in Patients With Sepsis Syndrome,"" JAMA, vol. 273(12):934-941 (1995).;;Barbuto, J.A.M. et al. ""Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes"" Proc. Am. Assoc. Cancer Res. 34:487, Abstract No. 2904 (Mar. 1993).;;Bendtzen, K. et al. ""Auto-antibodies to IL-1alpha and TNFalpha in Normal Individuals and in Infectious and Immunoinflammatory Disorders"" in The Physiological and Pathological Effects of Cytokines (Wiely-Liss, Inc., 1990) 447-52.;;Boekstegers, P. et al, ""Repeated administration of F(ab')2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,"" Shock, vol. 1(4):237-245 (1994) (abstract from Pub Med).;;Boyle, P. et al. ""A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- alpha"" Cell. Immunol. 152:556-68 (1993).;;Boyle, P. et al. ""The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFalpha on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope"" Cell. Immunol. 152:569-81 (1993).;;Brekke, Ole Henrik et al, ""Therapeutic Antibodies for Human Diseases at the Dawn of the Twenty-First Century,"" Nature, vol. 2:52-62 (2003).;;Chow, A.W. et al. ""Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFalpha, IL-1beta, and IL-6 levels in patients with sepsis syndrome"" Clinical Research 42:2 299A (1994).;;Cohen, Jonathan et al, ""INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis,"" Critical Care Medicine, vol. 24(9):1431-1440 (1996).;;Cox, J.P.L. et al. ""A directory of human germ-line V<sub/>ksegments reveals a strong bias in their usage"" Eur. J. Immunol. 24(2):827-36 (1994).;;Department of Surgery, University of Toronto Annual Report, Jul. 1, 1998-Jun. 30, 1999-found online at http://www.surg.med.utoronto.ca/AnnRep/AR98-99/index.html.;;Elliot, M.J. et al. ""Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha"" Arthritis & Rheumatism 36(12):1681-90 (1993).;;Feldmann, Marc et al, ""Anti-TNFalpha Therapy of Rheumatoid ARthritis: What Have We Learned?"" Annu. Rev. Immunol., vol. 19:163-196 (2001).;;Figini, Mariangela et al, ""In Vitro assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation,"" J. Mol. Biol., vol. 239:68-78 (1994).;;Fomsguaard, A. et al. ""Auto-antibodies to Tumor Necrosis Factor alpha in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections"" Scand. J. Immunol. 30:219-23 (1989).;;Griffiths, A.D. et al, ""Human anti-self antibodies with high specificity from phage display libraries"" The EMBO J. 12(2):725-34 (1993).;;Hawkins, Robert E. et al, ""Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,"" J. Mol. Biol., vol. 226:889-896 (1992).;;Holler, E. et al, ""Modulation of Acute Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation by Tumor Necrosis Factor alpha (TNFalpha) Release in the Course of Pretransplant Conditioning: Role of Conditioning Regimens and Prophylactic Application of a Monoclonal Antibody Neutralizing Human TNFalpha (MAK 195F),"" Blood, vol. 86(3):890-899 (1995).;;Hoogenboom, Hennie R. et al, ""converting rodent into human antibodies by guided selection,"" Antibody Engineering, Oxford University Press, pp. 169-185 (1996).;;Huse, W.D. et al. ""Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda"" Science 246:1275-81 (1989).;;Jespers, Laurent S. et al, ""Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen,"" Bio/Technology, vol. 12:899-903 (1994).;;Kempeni, Joachim, ""Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody,"" Ann. Rheum. Dis., vol. 59(Suppl. I):144-145 (2000).;;Lerner, R.A. et al. ""Antibodies without immunization"" Science 258:1313-14 (1992).;;Leusch, H-G. et al. Failure to demonstrate TNFalpha-specific autoantibodies in human sera by ELISA and Western blot J. Immunol. Methods 139:145-47 (1991).;;Lewis, Craig M. et al, ""Use of alanine scanning mutagenesis to improve the affinity of an anti gp120 (HIV) antibody,"" J. Cell. Biochem., vol. 18D, p. 215 (1994).;;Low, Nigel, thesis extract, Cambridge University (1996).;;Low, Nigel et al, ""Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,"" J. Mol. Biol., vol. 260:359-368 (1996).;;Marks, J.D. et al. ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"" J. Mol. Biol. 222:581-97 (1991).;;Medynski, Dan, ""Phage Display: All Dressed Up and Ready to Role,"" Bio/Technology, vol. 12:1134-1136 (1994).;;Möller et al. ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and vivo application"" Cytokine 2(3):162-69 (1990).;;Nilsson, Björn, ""Antibody engineering,"" Current Opinion in Structural Biology, vol. 5:450-456 (1995).;;Reinhart, K. et al, ""Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study,"" Crit. Care Med., vol. 24(5):733-742 (1996) (abstract from Pub Med).;;Reichmann, L. et al, ""Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement,"" Biochemistry, vol. 32(34):8848-8855 (1993) (abstract from Pub Med).;;Santora, L.C. et al, ""Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIAcore,"" Analytical Biochemistry, vol. 299:199-129 (2001).;;Thompson, J. et al, ""Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity,"" J. Mol. Biol., vol. 256(1):77-88 (1996) (abstract from Pub Med).;;Tomlinson, I.M. et al. ""The structural repertoire of the human V<sub/>k domain"" The EMBO J. 14(18):4628-38 (1995).;;Tomlinson, I.M. et al. ""The repertoire of human germline V<sub/>H sequences reveals about fifty groups of V<sub/>H segments with different hypervariable loops"" J. Mol. Biol. 227:776-98 (1992).;;Tracey, K.J. et al. ""Tumor necrosis factor: A pleiotropic cytokine and therapeutic target"" Annu. Rev. Med. 45:491-503 (1994).;;Van Der Poll, T. et al, ""Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees,"" Clin. Exp. Immunol., vol. 100:21-25 (1995).;;Vaughan, Tristan J. et al, ""Human antibodies by design,"" Nature Biotechnology, vol. 16:535-539 (1998).;;Ward, E. Sally et al, ""Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli,"" Nature, vol. 341:544-546 (1989).;;Winter, Greg et al, ""Making antibodies by phage display technology,"" Annu. Rev. Immunol., vol. 12:433-455 (1994).;;Foote et al, ""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,"" J. Mol. Biol., vol. 224:487-490 (1992).;;Osborn, Jane et al., ""From rodent reagents to human therapeutics using antibody guided selection,"" Methods, vol. 36:61-68 (2005).;;Queen, Cary et al., ""A humanized antibody that binds to the interleukin 2 receptor,"" Proc. Natl. Acad. Sci. USA, vol. 86:10029-10033 (1989).;;Winter et al. (1993) ""Humanized antibodies"" Immunol Today 14(6):243-246.;;Marks et al. (1992) ""By-Passing Immunization: Building High Affinity Human Antibodies By Chain Shuffling"" Bio/Technology 10:779.;;Office Action dated Jun. 18, 2007 from U.S. Appl. No. 10/163657.;;Office Action dated Jul. 3, 2008 from U.S. Appl. No. 10/622932.",EXPIRED
206,AT,T1,AT E239041 T1,116-347-815-590-312,2003-05-15,2003,AT 97906572 T,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFALPHA BINDEN,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/116-347-815-590-312,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
207,US,B2,US 8174970 B2,113-063-221-611-442,2012-05-08,2012,US 83694104 A,2004-04-30,US 83694104 A;;US 70474003 A;;US 71605103 A;;US 71696703 A;;US 71927003 A;;US 72219403 A;;US 71696803 A;;US 47065003 P,2003-05-15,"Methods of implementing dynamic QoS and/or bandwidth provisioning and related data networks, data service providers, routing gateways, and computer program products","A method of operating a data network may include establishing a data path through the data network between a routing gateway for a subscriber of the data network and a service provider providing a data service. Moreover, the data service may be provided for use at the routing gateway over the data path during a data session. A request may be received from the service provider wherein the request defines a data flow characteristic for the data path between the routing gateway and the service provider providing the data service during the data session. The data flow characteristic may then be transmitted to a node along the data path between the routing gateway and the service provider for enforcement of the data flow characteristic for the data path at the node. More particularly, the data session may be a point-to-point protocol data session. Related methods, data networks, data service providers, routing gateways, and computer program products are also discussed.",ADAMCZYK MARIA;;ANSCHUTZ THOMAS ARNOLD;;BLACKBURN ALAN RYAN;;CASSANOVA JEFFREY PATRICK;;HILL SAMMIE WALTER;;HOLT SCOTT CRANDALL;;HUSLAK NICHOLAS STEVEN;;MCQUAIDE JR ARNOLD CHESTER;;SHRUM JR EDGAR VAUGHAN;;STILLMAN SCOTT TRAYNHAM;;WRIGHT STEVEN ALLEN;;ZHANG LI;;AT & T IP I LP,ADAMCZYK MARIA;;ANSCHUTZ THOMAS ARNOLD;;BLACKBURN ALAN RYAN;;CASSANOVA JEFFREY PATRICK;;HILL SAMMIE WALTER;;HOLT SCOTT CRANDALL;;HUSLAK NICHOLAS STEVEN;;MCQUAIDE JR ARNOLD CHESTER;;SHRUM JR EDGAR VAUGHAN;;STILLMAN SCOTT TRAYNHAM;;WRIGHT STEVEN ALLEN;;ZHANG LI,AT&T INTELLECTUAL PROPERTY I L.P (2011-04-11);;BELLSOUTH INTELLECTUAL PROPERTY CORPORTION (2004-04-19),https://lens.org/113-063-221-611-442,Granted Patent,yes,114,129,10,51,0,H04L63/029;;H04L63/083;;H04L12/2859;;H04L47/2458;;H04L47/2408;;H04L47/2416;;H04L47/2441;;H04L63/102;;H04L63/029;;H04L63/083;;H04L12/2859;;H04L47/2458;;H04L47/2408;;H04L47/2416;;H04L47/2441;;H04L63/102;;H04L47/24;;H04W72/0446,H04L12/66;;H04L47/2416;;H04L47/31,370/230;;370/235,16,3,162-137-837-717-807;;080-861-178-216-64X;;079-187-850-007-743,10.1145/782896.782923;;10.1145/357489.357515;;10.1109/90.986522,"Blake et al., ""An Architecture for Differentiated Services,"" The Internet Society (Dec. 1998).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Proposed Draft: PD-00X, Revision 1 (Aug. 2002).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Revision 4 (Dec. 2002).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Revision 5 (Feb. 2003).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Revision 6 (Mar. 2003).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Straw Ballot Revision (7) (Mar. 2003).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WR-081, Straw Ballot Revision (8) (Mar. 2003).;;DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Working Text: WT-081, Letter Ballot Revision (9) (Jun. 2003).;;Anschutz et al., DSL Forum, ""DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services,"" Technical Report: TR-059 (Sep. 2003).;;U.S. Appl. No. 60/470,650, filed May 15, 2003, Adamczyk et al.;;About the DSL Forum ""Who We Are: Staff"" Retrieved from the Internet Aug. 3, 2007 at URL http://www.dslforum.org/about/staff.shtml.;;Anschutz et al. ""Architecture & Transport Working Group"" DSL Forum: Proposed Draft 37 pages, Aug. 2002.;;Battarbee, Katja ""Defining Co-Experience"" Proceedings of the 2003 International Conference on Designing Pleasurable Products and Interfaces DPPI '03, Jun. 2003, pp. 109-113.;;""BellSouth Teams with MyWay.com to Launch Next Generation Internet Portal"" Business Wire, Dec 8, 1999, [Retrieved Aug. 7, 2007 from the Internet at URL]: http://www.findarticles.com/p/articles/ml-mOEIN/is-1999-Dec-8/ai-58086123.;;Chaudhury, Abhijit, et al., ""Web Channels in E-commerce""' Communications of the ACM, vol. 44, Issue 1, Jan. 2001, pp. 99-104.;;Cobb, Jorge ""Preserving Quality of Service Guarantees in Spite of Flow Aggregation"" IEEE/ACM Transactions on Networking vol. 10, No. 1 Feb. 2002.",ACTIVE
208,US,A1,US 2012/0219564 A1,112-244-078-870-658,2012-08-30,2012,US 201213466892 A,2012-05-08,US 201213466892 A;;US 40146909 A;;US 23325205 A;;US 30235602 A;;US 54001800 A;;US 59922696 A,1996-02-09,Human Antibodies That Bind Human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBOTT BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/112-244-078-870-658,Patent Application,yes,0,10,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/158.1;;530/389.2,0,0,,,,EXPIRED
209,HU,B1,HU 230048 B1,144-098-689-907-913,2015-06-29,2015,HU P1300152 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Use of human tnf-alpha binding antibodies,,ABBVIE BIOTECHNOLOGY LTD,ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SALFELD JOCHEN G;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBVIE BIOTECHNOLOGY LTD, BM (2014-09-29)",https://lens.org/144-098-689-907-913,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
210,AU,B2,AU 2009/202707 B2,167-969-502-590-860,2013-01-10,2013,AU 2009/202707 A,2009-07-03,AU 2006/241387 A;;AU 2009/202707 A,2006-11-24,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kd= 10-8 M or less), a slow off rate for hTNFa dissociation (e.g., Kof~1 0 3 sec-1 or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/167-969-502-590-860,Granted Patent,no,1,0,5,5,0,A61K2039/505;;C07K16/241;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/622;;C07K2317/76;;C07K2317/92;;G01N2333/525;;G01N2800/10;;G01N2800/102,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
211,AU,B2,AU 722077 B2,170-369-654-258-567,2000-07-20,2000,AU 1997/021229 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W;;AU 1997/021229 A,1996-02-09,Human antibodies that bind human TNFalpha,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBOTT LABORATORIES (BERMUDA) LTD (2003-06-19);;ABBOTT BIOTECHNOLOGY LTD. (2004-06-17),https://lens.org/170-369-654-258-567,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
212,EP,A1,EP 0929578 A1,197-825-460-131-10X,1999-07-21,1999,EP 97906572 A,1997-02-10,US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBOTT LABORATORIES(BERMUDA)LTD., HAMILTON, BM (2004-01-29);;ABBVIE BIOTECHNOLOGY LTD., DE (2014-05-21);;*ABBOTT LABORATORIES (BERMUDA) LTD (2003-05-02);;ABBVIE BIOTECHNOLOGY LTD. (2014-06-05);;ABBOTT BIOTECHNOLOGY LTD., HAMILTON, BM (2004-07-08);;ABBOTT LABORATORIES (BERMUDA) LTD. (2004-02-02);;ABBOTT BIOTECHNOLOGY LTD. (2008-06-25);;*ABBOTT LABORATORIES (BERMUDA) LTDCLARENDON HOUSE, (2003-05-02);;ABBVIE BIOTECHNOLOGY LTD, BM (2014-10-15)",https://lens.org/197-825-460-131-10X,Patent Application,yes,0,6,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
213,HU,A2,HU P1500179 A2,009-224-269-108-488,1999-09-28,1999,HU P1500179 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,The use of human tnf-alpha binding antibodies,,ABBVIE BIOTECHNOLOGY LTD,ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SALFELD JOCHEN G;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/009-224-269-108-488,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
214,CN,B,CN 101302515 B,049-646-192-405-310,2013-11-06,2013,CN 200810108848 A,1997-02-10,US 3147696 P;;US 59922696 A,1996-02-09,Human antibodies that bind human TNF(alpha),,ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;MCGUINESS BRIAN T;;HOOGENBOOM HENDRICUS R J M;;MANKOVICH JOHN A;;ROBERTS ANDREW J;;SCHOENHAUT DAVID;;WHITE MICHAEL;;VAUGHAN TRISTAN J;;SAKORAFAS PAUL;;WILTON ALISON J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;ALLEN DEBORAH J,,https://lens.org/049-646-192-405-310,Granted Patent,no,0,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C12N15/09;;C12N15/13;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/28;;C12N15/63;;C12N15/64;;C12P21/00;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
215,RO,B1,RO 123028 B1,078-309-973-486-592,2010-07-30,2010,RO 200500050 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF ALPHA,"The invention relates to a recombinant human antibody that binds to the human tumour necrosis factor (hTNF alpha) which has affinity to hTNF alpha, Kd=10-8M or less and an off-rate constant koff of 1x10-3s -1 or less and neutralizes the activity in vitro and in vivo, and to a nucleic acid encoding the same, the host cell comprising a recombinant expression vector, and to a pharmaceutical composition comprising said antibody, administered for treating disorders in which the TNF alpha activity is detrimental.",ABBOTT LAB BERMUDA LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/078-309-973-486-592,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K14/525;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
216,CA,A1,CA 2243459 A1,073-790-971-320-216,1997-08-14,1997,CA 2243459 A,1997-02-10,US 3147696 P;;US 59922696 A;;US 9702219 W,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF.ALPHA.,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha.(e.g., Kd = 10-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., Koff = 10-3sec-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",BASF AG,WILTON ALISON J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;SCHOENHAUT DAVID;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;WHITE MICHAEL;;SAKORAFAS PAUL;;SALFELD JOCHEN G;;VAUGHAN TRISTAN J,,https://lens.org/073-790-971-320-216,Patent Application,no,0,8,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
217,EP,B1,EP 2397494 B1,082-746-827-062-249,2016-08-10,2016,EP 10184622 A,1997-02-10,EP 02022788 A;;EP 97906572 A;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNFalpha,,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBVIE BIOTECHNOLOGY LTD (2014-01-01),https://lens.org/082-746-827-062-249,Granted Patent,yes,5,2,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,3,0,,,"GRIFFITHS A D ET AL: ""HUMAN ANTI-SELF ANTIBODIES WITH HIGH SPECIFICITY FROM PHAGE DISPLAY LIBRARIES"", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 12, no. 2, 1 January 1993 (1993-01-01), pages 725-734, XP000645476, ISSN: 0261-4189;;CHOW A W ET AL: ""EFFECT OF MONOCLONAL ANTIBODY TO HUMAN TUMOR NECROSIS FACTOR (TNF MAB) ON TNALPHA, IL-1BETA AND IL-6 LEVELS IN PATIENTS WITH SEPSIS SYNDROME"", CLINICAL RESEARCH, THOROFARE, NJ, US, vol. 42, no. 2, 1 April 1994 (1994-04-01), page 299A, XP002032300, ISSN: 0009-9279;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899-903, XP000572619, ISSN: 0733-222X, DOI: 10.1038/NBT0994-899",EXPIRED
218,NO,D0,NO 983627 D0,124-488-639-845-521,1998-08-07,1998,NO 983627 A,1998-08-07,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Human antistoffer som binder human TNF<alfa>,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNES BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBVIE BIOTECHNOLOGY LTD, BM (2013-10-14)",https://lens.org/124-488-639-845-521,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
219,EP,A1,EP 2397494 A1,133-507-899-276-086,2011-12-21,2011,EP 10184622 A,1997-02-10,EP 02022788 A;;EP 97906572 A;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d  = 10 -8  M or less), a slow off rate for hTNFα dissociation ( e.g.,  K off  = 10 -3  sec -1  or less) and neutralize hTNFα activity  in vitro  and  in vivo.  An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBVIE BIOTECHNOLOGY LTD (2014-01-01),https://lens.org/133-507-899-276-086,Patent Application,yes,42,1,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,107,80,072-378-691-723-546;;040-701-579-915-050;;074-871-884-454-68X;;016-907-020-918-983;;011-796-204-010-792;;117-499-681-530-662;;006-117-436-368-816;;046-939-287-004-026;;085-191-504-989-317;;041-591-849-635-094;;054-329-283-530-645;;002-495-006-719-164;;021-113-833-013-619;;015-584-716-307-216;;092-412-882-661-570;;072-438-011-112-832;;006-342-252-521-899;;057-954-116-868-246;;072-378-691-723-546;;003-907-950-634-854;;041-956-664-134-903;;035-071-534-473-573;;071-901-988-318-434;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;066-749-017-721-197;;001-467-559-709-949;;143-467-932-790-298;;123-171-555-829-362;;071-707-020-428-907;;168-113-989-624-417;;044-369-216-298-341;;092-023-577-402-127;;022-179-293-052-569;;030-630-100-818-462;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;100-049-580-404-573;;033-797-614-829-293;;072-378-691-723-546;;005-119-615-003-591;;034-331-211-704-877;;025-395-146-381-464;;011-962-497-035-168;;065-145-385-150-339;;033-459-816-867-43X;;098-513-251-868-998;;063-873-022-003-842;;044-317-656-227-593;;011-114-894-374-225;;037-795-266-129-616;;048-153-224-318-923;;008-835-817-825-32X;;075-878-183-554-694;;004-001-063-582-854;;079-192-394-643-91X;;000-065-369-829-300;;128-904-140-606-949;;077-369-546-251-682;;032-821-336-726-761;;050-094-719-890-440;;070-452-766-365-174;;110-232-737-639-142;;028-469-508-809-412;;044-217-982-536-908;;012-422-300-553-121;;033-522-835-476-708;;097-358-265-091-151;;041-043-853-736-19X;;085-885-495-910-537;;167-234-008-883-687;;061-475-814-399-439;;031-974-874-348-471;;054-469-226-992-186;;007-667-472-783-358;;023-473-383-533-503;;063-233-860-095-920;;052-159-696-111-105,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7521646;;10.1038/nbt0994-899;;2413547;;10.1126/science.2413547;;10.1146/annurev.bi.57.070188.002445;;3052281;;10.1146/annurev.biochem.57.1.505;;10.1146/annurev.immunol.7.1.625;;10.1146/annurev.iy.07.040189.003205;;2540776;;1590993;;10.1146/annurev.iy.10.040192.002211;;10.1146/annurev.immunol.10.1.411;;0001590993;;10.1146/annurev.med.45.1.491;;8198398;;3889916;;pmc397878;;10.1073/pnas.82.11.3814;;3729942;;10.1016/0006-291x(86)91157-5;;3805735;;10.1016/0022-1759(87)90367-x;;10.1089/hyb.1987.6.359;;2442093;;10.1016/0161-5890(93)90106-l;;8232330;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1016/s0140-6736(94)90628-9;;7934491;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1016/0022-1759(91)90361-i;;2040812;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7703831;;10.1038/312724a0;;6392892;;3552045;;10.1021/bi00379a018;;2922046;;2922050;;10.1038/338225a0;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;8597629;;10.3233/hab-1995-6303;;10.1016/0161-5890(94)90100-7;;7935496;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;1804254;;7541226;;10.1002/jmr.300080122;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;10.1038/348552a0;;2247164;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;1385989;;10.3233/hab-1992-3204;;2531466;;10.1126/science.2531466;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;pmc52428;;10.1073/pnas.88.18.7978;;1896445;;8216416;;10.1002/art.1780360907;;8907592;;10.1007/bf02265123;;10.1097/00001756-199604260-00023;;8817534;;8619098;;10.1016/s0889-857x(21)00466-x;;10.1016/0958-1669(93)90055-2;;7764470;;10.1002/art.1780380202;;7848304;;pmc1534244;;8222316;;10.1111/j.1365-2249.1993.tb03441.x;;10.1093/rheumatology/34.4.334;;7788147;;10.1097/00007890-199409000-00007;;7940686;;10.1097/00007890-199501000-00025;;10.1097/00007890-199501270-00025;;7839455;;7832839;;10.1056/nejm199408113310606;;10.1126/science.3764421;;3764421;;10.1172/jci113459;;pmc442560;;3366898;;pmc1535044;;2117510;;10.1111/j.1365-2249.1990.tb03334.x;;7797011;;10.1016/0016-5085(95)90277-5;;10.1038/319516a0;;3511389;;10.1002/jbmr.5650030607;;3266953;;8442433;;10.1002/jbmr.5650080205;;7512360;;10.1016/8756-3282(93)90317-4;;2920991;;10.1002/hep.1840090302;;10.1111/j.1530-0277.1990.tb00482.x;;2190492;;10.1002/hep.1840200228;;8045508;;10.1016/0270-9139(94)90200-3;;10.1016/0168-8278(91)90945-8;;2051003;;pmc502205;;10.1136/jcp.47.12.1112;;7876386;;2188129;;10.1056/nejm199006073222302;;1924431;;10.1152/ajpheart.1994.267.1.h118;;8048575;;8148074;;10.1016/0305-4179(94)90104-x;;10.1152/ajpgi.1994.267.6.g1122;;7810659;;7992355;;10.1097/00007890-199412150-00003;;10.1016/0300-9572(95)00831-d;;7659869;;10.1007/bf00918154;;1512303;;pmc453150;;1721867;;10.1002/j.1460-2075.1991.tb04978.x,"GRIFFITHS A D ET AL: ""HUMAN ANTI-SELF ANTIBODIES WITH HIGH SPECIFICITY FROM PHAGE DISPLAY LIBRARIES"", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 12, no. 2, 1 January 1993 (1993-01-01), pages 725 - 734, XP000645476, ISSN: 0261-4189;;CHOW A W ET AL: ""EFFECT OF MONOCLONAL ANTIBODY TO HUMAN TUMOR NECROSIS FACTOR (TNF MAB) ON TNALPHA, IL-1BETA AND IL-6 LEVELS IN PATIENTS WITH SEPSIS SYNDROME"", CLINICAL RESEARCH, THOROFARE, NJ, US, vol. 42, no. 2, 1 April 1994 (1994-04-01), pages 299A, XP002032300, ISSN: 0009-9279;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899 - 903, XP000572619, ISSN: 0733-222X, DOI: 10.1038/NBT0994-899;;OLD, L., SCIENCE, vol. 230, 1985, pages 630 - 632;;BEUTLER, B.; CERAMI, A., ANNU. REV. BIOCHEM., vol. 57, 1988, pages 505 - 518;;BEUTLER, B.; CERAMI, A., ANNU. REV. IMMUNOL., vol. 7, 1989, pages 625 - 655;;MOELLER, A. ET AL., CYTOKINE, vol. 2, 1990, pages 162 - 169;;VASILLI, P., ANNU. REV. IMMUNOL., vol. 10, 1992, pages 411 - 452;;TRACEY, K.J.; CERAMI, A., ANNU. REV. MED., vol. 45, 1994, pages 491 - 503;;HAHN T ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3814 - 3818;;LIANG, C-M. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 137, 1986, pages 847 - 854;;HIRAI, M. ET AL., J. IMMUNOL. METHODS, vol. 96, 1987, pages 57 - 62;;FENDLY, B.M. ET AL., HYBRIDOMA, vol. 6, 1987, pages 359 - 370;;KNIGHT, D.M ET AL., MOL. IMMUNOL., vol. 30, 1993, pages 1443 - 1453;;ELLIOTT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1125 - 1127;;ELLIOT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1105 - 1110;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 556 - 568;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 569 - 581;;FOMSGAARD, A. ET AL., SCAND. J. IMMUNOL., vol. 30, 1989, pages 219 - 223;;BENDTZEN, K. ET AL., PROG. LEUKOCYTE BIOL., vol. 10B, 1990, pages 447 - 452;;LEUSCH, H-G. ET AL., J. IMMUNOL. METHODS, vol. 139, 1991, pages 145 - 147;;GRIFFITHS, A.D. ET AL., EMBO J., vol. 12, 1993, pages 725 - 734;;LIDBURY, A. ET AL., BIOTECHNOL. THER., vol. 5, 1994, pages 27 - 45;;PENNICA, D. ET AL., NATURE, vol. 312, 1984, pages 724 - 729;;DAVIS, J.M. ET AL., BIOCHEMISTRY, vol. 26, 1987, pages 1322 - 1326;;JONES, E.Y. ET AL., NATURE, vol. 338, 1989, pages 225 - 228;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;KIPRIYANOV, S.M. ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101;;KIPRIYANOV, S.M. ET AL., MOL. IMMUNOL., vol. 31, 1994, pages 1047 - 1058;;TAYLOR, L.D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295;;J6NSSON, U. ET AL., ANN. BIOL. CLIN., vol. 5, no. 1, 1993, pages 19 - 26;;JÖNSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627;;JOHNSSON, B. ET AL., J. MOL. RECOGNIT., vol. 8, 1995, pages 125 - 131;;JOHNNSON, B. ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages 268 - 277;;""Molecular Cloning; A Laboratory Manual"", 1989, COLD SPRING HARBOR, N.Y.;;""Current Protocols in Molecular Biology"", 1989, GREENE PUBLISHING ASSOCIATES;;KABAT, E.A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;TOMLINSON, I.M. ET AL.: ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COX, J.P.L. ET AL.: ""A Directory of Human Germ-line V K Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;GOEDDEL: ""Gene Expression Technology: Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;BOSS, M.A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R.J. KAUFMAN; P.A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;""the Pharmacia Recombinant Phage Antibody System"";;FUCHS ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1370 - 1372;;HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., JMOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;GARRAD ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;ARTHRITIS & RHEUMATISM, vol. 37, 1994, pages S295;;J. INVEST. MED., vol. 44, 1996, pages 235A;;ARTHRITIS & RHEUMATISM, vol. 38, 1995, pages 5185;;ARTHRITIS & RHEUMATISM, vol. 36, 1993, pages 1223;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S284;;AMER. J. PHYSIOL. - HEART AND CIRCULATORY PHYSIOLOGY, vol. 268, 1995, pages 37 - 42;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S282;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S81;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S82;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S131;;INFLAMMATION RESEARCH, vol. 45, 1996, pages 103 - 107;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 5280;;NEURO REPORT, vol. 7, 1996, pages 1209 - 1213;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S281;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S296;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages S308;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 5120;;DELUCA ET AL., RHEUM. DIS. CLIN. NORTH AM., vol. 21, 1995, pages 759 - 777;;RUSSELL, D; THOMPSON, R.C., CURR. OPIN. BIOTECH., vol. 4, 1993, pages 714 - 721;;AREND, W.P.; DAYER, J-M., ARTH. RHEUM., vol. 38, 1995, pages 151 - 160;;FAVA, R.A. ET AL., CLIN. EXP. IMMUNOL., vol. 94, 1993, pages 261 - 266;;RANKIN, E.C. ET AL., BR. J. RHEUMATOL., vol. 34, 1995, pages 334 - 342;;FIETZE, E. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 675 - 680;;EASON, J.D. ET AL., TRANSPLANTATION, vol. 59, 1995, pages 300 - 305;;SUTHANTHIRAN, M.; STROM, T.B., NEW ENGL. J. MED., vol. 331, 1994, pages 365 - 375;;TRACY, K.J. ET AL., SCIENCE, vol. 234, 1986, pages 470 - 474;;SUN, X-M. ET AL., J. CLIN. INVEST., vol. 81, 1988, pages 1328 - 133 1;;MACDONALD, T.T. ET AL., CLIN. EXP. IMMUNOL., vol. 81, 1990, pages 301 - 305;;VAN DULLEMEN, H.M. ET AL., GASTROENTEROLOGY, vol. 109, 1995, pages 129 - 135;;BERTOLINI, D.R. ET AL., NATURE, vol. 319, 1986, pages 516 - 518;;KONIG, A. ET AL., J. BONE MINER. RES., vol. 3, 1988, pages 621 - 627;;LERNER, U.H.; OHLIN, A., J. BONE MINER. RES., vol. 8, 1993, pages 147 - 155;;SHANKAR, G.; STERN, P.H., BONE, vol. 14, 1993, pages 871 - 876;;MCCLAIN, C.J.; COHEN, D.A., HEPATOLOGY, vol. 2, 1989, pages 349 - 351;;FELVER, M.E. ET AL., ALCOHOL. CLIN. EXP. RES., vol. 14, 1990, pages 255 - 259;;HANSEN, J. ET AL., HEPATOLOGY, vol. 20, 1994, pages 461 - 474;;SHERON, N. ET AL., J. HEPATOL., vol. 12, 1991, pages 241 - 245;;HUSSAIN, M.J. ET AL., J. CLIN. PATHOL., vol. 47, 1994, pages 1112 - 1115;;VAN DER POLL, T. ET AL., N. ENGL. J. MED., vol. 322, 1990, pages 1622 - 1627;;VAN DER POLL, T. ET AL., PROG. CLIN. BIOL. RES., vol. 367, 1991, pages 55 - 60;;GIROIR, B.P. ET AL., AM. J. PHYSIOL., vol. 267, 1994, pages H118 - 124;;LIU, X.S. ET AL., BURNS, vol. 20, 1994, pages 40 - 44;;SCALES, W.E. ET AL., AM. J. PHYSIOL., vol. 267, 1994, pages G1122 - 1127;;SERRICK, C. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 1158 - 1162;;YAO, Y.M. ET AL., RESUSCITATION, vol. 29, 1995, pages 157 - 168;;MCCAULEY, R.L. ET AL., J. CLIN. IMMUNOL., vol. 12, 1992, pages 300 - 308;;EMBO J, vol. 10, 1991, pages 4025 - 4031",EXPIRED
220,US,A1,US 2012/0269195 A1,159-834-675-351-691,2012-10-25,2012,US 201213461278 A,2012-05-01,US 201213461278 A;;US 83694104 A;;US 72219403 A;;US 71927003 A;;US 71696703 A;;US 71696803 A;;US 71605103 A;;US 70474003 A;;US 47065003 P,2003-05-15,METHODS OF IMPLEMENTING DYNAMIC QUALITY OF SERVICE OR BANDWIDTH PROVISIONING,"A method of operating a data network may include establishing a data path through the data network between a routing gateway and service provider equipment providing a data service. Moreover, the data service may be provided for use at the routing gateway over the data path during a data session. A request may be received from the service provider equipment where the request defines a data flow characteristic for the data path between the routing gateway and the service provider equipment providing the data service. The data flow characteristic may then be transmitted to a network element along the data path between the routing gateway and the service provider equipment. A request from service provider equipment can include an allowed bandwidth or prioritization. Related methods, data networks, data service providers, routing gateways, and computer program products are also discussed.",ADAMCZYK MARIA;;ANSCHUTZ THOMAS ARNOLD;;BLACKBURN ALAN RYAN;;CASSANOVA JEFFREY PATRICK;;HILL SAMMIE WALTER;;HOLT SCOTT CRANDALL;;HUSLAK NICHOLAS STEVEN;;MCQUAIDE JR ARNOLD CHESTER;;SHRUM JR EDGAR VAUGHAN;;STILLMAN SCOTT TRAYNHAM;;WRIGHT STEVEN ALLEN;;ZHANG LI;;AT & T IP I LP,ADAMCZYK MARIA;;ANSCHUTZ THOMAS ARNOLD;;BLACKBURN ALAN RYAN;;CASSANOVA JEFFREY PATRICK;;HILL SAMMIE WALTER;;HOLT SCOTT CRANDALL;;HUSLAK NICHOLAS STEVEN;;MCQUAIDE JR ARNOLD CHESTER;;SHRUM JR EDGAR VAUGHAN;;STILLMAN SCOTT TRAYNHAM;;WRIGHT STEVEN ALLEN;;ZHANG LI,AT&T INTELLECTUAL PROPERTY I LP (2004-04-19),https://lens.org/159-834-675-351-691,Patent Application,yes,1,7,10,51,0,H04L63/029;;H04L63/083;;H04L12/2859;;H04L47/2458;;H04L47/2408;;H04L47/2416;;H04L47/2441;;H04L63/102;;H04L63/029;;H04L63/083;;H04L12/2859;;H04L47/2458;;H04L47/2408;;H04L47/2416;;H04L47/2441;;H04L63/102;;H04L47/24;;H04W72/0446,H04L12/56;;H04L12/66;;H04L47/2416;;H04L47/31,370/389,0,0,,,,EXPIRED
221,NZ,A,NZ 546790 A,152-445-325-920-862,2008-05-30,2008,NZ 54679097 A,1997-02-10,US 59922696 A;;US 3147696 P;;NZ 53621697 A,1996-02-09,Human antibodies that bind human TNF(alpha),"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumour necrosis factor a (hTNFa) are provided. These antibodies have high affinity for hTNFa ( Kd of 10-8 M or less), a slow off rate for hTNFa dissociation (Koff of 10-3 sec-1 or less) and neutralize hTNFa cytotoxicity in a standard in vitro L929 assay with an IC50 of 10-7M or less. The antibodies, or antibody portions may be useful for inhibiting hTNFa activity in a human subject suffering from a disorder in which hTNFa activity is detrimental. Such disorders include sepsis, autoimmune diseases, infectious diseases, transplant rejection, malignancy, pulmonary disorder, intestinal disorder, cardiac disorder and inflammatory bone disorders.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/152-445-325-920-862,Patent Application,no,0,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;C12N15/09;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
222,AU,B2,AU 2004/202769 B2,176-334-239-196-74X,2006-08-31,2006,AU 2004/202769 A,2004-06-23,AU 2004/202769 A;;AU 2000/066649 A,2000-10-20,Human antibodies that bind human TNFalpha,,ABBVIE BIOTECHNOLOGY LTD,ROBERTS ANDREW J;;ALLEN DEBORAH J;;SAKORAFAS PAUL;;VAUGHAN TRISTAN J;;KAYMAKCALAN ZEHR;;WHITE MICHAEL;;LABKOVSKY BORIS;;SCHOENHAUT DAVID;;SALFELD JOCHEN G;;MCGUINESS BRIAN T;;MANKOVICH JOHN A;;HOOGENBOOM HENDRICUS R J M;;WILTON ALISON J,ABBOTT BIOTECHNOLOGY LTD (2005-12-01),https://lens.org/176-334-239-196-74X,Granted Patent,no,0,0,2,2,0,Y02A50/30,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,EXPIRED
223,RO,B1,RO 119831 B1,023-559-638-650-849,2005-04-29,2005,RO 9801269 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,"HUMAN ANTIBODY WHICH BINDS TO TNF ALPHA, WITH ANTI-INFLAMATORY EFFECT","The invention relates to an isolated human antibody or portion for binding the same to the antigen thereof, to a sequence of nucleic acid which encodes for this, to a recombinant expression vector, comprising this antibody, to a pharmaceutical composition, as well as to the use thereof in treating some disorders where the TNF alpha activity is noxious. According to the invention, the antibody comprises: a) a CDR3 range of the light chain, which comprises the aminoacid sequence of SEQ ID NO:3, or a modified sequence thereof, by a single aminoacid substitution of alanin, at the positions 1, 4, 5, 7 or 8, or by 1-5 conservative aminoacid substitutions, from the positions 1, 3, 4, 6, 7, 8 and/or 9; b) a CDR 3 range of the heavy chain, which comprises the SEQ ID NO:4 aminoacid sequence, or a modified sequence thereof, by a single aminoacid substitution of alanin, at the positions 2, 3, 4, 5, 6, 8, 9, 10 or 11, or by 1-5 conservative aminoacid substitutions, at the positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12; c) dissociation of human TNF alpha, with Kd of 1x10-8M or less and the rate constant Koff of 1x10-3S-1 or less, said constants being determined by the plasmon surface resonance and the human TNF alpha cytotoxicity neutralization in a L929 standard test, in vitro, with IC5 of 1x10-7M or less. The invention has aplicability in the medical field.",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/023-559-638-650-849,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;C12N15/09;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
224,US,A1,US 2012/0258114 A1,028-634-579-266-757,2012-10-11,2012,US 201213524525 A,2012-06-15,US 201213524525 A;;US 36945109 A;;US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMACALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMACALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/028-634-579-266-757,Patent Application,yes,6,18,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/63;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/145.1;;424/158.1;;435/320.1;;530/389.2;;530/387.3,0,0,,,,EXPIRED
225,AU,A,AU 1997/021229 A,047-400-247-824-940,1997-08-28,1997,AU 1997/021229 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W;;AU 1997/021229 A,1996-02-09,Human antibodies that bind human tnfalpha,,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBOTT LABORATORIES (BERMUDA) LTD (2003-06-19);;ABBOTT BIOTECHNOLOGY LTD. (2004-06-17),https://lens.org/047-400-247-824-940,Patent Application,no,0,4,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
226,SI,A,SI 9720020 A,049-557-974-071-12X,1999-10-31,1999,SI 9720020 A,1997-02-10,US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNF alpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor 'alpha' (hTNF'alpha') are disclosed. These antibodies have high affinity for hTNF'alpha'(e.g., Kd = 10-8 M or less), a slow off rate for hTNF'alpha' dissociation (e.g., Koff = 10-3sec-1 or less) and neutralize hTNF'alpha' activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF'alpha' and for inhibiting hTNF'alpha' activity, e.g., in a human subject suffering from a disorder in which hTNF'alpha' activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBOTT BIOTECHNOLOGY LTD.; BM (2005-03-10);;ABBVIE BIOTECHNOLOGY LTD.; BM (2014-04-08),https://lens.org/049-557-974-071-12X,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;C12N15/09;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
227,US,A1,US 2013/0330357 A1,074-776-317-067-063,2013-12-12,2013,US 201313965155 A,2013-08-12,US 201313965155 A;;US 201313736931 A;;US 57848709 A;;US 36945109 A;;US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/074-776-317-067-063,Patent Application,yes,12,6,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/158.1;;530/389.2,20,12,052-159-696-111-105;;105-804-318-922-613;;003-946-695-575-042;;095-334-545-560-259;;014-113-432-888-031;;027-477-313-726-928;;045-942-104-775-903;;051-707-000-800-833;;031-100-076-670-370;;001-779-867-387-972;;013-142-717-038-23X;;093-942-634-465-137,pmc453150;;1721867;;10.1002/j.1460-2075.1991.tb04978.x;;10.1084/jem.146.6.1585;;pmc2181919;;336836;;10.1002/art.1780300603;;3111490;;10.1006/jmbi.1996.0548;;8876650;;12218124;;10.4049/jimmunol.169.6.3076;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;12850000;;10.1016/s0006-291x(03)01131-8;;12079396;;10.1016/s0022-2836(02)00264-4;;16989900;;10.1016/j.molimm.2006.08.001;;10.1006/jmbi.1999.3192;;10543973;;10556035;;10.1006/jmbi.1999.3141;;1767345,"Keffer et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991 Dec;10(13):4025-31.;;Cromartie et al. Arthritis in rats after systemic injection of streptococcal cells or cell walls. J Exp Med. 1977 Dec 1;146(6):1585-602.;;Thompson et al. Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum. 1987 Jun;30(6):618-23.;;MacCallum et al. Journal of Molecular. Biology, 1996, Vol 262, pp. 732-745.;;De Pascalis et al. Journal of Immunology, 2002, Vol. 169, pp. 3076-3084.;;Rudikoff et al. Proc Natl Acad Sci USA 1982 Vol 79 pp 1979-1983.;;Casset et al. Biochemical and Biophysical Research Communications, 2003, Vol. 307, pp. 198-205.;;Vajdos et al. Journal of Molecular biology, 2002, Vol. 320, pp. 415-428.;;Holm et al. Molecular Immunology, 2007, Vol. 44, pp. 1075-1084.;;Chen et al. Journal of Molecular Biology, 1999, Vol. 293, pp. 865-881.;;Wu et al. Journal of Molecular Biology, 1999, Vol. 294, pp. 151-162.;;Tanaka et al. Comparison of clinical features of childhood and adult onset Still's disease. Ryumachi. [Rheumatism], (1991 Oct) Vol. 31, No. 5, pp. 511-8, Abstract only.;;Polyarthrits, from Stedman's Medical Dictionary Search [online]. [retrieved on April 6, 2014]. Retrieved from the Internet: .;;Polyarthritis, from Wikipedia, the free encyclopedia [online], [retrieved on April 6, 2014]. Retrieved from the internet: URL.;;U. S. Application No. 10623039, filed 07/18/2003;;U. S. Application No. 10623318, filed 07/18/2003;;U. S. Application No. 10693233, filed 10/24/2003;;U. S. Application No. 13774706, filed 02/22/2013;;U. S. Application No. 13927576, filed 06/26/2013;;U. S. Application No. 13957679, filed 08/02/2013",DISCONTINUED
228,NO,B1,NO 320657 B1,104-208-093-939-248,2006-01-09,2006,NO 20040154 A,2004-01-13,US 3147696 P;;US 59922696 A;;US 9702219 W,1996-02-09,"Farmasoytisk blanding omfattende human-antistoffer som binder TNFalfa, samt anvendelser derav",,ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON JANE;;MCGUINESS BRIAN T,"ABBVIE BIOTECHNOLOGY LTD, BM (2013-10-14)",https://lens.org/104-208-093-939-248,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
229,PT,E,PT 929578 E,124-685-951-300-406,2003-09-30,2003,PT 97906572 T,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,ANTICORPOS HUMANOS QUE SE LIGAM A TNFALFA HUMANO,,ABBOTT LAB BERMUDA LTD,WHITE MICHAEL;;WILTON ALISON JANE;;SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J,,https://lens.org/124-685-951-300-406,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
230,AU,A1,AU 2014/202693 A1,161-384-263-359-79X,2014-06-12,2014,AU 2014/202693 A,2014-05-16,AU 2013/257402 A;;AU 2014/202693 A,2013-11-11,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kd = 10-8 M or less), a slow off rate for hTNFa dissociation (e.g., Koff~1Osec-1 or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/161-384-263-359-79X,Patent Application,no,0,0,1,1,0,,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,DISCONTINUED
231,CN,A,CN 101712720 A,029-410-198-145-744,2010-05-26,2010,CN 200910225399 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNF alpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha (hTNF alpha ) are disclosed. These antibodies have high affinity for hTNF alpha (e.g., Kd = 10<-8> M or less), a slow off rate for hTNF alpha dissociation (e.g., Koff = 10<-3>sec<-1> or less) and neutralize hTNF alpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF alpha and for inhibiting hTNF alpha activity, e.g., in a human subject suffering from a disorder in which hTNF alpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;ZEHRA KAYMAKCALAN;;BORIS LABROVSKY;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;PAUL SAKORAFAS;;DAVID SCHOENHAUT;;VAUGHAN TRISTAN J;;MICHAEL WHITE;;WILTON ALISON J,,https://lens.org/029-410-198-145-744,Patent Application,no,0,2,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P3/04;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/46;;C07K19/00;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
232,CN,B,CN 1935260 B,063-038-017-930-968,2012-07-18,2012,CN 200610101825 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human tnfalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha (hTNF alpha ) are disclosed. These antibodies have high affinity for hTNF alpha (e.g., Kd=10-8 M or less), a slow off rate for hTNF alpha dissociation (e.g., Koff=1x10-3s-1 or less) and neutralize hTNF alpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF alpha and for inhibiting hTNF alpha activity, e.g., in a human subject suffering from a disorder in which hTNF alpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,DAVID SCHOENHAUT;;ZEHRA KAYMAKCALAN;;BORIS LABKOVSKY;;SALFELD JOCHEN G;;MICHAEL WHITE;;VAUGHAN TRISTAN J;;ALLEN DEBORAH J;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;WILTON ALISON J;;MANKOVICH JOHN A;;PAUL SAKORAFAS;;HOOGENBOOM HENDRICUS R J M,ABBVIE BIOTECHNOLOGY LTD. (2013-08-07),https://lens.org/063-038-017-930-968,Granted Patent,no,0,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K39/395;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
233,CZ,A3,CZ 247698 A3,081-150-454-908-139,1998-11-11,1998,CZ 247698 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES TO HUMAN TNF ALPHA,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORA J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/081-150-454-908-139,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
234,US,B2,US 8414894 B2,109-651-318-850-382,2013-04-09,2013,US 201113340805 A,2011-12-30,US 201113340805 A;;US 40146909 A;;US 23325205 A;;US 30235602 A;;US 54001800 A;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFα and methods of using same,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;MANKOVICH JOHN A;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;LABKOVSKY BORIS;;MCGUINNESS BRIAN T;;SAKORAFAS PAUL;;WHITE MICHAEL;;WILTON ALISON J;;KAYMAKCALAN ZEHRA;;ROBERTS ANDREW J;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;MANKOVICH JOHN A;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;LABKOVSKY BORIS;;MCGUINNESS BRIAN T;;SAKORAFAS PAUL;;WHITE MICHAEL;;WILTON ALISON J;;KAYMAKCALAN ZEHRA;;ROBERTS ANDREW J;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/109-651-318-850-382,Granted Patent,yes,102,53,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/00;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/142.1;;424/145.1;;424/158.1;;424/178.1;;435/7.1;;435/7.7;;435/7.9;;530/388.15;;530/388.23;;530/391.1,86,74,005-321-867-106-932;;082-560-368-073-508;;092-412-882-661-570;;072-438-011-112-832;;064-048-827-826-930;;101-630-891-707-104;;022-179-293-052-569;;026-408-993-198-966;;024-854-471-494-140;;003-185-616-989-105;;006-342-252-521-899;;033-261-430-402-230;;072-378-691-723-546;;005-119-615-003-591;;036-413-156-723-523;;033-797-614-829-293;;040-701-579-915-050;;030-874-783-814-532;;017-529-128-038-946;;057-954-116-868-246;;015-761-810-001-488;;010-916-105-450-247;;020-855-322-534-259;;061-726-307-774-867;;074-932-950-939-666;;053-341-149-236-635;;004-601-819-239-79X;;030-323-674-660-051;;003-841-586-111-459;;087-599-254-199-807;;098-176-334-504-327;;019-030-524-959-069;;092-023-577-402-127;;021-641-900-032-887;;006-117-436-368-816;;145-140-396-707-208;;042-623-879-457-954;;074-817-300-512-106;;031-729-641-207-089;;022-133-574-143-973;;077-341-362-901-551;;022-384-366-455-012;;088-581-950-418-154;;028-677-787-189-119;;041-315-340-063-133;;027-477-313-726-928;;088-851-255-233-972;;137-274-595-200-649;;026-144-631-995-304;;010-327-392-460-003;;032-820-729-763-323;;006-911-122-969-908;;006-626-799-687-686;;021-113-833-013-619;;038-613-711-274-229;;025-395-146-381-464;;085-277-440-303-853;;012-897-611-427-172;;050-836-464-727-069;;035-939-173-669-143;;077-815-816-621-813;;040-701-579-915-050;;002-495-006-719-164;;043-108-278-056-872;;046-104-560-723-30X;;048-379-681-038-232;;016-219-576-017-946;;001-900-209-379-77X;;020-753-772-581-741;;040-981-641-449-302;;003-595-371-167-198;;053-289-310-577-642;;032-071-991-081-664;;116-193-705-533-609,7884952;;10.1001/jama.1995.03520360048038;;10.1001/jama.273.12.934;;7735957;;10.1097/00024382-199404000-00001;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1038/nrd984;;12509759;;10.1097/00003246-199609000-00002;;8797612;;10.1002/eji.1830240409;;8149953;;18240199;;10.1002/art.23362;;10.1146/annurev.immunol.19.1.163;;11244034;;10.1006/jmbi.1994.1351;;8196048;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;1560463;;10.1016/0022-2836(92)91010-m;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;7620183;;10.1182/blood.v86.3.890.890;;2531466;;10.1126/science.2531466;;7521646;;10.1038/nbt0994-899;;pmc1766613;;11053087;;10.1136/ard.59.suppl_1.i44;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;8757799;;10.1006/jmbi.1996.0406;;10.1038/nbt0792-779;;1368267;;1748994;;10.1016/0022-2836(91)90498-u;;7765558;;10.1038/nbt1194-1134;;10.1016/1043-4666(90)90011-h;;1716486;;10.1016/0959-440x(95)80028-x;;8528760;;15848075;;10.1016/j.ymeth.2005.01.006;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;8364031;;10.1021/bi00085a016;;10.1097/00003246-199605000-00003;;8706447;;11730333;;10.1006/abio.2001.5380;;8609615;;10.1006/jmbi.1996.0069;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1146/annurev.med.45.1.491;;8198398;;7697917;;pmc1534281;;10.1111/j.1365-2249.1995.tb03598.x;;9624683;;10.1038/nbt0698-535;;10.1038/341544a0;;2677748;;8397764;;10.1016/0167-5699(93)90039-n;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;7935497;;10.1016/0161-5890(94)90101-5;;10.1016/1043-4666(92)90072-y;;1381227;;10.4049/jimmunol.164.3.1432;;10640759;;10.1038/nbt0595-475;;9634788;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.3.co;2-y;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.0.co;2-l;;8727325;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1423650;;10.3109/07388559209114235;;10.1111/j.1365-2249.1994.tb05522.x;;7994916;;pmc1534487;;10.3233/hab-1995-6206;;7492754;;9180069;;10.1126/science.276.5319.1665;;8159246;;10.1038/368856a0;;8783501;;10.1016/0167-5699(96)10025-6;;9265725;;10.1016/s0958-1669(97)80068-7;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/ng0594-13;;8075633;;pmc395221;;10.1002/j.1460-2075.1994.tb06626.x;;8045255;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;10.1111/j.1365-2141.1992.tb08212.x;;1379467;;7579668;;10.1016/0958-1669(95)80093-x;;7521646;;10.1038/nbt0994-899;;10.1016/0161-5890(93)90106-l;;8232330;;7494109;;10.3109/08830189509061738;;10.1016/s0021-9258(18)41952-7;;1644788;;7764095;;10.1038/nbt1093-1145;;10.1038/ng0297-146;;9020839;;9052775;;10.1038/386025a0;;10.1093/intimm/6.4.579;;8018598;;7957560;;10.1002/eji.1830241116;;8190629;;pmc307995;;10.1093/nar/22.8.1389;;10.1096/fasebj.10.10.8751726;;8751726;;10.1016/0022-2836(92)90894-p;;1404359;;9671778;;pmc21176;;10.1073/pnas.95.15.8910,"Abraham et al., ""Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor a in Patients with Sepsis Syndrome,"" JAMA, vol. 273(12):934-941 (1995).;;Barbuto et al., ""Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes"" Proc. Am. Assoc. Cancer Res,. 34:487, Abstr. 2904 (1993).;;Bendtzen et al., ""Auto-antibodies to IL-1alpha and TNFalpha in Normal Individuals and in Infectious and Immunoinflammatory Disorders"" The Physiological and Pathological Effects of Cytokines, 447-52 (1990).;;Boekstegers et al., ""Repeated administration of a F(ab')2 fragment of an anti-tumor recrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,"" Shock, vol. 1(4):237-245 (1994) (abstract from Pub Med).;;Boyle et al., ""A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- alpha"" Cell. Immunol., 152:556-68 (1993).;;Boyle et al., ""The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF.alpha. on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope"", Cell. Immunol., vol. 152, pp. 569-581, (1993).;;Brekke et al., ""Therapeutic antibodies for human diseases at the dawn of the twenty-first century,"" Nature Reviews/Drug Discovery, vol. 2:52-62 (2003).;;Chow et al.,""Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFalpha, IL-1beta, and IL-6 levels in patients with sepsis syndrome"" Clinical Research, vol. 42, No. 2 p. 299A (1994).;;Cohen et al.,""Intersept: An international, multicenter, placebo-controlled trial of monoclonal anitbody to human tumor necrosis factor-alpha in patients with sepsis,"" Crit Care Med, vol. 24(9):1431-1440 (1996).;;Cox et al., ""A directory of human germ-line VK segments reveals a strong bias in their usage""Eur. J. Immunol., 24(2):827-36 (1994).;;Department of Surgery, University of Toronto Annual Report, Jul. 1, 1998-Jun. 30, 1999-found online at http://www.surg.med.utoronto.ca/AnnRep/AR98-99/index.html.;;Elliot et al., ""Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha"" Arthritis & Rheumatism, 36(12):1681-90 (1993).;;Feldman et al., ""Anti-TNFalpha Therapy of Rheumatoid Arthritis: What Have We Learned?"" Annu. Rev. Immunol., vol. 19:163-196 (2001).;;Figini et al., ""In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation,"" J. Mol. Biol., vol. 239:68-78 (1994).;;Fomsgaard et al., ""Auto-antibodies to Tumour Necrosis Factor alpha in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections"" Scand. J. Immunol., 30:219-23 (1989).;;Foote et al. ""Antibody framework residues affecting the conformation of the hypervariable loops,"" J Mol Biol 224(2):487 (1992).;;Griffiths et al., ""Human anti-self antibodies with high specificity from phage display libraries"" The Embo J., 12(2):725-34 (1993).;;Hawkins et al., ""Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,"" J. Mol. Biol., vol. 226:889-896 (1992).;;Holler et al., ""Modulation of acute graft-versus-host-disease after allogeneic bone marrow ransplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F),"" Blood, vol. 86(3):890-899 (1995) (abstract from Pub Med).;;Hoogenboom et al., ""Converting rodent into human antibodies by guided selection,""Antibody Engineering, Oxford University Press, pp. 169-185 (1996).;;Huse et al., ""Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda"" Science, 246:1275-81 (1989).;;Jespers et al., ""Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen,"" Bio/Technology, vol. 12:899-903 (1994).;;Kempeni, ""Update on D2E7: a fully human anti-tumor necrosis factor alpha monoclonal antibody,"" Ann Rheum Dis, vol. 59(Suppl. 1)144-145 (2000).;;Lerner et al., ""Antibodies without immunization"" Science, 258:1313-14 (1992).;;Leusch et al., ""Failure to demonstrate TNFalpha-specific autoantibodies in human sera by ELISA and Western blot"" J. Immunol. Methods, 139:145-47 (1991).;;Lewis et al., ""Use of alanine scanning mutagenesis to improve the affinity of an anti gp120 (HIV) antibody."" J. Cell. Biochem., 18D:215 (1994).;;Low, thesis extract, Cambridge University (1996).;;Low et al., ""Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,"" J. Mol. Biol., vol. 260:359-368 (1996).;;Marks et al., ""By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,"" Biotechnology 10:779-783 (1992).;;Marks et al. ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"" J. Mol. Biol. 222:581-97 (1991).;;Medynski, ""Phage Display: All Dressed Up and Ready to Role,"" Bio/Technology, vol.12:1134-1136 (1994).;;Möller et al., ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and vivo application"" Cytokine, 2(3):162-69 (1990).;;Nilsson, ""Antibody engineering,"" Current Opinion in Structural Biology, vol. 5:450-456 (1995).;;Osbourn et al., ""From rodent reagents to human therapeutics using antibody guided selection,"" Methods 36(1):61 (2005).;;Queen et al., ""A humanized antibody that binds to the interleukin 2 receptor,"" PNAS USA, 86(24):10029 (1989).;;Riechmann et al., ""Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement,"" Biochemistry, vol. 32(34):8848-8855 (1993) (abstract from Pub Med).;;Reinhart et al., ""Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study."" 1996 Crit. Care. Med., vol. 24(5):733-742.;;Santora et al., ""Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIA core,"" Analytical Biochemistry, vol. 299:119-129 (2001).;;Thompson et al., ""Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity,"" J. Mol. Biol., vol. 256(1):77-88 (1996) (abstract from Pub Med).;;Tomlinson et al., ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,"" J. Mol. Biol., vol. 227:776-798 (1992).;;Tomlinson et al., ""The structural repertoire of the human Vkappadomain,"" The EMBO Journal, vol. 14(18):4628-4638 (1995).;;Tracey et al., ""Tumor Necrosis Factor: A Pleiotropic Cytokine and Therapeutic Target,""Annu. Rev. Med., vol. 45:491-503 (1994).;;Van Der Poll et al., ""Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees,"" Clin Exp Immunol, vol. 100:21-25 (1995).;;Vaughan et al., ""Human antibodies by design,"" Nature Biotechnology, vol. 16:535-539 (1998).;;Ward et al., ""Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli,"" Nature, vol. 341(6242):544-546 (1989).;;Winter et al, ""Humanized antibodies,"" Immunology Today, vol. 14(6):243-246 (1993).;;Winter et al., ""Making antibodies by phage display technology,"" Annu. Rev. Immunol., vol.12:433-455 (1994).;;Doring, E., Identification and Characterization of a TNFa Antagonist Derived from a Monoclonal Antibody (1994) Mol Immunol 31(14): 1059-1067.;;Thorp et al., Tumour Necrosis Factor Induction of ELAM-1 and ICAM-1 on Human Umbilical Vein Endothelial Cells-Analysis of Tumour Necrosis Factor Receptor Interaction (1992) Cytokine 4(4): 313.;;Tamura, M. et al. ""Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only"" Journal of Immunology (2000) vol. 164, pp. 1432-1441.;;Davies et al., ""Antibody VH domains as small recognition units."" Biotechnology, 13:475-479 (1995).;;Martin, A.C.R. ""Accessing the Kabat antibody sequence database by computer."" Proteins: Structure, Function and Genetics, 25:130-133 (1996).;;Rudikoff, et al., Single amino acid substitution altering antigen-binding specificity. Proc.Natl. Acad. Sci. USA, 70:1979-1983 (1982).;;Sandhu, J. ""Protein engineering of antibodies."" Critical Reviews in Biotechnology, 12:437-462 (1992).;;Sioud et al., ""Characterization of naturally occurring autoantibodies against tumour necrosis factor-alpha (TNF-alpha): in vitro function and precise epitope mapping by phage epitope library."" Clin Exp Immunol, 98:520-525 (1994).;;Teichmann, S. Declaration dated Dec. 7, 2010 from opposition appeal proceedings in EP 0929578.;;Tsuchiyama et al., ""Comparison of anti-TNF alpha autoantibodies in plasma and from EBV transformed lymphocytes of autoimmune and normal individuals."" Hum. Antibod. Hybridomas 6(2):73-76 (1995).;;Wedemayer et al., ""Structural insights into the evolution of an antibody combining site."" Science 276:1665-1669 (1997).;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications."" Nature, 368:856-859 (1994).;;Bruggemann, M., Neuberger, M.S., ""Strategies for expressing human antibody repertoires in transgenic mice,"" Immunol. Today 17:391-397 (1996).;;Bruggemann et al. ""Production of human antibody repertoires in transgenic mice"" Cur. Op. Biotechnol. 8:455-458 (1997).;;Cambridge Antibody Technology, advertisement of phage display services, Science vol. 253, No. 5018 (1991).;;Elliot et al., ""Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis,"" Lancet 344:1125-1127 (1994).;;Fishwild et al., ""High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice,"" Nature Biotechnology 14:845-851 (1996).;;Gram et al., ""In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library,"" PNAS 89:3576-3580 (1992).;;Green et al., ""Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,"" Nature Genetics 7:13-21 (1994).;;Griffiths et al., ""Isolation of high affinity human antibodies directly from large synthetic repertoires,"" EMBO J. 13:3245-3260 (1994).;;Harding et al., ""Class switching in human immunoglobulin transgenic mice,"" Ann. NY Acad. Sci. 764:536-547 (1995).;;Huang et al. ""Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia,"" Br. J. Haematol 81(2):231-234 (1992).;;Jakobovits, A., ""Production of fully human antibodies by transgenic mice,"" Curr. Op. Biotechnol. 6:561-566 (1995).;;Jespers et al.,""Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen,"" Nature Biotechnology 12:899-903 (1994).;;The Kennedy Institute of Rheumatology, 1995 Annual Scientific Report, ""Anti-TNF trials and studies of mechanisms of action"".;;Knight et al., ""Construction and initial characterization of a mouse-human chimeric anti-TNF antibody,"" Mol. Immunol. 30(16):1443-1453 (1993).;;Lonberg et al., ""Human Antibodies from Transgenic Mice,"" Int. Rev. Immunol. 13:65-93 (1995).;;Marks et al., ""Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system,"" J. Biol. Chem. 267:16007-16010 (1992).;;Marks et al., ""Human antibody fragments specific for human blood group antigens from a phage display library,"" Bio/Technology 11:1145-1150 (1993).;;Marks, ""Human Monoclonal Antibodies from V-gene Repertoires Expressed on Bacteriophage."" In Antibody Engineering, Second Edition, edited by Carl A.K. Borrebaeck (1995), pp. 53-88. New York: Oxford Univ. Press.;;Mendez et al., ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice,"" Nature Genetics 15:146-156 (1997).;;Neuberger M., et al., ""Mice perform a human repertoire"", Nature 386: 25-26 (1997).;;Salfeld, ""Development of a Fully Human Antibody to TNF by Phage Display Technology"", IBC Conference, Antibody Engineering, San Diego (1996).;;Taylor et al.,""Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,"" Int Immunol. 6:579-591 (1994).;;Wagner et al., ""The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human immunoglobulin gene miniloci,"" Eur. J. Immunol. 24:2672-2681 (1994).;;Wagner et al., ""Antibodies generated from human immunoglobulin miniloci in transgenic mice,"" Nucl. Acids Res. 22:1389-1393 (1994).;;Zou et al., ""Dominant expression of a 1.3 Mb human Ig kappa locus replacing mouse light chain production,"" FASEB J 10:1227-1232 (1996).;;Hoogenboom et al. ""By-passing immunisation: Human antibodies from synthetic repertoires of germline V.sub.H gene segments rearranged in vitro, "" J. Mol. Biol. 227:381-388.(1992).;;Rader et al. ""A phage display approach to rapid antibody humanization: Designed combinatorial V gene libraries"" Proc Natl Acad Sci USA 95:8910-8915 (1998).",EXPIRED
235,US,B2,US 7223394 B2,146-992-344-938-764,2007-05-29,2007,US 80118501 A,2001-03-07,US 80118501 A;;US 12509899 A;;US 3147696 P;;US 9702219 W;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1998-11-18);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/146-992-344-938-764,Granted Patent,yes,25,202,135,181,36,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/142.1;;424/145.1;;424/158.1;;530/388.15;;530/388.23;;530/389.2,43,36,092-412-882-661-570;;072-438-011-112-832;;022-179-293-052-569;;058-666-530-378-058;;006-342-252-521-899;;072-378-691-723-546;;033-797-614-829-293;;017-529-128-038-946;;057-954-116-868-246;;020-855-322-534-259;;074-932-950-939-666;;092-023-577-402-127;;021-641-900-032-887;;006-117-436-368-816;;031-729-641-207-089;;005-321-867-106-932;;082-560-368-073-508;;064-048-827-826-930;;024-854-471-494-140;;003-185-616-989-105;;005-119-615-003-591;;036-413-156-723-523;;030-874-783-814-532;;015-761-810-001-488;;061-726-307-774-867;;053-341-149-236-635;;003-841-586-111-459;;087-599-254-199-807;;098-176-334-504-327;;019-030-524-959-069;;145-140-396-707-208;;042-623-879-457-954;;074-817-300-512-106;;022-133-574-143-973;;101-630-891-707-104;;040-701-579-915-050,7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1002/eji.1830240409;;8149953;;8250987;;10.1002/art.1780361206;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;2531466;;10.1126/science.2531466;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;1748994;;10.1016/0022-2836(91)90498-u;;10.1016/1043-4666(90)90011-h;;1716486;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1146/annurev.med.45.1.491;;8198398;;8397764;;10.1016/0167-5699(93)90039-n;;7884952;;10.1001/jama.1995.03520360048038;;10.1001/jama.273.12.934;;7735957;;10.1097/00024382-199404000-00001;;10.1038/nrd984;;12509759;;10.1146/annurev.immunol.19.1.163;;11244034;;10.1006/jmbi.1994.1351;;8196048;;10.1016/0022-2836(92)90639-2;;1507232;;7620183;;10.1182/blood.v86.3.890.890;;pmc1766613;;11053087;;10.1136/ard.59.suppl_1.i44;;8757799;;10.1006/jmbi.1996.0406;;7765558;;10.1038/nbt1194-1134;;10.1016/0959-440x(95)80028-x;;8528760;;8364031;;10.1021/bi00085a016;;10.1097/00003246-199605000-00003;;8706447;;11730333;;10.1006/abio.2001.5380;;8609615;;10.1006/jmbi.1996.0069;;7697917;;pmc1534281;;10.1111/j.1365-2249.1995.tb03598.x;;9624683;;10.1038/nbt0698-535;;10.1038/341544a0;;2677748;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;10.1097/00003246-199609000-00002;;8797612;;7521646;;10.1038/nbt0994-899,"Barbuto, J.A.M., et al. ""Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes"", Abstract 2904, Proc. Am. Assoc. Cancer Res., vol. 34, p. 487 (Mar. 1993).;;Bendtzen, K. et al., ""Auto-Antibodies to IL-1.alpha. and TNF.alpha. in Normal Individuals and in Infectious and Immunoinflammatory Disorders"", in The Physiological and Pathological Effects of Cytokines, pp. 447-452, Wiley-Liss Inc. (1990).;;Boyle, P. et al. ""A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor-.alpha."", Cell. Immunol., vol. 152, pp. 556-568 (1993).;;Boyle, P. et al. ""The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF.alpha. on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope"", Cell. Immunol., vol. 152, pp. 569-581, (1993).;;Chow, A.W. et al. ""Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFalpha, IL-1beta, and IL-6 levels in patients with sepsis syndrome"" Clinical Research, vol. 42, No. 2 p. 299A (1994).;;Cox, J.P.L. et al., ""A directory of human germ-line V<SUB>x </SUB>segments reveals a strong bias in their usage"", Eur. J. Immunol., vol. 24, pp. 827-836 (1994).;;Elliott, M.J. et al., ""Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor .alpha."", Arthritis & Rheumatism, vol. 36, No. 12, pp. 1681-1690 (1993).;;Fomsgaard, A. et al., ""Auto-antibodies to Tumor Necrosis Factor .alpha. in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections"", Scand. J. Immunol., vol. 30, pp. 219-223 (1989).;;Griffiths, A.D. et al., ""Human anti-self antibodies with high specificity from phage display libraries"", EMBO Journal, vol. 12, No. 2, pp. 725-734 (1993).;;Huse, W.D. et al., ""Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda"", Science, vol. 246, pp. 1275-1281 (1989).;;Lerner, R.A. et al., ""Antibodies without immunization"", Science, vol. 258, pp. 1313-1314 (1992).;;Leusch, H-G. et al. ""Failure to demonstrate TNF.alpha.-specific autoantibodies in human sera by ELISA and Western blot"", J. Immunol. Methods, vol. 139, pp. 145-147, (1991).;;Lewis, et al., ""Use of alanine scanning mutagenesis to improve the affinity of an anti-gp120(HIV) antibody"", J. Cell. Biochem. Suppl. vol. 18D, p. 215 (1994).;;Marks, J.D. et al., ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"", J. Mol. Biol. , vol. 222, pp. 581-597 (1991).;;Moller, A. et al. ""Monoclonal antibodies to human tumor necrosis factor .alpha.: in vitro and in vivo application"", Cytokine, vol. 2, No. 3, pp. 162-169 (1990).;;Tomlinson, I.M. et al., ""the repertoire of human germline V<SUB>H </SUB>sequences reveals about fifty groups of V<SUB>H </SUB>segments with different hypervariable loops"", J. Mol. Biol., vol. 227, pp. 776-798 (1992).;;Tomlinson, I.M. et al., ""The structure repertoire of the human V<SUB>k </SUB>domain"", EMBO, vol. 14, No. 18, pp. 4628-4638 (1995).;;Tracey, K.J. et al., ""Tumor necrosis factor: A pleiotropic cytokine and therapuetic target"", Annu. Rev. Med., vol. 45, pp. 491-503 (1994).;;Winter, G. et al., ""Humanized antibodies"", Immunology Today, vol. 14, No. 6, pp. 243-246 (1993).;;Abraham, Edward, et al., ""Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor alpha in Patients with Sepsis Syndrome,"" JAMA, vol. 273(12):934-941 (1995).;;Boekstegers, P., et al., ""Repeated administration of a F(ab')2 fragment of an anti-tumor recrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,"" Shock, vol. 1(4):237-245 (1994) (abstract from Pub Med).;;Brekke, Ole Henrik, et al., ""Therapeutic antibodies for human diseases at the dawn of the twenty-first century,"" Nature Reviews/Drug Discovery, vol. 2:52-62 (2003).;;Department of Surgery, University of Toronto Annual Report, Jul. 1, 1998-Jun. 30, 1999-found online at http://www.surg.med.utoronto.ca/AnnRep/AR98<SUB>-</SUB>99/index.html.;;Feldman, Marc, et al., ""Anti-TNFalpha Therapy of Rheumatoid Arthritis: What Have We Learned?"" Annu. Rev. Immunol., vol. 19:163-196 (2001).;;Figini, Mariangela, et al., ""In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation,"" J. Mol. Biol., vol. 239:68-78 (1994).;;Hawkins, Robert E., et al., ""Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,"" J. Mol Biol., vol. 226:889-896 (1992).;;Holler, E., et al., ""Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F),"" Blood, vol. 86(3):890-899 (1995) (abstract from Pub Med).;;Hoogenboom, Hennie R., et al., ""Converting rodent into human antibodies by guided selection,"" Antibody Engineering, Oxford University Press, pp. 169-185 (1996).;;Kempeni, Joachim, ""Update of D2E7: a fully human anti-tumor necrosis factor alpha monoclonal antibody,"" Ann Rheum Dis, vol. 59(Suppl. I):144-145 (2000).;;Low, Nigel N., thesis extract, Cambridge University (1996).;;Low, Nigel M., et al., ""Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,"" J. Mol. Biol., vol. 260:359-368 (1996).;;Medynski, Dan, ""Phage Display. All Dressed Up and Ready to Role,"" Bio/Technology, vol. 12:1134-1136 (1994).;;Nilsson, Björn, ""Antibody engineering,"" Current Opinion in Structural Biology, vol. 5:450-456 (1995).;;Riechmann, L., et al , ""Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement,"" Biochemistry, vol. 32(34):8848-8855 (1993) (abstract from Pub Med).;;Reinhart, K., et al., ""Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study,"" Crit Care Med, vol. 24(5):1608 (1996) (abstract from Pub Med).;;Santora, L.C., et al., ""Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIA core,"" Analytical Biochemistry, vol. 299:119-129 (2001).;;Thompson, J., et al., ""Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity,"" J. Mol Biol., vol. 256(1):77-88 (1996) (abstract from Pub Med).;;Van Der Poll, T., et al., ""Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees,"" Clin Exp Immunol, vol. 100:21-25 (1995).;;Vaughan, Tristan J., et al., ""Human antibodies by design,"" Nature Biotechnology, vol. 16:535-539 (1998).;;Ward, E. Sally, et al., ""Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli,"" Nature, vol. 341(6242):544-546 (1989).;;Winter, Greg, et al., ""Making antibodies by phage display technology,"" Annu. Rev Immunol., vol. 12:433-455 (1994).;;Cohen, Jonathan, et al., ""Intersept: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis,"" Crit Care Med, vol. 24(9):1431-1440 (1996).;;Jespers, Laurent S., et al., ""Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen,"" Bio/Technology, vol. 12:899-903 (1994).",EXPIRED
236,WO,A1,WO 1997/029131 A1,170-821-400-004-362,1997-08-14,1997,US 9702219 W,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF alpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα(e.g., Kd = 10-8 M or less), a slow off rate for hTNFα dissociation (e.g., K¿off? = 10?-3sec-1¿ or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",BASF AG;;SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/170-821-400-004-362,Patent Application,yes,4,456,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,2,1,072-378-691-723-546,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990,"GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"", EMBO J., vol. 12, no. 2, 1993, pages 725 - 734, XP000645476;;CHOW ET AL.: ""Effect of monoclonal antibody to human TNF on TNFalpha, IL-1beta and IL-6 levels in patients with sepsis syndrome"", CLINICAL RESEARCH, vol. 42, no. 2, April 1994 (1994-04-01), pages 299a, XP002032300",PATENTED
237,US,B1,US 6509015 B1,185-936-973-540-271,2003-01-21,2003,US 54001800 A,2000-03-31,US 54001800 A;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFa,"
    Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) are disclosed. These antibodies have high affinity for hTNF (e.g., K _{ d } 10 ^{ 8 } M or less), a slow off rate for hTNF dissociation (e.g., K _{ off } 10 ^{ 3 } sec ^{ 1 } or less) and neutralize hTNF activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF and for inhibiting hTNF activity, e.g., in a human subject suffering from a disorder in which hTNF activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention. 
",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBOTT BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/185-936-973-540-271,Granted Patent,yes,22,385,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/142.1;;424/85.2;;424/145.1;;424/800;;424/810,19,15,092-412-882-661-570;;072-438-011-112-832;;022-179-293-052-569;;026-408-993-198-966;;006-342-252-521-899;;072-378-691-723-546;;033-797-614-829-293;;017-529-128-038-946;;057-954-116-868-246;;020-855-322-534-259;;074-932-950-939-666;;092-023-577-402-127;;021-641-900-032-887;;006-117-436-368-816;;031-729-641-207-089,7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1002/eji.1830240409;;8149953;;18240199;;10.1002/art.23362;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;2531466;;10.1126/science.2531466;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;1748994;;10.1016/0022-2836(91)90498-u;;10.1016/1043-4666(90)90011-h;;1716486;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1146/annurev.med.45.1.491;;8198398;;8397764;;10.1016/0167-5699(93)90039-n,"Barbuto, J.A.M. et al. ""Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes"" Proc. Am. Assoc. Cancer Res. 34:487, Abstract No. 2904. (Mar. 1993).;;Bendtzen, K. et al. ""Auto-antibodies to IL-1alpha and TNFalpha in Normal Individuals and in Infectious and Immunoinflammatory Disorders"" in The Physiological and Pathological Effects of Cytokines (Wiely-Liss, Inc., 1990) 447-52.;;Boyle, P. et al. ""A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor-alpha"" Cell. Immunol. 152:556-68 (1993).;;Boyle, P. et al. ""The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFalpha on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope"" Cell. Immunol. 152:569-81 (1993).;;Chow, A.W. et al. ""Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFalpha, IL-1beta, and IL-6 levels in patients with sepsis syndrome"" Clinical Research 42:2 299A (1994).;;Cox, J.P.L. et al. ""A directory of human germ-line Vksegments reveals a strong bias in their usage"" Eur. J. Immunol. 24(2):827-36 (1994).;;Elliot, M.J. et al. ""Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha"" Arthritis & Rheumatism 36(12):1681-90 (1993).;;Fomsguaard, A. et al. ""Auto-antibodies to Tumor Necrosis Factor alpha in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections"" Scand. J. Immunol. 30:219-23 (1989).;;Griffiths, A.D. et al. ""Human anti-self antibodies with high specificity from phage display libraries"" The EMBO J. 12(2):725-34 (1993).;;Huse, W.D. et al. ""Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda"" Science 246:1275-81 (1989).;;Lerner, R.A. et al. ""Antibodies without immunization"" Science 258:1313-14 (1992).;;Leusch, H-G. et al. Failure to demonstrate TNFalpha-specific autoantibodies in human sera by ELISA and Western blot J. Immunol. Methods 139:145-47 (1991).;;Lewis et al. J. Cell. Biochem. 18D:215 (1994).;;Marks, J.D. et al. ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"" J. Mol. Biol. 222:581-97 (1991).;;Möller et al. ""Monoclonal antibodies to human tumors necrosis factor alpha: in vitro and vivo application"" Cytokine 2(3):162-69 (1990).;;Tomlinson, I.M. et al. ""The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops"" J. Mol. Biol. 227:776-98 (1992).;;Tomlinson, I.M. et al. ""The structural repertoire of the human Vk domain"" The EMBO J. 14(18):4628-38 (1995).;;Tracey, K.J. et al. ""Tumor necrosis factor: A pleiotropic cytokine and therapeutic target"" Annu. Rev. Med. 45:491-503 (1994).;;Winter, G. et al. ""Humanized antibodies"" Immunol. Today 14(6):243-46 (1993).",EXPIRED
238,US,B1,US 6258562 B1,004-644-735-761-855,2001-07-10,2001,US 12509899 A,1999-03-16,US 12509899 A;;US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha.(hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha. (e.g., K.sub.d =10.sup.-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K.sub.off =10.sup.-3 sec.sup.-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELISCHAFT (1998-10-29);;ABBOTT BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/004-644-735-761-855,Granted Patent,yes,18,616,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;C12N15/09;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,435/69.6;;435/335;;435/320.1;;536/23.53,19,15,031-729-641-207-089;;092-412-882-661-570;;072-438-011-112-832;;022-179-293-052-569;;058-666-530-378-058;;006-342-252-521-899;;072-378-691-723-546;;033-797-614-829-293;;017-529-128-038-946;;057-954-116-868-246;;020-855-322-534-259;;074-932-950-939-666;;021-641-900-032-887;;092-023-577-402-127;;006-117-436-368-816,8397764;;10.1016/0167-5699(93)90039-n;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1002/eji.1830240409;;8149953;;8250987;;10.1002/art.1780361206;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;2531466;;10.1126/science.2531466;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;1748994;;10.1016/0022-2836(91)90498-u;;10.1016/1043-4666(90)90011-h;;1716486;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;1404388;;10.1016/0022-2836(92)90223-7;;10.1146/annurev.med.45.1.491;;8198398,"Winter, G. et al., ""Humanized antibodies"", Immunology Today, vol. 14, No. 6, pp. 243-246 (1993).;;Barbuto, J.A.M., et al. ""Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes"", Abstract 2904, Proc. Am. Assoc. Cancer Res., vol. 34, p. 487, Mar. 1993.;;Bendtzen, K. et al. ""Auto-Antibodies to IL-1alpha and TNFalpha in Normal Individuals and in Infectious and Immunoinflammatory Disorders"", in The Physiological and Pathological Effects of Cytokines, pp. 447-452, Wiley-Liss Inc., 1990.;;Boyle, P. et al. ""A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor-alpha"", Cell. Immunol., vol. 152, pp. 556-568, (1993).;;Boyle, P. et al. ""The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFalpha on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope"", Cell. Immunol., vol. 152, pp. 569-581, (1993).*;;Chow et al., ""Effect of monoclonal antibody to human TNF on TNFalpha,IL-1beta and IL-6 levels in patients with sepsis syndrome,"" Clinical Research, 42(2):299a (Apr. 1994).*;;Cox, J.P.L. et al., ""A directory of human germ-line Vx segments reveals a strong bias in their usage"", Eur. J. Immunol., vol. 24, pp. 827-836 (1994).*;;Elliott, M.J. et al., ""Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha"", Arthritis & Rheumatism, vol. 36, No. 12, pp. 1681-1690 (1993).*;;Fomsgaard, A. et al. ""Auto-antibodies to Tumor Necrosis Factor alpha in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections"", Scand. J. Immunol., vol. 30, pp. 219-223, (1989).*;;Griffiths, A.D. et al., ""Human anti-self antibodies with high specificity from phage display libraries"", EMBO Journal, vol. 12, No. 2, pp. 725-734 (1993).*;;Huse, W.D. et al., ""Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda"", Science, vol. 246, pp. 1275-1281 (1989).*;;Lerner, R.A. et al., ""Antibodies without immunization"", Science, vol. 258, pp. 1313-1314 (1992).*;;Leusch, H-G. et al. ""Failure to demonstrate TNFalpha-specific autoantibodies in human sera by ELISA and Western blot"", J. Immunol. Methods, vol. 139, pp. 145-147, (1991).*;;Marks, J.D. et al., ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"", J. Mol. Biol., vol. 222, pp. 581-597 (1991).*;;Möller, A. et al. ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and in vivo application"", Cytokine, vol 2, No. 3, pp. 162-169 (1990).*;;Lewis, et al., J. Cell. Biochem vol. 18D, p. 215, (1994).*;;Tomlinson, I.M. et al., ""The structural repertoire of the human Vkdomain"", EMBO, vol. 14, No. 18, pp. 4628-4638 (1995).*;;Tomlinson, I.M. et al., ""The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops"", J. Mol. Biol., vol. 227, pp. 776-798 (1992).*;;Tracey, K.J. et al., ""Tumor necrosis factor: A pleiotropic cytokine and therapuetic target"", Annu. Rev. Med., vol. 45, pp. 491-503 (1994).*",EXPIRED
239,CN,B,CN 101003573 B,007-991-695-030-585,2014-02-26,2014,CN 200610156666 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human tnfalpha,,ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;LABKOVSKY BORIS;;MCGUINNESS BRIAN T;;KAYMAKCALAN ZEHRA;;HOOGENBOOM HENDRICUS R J M;;MANKOVICH JOHN A;;WILTON ALISON J;;ALLEN DEBORAH J;;VAUGHAN TRISTAN J;;SCHOENHAUT DAVID;;WHITE MICHAEL,,https://lens.org/007-991-695-030-585,Granted Patent,no,0,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
240,EP,A1,EP 2305713 A1,067-648-292-291-631,2011-04-06,2011,EP 10184680 A,1997-02-10,EP 02022788 A;;EP 97906572 A;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d  = 10 -8  M or less), a slow off rate for hTNFα dissociation  (e.g.,  K off  = 10 -3  sec -1  or less) and neutralize hTNFα activity  in vitro  and  in vivo.  An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBVIE BIOTECHNOLOGY LTD (2014-01-01),https://lens.org/067-648-292-291-631,Patent Application,yes,42,0,45,181,2,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,106,81,072-378-691-723-546;;040-701-579-915-050;;074-871-884-454-68X;;016-907-020-918-983;;011-796-204-010-792;;117-499-681-530-662;;006-117-436-368-816;;046-939-287-004-026;;085-191-504-989-317;;041-591-849-635-094;;054-329-283-530-645;;002-495-006-719-164;;021-113-833-013-619;;015-584-716-307-216;;092-412-882-661-570;;072-438-011-112-832;;006-342-252-521-899;;057-954-116-868-246;;072-378-691-723-546;;003-907-950-634-854;;041-956-664-134-903;;035-071-534-473-573;;071-901-988-318-434;;074-817-300-512-106;;017-150-654-990-340;;002-264-966-090-625;;066-749-017-721-197;;001-467-559-709-949;;143-467-932-790-298;;123-171-555-829-362;;071-707-020-428-907;;168-113-989-624-417;;044-369-216-298-341;;092-023-577-402-127;;022-179-293-052-569;;030-630-100-818-462;;117-663-803-983-152;;051-940-176-386-905;;029-667-686-534-996;;100-049-580-404-573;;033-797-614-829-293;;072-378-691-723-546;;005-119-615-003-591;;034-331-211-704-877;;025-395-146-381-464;;011-962-497-035-168;;065-145-385-150-339;;033-459-816-867-43X;;098-513-251-868-998;;063-873-022-003-842;;044-317-656-227-593;;011-114-894-374-225;;037-795-266-129-616;;048-153-224-318-923;;008-835-817-825-32X;;075-878-183-554-694;;004-001-063-582-854;;079-192-394-643-91X;;000-065-369-829-300;;128-904-140-606-949;;077-369-546-251-682;;032-821-336-726-761;;050-094-719-890-440;;070-452-766-365-174;;110-232-737-639-142;;028-469-508-809-412;;044-217-982-536-908;;012-422-300-553-121;;033-522-835-476-708;;097-358-265-091-151;;041-043-853-736-19X;;085-885-495-910-537;;167-234-008-883-687;;061-475-814-399-439;;031-974-874-348-471;;054-469-226-992-186;;007-667-472-783-358;;023-473-383-533-503;;063-233-860-095-920;;052-159-696-111-105;;074-817-300-512-106,10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7521646;;10.1038/nbt0994-899;;2413547;;10.1126/science.2413547;;10.1146/annurev.bi.57.070188.002445;;3052281;;10.1146/annurev.biochem.57.1.505;;10.1146/annurev.immunol.7.1.625;;10.1146/annurev.iy.07.040189.003205;;2540776;;1590993;;10.1146/annurev.iy.10.040192.002211;;10.1146/annurev.immunol.10.1.411;;0001590993;;10.1146/annurev.med.45.1.491;;8198398;;3889916;;pmc397878;;10.1073/pnas.82.11.3814;;3729942;;10.1016/0006-291x(86)91157-5;;3805735;;10.1016/0022-1759(87)90367-x;;10.1089/hyb.1987.6.359;;2442093;;10.1016/0161-5890(93)90106-l;;8232330;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1016/s0140-6736(94)90628-9;;7934491;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1016/0022-1759(91)90361-i;;2040812;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;7703831;;10.1038/312724a0;;6392892;;3552045;;10.1021/bi00379a018;;2922046;;2922050;;10.1038/338225a0;;10.1038/341544a0;;2677748;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0969-2126(94)00113-8;;7704521;;8597629;;10.3233/hab-1995-6303;;10.1016/0161-5890(94)90100-7;;7935496;;1475190;;10.1093/nar/20.23.6287;;pmc334518;;1804254;;7541226;;10.1002/jmr.300080122;;1404388;;10.1016/0022-2836(92)90223-7;;10.1002/eji.1830240409;;8149953;;10.1038/348552a0;;2247164;;25291200;;10.1016/0167-5699(85)90161-6;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;1385989;;10.3233/hab-1992-3204;;2531466;;10.1126/science.2531466;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;10.1038/352624a0;;1907718;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1093/nar/19.15.4133;;pmc328552;;1908075;;pmc52428;;10.1073/pnas.88.18.7978;;1896445;;8216416;;10.1002/art.1780360907;;8907592;;10.1007/bf02265123;;10.1097/00001756-199604260-00023;;8817534;;8619098;;10.1016/s0889-857x(21)00466-x;;10.1016/0958-1669(93)90055-2;;7764470;;10.1002/art.1780380202;;7848304;;pmc1534244;;8222316;;10.1111/j.1365-2249.1993.tb03441.x;;10.1093/rheumatology/34.4.334;;7788147;;10.1097/00007890-199409000-00007;;7940686;;10.1097/00007890-199501000-00025;;10.1097/00007890-199501270-00025;;7839455;;7832839;;10.1056/nejm199408113310606;;10.1126/science.3764421;;3764421;;10.1172/jci113459;;pmc442560;;3366898;;pmc1535044;;2117510;;10.1111/j.1365-2249.1990.tb03334.x;;7797011;;10.1016/0016-5085(95)90277-5;;10.1038/319516a0;;3511389;;10.1002/jbmr.5650030607;;3266953;;8442433;;10.1002/jbmr.5650080205;;7512360;;10.1016/8756-3282(93)90317-4;;2920991;;10.1002/hep.1840090302;;10.1111/j.1530-0277.1990.tb00482.x;;2190492;;10.1002/hep.1840200228;;8045508;;10.1016/0270-9139(94)90200-3;;10.1016/0168-8278(91)90945-8;;2051003;;pmc502205;;10.1136/jcp.47.12.1112;;7876386;;2188129;;10.1056/nejm199006073222302;;1924431;;10.1152/ajpheart.1994.267.1.h118;;8048575;;8148074;;10.1016/0305-4179(94)90104-x;;10.1152/ajpgi.1994.267.6.g1122;;7810659;;7992355;;10.1097/00007890-199412150-00003;;10.1016/0300-9572(95)00831-d;;7659869;;10.1007/bf00918154;;1512303;;pmc453150;;1721867;;10.1002/j.1460-2075.1991.tb04978.x;;10.1038/341544a0;;2677748,"GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"", EMBO J., vol. 12, no. 2, 1993, pages 725 - 734, XP000645476;;JESPERS L S ET AL: ""GUIDING THE SELECTION OF HUMAN ANTIBODIES FROM PHAGE DISPLAY REPERTOIRES TO A SINGLE EPITOPE OF AN ANTIGEN"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 12, no. 9, 1 September 1994 (1994-09-01), pages 899 - 903, XP000572619, ISSN: 0733-222X;;OLD, L., SCIENCE, vol. 230, 1985, pages 630 - 632;;BEUTLER, B.; CERAMI, A., ANNU. REV. BIOCHEM., vol. 57, 1988, pages 505 - 518;;BEUTLER, B.; CERAMI, A., ANNU. REV. IMMUNOL., vol. 7, 1989, pages 625 - 655;;MOELLER, A. ET AL., CYTOKINE, vol. 2, 1990, pages 162 - 169;;VASILLI, P., ANNU. REV. IMMUNOL., vol. 10, 1992, pages 411 - 452;;TRACEY, K.J.; CERAMI, A., ANNU. REV. MED., vol. 45, 1994, pages 491 - 503;;HAHN T ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3814 - 3818;;LIANG, C-M. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 137, 1986, pages 847 - 854;;HIRAI, M. ET AL., J. IMMUNOL. METHODS, vol. 96, 1987, pages 57 - 62;;FENDLY, B.M. ET AL., HYBRIDOMA, vol. 6, 1987, pages 359 - 370;;KNIGHT, D.M ET AL., MOL. IMMUNOL., vol. 30, 1993, pages 1443 - 1453;;ELLIOTT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1125 - 1127;;ELLIOT, M.J. ET AL., LANCET, vol. 344, 1994, pages 1105 - 1110;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 556 - 568;;BOYLE, P. ET AL., CELL. IMMUNOL., vol. 152, 1993, pages 569 - 581;;FOMSGAARD, A. ET AL., SCAND. J. IMMUNOL., vol. 30, 1989, pages 219 - 223;;BENDTZEN, K. ET AL., PROG. LEUKOCYTE BIOL., vol. 10B, 1990, pages 447 - 452;;LEUSCH, H-G. ET AL., J. IMMUNOL. METHODS, vol. 139, 1991, pages 145 - 147;;GRIFFITHS, A.D. ET AL., EMBO J., vol. 12, 1993, pages 725 - 734;;LIDBURY, A. ET AL., BIOTECHNOL. THER., vol. 5, 1994, pages 27 - 45;;PENNICA, D. ET AL., NATURE, vol. 312, 1984, pages 724 - 729;;DAVIS, J.M. ET AL., BIOCHEMISTRY, vol. 26, 1987, pages 1322 - 1326;;JONES, E.Y. ET AL., NATURE, vol. 338, 1989, pages 225 - 228;;WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;HOLLIGER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;POLJAK, R.J. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123;;KIPRIYANOV, S.M. ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, vol. 6, 1995, pages 93 - 101;;KIPRIYANOV, S.M. ET AL., MOL. IMMUNOL., vol. 31, 1994, pages 1047 - 1058;;TAYLOR, L.D. ET AL., NUCL. ACIDS RES., vol. 20, 1992, pages 6287 - 6295;;J6NSSON, U. ET AL., ANN. BIOL. CLIN., vol. 5, no. 1, 1993, pages 19 - 26;;JÖNSSON, U. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 620 - 627;;JOHNSSON, B. ET AL., J. MOL. RECOGNIT., vol. 8, 1995, pages 125 - 131;;JOHNNSON, B. ET AL., ANAL. BIOCHEM., vol. 198, 1991, pages 268 - 277;;""Molecular Cloning; A Laboratory Manual"", 1989, COLD SPRING HARBOR;;""Current Protocols in Molecular Biology"", 1989, GREENE PUBLISHING ASSOCIATES;;KABAT, E.A. ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, NIH PUBLICATION NO. 91-3242;;TOMLINSON, I.M. ET AL.: ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops"", J. MOL. BIOL., vol. 227, 1992, pages 776 - 798;;COX, J.P.L. ET AL.: ""A Directory of Human Germ-line V K Segments Reveals a Strong Bias in their Usage"", EUR. J. IMMUNOL., vol. 24, 1994, pages 827 - 836;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;GOEDDEL: ""Gene Expression Technology: Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS;;BOSS, M.A.; WOOD, C. R., IMMUNOLOGY TODAY, vol. 6, 1985, pages 12 - 13;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R.J. KAUFMAN; P.A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;FUCHS ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1370 - 1372;;HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85;;HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HAWKINS ET AL., JMOL BIOL, vol. 226, 1992, pages 889 - 896;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580;;GARRAD ET AL., BIOLTECHNOLOGY, vol. 9, 1991, pages 1373 - 1377;;HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137;;BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982;;""Sustained and Controlled Release Drug Delivery Systems"", 1978, MARCEL DEKKER, INC.;;ARTHRITIS & RHEUMATISM, vol. 37, 1994, pages 295;;J. INVEST. MED., vol. 44, 1996, pages 235A;;ARTHRITIS & RHEUMATISM, vol. 38, 1995, pages 5185;;ARTHRITIS & RHEUMATISM, vol. 36, 1993, pages 1223;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 284;;AMER. J. PHYSIOL. - HEART AND CIRCULATORY PHYSIOLOGY, vol. 268, 1995, pages 37 - 42;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 282;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 81;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 82;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 131;;INFLAMMATION RESEARCH, vol. 45, 1996, pages 103 - 107;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 5280;;NEURO REPORT, vol. 7, 1996, pages 1209 - 1213;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 281;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 296;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 308;;ARTHRITIS & RHEUMATISM, vol. 39, no. 9, 1996, pages 5120;;DELUCA ET AL., RHEUM. DIS. CLIN. NORTH AM., vol. 21, 1995, pages 759 - 777;;RUSSELL, D; THOMPSON, R.C., CURR. OPIN. BIOTECH., vol. 4, 1993, pages 714 - 721;;AREND, W.P.; DAYER, J-M., ARTH. RHEUM., vol. 38, 1995, pages 151 - 160;;FAVA, R.A. ET AL., CLIN. EXP. IMMUNOL., vol. 94, 1993, pages 261 - 266;;RANKIN, E.C. ET AL., BR. J. RHEUMATOL., vol. 34, 1995, pages 334 - 342;;FIETZE, E. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 675 - 680;;EASON, J.D. ET AL., TRANSPLANTATION, vol. 59, 1995, pages 300 - 305;;SUTHANTHIRAN, M.; STROM, T.B., NEW ENGL. J. MED., vol. 331, 1994, pages 365 - 375;;TRACY, K.J. ET AL., SCIENCE, vol. 234, 1986, pages 470 - 474;;SUN, X-M. ET AL., J. CLIN. INVEST., vol. 81, 1988, pages 1328 - 133 1;;MACDONALD, T.T. ET AL., CLIN. EXP. IMMUNOL., vol. 81, 1990, pages 301 - 305;;VAN DULLEMEN, H.M. ET AL., GASTROENTEROLOGY, vol. 109, 1995, pages 129 - 135;;BERTOLINI, D.R. ET AL., NATURE, vol. 319, 1986, pages 516 - 518;;KONIG, A. ET AL., J. BONE MINER. RES., vol. 3, 1988, pages 621 - 627;;LERNER, U.H.; OHLIN, A., J. BONE MINER. RES., vol. 8, 1993, pages 147 - 155;;SHANKAR, G.; STERN, P.H., BONE, vol. 14, 1993, pages 871 - 876;;MCCLAIN, C.J.; COHEN, D.A., HEPATOLOGY, vol. 2, 1989, pages 349 - 351;;FELVER, M.E. ET AL., ALCOHOL. CLIN. EXP. RES., vol. 14, 1990, pages 255 - 259;;HANSEN, J. ET AL., HEPATOLOGY, vol. 20, 1994, pages 461 - 474;;SHERON, N. ET AL., J. HEPATOL., vol. 12, 1991, pages 241 - 245;;HUSSAIN, M.J. ET AL., J. CLIN. PATHOL., vol. 47, 1994, pages 1112 - 1115;;VAN DER POLL, T. ET AL., N. ENGL. J. MED., vol. 322, 1990, pages 1622 - 1627;;VAN DER POLL, T. ET AL., PROG. CLIN. BIOL. RES., vol. 367, 1991, pages 55 - 60;;GIROIR, B.P. ET AL., AM. J. PHYSIOL., vol. 267, 1994, pages 118 - 124;;LIU, X.S. ET AL., BURNS, vol. 20, 1994, pages 40 - 44;;SCALES, W.E. ET AL., AM. J. PHYSIOL., vol. 267, 1994, pages 1122 - 1127;;SERRICK, C. ET AL., TRANSPLANTATION, vol. 58, 1994, pages 1158 - 1162;;YAO, Y.M. ET AL., RESUSCITATION, vol. 29, 1995, pages 157 - 168;;MCCAULEY, R.L. ET AL., J. CLIN. IMMUNOL., vol. 12, 1992, pages 300 - 308;;EMBO J, vol. 10, 1991, pages 4025 - 4031;;WARD E S ET AL: ""BINDING ACTIVITIES OF A REOPERTOIRE OF SINGLE IMMUNOGLOBULIN VARIABLE DOMAINS SECRETED FROM ESCHERICHIA COLI"", NATURE: INTERNATIONAL WEEKLY JOURNAL OF SCIENCE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 341, no. 6242, 12 October 1989 (1989-10-12), pages 544 - 546, XP000086104, ISSN: 0028-0836, DOI: 10.1038/341544A0",DISCONTINUED
241,UY,A1,UY 27006 A1,099-824-002-720-348,2002-04-26,2002,UY 27006 A,2001-10-31,UY 27006 A,2001-10-31,ANTICUERPOS HUMANOS QUE LIGAN EL TNF ALFA HUMANO,"Se dan a conocer anticuerpos humanos, de preferencia anticuerpos humanos recombinantes que se ligan específicamente a un factor de necrosis de tumor humano alfa(hTNFalfa). Estos anticuerpos tienen gran afinidad para hTNFalfa (v.g. K= 10-8M o menos), un régimen de disociación lento para disociación de hTNFalfa (v.g. COF=10-3 sec-1 o menos) y neutralizan la actividad de hTNFalfa in vitro e in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de ligazón de antígeno del mismo. Los anticuerpos o porciones de anticuerpos de la invención son útiles para detectar hTNFalfa y para inhibir la actividad de hTNFalfa v.g. en pacientes humanos que padecen de un trastorno en el cual es perjudicial la actividad de hTNFalfa. Los ácidos nucleicos, vectores y células huésped para expresar los anticuerpos humanos recombinantes de la invención y los métodos para sintetizar los anticuerpos humanos recombinantes, también quedan abarcados mediante la invención",ABBOTT DEUTSCHLAND HOLDING GMB,KAYMAKCALAN ZEHRA;;SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/099-824-002-720-348,Patent Application,no,0,0,1,1,0,,,,0,0,,,,DISCONTINUED
242,TR,T2,TR 199801532 T2,137-302-095-679-345,1998-11-23,1998,TR 9801532 T,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,Insan TNFalfa 'sini baglayan insan antikorlari.,"Spesifik olarak insandaki tümör nekroz faktörü alfa (hTNFalfa) ile bag kuran insandaki antikorlarin, tercihen yeniden birlesen türde olanlari açiklanmaktadir. Söz konusu antikorlarin hTNFalfa (örnegin, Kd=10-8M veya daha az) egilimleri yüksek, hTNFalfa çözülmesi için hizlari düsük (örnegin, Koff=10-3 san-1 veya daha az) ve yasayan beden disinda ve yapay ortam içinde ve bitki veya hayvanin yasayan bünyesi içindeki hTNFalfa aktivitesini nötralize ederler. Bulusun antikorlari eksiksiz türde olabilecegi gibi bunun antijen-baglayici kismi da olabilir. Bulusun antikorlari , veya kisimlari hTNFalfa dedektörü olarak ve hTNFalfa aktivitesini önleyici olarak faydalidir, örnegin hTNFalfa aktivitesinin caydirici oldugu bir hastalik sikayeti olan hastada oldugu gibi. Nükleik asitler, vektörler ve bulusun yeniden birlesen insandaki antikorlari tanimlamada konakçi hücreler, ve yeniden birlesen insandaki antikorlarin sentezi için yöntemler ayrica bulus kapsaminda açiklanmaktadir.",BASF AG,SALFELD JACHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MACGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/137-302-095-679-345,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
243,HK,A1,HK 1214610 A1,171-059-617-140-810,2016-07-29,2016,HK 16102512 A,2016-03-04,US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFALPHA TNF,,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/171-059-617-140-810,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K/;;A61K/;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N/;;C12N1/21;;C12N5/10;;C12P21/08;;G01N/;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,PENDING
244,BR,B8,BR PI9715219 B8,179-020-207-828-068,2015-07-07,2015,BR 9715219 A,1997-02-10,US 59922696 A;;US 3147696 P;;BR 9707379 A,1996-02-09,"Vetor recombinante de expressão, e célula hospedeira procariótica.",,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABROVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBVIE BIOTECHNOLOGY LTD. (BM) (2015-06-09),https://lens.org/179-020-207-828-068,Amended Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
245,US,A1,US 2003/0219438 A1,194-051-593-478-857,2003-11-27,2003,US 30235602 A,2002-11-22,US 30235602 A;;US 54001800 A;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFalpha,"
    Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor (hTNF) are disclosed. These antibodies have high affinity for hTNF (e.g., K _{d} 10 ⁸ M or less), a slow off rate for hTNF dissociation (e.g., K _{off} 10 ³ sec ¹ or less) and neutralize hTNF activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF and for inhibiting hTNF activity, e.g., in a human subject suffering from a disorder in which hTNF activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention. 
",SALFELD JOCHEN G.;;ALLEN DEBORAH J.;;HOOGENBOOM HENDRICUS R.J.M.;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A.;;MCGUINNESS BRIAN T.;;ROBERTS ANDREW J.;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J.;;WHITE MICHAEL;;WILTON ALISON J.,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBOTT BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/194-051-593-478-857,Patent Application,yes,0,131,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/145.1;;530/388.23;;424/85.2;;435/7.1;;435/69.1;;435/320.1;;435/335;;536/23.53,0,0,,,,DISCONTINUED
246,US,B2,US 8206714 B2,197-511-743-113-137,2012-06-26,2012,US 36945109 A,2009-02-11,US 36945109 A;;US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/197-511-743-113-137,Granted Patent,yes,99,55,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/142.1;;424/145.1;;424/158.1;;424/810,93,80,005-321-867-106-932;;082-560-368-073-508;;092-412-882-661-570;;072-438-011-112-832;;064-048-827-826-930;;101-630-891-707-104;;022-179-293-052-569;;077-341-362-901-551;;026-408-993-198-966;;024-854-471-494-140;;003-185-616-989-105;;006-342-252-521-899;;033-261-430-402-230;;072-378-691-723-546;;005-119-615-003-591;;036-413-156-723-523;;033-797-614-829-293;;040-701-579-915-050;;030-874-783-814-532;;017-529-128-038-946;;057-954-116-868-246;;015-761-810-001-488;;010-916-105-450-247;;020-855-322-534-259;;061-726-307-774-867;;074-932-950-939-666;;053-341-149-236-635;;004-601-819-239-79X;;030-323-674-660-051;;116-193-705-533-609;;003-841-586-111-459;;087-599-254-199-807;;027-477-313-726-928;;098-176-334-504-327;;019-030-524-959-069;;022-384-366-455-012;;092-023-577-402-127;;021-641-900-032-887;;006-117-436-368-816;;145-140-396-707-208;;042-623-879-457-954;;074-817-300-512-106;;031-729-641-207-089;;022-133-574-143-973;;006-911-122-969-908;;006-626-799-687-686;;021-113-833-013-619;;038-613-711-274-229;;025-395-146-381-464;;085-277-440-303-853;;072-378-691-723-546;;012-897-611-427-172;;050-836-464-727-069;;005-119-615-003-591;;032-071-991-081-664;;035-939-173-669-143;;077-815-816-621-813;;040-701-579-915-050;;002-495-006-719-164;;032-820-729-763-323;;043-108-278-056-872;;020-855-322-534-259;;010-916-105-450-247;;046-104-560-723-30X;;048-379-681-038-232;;016-219-576-017-946;;074-932-950-939-666;;001-900-209-379-77X;;020-753-772-581-741;;040-981-641-449-302;;003-595-371-167-198;;053-289-310-577-642;;028-677-787-189-119;;041-315-340-063-133;;027-477-313-726-928;;088-851-255-233-972;;137-274-595-200-649;;026-144-631-995-304;;010-327-392-460-003;;088-581-950-418-154,7884952;;10.1001/jama.1995.03520360048038;;10.1001/jama.273.12.934;;7735957;;10.1097/00024382-199404000-00001;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1038/nrd984;;12509759;;10.1097/00003246-199609000-00002;;8797612;;10.1002/eji.1830240409;;8149953;;7935497;;10.1016/0161-5890(94)90101-5;;18240199;;10.1002/art.23362;;10.1146/annurev.immunol.19.1.163;;11244034;;10.1006/jmbi.1994.1351;;8196048;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;1560463;;10.1016/0022-2836(92)91010-m;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;7620183;;10.1182/blood.v86.3.890.890;;2531466;;10.1126/science.2531466;;7521646;;10.1038/nbt0994-899;;pmc1766613;;11053087;;10.1136/ard.59.suppl_1.i44;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;8757799;;10.1006/jmbi.1996.0406;;10.1038/nbt0792-779;;1368267;;1748994;;10.1016/0022-2836(91)90498-u;;7765558;;10.1038/nbt1194-1134;;10.1016/1043-4666(90)90011-h;;1716486;;10.1016/0959-440x(95)80028-x;;8528760;;15848075;;10.1016/j.ymeth.2005.01.006;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;8364031;;10.1021/bi00085a016;;10.1097/00003246-199605000-00003;;8706447;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;11730333;;10.1006/abio.2001.5380;;8609615;;10.1006/jmbi.1996.0069;;10.1016/1043-4666(92)90072-y;;1381227;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1146/annurev.med.45.1.491;;8198398;;7697917;;pmc1534281;;10.1111/j.1365-2249.1995.tb03598.x;;9624683;;10.1038/nbt0698-535;;10.1038/341544a0;;2677748;;8397764;;10.1016/0167-5699(93)90039-n;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;8783501;;10.1016/0167-5699(96)10025-6;;9265725;;10.1016/s0958-1669(97)80068-7;;7934495;;10.1016/s0140-6736(94)90632-7;;10.1038/nbt0796-845;;9631008;;pmc4119940;;25033887;;1565653;;pmc48911;;10.1073/pnas.89.8.3576;;10.1038/ng0594-13;;8075633;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;pmc395221;;10.1002/j.1460-2075.1994.tb06626.x;;8045255;;10.1111/j.1749-6632.1995.tb55879.x;;7486582;;10.1016/0022-2836(92)90639-2;;1507232;;10.1016/0022-2836(92)90894-p;;1404359;;10.1111/j.1365-2141.1992.tb08212.x;;1379467;;7579668;;10.1016/0958-1669(95)80093-x;;7521646;;10.1038/nbt0994-899;;10.1016/0161-5890(93)90106-l;;8232330;;8159246;;10.1038/368856a0;;7494109;;10.3109/08830189509061738;;1748994;;10.1016/0022-2836(91)90498-u;;10.1038/nbt0792-779;;1368267;;10.1016/s0021-9258(18)41952-7;;1644788;;7764095;;10.1038/nbt1093-1145;;10.1038/ng0297-146;;9020839;;10.1016/1043-4666(90)90011-h;;1716486;;9052775;;10.1038/386025a0;;10.1093/intimm/6.4.579;;8018598;;7957560;;10.1002/eji.1830241116;;8190629;;pmc307995;;10.1093/nar/22.8.1389;;10.1096/fasebj.10.10.8751726;;8751726;;10.1038/nbt0595-475;;9634788;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.3.co;2-y;;10.1002/(sici)1097-0134(199605)25:1<130::aid-prot11>3.0.co;2-l;;8727325;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;1423650;;10.3109/07388559209114235;;10.1111/j.1365-2249.1994.tb05522.x;;7994916;;pmc1534487;;10.3233/hab-1995-6206;;7492754;;9180069;;10.1126/science.276.5319.1665;;10.4049/jimmunol.164.3.1432;;10640759,"Abraham et al., ""Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor alpha in Patients with Sepsis Syndrome,"" JAMA, vol. 273(12):934-941 (1995).;;Barbuto et al. ""Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes"" Proc. Am. Assoc. Cancer Res,. 34:487, Abstr. 2904 (1993).;;Bendtzen et al. ""Auto-antibodies to IL-1alpha and TNFalpha in Normal Individuals and in Infectious and Immunoinflammatory Disorders"" The Physiological and Pathological Effects of Cytokines, 447-52 (1990).;;Boekstegers et al., ""Repeated administration of a F(ab')2 fragment of an anti-tumor recrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,"" Shock, vol. 1(4):237-245 (1994) (abstract from Pub Med).;;Boyle et al. ""A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- alpha"" Cell. Immunol., 152:556-68 (1993).;;Boyle et al. ""The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNF.alpha. on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope"", Cell. Immunol., vol. 152, pp. 569-581, (1993).;;Brekke , et al., ""Therapeutic antibodies for human diseases at the dawn of the twenty-first century,"" Nature Reviews/Drug Discovery, vol. 2:52-62 (2003).;;Chow et al. ""Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFalpha, IL-1beta, and IL-6 levels in patients with sepsis syndrome"" Clinical Research, vol. 42, No. 2 p. 299A (1994).;;Cohen et al., ""Intersept: An international, multicenter, placebo-controlled trial of monoclonal anitbody to human tumor necrosis factor-alpha in patients with sepsis,"" Crit Care Med, vol. 24(9):1431-1440 (1996).;;Cox et al. ""A directory of human germ-line Vkappasegments reveals a strong bias in their usage"" Eur. J. Immunol., 24(2):827-36 (1994).;;Department of Surgery, University of Toronto Annual Report, Jul. 1, 1998-Jun. 30, 1999-found online at http://www.surg.med.utoronto.ca/AnnRep/AR98-99/index.html.;;Doring et al. ""Identification and Characterization of a TNFa antagonist derived from a monoclonal antibody"" Mol Immunol 31:1059-1067 (1994).;;Elliot et al. ""Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha"" Arthritis & Rheumatism, 36(12):1681-90 (1993).;;Feldman et al., ""Anti-TNFalpha Therapy of Rheumatoid Arthritis: What Have We Learned?"" Annu. Rev. Immunol., vol. 19:163-196 (2001).;;Figini et al., ""In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation,"" J. Mol. Biol., vol. 239:68-78 (1994).;;Fomsgaard. et al. ""Auto-antibodies to Tumour Necrosis Factor alpha in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections"" Scand. J. Immunol., 30:219-23 (1989).;;Foote et al. ""Antibody framework residues affecting the conformation of the hypervariable loops,"" J Mol Biol 224(2):487 (1992).;;Griffiths et al. ""Human anti-self antibodies with high specificity from phage display libraries"" The EMBO J., 12(2):725-34 (1993).;;Hawkins et al., ""Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,"" J. Mol. Biol., vol. 226:889-896 (1992).;;Holler et al., ""Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F),"" Blood, vol. 86(3):890-899 (1995) (abstract from Pub Med).;;Hoogenboom et al., ""Converting rodent into human antibodies by guided selection,"" Antibody Engineering, Oxford University Press, pp. 169-185 (1996).;;Huse et al. ""Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda"" Science, 246:1275-81 (1989).;;Jespers, Laurent S., et al., Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen, Bio/Technology, vol. 12:899-903 (1994).;;Kempeni ""Update on D2E7: a fully human anti-tumor necrosis factor alpha monoclonal antibody,"" Ann Rheum Dis, vol. 59(Suppl. I):144-145 (2000).;;Lerner et al. ""Antibodies without immunization"" Science, 258:1313-14 (1992).;;Leusch et al. ""Failure to demonstrate TNFalpha-specific autoantibodies in human sera by ELISA and Western blot"" J. Immunol. Methods, 139:145-47 (1991).;;Lewis et al. ""Use of alanine scanning mutagenesis to improve the affinity of an anti gp120 (HIV) antibody."" J. Cell. Biochem., 18D:215 (1994).;;Low, Nigel M., thesis extract, Cambridge University (1996).;;Low, Nigel M., et al., ""Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,"" J. Mol. Biol., vol. 260:359-368 (1996).;;Marks et al., ""By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,"" Biotechnology 10:779-783 (1992).;;Marks et al. ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"" J. Mol. Biol. 222:581-97 (1991).;;Medynski ""Phage Display: All Dressed Up and Ready to Role,"" Bio/Technology, vol. 12:1134-1136 (1994).;;Möller et al. ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and vivo application"" Cytokine, 2(3):162-69 (1990).;;Nilsson ""Antibody engineering,"" Current Opinion in Structural Biology, vol. 5:450-456 (1995).;;Osbourn et al. ""From rodent reagents to human therapeutics using antibody guided selection,"" Methods 36(1):61 (2005).;;Queen et al., ""A humanized antibody that binds to the interleukin 2 receptor,"" PNAS USA, 86(24):10029 (1989).;;Rader et al. ""A phage display approach to rapid antibody humanization: Designed combinatorial V gene libraries"" Proc Natl Acad Sci USA 95:8910-8915 (1998).;;Riechmann et al., ""Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement,"" Biochemistry, vol. 32(34):8848-8855 (1993) (abstract from Pub Med).;;Reinhart et al., ""Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study,"" Crit Care Med, vol. 24(5):1608 (1996) (abstract from Pub Med).;;Rudikoff et al. ""Single Amino Acid Substitution Altering Antigen-Binding Specificity"" Proc Natl Acad Sci USA 79:1979-1983 (1982).;;Santora et al., ""Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Using Cation Exchange, Size Exclusion Chromatography, and BIA core,"" Analytical Biochemistry, vol. 299:119-129 (2001).;;Thompson et al., ""Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity,"" J. Mol. Biol., vol. 256(1):77-88 (1996) (abstract from Pub Med).;;Thorp et. al. ""Tumour Necrosis Factor Induction of ELAM-1 and ICAM-1 on Human Umbilical Vein Endothelial Cells-Analysis of Tumour Necrosis Factor Receptor Interactions"" Cytokine 4:313-319 (1992).;;Tomlinson et al., ""The Repertoire of Human Germline VH Sequences Reveals about Fifty Groups of VH Segments with Different Hypervariable Loops,"" J. Mol. Biol., vol. 227:776-798 (1992).;;Tomlinson et al., ""The structural repertoire of the human Vkappadomain,"" The EMBO Journal, vol. 14(18):4628-4638 (1995).;;Tracey et al., ""Tumor Necrosis Factor: A Pleiotropic Cytokine and Therapeutic Target,"" 9Annu. Rev. Med., vol. 45:491-503 (1994).;;Van Der Poll et al., ""Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees,"" Clin Exp Immunol, vol. 100:21-25 (1995).;;Vaughan et al., ""Human antibodies by design,"" Nature Biotechnology, vol. 16:535-539 (1998).;;Ward et al., ""Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli,"" Nature, vol. 341(6242):544-546 (1989).;;Winter et al, ""Humanized antibodies,"" Immunology Today, vol. 14(6):243-246 (1993).;;Winter et al., ""Making antibodies by phage display technology,"" Annu. Rev. Immunol., vol. 12:433-455 (1994).;;Bruggemann, M., Neuberger, M.S., ""Strategies for expressing human antibody repertoires in transgenic mice, "" Immunol. Today 17:391-397 (1996).;;Bruggemann et al. ""Production of human antibody repertoires in transgenic mice"" Cur. Op. Biotechnol. 8:455-458 (1997).;;Cambridge Antibody Technology, advertisement of phage display services, Science vol. 253, No. 5018 (1991).;;Elliot et al., ""Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis,"" Lancet 344:1125-1127 (1994).;;Fishwild et al., ""High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice,"" Nature Biotechnology 14:845-851 (1996).;;Gram et al., ""In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library,"" PNAS 89:3576-3580 (1992).;;Green et al., ""Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs,"" Nature Genetics 7:13-21 (1994).;;Griffiths et al., ""Human anti-self antibodies with high specificity from phage display libraries,"" EMBO J. 12:725-734 (1993).;;Griffiths et al., ""Isolation of high affinity human antibodies directly from large synthetic repertoires,"" EMBO J. 13:3245-3260 (1994).;;Harding et al., ""Class switching in human immunoglobulin transgenic mice,"" Ann. NY Acad. Sci. 764:536-547 (1995).;;Hawkins et al., ""Selection of phage antibodies by binding affinity. Mimicking affinity maturation,"" J. Mol. Biol. 226:889-896 (1992).;;Hoogenboom et al., ""By-passing immunisation: Human antobodies from synthetic repertoires of germline VH gene segments rearranges in vitro,"" J. Mol. Biol. 227:381-388 (1992).;;Huang et al. ""Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia,"" Br. J. Haematol 81(2):231-234 (1992).;;Jakobovits, A., ""Production of fully human antibodies by transgenic mice,"" Curr. Op. Biotechnol. 6:561-566 (1995).;;Jespers et al., ""Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen,"" Nature Biotechnology 12:899-903 (1994).;;The Kennedy Institute of Rheumatology, 1995 Annual Scientific Report, ""Anti-TNF trials and studies of mechanisms of action"".;;Knight et al., ""Construction and initial characterization of a mouse-human chimeric anti-TNF antibody,"" Mol. Immunol. 30(16):1443-1453 (1993).;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications,"" Nature 368:856-859 (1994).;;Lonberg et al., ""Human Antibodies from Transgenic Mice,"" Int. Rev. Immunol. 13:65-93 (1995).;;Marks et al., ""Bypassing immunization Human antibodies from V-gene libraries displayed on phage,"" J. Mol. Biol. 222:581-597 (1991).;;Marks et al., ""Bypassing immunization: High affinity human antibodies by chain shuffling,"" Bio/Technology 10:779-783 (1992).;;Marks et al., ""Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system,"" J. Biol. Chem. 267:16007-16010 (1992).;;Marks et al., ""Human antibody fragments specific for human blood group antigens from a phage display library,"" Bio/Technology 11:1145-1150 (1993).;;Marks, ""Human Monoclonal Antibodies from V-gene Repertoires Expressed on Bacteriophage."" in Antibody Engineering, Second Edition, edited by Carl A.K. Borrebaeck (1995), pp. 53-88. New York: Oxford Univ. Press.;;Mendez et al., ""Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice,"" Nature Genetics 15:146-156 (1997).;;Moller et al., ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and in vivo application,"" Cytokine 2(3):162-169 (1990).;;Neuberger M., et al., ""Mice perform a human repertoire"", Nature 386: 25-26 (1997).;;Salfeld, ""Development of a Fully Human Antibody to TNF by Phage Display Technology"", IBC Conference, Antibody Engineering, San Diego (1996), 36 pages.;;Taylor et al.,""Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM,"" Int. Immunol. 6:579-591 (1994).;;Wagner et al., ""The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human immunoglobulin gene miniloci,"" Eur. J. Immunol. 24:2672-2681 (1994).;;Wagner et al., ""Antibodies generated from human immunoglobulin miniloci in transgenic mice,"" Nucl. Acids Res. 22:1389-1393 (1994).;;Zou et al., ""Dominant expression of a 1.3 Mb human Ig kappa locus replacing mouse light chain production,"" FASEB J 10:1227-1232 (1996).;;Davies et al., ""Antibody VH domains as small recognition units."" Biotechnology, 13:475-479 (1995).;;Lonberg et al., ""Antigen-specific human antibodies from mice comprising four distinct genetic modifications."" Nature, 368:856-859 (1994).;;Martin, A.C.R. ""Accessing the Kabat antibody sequence database by computer."" Proteins: Structure, Function and Genetics, 25:130-133 (1996).;;Rudikoff, et al., Single amino acid substitution altering antigen-binding specificity. Proc. Natl.Acad. Sci. USA, 70:1979-1983 (1982).;;Sandhu, J. ""Protein engineering of antibodies."" Critical Reviews in Biotechnology, 12:437-462 (1992).;;Sioud et al., ""Characterization of naturally occurring autoantibodies against tumour necrosis factor-alpha (TNF-alpha): in vitro function and precise epitope mapping by phage epitope library."" Clin Exp Immunol, 98:520-525 (1994).;;Teichmann, S. Declaration dated Dec. 7, 2010 from opposition proceedings in EP 0929578.;;Tsuchiyama et al., ""Comparison of anti-TNF alpha autoantibodies in plasma and from EBV transformed lymphocytes of autoimmune and normal individuals."" Hum. Antibod. Hybridomas 6(2):73-76 (1995).;;Wedemayer et al., ""Structural insights into the evolution of an antibody combining site."" Science 276:1665-1669 (1997).;;Tamura, M. et al. ""Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only"" Journal of Immunology (2000) vol. 164, pp. 1432-1441.",EXPIRED
247,SK,B6,SK 284040 B6,014-819-436-368-150,2004-08-03,2004,SK 106298 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor 'alpha' (hTNF'alpha') are disclosed. These antibodies have high affinity for hTNF'alpha'(e.g., Kd = 10exp(-8) M or less), a slow off rate for hTNF'alpha' dissociation (e.g., Koff = 10exp(-3) sec-1 or less) and neutralize hTNF'alpha' activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF'alpha' and for inhibiting hTNF'alpha' activity, e.g., in a human subject suffering from a disorder in which hTNF'alpha' activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT LAB BERMUDA LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBVIE BIOTECHNOLOGY LTD., HAMILTON, BM (2013-10-14)",https://lens.org/014-819-436-368-150,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
248,AU,A,AU 2000/066649 A,073-769-239-850-092,2001-12-06,2001,AU 2000/066649 A,2000-10-20,AU 2000/066649 A;;AU 1997/021229 A,1997-02-10,Human antibodies that bind human TNFalpha,,ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;WILTON ALISON J;;WHITE MICHAEL;;VAUGHAN TRISTAN J;;SCHOENHAUT DAVID;;HOOGENBOOM HENDRICUS R J M;;SAKORAFAS PAUL;;ROBERTS ANDREW J;;MCGUINESS BRIAN T;;MANKOVICH JOHN A;;LABKOVSKY BORIS;;KAYMAKCALAN ZEHR;;ALLEN DEBORAH J,ABBOTT LABORATORIES (BERMUDA) LTD (2003-06-19),https://lens.org/073-769-239-850-092,Patent Application,no,0,0,2,2,0,Y02A50/30,A61K39/395;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,EXPIRED
249,US,B2,US 8787161 B2,079-372-647-206-039,2014-07-22,2014,US 201213461278 A,2012-05-01,US 201213461278 A;;US 83694104 A;;US 72219403 A;;US 71927003 A;;US 71696703 A;;US 71696803 A;;US 71605103 A;;US 70474003 A;;US 47065003 P,2003-05-15,Methods of implementing dynamic quality of service or bandwidth provisioning,"A method of operating a data network may include establishing a data path through the data network between a routing gateway and service provider equipment providing a data service. Moreover, the data service may be provided for use at the routing gateway over the data path during a data session. A request may be received from the service provider equipment where the request defines a data flow characteristic for the data path between the routing gateway and the service provider equipment providing the data service. The data flow characteristic may then be transmitted to a network element along the data path between the routing gateway and the service provider equipment. A request from service provider equipment can include an allowed bandwidth or prioritization. Related methods, data networks, data service providers, routing gateways, and computer program products are also discussed.",ADAMCZYK MARIA;;ANSCHUTZ THOMAS ARNOLD;;BLACKBURN ALAN RYAN;;CASSANOVA JEFFREY PATRICK;;HILL SAMMIE WALTER;;HOLT SCOTT CRANDALL;;HUSLAK NICHOLAS STEVEN;;MCQUAIDE JR ARNOLD CHESTER;;SHRUM JR EDGAR VAUGHAN;;STILLMAN SCOTT TRAYNHAM;;WRIGHT STEVEN ALLEN;;ZHANG LI;;AT & T IP I LP,ADAMCZYK MARIA;;ANSCHUTZ THOMAS ARNOLD;;BLACKBURN ALAN RYAN;;CASSANOVA JEFFREY PATRICK;;HILL SAMMIE WALTER;;HOLT SCOTT CRANDALL;;HUSLAK NICHOLAS STEVEN;;MCQUAIDE JR ARNOLD CHESTER;;SHRUM JR EDGAR VAUGHAN;;STILLMAN SCOTT TRAYNHAM;;WRIGHT STEVEN ALLEN;;ZHANG LI,AT&T INTELLECTUAL PROPERTY I LP (2004-04-19),https://lens.org/079-372-647-206-039,Granted Patent,yes,21,3,10,51,0,H04L63/029;;H04L63/083;;H04L12/2859;;H04L47/2458;;H04L47/2408;;H04L47/2416;;H04L47/2441;;H04L63/102;;H04L63/029;;H04L63/083;;H04L12/2859;;H04L47/2458;;H04L47/2408;;H04L47/2416;;H04L47/2441;;H04L63/102;;H04L47/24;;H04W72/0446,H04L12/28;;H04L12/66;;H04L47/2416;;H04L47/31,370/230;;370/235,9,0,,,"""DSL Forum, DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services"", Working Text: WT-081, Revision 4, Dec. 2002.;;""DSL Forum, DSL Evolution-Architecture Requirements for the Support of QoS-Enabled IP Services"", Working Text: WT-081, Revision 6, Mar. 2003.;;""DSL Forum, DSL Evolution-Architecture Requirements for the Support ofQoS-Enabled IP Services"", Working Text: WT-081, Revision 5, Feb. 2003.;;""DSL Forum, DSL Evolution-Architecture Requirements for the Support ofQoS-Enabled IP Services"", Working Text: WT-081, Letter Ballot Revision (9), Jun. 2003.;;""DSL Forum, DSL Evolution-Architecture Requirements for the Support ofQoS-Enabled IP Services"", Working Text: WT-081, Straw Ballot Revision (7), Mar. 2003.;;""DSL Forum, DSL Evolution-Architecture Requirements for the Support ofQoS-Enabled IP Services"", Working Text: WT-081, Straw Ballot Revision (8), Mar. 2003.;;""DSL Forum, DSL Evolution-Architecture Requirements for the Support ofQoS-Enabled IP Services"", Proposed Draft: PD-00X, Revision I, Aug. 2002.;;Anschutz, et al., ""DSL Evolution-Architecture Requirements for the Support ofQoS-Enabled IP Services"", Technical Report: TR-059, Sep. 2003.;;Blake, et al., ""An Architecture for Differentiated Services"", The Internet Society, Dec. 1998.",EXPIRED
250,NO,B1,NO 322755 B1,084-115-039-318-858,2006-12-04,2006,NO 20040052 A,2004-01-07,US 3147696 P;;US 59922696 A;;US 9702219 W,1996-02-09,"Anvendelse av et antistoff og minst ett ytterligere terapeutisk middel, isolerte human-antistoffer inkludert D2E7, derivatisert eller bundet til minst ett funksjonelt molekyl, isolerte human-antistoffer og fragmenter derav, samt isolerte nukleinsyrer.",,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNES BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON JANE,"ABBOTT BIOTECHNOLOGY LTD, BM (2013-10-07);;ABBVIE BIOTECHNOLOGY LTD, BM (2013-10-14)",https://lens.org/084-115-039-318-858,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/13;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
251,US,B2,US 7541031 B2,102-401-106-469-559,2009-06-02,2009,US 78790107 A,2007-04-17,US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,Methods for treating rheumatoid arthritis using human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1998-11-18);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/102-401-106-469-559,Granted Patent,yes,74,146,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/495;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/142.1;;424/145.1;;424/158.1;;424/810;;514/249,51,42,116-193-705-533-609;;027-477-313-726-928;;005-321-867-106-932;;082-560-368-073-508;;092-412-882-661-570;;072-438-011-112-832;;064-048-827-826-930;;101-630-891-707-104;;022-179-293-052-569;;026-408-993-198-966;;024-854-471-494-140;;003-185-616-989-105;;006-342-252-521-899;;072-378-691-723-546;;005-119-615-003-591;;036-413-156-723-523;;033-797-614-829-293;;040-701-579-915-050;;030-874-783-814-532;;017-529-128-038-946;;057-954-116-868-246;;015-761-810-001-488;;010-916-105-450-247;;061-726-307-774-867;;074-932-950-939-666;;053-341-149-236-635;;003-841-586-111-459;;087-599-254-199-807;;098-176-334-504-327;;019-030-524-959-069;;092-023-577-402-127;;021-641-900-032-887;;006-117-436-368-816;;145-140-396-707-208;;042-623-879-457-954;;074-817-300-512-106;;031-729-641-207-089;;022-133-574-143-973;;020-855-322-534-259;;033-261-430-402-230;;004-601-819-239-79X;;030-323-674-660-051,9671778;;pmc21176;;10.1073/pnas.95.15.8910;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;7884952;;10.1001/jama.1995.03520360048038;;10.1001/jama.273.12.934;;7735957;;10.1097/00024382-199404000-00001;;7504981;;10.1006/cimm.1993.1312;;7504982;;10.1006/cimm.1993.1313;;10.1038/nrd984;;12509759;;10.1097/00003246-199609000-00002;;8797612;;10.1002/eji.1830240409;;8149953;;18240199;;10.1002/art.23362;;10.1146/annurev.immunol.19.1.163;;11244034;;10.1006/jmbi.1994.1351;;8196048;;10.1111/j.1365-3083.1989.tb01204.x;;2788302;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90639-2;;1507232;;7620183;;10.1182/blood.v86.3.890.890;;2531466;;10.1126/science.2531466;;7521646;;10.1038/nbt0994-899;;pmc1766613;;11053087;;10.1136/ard.59.suppl_1.i44;;1455226;;10.1126/science.1455226;;10.1016/0022-1759(91)90361-i;;2040812;;8757799;;10.1006/jmbi.1996.0406;;10.1038/nbt0792-779;;1368267;;7765558;;10.1038/nbt1194-1134;;10.1016/1043-4666(90)90011-h;;1716486;;10.1016/0959-440x(95)80028-x;;8528760;;8364031;;10.1021/bi00085a016;;10.1097/00003246-199605000-00003;;8706447;;11730333;;10.1006/abio.2001.5380;;8609615;;10.1006/jmbi.1996.0069;;1404388;;10.1016/0022-2836(92)90223-7;;pmc394555;;7556106;;10.1002/j.1460-2075.1995.tb00142.x;;10.1146/annurev.med.45.1.491;;8198398;;7697917;;pmc1534281;;10.1111/j.1365-2249.1995.tb03598.x;;9624683;;10.1038/nbt0698-535;;10.1038/341544a0;;2677748;;8397764;;10.1016/0167-5699(93)90039-n;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;1748994;;10.1016/0022-2836(91)90498-u;;1560463;;10.1016/0022-2836(92)91010-m;;15848075;;10.1016/j.ymeth.2005.01.006;;pmc298637;;2513570;;10.1073/pnas.86.24.10029,"Rader et al, Proc. Natl. Acad. Sci. USA, vol. 95, 8910-8915, 1998.;;Rudikoff et al, Proc. Natl. Acad. Sci. USA, vol. 79, 1979-1983, 1982.;;Abraham, Edward, et al., ""Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor alpha in Patients with Sepsis Syndrome,"" JAMA, vol. 273(12):934-941 (1995).;;Barbuto, J.A.M. et al. ""Production of Neutralizing Antibodies to Tumor Necrosis Factor by Human Tumor-Infiltrating B Lymphocytes"" Proc. Am. Assoc. Cancer Res. 34:487, Abstract No. 2904 (Mar. 1993).;;Bendtzen, K. et al. ""Auto-antibodies to IL-1alpha and TNFalpha in Normal Individuals and in Infectious and Immunoinflammatory Disorders"" in The Physiological and Pathological Effects of Cytokines (Wiley-Liss, Inc., 1990) 447-52.;;Boekstegers, P., et al., ""Repeated administration of a F(ab')2 fragment of an anti-tumor recrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels,"" Shock, vol. 1(4):237-245 (1994).;;Boyle, P. et al. ""A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor- alpha"" Cell. Immunol. 152:556-68 (1993).;;Boyle, P. et al. ""The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFalpha on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope"" Cell. Immunol. 152:569-81 (1993).;;Brekke, Ole Henrik, et al., ""Therapeutic antibodies for human diseases at the dawn of the twenty-first century,"" Nature Reviews/Drug Discovery, vol. 2:52-62 (2003).;;Chow, A.W. et al. ""Effect of monoclonal antibody on human tumor necrosis factor (TNF MAb) on TNFalpha, IL-1beta, and IL-6 levels in patients with sepsis syndrome"" Clinical Research 42:2 299A (1994).;;Cohen, Jonathan, et al., ""Intersept: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis,"" Crit Care Med, vol. 24(9):1431-1440 (1996).;;Cox, J.P.L. et al. ""A directory of human germ-line Vkappasegments reveals a strong bias in their usage"" Eur. J. Immunol. 24(2);827-36 (1994).;;Department of Surgery, University of Toronto Annual Report, Jul. 1, 1998-Jun. 30, 1999-found online at http://www.surg.med.utoronto.ca/AnnRep/AR98-99/index.html.;;Elliot, M.J. et al. ""Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha"" Arthritis & Rheumatism 36(12):1681-90 (1993).;;Feldman, Marc, et al., ""Anti-TNF∝ Therapy of Rheumatoid Arthritis: What Have We Learned?"" Annu. Rev. Immunol., vol. 19:163-196 (2001).;;Figini, Mariangela, et al., ""In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation,"" J. Mol. Biol., vol. 239:68-78 (1994).;;Fomsguaard, A. et al. ""Auto-antibodies to Tumor Necrosis Factor alpha in Healthy Humans and Patients with Inflammatory Diseases and Gram-Negative Bacterial Infections"" Scand. J. Immunol. 30:219-23 (1989).;;Griffiths, A.D. et al. ""Human anti-self antibodies with high specificity from phage display libraries"" The EMBO J. 12(2):725-34 (1993).;;Hawkins, Robert E., et al., ""Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation,"" J. Mol. Biol., vol. 226:889-896 (1992).;;Holler, E., et al., ""Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F),"" Blood, vol. 86(3):890-899 (1995).;;Hoogenboom, Hennie R., et al., ""Converting rodent into human antibodies by guided selection,"" Antibody Engineering, Oxford University Press, pp. 169-185 (1996).;;Huse, W.D. et al. ""Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda"" Science 246:1275-81 (1989).;;Jespers, Laurent S., et al., ""Guiding the Selection of Human Antibodies from Phage Display Repertoires to a Single Epitope of an Antigen,"" Bio/Technology, vol. 12:899-903 (1994).;;Kempeni, Joachim, ""Update on D2E7: a fully anti-tumor necrosis factor alpha monoclonal antibody,"" Ann Rheum Dis, vol. 59(Suppl. I):144-145 (2000).;;Lerner, R.A. et al. ""Antibodies without immunization"" Science 258:1313-14 (1992).;;Leusch, H-G. et al. Failure to demonstrate TNFalpha-specific autoantibodies in human sera by ELISA and Western blot J. Immunol. Methods 139:145-47 (1991).;;Lewis et al. J. Cell. Biochem. 18D:215 (1994).;;Low, Nigel M., thesis extract, Cambridge University (1996).;;Low, Nigel M., et al., ""Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,"" J. Mol. Biol., vol. 260:359-368 (1996).;;Marks, James D. et al., ""By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,"" Biotechnology, vol. 10:779-783 (1992).;;Medynski, Dan, ""Phage Display: All Dressed Up and Ready to Roll,"" Bio/Technology, vol. 12:1134-1136 (1994).;;Möller et al. ""Monoclonal antibodies to human tumor necrosis factor alpha: in vitro and vivo application"" Cytokine 2(3):162-69 (1990).;;Nilsson, Björn, ""Antibody engineering,"" Current Opinion in Structural Biology, vol. 5:450-456 (1995).;;Riechmann, L., et al., ""Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement,"" Biochemistry, vol. 32(34):8848-8855 (1993).;;Reinhart, K., et al., ""Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study,"" Crit Care Med, vol. 24(5):1608 (1996).;;Santora, L.C., et al., ""Characterization of Noncovalent Complexes of Recombinant Human Monoclonal Antibody and Antigen Cation Exchange, Size Exclusion Chromatography, and BIA core,"" Analytical Biochemistry, vol. 299:119-129 (2001).;;Thompson, J., et al., ""Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity,"" J. Mol. Biol., vol. 256(1):77-88 (1996).;;Tomlinson, I.M. et al. ""The repertoire of human germline V<sub/>H sequences reveals about fifty groups of V<sub/>H segments with different hypervariable loops"" J. Mol. Biol. 227:776-98 (1992).;;Tomlinson, I.M. et al. ""The structural repertoire of the human Vkappadomain"" The EMBO J. 14(18):4628-38 (1995).;;Tracey, K.J. et al. ""Tumor necrosis factor: A pleiotropic cytokine and therapeutic target"" Annu. Rev. Med. 45:491-503 (1994).;;Van Der Poll, T., et al., ""Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees,"" Clin Exp Immunol, vol. 100:21-25 (1995).;;Vaughan, Tristan J., et al., ""Human antibodies by design,"" Nature Biotechnology, vol. 16:535-539 (1998).;;Ward, E. Sally, et al., ""Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli, "" Nature, vol. 341(6242):544-546 (1989).;;Winter, G. et al., ""Humanized antibodies"", Immunology Today, vol. 14(6):243-246 (1993).;;Winter, Greg, et al., ""Making antibodies by phage display technology,"" Annu. Rev. Immunol., vol. 12:433-455 (1994).;;Marks, J.D. et al. ""By-passing immunization: Human antibodies from V-gene libraries displayed on phage"" J. Mol. Biol., 222:581-97 (1991).;;Foote, Jefferson et al., ""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,"" J. Mol. Biol. vol. 224:487-490 (1992).;;Osbourn, Jane et al., ""From rodent reagents to human therapeutics using antibody guided selection,"" Methods, vol. 36:61-68 (2005).;;Queen, Cary et al., ""A humanized antibody that binds to the interleukin 2 receptor,"" Proc. Natl. Acad. Sci. USA, vol. 86:10029-10033 (1989).;;Office Actions cited during prosecution of US Patent No. 7,223,394.;;Office Actions cited during prosecution of US Patent No. 6,509,015.",EXPIRED
252,BR,B1,BR 9715219 B1,115-746-710-031-700,2010-02-23,2010,BR 9715219 A,1997-02-10,US 59922696 A;;US 3147696 P;;BR 9707379 A,1996-02-09,"vetor recombinante de expressço, e cÉlula hospedeira procariàtica.",,,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABROVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBVIE BIOTECHNOLOGY LTD. (BM) (2015-06-09),https://lens.org/115-746-710-031-700,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
253,PL,A1,PL 328411 A1,157-544-802-315-514,1999-01-18,1999,PL 32841197 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,HUMAN ANTIBODIES CAPABLE TO BOND HUMAN TNF ALPHA,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/157-544-802-315-514,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;C12N15/09;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
254,AU,B2,AU 2012/261708 B2,187-317-868-908-409,2014-02-20,2014,AU 2012/261708 A,2012-12-07,AU 2009/202707 A;;AU 2012/261708 A,2009-07-03,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFa) are disclosed. These antibodies have high 5 affinity for hTNFa (e.g., Kd = 10~8 M or less), a slow off rate for hTNFa dissociation (e.g., Korr~10~3sec-' or less) and neutralize hTNFa activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFa and for inhibiting hTNFa activity, e.g., in a human subject suffering from a 10 disorder in which hTNFa activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",ABBVIE BIOTECHNOLOGY LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHR;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J;;SCHOENHAUT DAVID,,https://lens.org/187-317-868-908-409,Granted Patent,no,2,0,2,2,0,,C07K16/24;;A61K39/395;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/64;;G01N33/68,,0,0,,,,INACTIVE
255,CN,B,CN 101343324 B,195-158-075-226-04X,2015-06-24,2015,CN 200810212687 A,1997-02-10,US 59922696 A;;US 3147696 P,1996-02-09,Method for the inhibition of human TNF alpha activity,,ABBOTT BIOTECH LTD,MANKOVICH JOHN A;;WHITE MICHAEL;;VAUGHAN TRISTAN J;;SCHOENHAUT DAVID;;ROBERTS ANDREW J;;SALFELD JOCHEN G;;ALLEN DEBORAH J;;LABKOVSKY BORIS;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;MCGUINNESS BRIAN T;;WILTON ALISON J;;SAKORAFAS PAUL,,https://lens.org/195-158-075-226-04X,Granted Patent,no,0,0,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/63;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
256,HU,B1,HU 221984 B1,088-647-558-382-010,2003-03-28,2003,HU P9901874 A,1997-02-10,US 59922696 A;;US 3147696 P;;US 9702219 W,1996-02-09,"HUMAN ANTIBODIES BINDING HUMAN TNFALFA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF AND USE THEREOF","A találmány tárgya izolált TNF?-kötő humán antitest vagy antigénkötőrésze, amely a) a humán TNF?-tól 1×10–3 s–1 vagy ennél kisebb Koff-értékkel és 1×10–8 M vagy ennél kisebb Kd-értékkel disszociál,mindkettőt felületi plazmonrezonanciával meghatározva; b) könnyű láncCDR3 doménje 3. számú aminosavszekvenciát vagy az 1., 4., 5., 7. vagy8. pozícióban egyetlen ala- ninhelyettesítéssel, vagy az 1., 3., 4.,6., 7., 8. és/vagy 9. pozícióban 1–5 konzervatívaminosavhelyettesítéssel módosított 3. számú aminosavszekvenciáttartalmaz; c) nehéz lánc CDR3 doménje 4. számú aminosavszekvenciátvagy a 2., 3., 4., 5., 6., 8., 9., 10. vagy 11. pozícióban egyetlenalaninhelyettesítéssel, vagy a 2., 3., 4., 5., 6., 8., 9., 10., 11.és/vagy 12. pozícióban 1–5 konzervatív amino- savhelyettesítésselmódosított aminosavszekvenciát tartalmaz; és d) 1×10–7 M vagy ennélkisebb IC50-értékkel rendelkezik. A találmány a fenti antitestekettartalmazó gyógyszerkészítményekre és az antitestek alkalmazására isvonatkozik. ŕ",BASF AG,ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SALFELD JOCHEN G;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBOTT LABORATORIES (BERMUDA) LTD., BM (2003-06-28);;ABBOTT BIOTECHNOLOGY LTD., BM (2005-02-28);;ABBVIE BIOTECHNOLOGY LTD, BM (2014-07-28)",https://lens.org/088-647-558-382-010,Granted Patent,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
257,US,A1,US 2003/0092059 A1,124-251-009-565-589,2003-05-15,2003,US 80118501 A,2001-03-07,US 80118501 A;;US 12509899 A;;US 3147696 P;;US 9702219 W;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFalpha,"
    Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNF) are disclosed. These antibodies have high affinity for hTNF (e.g., K _{d} 10 ⁸ M or less), a slow off rate for hTNF dissociation (e.g., K _{off} 10 ³ sec ¹ or less) and neutralize hTNF activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF and for inhibiting hTNF activity, e.g., in a human subject suffering from a disorder in which hTNF activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention. 
",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1998-11-18);;ABBVIE BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/124-251-009-565-589,Patent Application,yes,1,49,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;C12N15/09;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,435/7.1;;530/388.23,0,0,,,,EXPIRED
258,NZ,A,NZ 562935 A,137-623-895-967-203,2009-06-26,2009,NZ 56293597 A,1997-02-10,US 3147696 P;;US 59922696 A,1996-02-09,Human antibodies that bind human TNFalpha,"Provided is the use of an isolated human antibody, or antigen-binding portion thereof, in the manufacture of a medicament for the treatment of rheumatoid arthritis in combination with methotrexate, wherein the isolated human antibody, or an antigen-binding portion thereof, dissociates from human TNFalpha with a Kd of 1 x 10-8 M or less and a Koff rate constant of 1 x 10-3 s-1 or less, both determined by surface plasmon resonance, neutralizes human TNFalpha cytotoxicity in a standard in vitro L929 assay with an IC50 of 1 x 10-7 M or less, and neutralizes TNFalpha-induced cellular activation in a standard in vitro assay for TNFalpha-induced ELAM-I expression on human umbilical vein endothelial cells (HUVEC).",ABBOTT BIOTECH LTD,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,,https://lens.org/137-623-895-967-203,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;C12N15/09;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
259,CA,C,CA 2389943 C,136-884-013-970-101,2009-04-07,2009,CA 2389943 A,1997-02-10,CA 2243459 A;;US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNF.ALPHA.,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha. (e.g., K d = 10 -8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K off = 10 -3sec-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full--length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",BASF AG,WHITE MICHAEL;;VAUGHAN TRISTAN J;;WILTON ALISON J;;KAYMAKCALAN ZEHRA;;HOOGENBOOM HENDRICUS R J M;;ALLEN DEBORAH J;;SCHOENHAUT DAVID;;LABKOVSKY BORIS;;SAKORAFAS PAUL;;SALFELD JOCHEN G;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;MANKOVICH JOHN A,,https://lens.org/136-884-013-970-101,Granted Patent,no,0,0,45,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C12N15/09;;C12N15/13;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12N15/28;;C12N15/63;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,EXPIRED
260,EP,A2,EP 1285930 A2,159-455-216-118-823,2003-02-26,2003,EP 02022788 A,1997-02-10,EP 97906572 A;;US 59922696 A;;US 3147696 P,1996-02-09,Human antibodies that bind human TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα ( e.g ., K d  = 10 -8  M or less), a slow off rate for hTNFα dissociation ( e.g ., K off  = 10 -3  sec -1  or less) and neutralize hTNFα activity  in vitro  and  in vivo . An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity,  e.g. , in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,ABBVIE BIOTECHNOLOGY LTD (2014-01-01);;ABBOTT LABORATORIES (BERMUDA) LTD. (2003-08-13);;ABBOTT BIOTECHNOLOGY LTD (2004-03-31),https://lens.org/159-455-216-118-823,Patent Application,yes,0,5,45,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;C07K2317/92;;Y10S424/81;;Y10S530/868;;Y10S424/80;;C07K16/241;;A61P1/00;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K2317/92;;A61K2039/505;;C07K2317/56;;C07K2317/565;;A61K38/00;;C07K2317/21;;Y10S424/81;;Y10S424/80;;Y10S530/868;;Y02A50/30;;C07K16/241,C07K16/24;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C12N1/21;;C12N5/10;;C12N15/13;;C12N15/28;;C12N15/64;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
261,EP,B1,EP 0929578 B1,185-439-302-428-847,2003-05-02,2003,EP 97906572 A,1997-02-10,US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,,BASF AG,SALFELD JOCHEN G;;ALLEN DEBORAH J;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;HOOGENBOOM HENDRICUS R J M;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,"ABBOTT LABORATORIES(BERMUDA)LTD., HAMILTON, BM (2004-01-29);;ABBVIE BIOTECHNOLOGY LTD., DE (2014-05-21);;*ABBOTT LABORATORIES (BERMUDA) LTD (2003-05-02);;ABBVIE BIOTECHNOLOGY LTD. (2014-06-05);;ABBOTT BIOTECHNOLOGY LTD., HAMILTON, BM (2004-07-08);;ABBOTT LABORATORIES (BERMUDA) LTD. (2004-02-02);;ABBOTT BIOTECHNOLOGY LTD. (2008-06-25);;*ABBOTT LABORATORIES (BERMUDA) LTDCLARENDON HOUSE, (2003-05-02);;ABBVIE BIOTECHNOLOGY LTD, BM (2014-10-15)",https://lens.org/185-439-302-428-847,Granted Patent,yes,4,3,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;C12N15/09;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,2,0,,,"EMBO J., vol. 12, no. 2, 1993, pages 725-734, XP000645476 GRIFFITH ET AL.: ""Human anti-self antibodies with high specifity fom phage display libraries"" cited in the application;;CLINICAL RESEARCH, vol. 42, no. 2, April 1994, page 299a XP002032300 CHOW ET AL.: ""Effect of monoclonal antibody to human TNF on TNFalpha, IL-1beta and IL-6 levels in patients with sepsis syndrome""",EXPIRED
262,US,A1,US 2010/0040604 A1,196-809-473-602-12X,2010-02-18,2010,US 57848709 A,2009-10-13,US 57848709 A;;US 36945109 A;;US 78790107 A;;US 80118501 A;;US 12509899 A;;US 9702219 W;;US 59922696 A;;US 3147696 P,1996-02-09,HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha,"Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d =10 −8 M or less), a slow off rate for hTNFα dissociation (e.g., K off =10 −3 sec −1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.",SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,SALFELD JOCHEN G;;ALLEN DEBORAH J;;HOOGENBOOM HENDRICUS R J M;;KAYMAKCALAN ZEHRA;;LABKOVSKY BORIS;;MANKOVICH JOHN A;;MCGUINNESS BRIAN T;;ROBERTS ANDREW J;;SAKORAFAS PAUL;;SCHOENHAUT DAVID;;VAUGHAN TRISTAN J;;WHITE MICHAEL;;WILTON ALISON J,BASF AKTIENGESELLSCHAFT (1996-04-29);;ABBOTT BIOTECHNOLOGY LTD (2003-02-05),https://lens.org/196-809-473-602-12X,Patent Application,yes,98,58,135,181,37,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,A61K39/395;;A61K31/00;;C12N15/09;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,424/130.1,0,0,,,,EXPIRED
263,HK,A1,HK 1125951 A1,068-783-274-547-793,2009-08-21,2009,HK 09104484 A,2009-05-16,US 59922696 A;;US 3147696 P,1996-02-09,A METHOD FOR INHIBITING HUMAN TNF ACTIVITY IN VITRO TNF,,ABBVIE BIOTECHNOLOGY LTD,JG JOCHEN G SALFELD;;DJ DEBORAH J ALLEN;;ZEHRA KAYMAKCALAN Z;;BORIS LABKOVSKY B;;JA JOHN A MANKOVICH;;BT BRIAN T MCGUINESS;;AJ ANDREW J ROBERTS;;PAUL SAKORAFAS P;;HRJM HENDRICUS R J M HOOGENBOOM;;DAVID SCHOENHAUT D;;TJ TRISTAN J VAUGHAN;;MICHAEL WHITE M;;AJ ALISON J WILTON,,https://lens.org/068-783-274-547-793,Patent Application,no,0,0,135,181,0,A61K38/00;;A61K2039/505;;C07K2317/21;;C07K2317/56;;C07K2317/565;;Y10S424/81;;C07K16/241;;A61P1/00;;A61P1/02;;A61P1/04;;A61P1/16;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P21/00;;A61P25/00;;A61P27/02;;A61P29/00;;A61P29/02;;A61P3/04;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/20;;A61P31/22;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P37/08;;A61P39/02;;A61P43/00;;A61P7/00;;A61P7/02;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/08;;A61P9/10;;A61P3/10;;Y02A50/30;;C07K16/24;;A61K39/395;;C12N5/10;;C12N15/11;;C12N15/64;;C07K2317/565;;C07K2317/56;;A61K2039/505;;C07K2317/21;;A61K38/00;;Y10S424/81;;Y02A50/30;;C07K16/241,C07K/;;A61K/;;C12N15/09;;A61K31/00;;A61K31/40;;A61K31/403;;A61K31/404;;A61K31/415;;A61K31/4164;;A61K31/4178;;A61K31/505;;A61K31/517;;A61K31/52;;A61K31/529;;A61K31/57;;A61K31/573;;A61K31/675;;A61K38/00;;A61K38/04;;A61K38/16;;A61K39/39;;A61K39/395;;A61P/;;A61P1/00;;A61P1/04;;A61P1/16;;A61P3/10;;A61P7/00;;A61P7/04;;A61P9/00;;A61P9/04;;A61P9/10;;A61P11/00;;A61P11/16;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/06;;A61P25/00;;A61P27/02;;A61P29/02;;A61P31/00;;A61P31/04;;A61P31/12;;A61P31/18;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/02;;A61P37/06;;A61P37/08;;A61P39/02;;C07K16/24;;C12N/;;C12N1/21;;C12N5/10;;C12P21/08;;G01N33/53;;G01N33/543;;G01N33/564;;G01N33/576;;G01N33/68,,0,0,,,,DISCONTINUED
264,US,A1,US 2022/0100930 A1,191-898-212-381-379,2022-03-31,2022,US 202117487598 A,2021-09-28,US 202117487598 A;;US 202063084277 P,2020-09-28,Tessellation and Connection System for Space Assembly of Modular Units,The present disclosure describes systems and methods for mapping a planar surface to a curved surface. One such method comprises providing a planar lattice pattern having identical regular polygon shapes which can be truss support modules for supporting a curved surface structure. Method further include determining respective positions of the nodal points of the identical polygon shapes by placing a starting nodal point on an axis of symmetry of the planar lattice pattern and iteratively positioning each nodal point in relation to already placed neighboring nodes to make a distance between a currently positioned nodal point optimally close with a set value of the planar lattice pattern. Method still further comprises forming a curved lattice pattern of the truss support module based on the positions of the nodal points of the identical polygon shapes.,NASA,DOGGETT WILLIAM R;;WHITE BRACE W/;;DORSEY JOHN T;;CLINE JULIA E;;KANG DAVID;;SONG KYONGCHAN;;TETER JR JOHN E;;PADDOCK DAVID A;;WONG I O K M;;MIKHOPADHYAY ROUNAK;;MARTIN ROBERT F;;COSGROVE PATRICK A;;SHEAFFER DAMON E;;ALLEN B DANETTE;;WALTZ WALTER J;;WILLIAMS RALPH A;;SHAZLY SHERIF A;;COOPER JOHN R;;VAUGHAN MATTHEW P;;PLANT JAMES V,,https://lens.org/191-898-212-381-379,Patent Application,yes,0,1,1,1,0,G06F30/13;;G06F30/23;;G06F2111/20;;G06F30/13;;G06F30/23,G06F30/23;;G06F30/13,,0,0,,,,PENDING
